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CHAPTER I 
REVIEW OF THE LITERATURE 
I. HEPARINS 
A. History of Heparin 
While studying the thromboplastic action of cephalin, a medical 
student named Jay Mcclean made the serendipitous finding of a phospho-
lipid anticoagulant in liver extracts (McClean 1916). Soon after, in 
1922, a water-soluble glycosaminoglycan complex was discovered by 
Howell, and named heparin because of its abundance in liver (Howell 
1922). Through the work of Scott and Charles (1936), heparin became 
available in sufficient purity and quantity to make its use in physiol-
ogical and clinical experiments feasible. In vitro studies by Wessler 
and Yin, in the early 1970s, demonstrated that thrombosis could be 
controlled by a block in the coagulation cascade which could lead to an 
inhibition of thrombin generation and an inhibition of clotting 
(Wessler 1974; Yin et al. 1973). Clinical trials by Kakaar et al. in 
1979 have contributed to the development of low molecular weight 
heparins as therapeutic agents. Significant advances in the structure 
activity relationship of low molecular weight heparins by Choay et al. 
(1983) has lead to the chemical synthesis of a pentasaccharide which 
contains the minimal binding site of heparin for antithrombin III (AT 
III). 
1 
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B. The Biosynthesis of Heparin 
Heparin is synthesized as a proteoglycan complex, by connective 
tissue type mast cells. The synthesis of the glycosaminoglycan is 
initiated by attachment of a carbohydrate-protein linkage region to 
serine residues of a specific polypeptide chain (Silbert 1967, Lindahl 
et al. 1977). After the linkage region is formed the polymer chain of 
the glycosaminoglycan is assembled by the alternate attachment of N-
acetylglucosamine and glucuronic acid. This initial synthesis is 
followed by postsynthetic modifications which can be divided into four 
major categories. Initially, glucosamine residues are partially N-
deacylated and the exposed amino groups serve as acceptors of S04 - 3 
ions in a transfer reaction with phosphoadenosyl phosphosulfate (PAPS). 
Secondly, glucuronic residues are epimerized to iduronic acid moieties. 
Thirdly, the iduronic acid residues and some glucuronic residues are 
sulfated at the C-2 position. Fourthly, the glucosamine moieties are 
ester desulfated to a variable extent at C-3 and C-6 positions (Silbert 
1967, Lindahl et al., 1977, Jacobson et al. 1979, Roden and Horowitz 
1977). The biosynthesis of heparin does not occur in a random manner, 
although the regulation of these complex events is yet unclear. 
Sulfation occurs preferentially in those regions of the chain where the 
amino sugar residues have been N-deacylated and N-sulfated and where 
glucuronic residues have been epimerized to 1-iduronic acid (Casu 
1985). The final product of this synthetic pathway is termed heparin 
proteoglycan or macromolecular heparin (Yurt et al. 1978; Robinson et 
al. 1978) and is thought to consist of a core protein of unknown size 
3 
with glycosaminoglycan chains of 30,000 to 100,000 daltons, which 
resembles a bottlebrush (Arnott and Winter 1977). 
After heparin is synthesized, it can be modified by three 
different types of lysosomal enzymes: (1) proteases which can cleave 
the polypeptide chain, (2) endoglycosidases which can cleave between 
glucuronic acid and glucosamine residues (Horner 1972; Oosta et al. 
1982) and (3) exoglycosidases that remove monosaccharide units from the 
nonreducing end of the "released" complex carbohydrate species (Neu-
field et al. 1975). This degradation takes prior to purification of 
the glycosaminoglycan. 
C. Biological Function of Heparin 
Heparin ls primarily located in the mast cells of a variety of 
organs, including the liver, lungs, heart, kidneys and intestines. The 
concomitant occurrence of heparin and histamine in mast cell granules 
has lead to suggestions that these two biologically active compounds 
may be stored together as an inactive complex (Unvas 1974). An .in 
vitro complex arising from the ionic binding between the ester sulphate 
groups of the heparin and the amino groups of the histamine was taken 
to support this hypothesis (Unvas 1974). Ultrastructural analysis of 
human lung mast cells demonstrates that the contents of the secretory 
granules are packaged in a highly ordered crystalline array, suggesting 
that such complexes occur (Schwartz and Bradford 1986). A unique 
property of heparin in the mast cells is the high degree of sulfation 
of heparin which creates an enormous electrostatic charge that can act 
as a cation exchanger in the granule. In addition, heparin may function 
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to regulate the osmotic pressure of the granule in the mast cell 
(Caulfield et al. 1980). 
There is no direct evidence that mast cells secrete heparin into 
the bloodstream. Blood coagulability is generally not effected when 
mastocytomas of varying degrees of differentiation occur in man, 
rodents, cattle, cats and dogs, even when large tumors are present 
(Sagher and Even-Paz 1967). 
D. Chemistry of Heparins 
Heparin structure consists of a regular and an irregular region. 
The regular region contains trisulfated disaccharide units (I2s-
Ans,6s(alpha-l,4-linked L-iduronic acid 2-sulfate)-(D-glucosamine N,6-
disulfate)) which are interrupted by other usually less sulfated 
sequences (Casu 1984). Contained within the regular sequences of the 
heparin regions is a unique sequence, a pentasaccharide, which binds 
tightly to antithrombin III (AT III) with a Ka- 7xl06 M- 1 forming an 
equimolar complex with and enhancing the inhibition of factor Xa by AT 
III. The pentasaccharide represents the minimal binding sequence of 
heparin for AT III (Choay et al. 1983). 
Approximately 30% of heparin preparations on a weight basis are 
able to bind to AT III and potentiate the inhibition of the coagulation 
proteases (Choay and Petitou 1986). As many as 21 different subfrac-
tions have been described in heparin, (McDuffie et al. 1975 and 
Dietrich et al. 1975) however, only 25% to 35% of a given heparin 
preparation binds tightly to AT III and this high affinity fraction is 
responsible for 85 to 90 % of the anticoagulant activity of heparin 
(Lam et al. 1976). Most heparin oligosaccharides which bind to AT III 
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affinity columns differ in size as well as internal composition which 
suggests that some residues may be either critical or essential for 
activity while others may be nonessential fo,r activity (Casu et al. 
1981). 
Clinically used heparin is heterogenous with respect to struc-
ture, molecular size, degree of sulfation and anticoagulant activity. 
Fragments of heparin have molecular weights which range from 6,000 to 
more than 30,000 daltons with the largest fraction being between 10,000 
and 15,000 daltons (Andersson and Barrowcliffe et al. 1979; Hook et 
al., 1976). The degree of sulfation contributes to the anticoagulant 
activity of heparin. A relationship exists between the anticoagulant 
potency of a heparin and the linear charge density of a series of 
heparin fractions (Hurst et al. 1979). The anticoagulant activity of 
fractions with similar molecular weight profiles increases with 
increasing charge density. However, differences in molecular weight 
produce larger differences in anticoagulant potency than differences in 
anionic density (Hurst et al. 1981). 
Heparins obtained from various organs and different heparin 
preparations from the same organ contain differing proportions of 
regular and irregular sequences which include the linkage region or AT 
III binding sequence. Typically beef lung heparin contains a larger 
proportion of the regular trisulfated disaccharide sequences than 
heparin from porcine mucosal origin. Electrophoresis of heparin in 
cationic buffers provides further evidence of the heterogeneity of 
heparin (Casu 1984). In these systems, heparin can be subfractionated 
into slow moving and fast moving components and preparations from beef 
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lung usually contain more slow moving species than porcine mucosal 
heparins. 
E. Fractionated and Depolymerized Low Molecular Weight Heparins 
Low molecular weight heparin fractions and fragments have been 
prepared from conventional heparin by several methods. Procedures such 
as gel filtration, ion exchange chromatography, partition fractionation 
and affinity chromatography separate the heparin structures based on 
physiochemical characteristics without cleaving the heparin molecule. 
Gel filtration has been used to elucidate the molecular weight of the 
heparin components (Losito 1981). Studies using specific molecular 
weight components of heparin have shown that anticoagulant activity 
increases with the size of the molecule and that anti Ila inhibition is 
more dependant on molecular weight than is anti Xa activity (Andersson 
et al. 1979). Ion exchange chromatography has been used to separate 
fractions which have varying anticoagulant activity. Partition 
fractionation procedures have been used to produce heparins with 
varying degrees of sulfation which parallel the anticoagulant activity 
of heparins. Low molecular weight heparin has also been fractionated 
on affinity columns of substances such as AT III, heparin cofactor II, 
or thrombin (Choay and Petitou 1986). 
Low molecular weight heparin can also be produced by a variety 
of techniques which cleave the heparin molecule including: heparinase 
treatment, nitrous acid degradation, perioxadative oxidation followed 
by either reduction and mild acid hydrolysis or alkaline cleavage 
fractionation with dilute acid followed by re-N-sulfation of N-desul-
fated fragments or with chlorosulfonic acid (Casu 1984). 
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End residues of fragments are typical of the specific method of 
depolymerization. Heparinase splits glycosidic bonds between N-
sulfated glucosamine and iduronic 2-sulfate residues producing frag-
ments terminating with 4,5-unsaturated iduronic acid 2-sulfate at the 
nonreducing end and N-sulfated glucosamine at the reducing end (Linker 
et al. 1977). Nitrous acid splits glycosidic bonds between N-sulfated 
glucosamine and uronic acid, producing fragments with 2, 5-anhydroman-
nose at the reducing end (Cifonelli et al. 1976). Periodate oxidation 
splits the C-2, C-3 bonds of nonsulfated uronic acids, making the 
glycosidic bonds of modified residues labile to alkali or (when 
reduced) to acid (Casu 1984). Direct acid hydrolysis preferentially 
causes N-desulfation (Conrad 1981) while chlorosulfonic acid can be 
used to depolymerize and resulfate heparin fragments in one step with 
the end result being a "supersulfated" heparin fragment with ap-
proximately one extra sulfate group per disaccharide unit. 
Apart from differences in the yield of these fragments from the 
variety of fragmentation procedures, the method of depolymerization, in 
theory, may influence the binding sequence to antithrombin III. In 
principle, nitrous acid could split some glycosidic linkages in the 
region of the active site for AT III and perioxadative cleavage could 
conceivably modify the active site for AT III. However, it has been 
reported the 3-0 sulfo group on A*NS·6S has some stabilizing influence 
of the corresponding glycosidic linkage (Casu 1981). It has not been 
determined whether the end group influences the anticoagulant activity 
of heparin, however, end groups influence the metabolism of the heparin 
(Linhart personal communication). 
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Methods which fragment heparin may be preferred over frac-
tionation techniques since the yield of low molecular weight heparin 
obtained through chromatographic techniques is only about 10 to 15 % 
with the use of carefully controlled depolymerization techniques nearly 
100 % of the sample can be converted to the molecular weight range of 
choice (Barlow and Petracek 1986). 
F. Qyerview of Hemostasis 
Prior to a detailed discussion of the interaction of heparins 
with the components of the hemostatic system, an overview of the 
current knowledge on this subject is presented. A schematic diagram of 
the coagulation cascade is shown in Appendix I. 
Blood normally circulates through the vascular system without 
activation of the coagulation proteins or platelets and without 
hemorrhage. An injury to a vessel, however, initiates a complex chain 
of events resulting in the formation of fibrin. Hemostasis is main-
tained through the interaction of the coagulation and fibrinolytic 
systems, platelets and the endothelium. The process of coagulation may 
be described as a waterfall or cascade involving cofactors, enzymes and 
substrates. Most coagulation enzymes are zymogens containing serine, 
histidine and aspartic acid in their active sites in addition to 
containing binding regions to cellular surfaces, phospholipids, cell 
membranes and connective tissue. The molecular assembly of cofactor, 
enzyme and substrate is a recurrent theme in blood coagulation designed 
for maximal efficiency and speed of molecular reactions. Negatively 
charged surfaces provide the reaction surface in the early part of the 
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cascade while later phospholipid or platelet membranes provide the 
surface for reaction in the later part of the cascade. 
The initiation of blood coagulation occurs through either the 
activation of the intrinsic or extrinsic pathway. The intrinsic 
pathway becomes activated when the coagulation factor XII comes in 
contact with a foreign surface such as a damaged vessel wall or 
prosthetic device and becomes activated to factor XIIa. Factor XIIa in 
the presence of ca+2 converts zymogen factor XI to factor IXa. Factor 
IXa in the presence of factor VIII and phospholipid activates factor X 
to factor Xa. 
The extrinsic system is involved in response to an injury in the 
vessel wall and also converts factor X to factor Xa. Components of the 
extrinsic system include factor VII, a vitamin K dependant enzyme, 
tissue factor or thromboplastin, a phospholipid which acts as a 
cofactor in the conversion of factor X to factor Xa by factor VIIa. 
Once factor Xa is formed by either the extrinsic or intrinsic pathway, 
it converts prothrombin to thrombin which cleaves fibrinogen to fibrin. 
Thrombin occupies a central role in hemostatic plug formation and 
limitation as it acts on multiple substrates including fibrinogen, 
factor XIII, factor V and factor VIII, platelet membrane glycoprotein V 
and protein C (Colman et al. 1987). The final two steps of the 
coagulation are termed the common pathway. 
Platelets play an important role in coagulation by releasing 
substances which stimulate vessel wall constriction and by forming a 
primary platelet plug at a site of vessel injury. Many of the coagula-
tion factors are attached to the platelet surface where activation of 
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the coagulation factors takes place. Platelets, upon activation, 
release substances from their granules which influence blood coagula-
tion. One such substance released from the dense granules is platelet 
factor 4 which complexes with heparin and neutralizes its activity. 
Many plasma proteolytic inhibitors control and limit the extent 
of coagulation and fibrinolysis. C1 inhibitor is the major plasma 
inhibitor of factor XII (Liu et al. 1979), while alpha1 antitrypsin is 
the major inhibitor of factor XIa (Ratnoff et al. 1977). AT III is the 
major inhibitor of factor Xa, XIa and thrombin (Colman et al. 1988). 
The interaction between AT III and heparin is responsible for most of 
the anticoagulant effects of heparin. 
Fibrinolysis, a physiologic mechanism for limiting clot forma-
tion resembles the coagulation cascade in its zymogens, feedback 
potentiation and inhibition and plasma inhibitors. Endothelial cells 
release tissue plasminogen activator which convert plasminogen to 
plasmin. Once plasmin is produced locally on the hemostatic plug, the 
potential for fibrin degradation exists. An intricate balance exists 
between the simultaneous forces which either promote or inhibit 
coagulation and platelet aggregation. The balance between profibrinol-
ytic and antifibrinolytic reactions, in addition to cellular mechanisms 
may eventually lead to clot reduction (Colman et al. 1987). 
G. Mechanism of Action of Heparins 
The primary mechanism of the anticoagulant actions of heparin 
occurs through association of heparin with AT III, an alpha2 globulin 
with a molecular weight of approximately 64,000 daltons (Abligaard et 
al. 1967). Heparin forms a stable complex through binding allosteric 
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lysyl residues on antithrombin III. This results in a conformational 
change in the protein and allows the critical arginine residue on AT 
III to be more readily available to interact with the serine active 
site in a specific activated enzyme. The reactivity between arginine 
and active serine sites has lead to the hypothesis that heparin-
antithrombin III complexes inhibit other serine proteases in addition 
to thrombin (Rosenberg et al. 1975; Atha et al. 1987). It has been 
demonstrated in vitro that the heparin-antithrombin III complexes exert 
their anticoagulant effects by inhibiting factors XIIa, XIa, Xa, IXa 
and thrombin (Rosenberg et al. 1975). Although most of the in vitro 
anticoagulant activity of heparin can be related to heparin molecules 
with high affinity for AT III, antithrombotic effects of heparin have 
been described which are independent of AT III (Ofosu et al. 1981). 
These include potentiation of the effects of high affinity heparin by 
low affinity heparin, binding of heparin to endothelium and the direct 
inhibition of heparin on several thrombin dependant reactions including 
factor V and factor VIII activation (Hurst et al. 1983). Heparin also 
inhibits thrombin through heparin cofactor II, a glycoprotein of 65,600 
daltons (Colman et al. 1987). In vitro, the thrombin inhibitory effect 
has been demonstrated at higher concentrations of heparin that is 
necessary to inhibit thrombin through AT III (Andrew et al. 1986). 
H. In Vitro Effects of Heparins 
1. Anticoagulant and Antiprotease Effects 
The heterogeneity and polydisperse nature of heparin does not 
permit the direct measurement of heparin concentration by chemical 
methods, rather, measurement of heparin activity has been used to 
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approximate the actual concentration of heparin administered. For 
many years the anticoagulant activities of heparin have been evaluated 
using nonspecific global assays such as the USP assay and APTT tests. 
These assays, however, proved to be insensitive to the newly developed 
low molecular weight heparins. Newer assays have been developed which 
are more sensitive to the antiprotease activities of heparin and are 
useful in the monitoring of low molecular weight heparins. These 
assays include: serine protease inhibition assays such as anti factor 
Xa and anti factor Ila methods, serine protease generation tests, 
fibrinopeptide A generation tests, thrombin generation tests as well as 
complex combination tests such as the HeptestR which combines enzyme 
generation, protease inhibition, and clot formation (Fareed et al. 
1980). 
A molecular weight dependence of the anticoagulant activity of 
heparin has been demonstrated using the more specific antifactor 
assays. Denton et al. (1983) and Mardigian and Trillou (1983) have 
determined that an octadecasaccharide was the minimum length of heparin 
chain necessary to accelerate the neutralization of thrombin by AT III. 
Low molecular weight heparins of < 5,600 daltons do not show any 
significant antithrombin activity. This molecular weight corresponds 
to the minimum size of heparin to accelerate thrombin inhibition in the 
presence of AT III (Oosta et al. 1981) . Inhibition of factor Xa, 
however, did not show a similar correlation to molecular weight. Unlike 
the anti factor Ila effects of heparin. both low and high molecular 
weight heparin molecules are capable of inhibiting factor Xa. The anti 
Xa activity of heparin increases with decreasing molecular weight in 
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both amidolytic and clot based assays (Lane et al. 1978; Andersson et 
al. 1979; Emanuele 1987). Choay et al. (1980; 1983) and Lindahl and 
Bjork (1983) determined that the minimal binding site of heparin for AT 
Ill was restricted to a pentasaccharide sequence. 
At equigravimetric concentrations, unfractionated heparin 
contains greater anti Xa and anti Ila activity than many low molecular 
weight heparins (Walenga 1986). When comparing antiprotease activities 
within a single heparin preparation, one would expect to see ap-
proximately equal anti Xa and Ila activity. A greater proportion of 
anti Xa activity to anti Ila activity is seen however with low 
molecular weight heparin preparations (Walenga 1986). This difference 
in relative activity between low molecular weight heparin and unfrac-
tionated heparin is due to the fact that low molecular weight heparins 
contain a greater proportion of oligosaccharides (>50%) which inhibit 
factor Xa activity. Commercial heparins contain only 5% saccharides 
with a molecular weight< 4,200 daltons (the minimum weight required to 
inhibit thrombin). 
Some low molecular weight heparins can inhibit thrombosis in 
vivo while possessing minimal or no anticoagulant activity in vitro 
(Walenga 1987). New terminology has been introduced which expresses 
the discrepancy between the in vitro and in vivo activities of these 
antithrombotic agents. Anticoagulant activity is defined as the 
ability to inhibit either the activation of prothrombin and/or factor 
X or the activated enzymes (thrombin and factor Xa respectively). 
Antithrombotic activity is defined as the in vivo prevention of 
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thrombosis or the inhibition of the extension of established thrombi 
(de Prost 1986). 
2. Interactions With Platelets 
A wide spectrwn of in vitro results on the interaction of heparin 
with platelets has been reported. These include the inhibition of 
platelet aggregation and release (Han et al. 1974), potentiation both 
in vitro and in vivo (Thompson et al. 1973; Heptinstal et al. 1977) or 
no detectable effect (MacFarlane et al. 1975). These differences in 
experimental results may depend upon the source of heparin or the 
experimental protocol used in the studies. Heparin blocks the action 
of thrombin on platelets, while the other activities of platelets may 
proceed despite the administration of heparin (Salzman et al. 1980). 
Heparin enhances platelet release induced by ADP, however there is no 
significant effect of low molecular weight heparins on platelets 
(Fabris et al. 1983). 
Heparin enhances platelet aggregation in citrated platelet rich 
plasma after induction by various agonists such as ADP and epinephrine. 
This action is blocked by substances that elevate cAMP and by EDTA but 
not by inhibitors of the cyclooxygenase pathway (Salzman et al. 1980). 
A molecular weight dependance of the enhancement of platelet aggrega-
tion by heparin has been reported. Fractions of high molecular weight 
heparin (20,000 daltons) were more reactive with platelets than 
fractions of low molecular weight heparin (7,000 daltons). Brace et 
al. (1986) have demonstrated a molecular weight dependance on platelet 
aggregation using subfractions of a low molecular weight heparin, PK 
10169. Preparation of high molecular weight heparin of high and low 
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affinity were equally active in the induction of platelet aggregation. 
No correlation between the anticoagulant, antifactor Xa, antifactor Ila 
activities of the heparins and platelet aggregation was noted. 
Heparin does not induce aggregation in washed platelets which 
suggests that there is not a direct interaction between platelets and 
heparin (Fabris et al. 1983; Westwick et al. 1986). Binding of heparin 
to AT III has been reported to inhibit the interaction of heparin with 
platelets. Shanberge et al. (1986) have demonstrated that platelets 
bind heparin but not heparin-AT III complexes. Heparin has been shown 
by O'Brien et al. (1969) and Fabris et al. (1983) to inhibit platelet 
release induced by collagen in PRP. Heparin may alter the surface 
charge of platelets and interfere with platelet-collagen interactions. 
3. Heparins and Fibrinolysis 
Heparin has a dual effect on fibrinolysis in vitro. Levels 
> 125 µg/ml of this agent inhibited fibrinolysis mediated by human 
urokinase, human euglobulin fractions and human plasma, while lower 
heparin concentrations (5 µg/ml) have been shown to enhance fibrinoly-
sis in vitro (Von Kaulla et al. 1958). More recently Paques et al. 
(1986) and Fears et al. (1988) have demonstrated a concentration 
dependant stimulation of plasminogenolytic and fibrinogenolytic 
activity of both urinary and tissue type plasminogen activators in the 
presence of heparin. In the presence of soluble fibrin, however these 
effects of heparin on tPA were attenuated (Fears et al. 1988). 
Heparin also decreased the fibrin specificity of tPA and consequently 
caused a cleavage of fibrinogen. This may be related to any increased 
bleeding observed when these agents are used in combination. In 
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addition, if these influences of heparin and fibrin also occur in vivo, 
then, in the presence of heparin, the relative fibrin enhancement of 
tPA will be diminished and the likelihood of systemic activation by tPA 
is increased (Fears et al. 1988). Markwardt et al. (1977), have shown 
that heparin induces the release of plasminogen activator using an 
isolated pig ear preparation. 
I. In Vivo Effects of Heparin 
1. Studies in Animal Models 
The ideal ratio of the antifactor Xa and antifactor Ila ac-
tivities of heparins needed to achieve optimal antithrombotic effects 
has not been determined. Antithrombotic effects which are achieved by 
inhibiting factor Xa alone are limited in their control of various 
thrombogenic triggers. Better antithrombotic effects are achieved by 
heparin or heparin-like substances capable of influencing the inactiva-
tion and or generation of thrombin. The ability of heparin or a 
heparinoid to potentiate the inactivation or the generation of thrombin 
appears to be an important predictor of antithrombotic effect observed 
in vivo (Buchanan et al. 1984). Heparin fractions with predominately 
anti factor Xa activities are likely to be weak inhibitors of thrombin 
generation. Heparin or related substances which exhibit thrombin 
inhibition are more active against thrombosis as demonstrated in a 
modified Wessler model than agents with sole inhibitory activity 
towards factor Xa activity. Although the anti Xa levels of standard 
heparin and an octasaccharide were similar (0.28-32 U/ml), heparin (10 
anti Xa U/kg) inhibited thrombus formation by 90%, while octasaccharide 
(10 anti Xa U/kg) inhibited thrombus formation by 41%. Dermatan 
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sulfate (500 µg/kg i. v.), which represents a gravimetric amount 5 
times heparin and exhibits no anti Xa activity inhibited thrombus 
formation by 95%. Also higher doses of octasaccharide which increased 
anti Xa to higher levels had no further effect on thrombus formation 
(Buchanan et al. 1984). 
Similarly, Walenga et al. (1987) have demonstrated that a 
pentasaccharide representing the critical sequence required in heparin 
for binding to AT III, however, devoid of any anti factor Ila activity 
was capable of inhibiting thrombosis induced by four different throm-
bogenic challenges. The agents used for the induction of thrombosis in 
a modified Wessler model included thromboplastin, an activated proth-
rombin complex concentrate, a nonactivated prothrombin complex con-
centrate administered simultaneously with Russell's viper venom, and 
activated factor X. The studies demonstrated that oligosaccharides 
devoid of antifactor Ila activity but containing high antifactor Xa 
activity were capable of inhibiting thrombosis induced in rabbit stasis 
models, however, higher doses of these agents as compared to heparin 
were required for this effect. 
In the treatment of thrombosis, prophylaxis as well as therapeu-
tic intervention to inhibit thrombus extension is important. Low 
molecular weight heparins (CY 216 and PK 10169) and heparin were shown 
to be equipotent at doses of 42-62.5 anti Xa U/kg/hr in preventing the 
accretion of 1251-fibrin onto venous thrombi preformed in rabbit 
jugular veins (Boneu et al. 1985). Low molecular weight heparins, 
therefore, could be used for the treatment as well as prophylaxis of 
thrombosis. The ED50 for the antithrombotic effects of low molecular 
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weight heparins ranged from 40 to 80 µg/kg as compared to an EDso of 
approximately 30 µg/kg for unfractionated heparin as demonstrated in a 
stasis thrombosis model (Fareed et al. 1988). 
Many theories have been proposed to explain the potentiation of 
the actions of high affinity heparin oligosaccharides by low affinity 
heparin in vivo. These include: the binding of low affinity heparin to 
antiheparin proteins in plasma, interactions of the low affinity 
heparin with vascular endothelial cells or providing an alternative 
substrate to endoglycosidase enzymes located in platelets (Barrowcliffe 
et al. 1984). Two heparin fractions: one with high affinity to AT III 
and one with low affinity to AT III were compared with unfractionated 
heparin in both in vitro assays and in an experimental model of stasis 
thrombosis (Merton et al. 1984). Although the in vitro activity of 
high affinity heparin was twice that of unfractionated heparin, the 
high affinity heparin had less antithrombotic activity than the 
unfractionated heparin. The low 
inactive, both in vitro and in vivo. 
affinity heparin was virtually 
A mixture of 30 µg/kg of high 
affinity heparin and 50 µg/kg of low affinity heparin given intraven-
ously was as effective as unfractionated heparin (80 µg/kg i. v.). 
These studies demonstrate that low affinity heparin potentiates the 
actions of high affinity heparin in vivo. 
With the development of low molecular weight heparins, it became 
possible to dissociate the antithrombotic and hemorrhagic effects of 
these agents, thus improving their therapeutic potential (Cade et al. 
1984). Low molecular weight heparins produce less bleeding than 
unfractionated heparin, however no strong relationship exists between 
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blood loss and the effects on antifactor Xa levels, APTT, thrombin 
clotting time as measured ex vivo (Cade et al. 1984). 
Heparin fractions of low molecular weight with high antifactor 
Xa activity/APTT activity ratios exhibit antithrombotic activity and 
are associated with a reduced incidence of bleeding (Mattsson et al. 
1985). Doutremepuich et al. (1986) have demonstrated that a low 
molecular weight heparin, CY 216, had lower hemorrhagic effects than 
heparin as measured in a rabbit ear blood loss model. At doses of 
heparin (1408 anti-factor Xa U/kg) and CY 216 (1600 anti-factor Xa 
U/kg) with similar anti Xa activities, the blood loss values for 
heparin were significantly greater (p<.05) than for CY 216. Studies on 
the time course of antiprotease, antithrombotic and bleeding effects of 
heparins in rats by Hobblelen et al. (1985) have shown that the time 
response curves for the antithrombotic effects of heparins parallels 
those of the antifactor Xa activity whereas the time response curves 
for bleeding were more related to the effects on thrombin. 
2. Pharmacokinetics/Pharmacodynamics of Heparins 
The pharmacokinetics of heparin are nonlinear, dose dependant, 
time dependant and assay dependant (Cocchetto and Bjornsson 1984). 
These properties contribute to the variations seen in anticoagulation 
for patients given a certain dose of heparin. Pharmacokinetic para-
meters depend upon the assay used to determine heparin activity. APTT 
activity has been reported to disappear faster than anti Xa activity 
shortly after drug administration (de Swaart et al. 1982). Four fold 
variation in the t 1/2 of a low molecular weight heparin was seen by 
Dawes et al. (1986) and was dependant upon whether concentration was 
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measured directly or anti Xa, or anti Ila methods were used (Dawes et 
al. 1986). 
The dose and route of administration of heparin depends upon the 
clinical indication. Heparin is not effective by oral administration 
and is given either by deep subcutaneous injection, intermittent 
intravenous injection or by intravenous infusion. The dose of heparin 
is adjusted according to the patients coagulation test results. The 
APTT should be elevated to approximately 1. 5 to 2 times the control 
value (Salzman 1975). 
For subcutaneous administration of heparin, 5,000 U of heparin 
is given initially by intravenous injection and followed by 10,000 to 
20,000 U given subcutaneously. Then 8,000 to 10,000 U of a concentrated 
solution are given every 8 hours subcutaneously. For intermittent 
intravenous injection of heparin, 5,000 to 10,000 U of heparin is 
administered every 4 to 6 hours. For continuous intravenous infusion, 
an initial injection of 5,000 U of heparin then an additional 15,000 to 
35,000 U are administered over a period of 24 hours. Patients 
undergoing open heart surgery should receive an initial dose of 150 
U/kg of heparin. Frequently a dose of 300 U/kg is used for procedures 
estimated to last less than 60 minutes; or 400 U/kg for those estimated 
to last longer than 60 minutes. Low dose heparin given prior to and 
after surgery has been shown to reduce the incidence of postoperative 
deep venous thrombosis. The most widely used dose is 5,000 U, 2 hours 
before surgery and 5,000 U every 8 to 12 hours after for 7 days until 
the patient is fully ambulatory (Physician's Desk Reference 1989). 
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a. Absorption of Heparins 
Heparin is not absorbed to any great extent by gastrointestinal 
mucosa, due to its negatively charged high molecular weight components. 
oral absorption of heparin is variable because of its uncertain 
absorption from the G.I. tract and its instability in digestive juices, 
in addition, intestinal flora has also been noted to degrade heparin 
(Brufani et al. 1982). The N-sulfate groups of heparin are easily 
hydrolyzed in acidic medium which may result in a substantial loss of 
anticoagulant activity. While heparins of molecular weight >6000 
daltons do not cross the intestinal barrier, low molecular weight 
heparins (mean molecular weight approximately 4500 daltons) are 
absorbed from the gastrointestinal tract at very high doses (60 mg/kg). 
Heparins have been complexed with bile salts, (Ziv et al. 1983; 
Guarini et al. 1985) surface active agents (Stanzani et al. 1981) and 
encapsulated within liposomes (Ueno et al. 1982) in order to facilitate 
gastrointestinal absorption in experimental animals. The lower 
molecular weight of the newly developed heparins has facilitated the 
study of percutaneously applied low molecular weight heparins (Rodemer 
et al. 1986). Absorption of low molecular heparin in healthy subjects 
was meager at the doses studied (100-250 anti Xa units). It is 
conceivable however, that with better carrier substances absorption by 
percutaneous route could be improved. The rate of absorption depends 
upon the injection site and has been shown to exhibit intrastrain or 
interstrain variations in experimental animals. Variations in the 
subcutaneous absorption between two strains of mice have been reported 
22 
by sue (1979). Variability in the subcutaneous absorption of unfrac-
tionated heparin has been reported in man, although these variations 
decreased with decreasing molelcular weight, this variability could not 
be correlated to any physical parameter such as age, height or weight. 
A barrier to absorption exists which discriminates against larger 
molecules such that the 6 fold variation in AUC values between subjects 
observed with unfractionated heparin was reduced to 1. 5 fold for low 
molecular weight heparin CY 222 (Dawes et al. 1986). 
It was generally assumed that the activity of heparins in vivo 
resembled their in vitro anticoagulant and antiprotease activity 
profiles. However, differences between these two situations exist. 
Investigators have shown that heparin is not inert as it circulates in 
the plasma. Endogenous heparin can bind to the glycocalyx and be 
phagocytosed (Barzu et al. 1985). While the uptake of heparin is well 
documented, there is only indirect evidence for its eventual release in 
an undegraded form (Mahadoo and Jacques 1979). Extended anticoagulant 
responses observed with more indirect routes of administration could be 
related to either a slow absorption from the site of administration or 
a slow release of heparin which is sequestered by the reticuloen-
dothelial system. The duration of anticoagulant response (paren-
theses indicate half life) increases with the route that allows for 
greater cellular uptake of heparin as follows: intrapulmonary (14 days) 
> subcutaneous (6-8 hrs)> intramuscular (4-6 hrs)> intravenous (2-4 
hrs), (Mahadoo et al. 1979). 
It has been postulated by Mahadoo et al. (1979), that a cellular 
pool exists which modulates the level of heparin in the circulation and 
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may be related to endothelial cell binding of heparin. An increase in 
the size of the cellular pool causes a decreased availability of 
heparin to the circulating blood. This pool may act as a storage depot 
from which stored heparin is gradually released to the circulation. 
The degree of cellular uptake varies between the different sites of 
administration as follows: lung >peritoneal cavity > skin > muscle 
corresponds to the cell population of reticuloendothelial cells at the 
site of administration (Mahadoo and Jaques 1979). Heparin is rapidly 
absorbed and metabolized after parenteral administration. Although 
after intrapulmonary administration 90% of the drug is absorbed in 24 
hours while the anticoagulant response lasts for more than one week. 
This suggests that heparin is sequestered and released into the 
circulation (Jaques et al. 1976). 
Low molecular weight heparin is absorbed from subcutaneous sites 
to a greater extent than standard heparin. After subcutaneous ad-
ministration of 7500 anti Xa U, the anti Xa activity of heparin is 
absorbed to a lesser degree than CY 216 (Harenberg et al. 1986). 
Twelve hours after the administration of 5000 anti Xa IU of heparin and 
a low molecular weight heparin, higher anti Xa levels were seen for the 
low molelcular weight heparin than the unfractionated heparin ever 
produced (Bergvist et al. 1983). 
b. Endogenous Distribution of Heparins 
The polycomponent nature of heparin makes the study of its 
distribution within the body difficult. Since heparin contains many 
different molecular species with varying structures and degree of 
sulfation, it is not possible to uniformly radiolabel heparins. 
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However, radiolabelling studies have been performed and have shown that 
after intravenous administration, the anticoagulant activity of heparin 
disappears exponentially with a slightly faster initial disappearance 
which may be representative of endothelial uptake (Jacques 1979). 
Once heparin enters the vascular compartment it binds to many 
plasma proteins including AT III, albumin, globulins, fibrinogen, 
fibronectin, lipoproteins, and platelet factor 4 (Cocchetto and 
Bjornsson 1984). Heparin is also taken up by vascular endothelium and 
tissue macrophages (Mahadoo 1978). 
The distribution of 35s heparin fragments (1 mg/kg i. v.) was 
studied in rats by Larsen et al. (1984). Low levels of radioactivity 
were present in all organs and tissues with an overall recovery of 
radioactivity of 94.4 %. 78% of organ bound radioactivity was as-
sociated with the liver, kidneys and intestines. The highest disposi-
tion of radioactivity was found in the liver while the highest specific 
activity (dose/gram) was associated with the kidneys. The organ 
distribution of heparin and low molecular heparin is similar. Both 
drugs exhibit a selective distribution in various organs especially 
those endowed with reticuloendothelial tissue (Danishefsky and Eiber 
1959). 
c. Half Life of Heparins 
The t1;2 of low molecular weight heparin is usually 2 to 3 times 
the t1;2 of unfractionated heparin and is dependant on the dose, route 
of administration and assay used to detect anticoagulant activity 
(Lockner et al. 1986; Fareed et al. 1986). The t1;2 of heparin 
increases with increasing dose (Estes et al. 1969). The immediate 
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mechanism underlying the dose dependant kinetics of heparin, in rats, 
appears to be a decrease in total clearance and an increase in app~rent 
vd with increasing dose (Bjornsson et al. 1981). 
In primates, the t1;2 of unfractionated heparin (250 µg/kg i.v.) 
as measured by the HeptestR is approximately 30 minutes while the t1;2 
of low molecular weight heparin CY 216 (1 mg/kg i. v.) is 1 hour 
(Emanuele 1987). After subcutaneous administration, the half life of 
CY 216 is longer than for unfractionated heparin. The t1;2 of CY 216 
(1 mg/kg s.c.) is reported to be 144 minutes while the t1;2 of unfrac-
tionated heparin (1 mg/kg sc) is 94 minutes as determined by the 
HeptestR (Emanuele 1987). 
Binding to plasma proteins such as the AT Ill increases the t1;2 
of heparin. AT Ill heparin complexes disappear more slowly from the 
circulation than heparin which is not bound to AT Ill. The t1;2 of a 
hexadecasaccharride complexed to AT Ill and a dodecasaccharide com-
plexed to AT Ill is 30 times longer than that of heparin and 10 times 
longer than AT III-heparin complexes in rabbits (Mattsson et al. 1985). 
The encapsulation of heparin in liposomes also increases the t1;2 of 
intravenously administered heparin three times in rats (Kim et al. 
1986). 
In addition to having an increased t1;2 which permits once daily 
injections of low molecular weight heparins, these drugs also exhibit 
increased bioavailability as compared to heparin after subcutaneous 
injection (Palm and Mattson 1987). The low molecular weight heparin, 
FragminR, is 86% bioavailable after subcutaneous administration as 
compared to 10% for unfractionated heparin (Lockner et al. 1986). 
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d. Metabolism of Heparins 
In 1945, Monkhouse and Dickie observed that heparin had a longer 
survival time in the circulation after blocking the reticuloendothelial 
system (RES) of rabbits with thorotrast (Monkhouse and Dickie 1954). 
This suggests that heparin is eliminated via the RES. Heparin is 
desulfated by N-sulfatases and sulfamidases of the liver and subse-
quently depolymerized into oligosaccharides (Cocchetto and Bjornsson 
1984). Other investigators have shown that cells of the RES can 
phagocytose heparin and store it for varying lengths of time (Oh et al. 
1973). Endothelial cells selectively bind those chains of heparin 
which have a higher molecular weight, greater charge density and 
greater anticoagulant activity. Fragments released back into the 
circulation exhibit low· anti Ila activity but retain their anti Xa 
activity (Barzu et al. 1987). Heparin structural determinants for the 
anti Xa activity are more resistant to enzymatic attack in comparison 
to those responsible for the antithrombin activity (Mastacchi and 
Barbati 1987). Endocytosis may be followed by depolymerization of 
internalized heparin by lysosomal enzymes. 
Heparins are differentially metabolized by kidneys. Low molecu-
lar weight heparin is a poorer substrate for renal lysosomal inac-
tivators than unfractionated heparin (Mastacchi and Barbanti 1987). 
e. Clearance of Heparins 
The liver and kidneys play a fundamental role in the elimination 
of heparin. Heparin elimination is prolonged in rabbits with renal 
dysfunction and with reticuloendothelial systems that are blocked by 
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various agents (Palm and Mattson 1987). In humans, cirrhosis of the 
liver leads to an increase in the half life of heparin (Teien 1977). 
severe impairment of renal function does not alter the half life of 
standard heparin but prolongs the t1;2 of low molecular weight heparin 
(Goudable et al. 1986). Clearance of heparin activity may result from 
a combination of saturable and a nonsaturable mechanisms (De Swart 
1982). The saturable mechanism may be related to heparin binding to 
the endothelium and reticuloendothelial cells (Dawes and Pepper 1979) 
while nonsaturable mechanisms may be related to renal elimination of 
heparin (Piper 1947). 
Only small amounts of heparin are excreted unchanged in the 
urine which suggests that circulating metabolites of heparin exist in 
plasma. In addition, the extent of urinary excretion of heparin is 
dependant upon the molecular weight of heparin. Low molecular weight 
heparin is cleared more readily by the kidneys. By 5 hours, in rats, 
54% of injected heparin, 83% of hexasaccharides and 89% of disac-
charides are present in the urine (Larsen et al. 1986). The mechanism 
through which heparin and low molecular weight heparin are cleared by 
the kidneys differs. Standard heparin is cleared through by an active 
and saturable cellular mechanism while low molecular weight heparin is 
cleared by renal filtration (Goudable et al. 1986). 
Boneu et al. (1987) studied the disappearance of 1251 heparin in 
rabbits and found a dose dependant increase in the biologic t1;2 of 
heparin due to a decrease in the total clearance of the anticoagulant. 
Saturable mechanisms of elimination predominate at low therapeutic 
doses of heparin, (<100 antifactor Xa U/kg) while nonsaturable 
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mechanisms predominate at higher doses (Boneu et al. 1987). However, 
saturable mechanisms contribute little to the disappearance of low 
molecular weight heparins. These agents are cleared primarily by 
nonsaturable routes such as renal excretion. Low molecular weight 
heparins also exhibit dose dependant clearances. Longer biological 
effects have been observed for low molecular weight heparin than for 
heparin at low doses. However, at higher doses, low molecular weight 
heparins are cleared faster than standard heparin (Boneu et al. 1987; 
Samama et al. 1989). 
Factors such as affinity to AT III, and molecular weight in-
fluence the disappearance rates of heparin. Heparin molecules with 
varying degrees of affinity to AT III are cleared at different rates. 
Equigravimetric amounts of 125I-low affinity heparin disappeared 3 
times faster than 125I-standard heparin (de Swart 1984). AT III 
heparin complexes disappear more rapidly from the plasma than free AT 
III. 125 I AT III disappears according to a double exponential curve 
with a half life in the second phase of 56.8 in the absence of heparin 
and 33. 7 hours in the presence of heparin (de Swart et al. 1984). 
Molecular weight also influences the disappearance rate of heparins. 
CY 222 an ultra low molecular weight heparin (mean Mr of 2,500 daltons) 
was cleared faster than CY 216 with a mean Mr of 4,500 daltons (Dawes 
et al. 1986). 
3. Interactions With Platelets 
Clinical complications of heparin therapy involving platelets 
include bleeding and thrombocytopenia. Two thrombocytopenic syndromes 
have been described in patients receiving heparin. The first involves 
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a transient, minor reduction in platelet count which occurs shortly 
after intravenous injection. In the second
1
case, a more severe throm-
bocytopenia occurs 5 to 9 days after the initiation of heparin therapy. 
Approximately 5% of all patients on heparin therapy may develop this 
severe type of thrombocytopenia which may be associated with arterial 
thrombosis, stroke, heart attack or death (Kelton et al. 1986). 
Low molecular weight heparins exhibit reduced platelet reac-
tivity, and have been used in clinical situations where it was desira-
ble to minimize any platelets effects which may be induced by the 
unfractionated heparin (Horellou et al. 1984). Low molecular weight 
heparins have been useful in the treatment of heparin induced throm-
bocytopenia. Appropriate laboratory tests, however, should be per-
formed before low molecular weight heparin is administered to patients 
who are suffering from thrombocytopenia in order to test for cross 
reactivity between heparin antibodies and low molecular weight heparins 
(Messmore et al. 1983). 
4. Heparin and Fibrinolysis 
Many investigators have reported that heparin and related 
substances enhance fibrinolytic activity in both animal models and 
human volunteers (Fareed et al. 1985; Arnesson et al. 1987; Paques et 
al. 1986). Increased fibrinolytic activity after the administration of 
heparin may depend upon molecular weight and degree of sulfation of the 
heparin, enzyme activation or induction of tPA synthesis. Vinazzer et 
al. (1982) determined that the activation of fibrinolysis partly 
depends on the molecular weight and degree of sulfation of the heparin. 
In a rabbit model of thrombolysis, low molecular weight heparins CY 216 
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and CY 222 were shown to have a more pronounced potentiation of the 
effects of rtPA (recombinant tissue plasminogen activator) and scUPA 
(single chain urokinase plasminogen activator) than with unfractionated 
heparin (Stassen et al. 1987). Another possible mechanism for in-
creased fibrinolytic activity in the presence of heparin involves the 
activation of factor XII and kallikrein (Fareed et al. 1985). Recent-
ly, it has been shown that heparin induces the synthesis of tPA in 
human fibroblasts in the presence of an endothelial cell growth factor 
(Rappaport et al. 1986). 
Vairel et al. (1983) have demonstrated a decrease in anti-
thrombotic activity of heparin in a rabbit model after administration 
of a fibrinolytic inhibitor, epsilon amino caproic acid. This suggests 
that some of the antithrombotic activity of heparin may be related to 
fibrinolytic effects induced by heparin. 
Low dose heparin (5000 IU) in women undergoing surgery for 
mammary hyperplasia has been shown to increase tPA antigen before and 
after venous stasis, with no differences in plasminogen activator 
inhibitor activity between groups. This suggests that the increase in 
activity may due to an increase in tPA synthesis in the endothelium 
(Arnesen et al. 1987). 
5. Lipolytic Effects of Heparin 
Besides inhibiting the coagulation process, administration of 
heparin has a marked effect on the metabolism of plasma lipids (Persson 
et al. 1985) . Heparin releases two forms of lipoprotein lipase into 
the circulation upon in vivo administration. One form of lipoprotein 
lipase is released from the liver and the release of this lipase is 
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resistant to protamine neutralization. The release of the other 
lipoprotein lipase is inhibited by protamine and catalyzes the hydroly-
sis of plasma triglycerides and induces rapid lipolysis in the blood-
stream (Krauss et al. 1974). This leads to a substantial elevation in 
the plasma level of free fatty acids and partial glycerides (Persson et 
al. 1985; Nilsson-Ehle et al. 1980). The use of low molecular weight 
heparins as antithrombotic agents is associated with lower plasma 
lipolytic activity than with standard heparin (Persson et al. 1987). 
Subcutaneous administration of 5000 anti Xa units resulted in sig-
nificantly higher anti factor Xa activity but a lower release of 
lipoprotein lipase and hepatic lipase than heparin. 
6. Toxicity of Heparins 
Acute, subacute and chronic toxicological studies of a low 
molecular weight heparin were performed by Borelli and Bertolli (1986) 
in rats. 10 mg/kg of heparin presented effects similar to those shown 
by the low molecular weight heparin (20 mg/kg). A low molecular weight 
heparin (OP/LMWH) elicited no evidence of teratogenicity when ad-
ministered by subcutaneous route during the period of organogenesis to 
pregnant rats at doses up to 10 mg/kg/day. In reproductive studies 
there were no effects on conception or pregnancy in male or female rats 
at dosages up to 10 mg/kg/day, by subcutaneous route (Bertoli and 
Borelli 1986). 
Adverse effects associated with the therapeutic use of heparin 
in man can be categorized into three groups. These are complications 
resulting from acute heparin administration, chronic heparin therapy 
and those associated with heparin neutralization. Acute complications 
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associated with heparin therapy include anaphylaxis, transient throm-
bocytopenia, arterial embolism and the most frequent complication of 
heparin therapy, hemorrhage (Gervin 1975). 
With the development of purified forms of heparin, anaphylaxis 
has become a rare complication of heparin therapy. Frequent anaphylac-
tic reactions to heparin, noted during the early period of heparin 
development, were a result of allergic responses to heparin con-
taminants rather than to the drug itself. Highly purified forms of 
heparin have decreased the incidence of anaphylaxis which now occurs in 
less than 1 % of all persons receiving heparin. However, mild broncho-
constriction, lacrimation, urticaria and rhinitis may occur in ap-
proximately 5 per cent of patients (Chernoff 1950). 
Thrombocytopenia may occur four to seven days after the initia-
tion of therapy and may be complicated by significant bleeding. 
Arterial emboli have been reported in a limited number of occurrences, 
7 to 15 days after the onset of subcutaneously or intramuscularly 
administered heparin therapy. The emboli are composed primarily of 
platelet aggregates in a fibrin matrix. These occur only in the 
arterial system and may result from heparin induced platelet aggrega-
tion (Gervin 1975). 
The most frequent complication of heparin therapy is hemorrhage 
with the incidence of hemorrhage during heparinization being from 8 to 
33%. A wide spectrum and severity of hemorrhage during heparin therapy 
may occur and may vary from mild mucosal oozing to massive intracrani-
al, intrathoracic, gastrointestinal or genitourinary bleeding (Gervin 
1975). Patients with low body weight or small stature manifest a 
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greater prolongation of in vitro clotting times than persons with an 
average size and weight (Gervin 1975). However, there is no correla-
tion between heparin dosage, prolongation of in vitro coagulation 
studies and hemorrhage. Elderly women, however, may have a 50% greater 
incidence of bleeding during heparinization than the population at 
large. 
Recent attention has been directed to the intraoperative use of 
small doses of heparin. The treatment of patients with small doses of 
subcutaneously administered heparin is called the minidose regimen for 
heparinization and consists of subcutaneous administration of 5,000 to 
10,000 IU prior to and at given intervals after surgical procedures 
(Gervin 1975). 
II. PROTAMINE 
A. History of Protamine 
Friedrick Miescher began investigations of the cell nucleus in 
1874 which led to the identification of a nitrogenous base bound to 
nuclear material of Rhine salmon sperm heads and he named this sub-
stance protamine (Miescher 1874). In 1928, Kossel classified prota-
mines into 3 groups according to the number and kinds of amino acids 
each contained. Monoprotamines contain only arginine as their basic 
amino acid. Clupeine, salmine and iridine are examples of monoprota-
mines. Diprotamines contain two kinds of basic amino acids: arginine 
plus either lysine or histidine. Cyprinine, crenilabrine and barbine 
are reported to belong to the group containing histidine and arginine. 
Triprotamines contain all three basic amino acids and include prota-
mines such as sturine (Kossel 1928). Among proteins studied at that 
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time, protamines possessed the simplest amino acid compositions and 
M.eischer and his colleagues established the fundamentals of protein 
chemistry using protamines as prototypes (Horrow 1985). 
In 1900, Thompson demonstrated that protamine possessed slight 
anticoagulant activity and speculated that if protamine was complexed 
to heparin, the activity of heparin may be prolonged in a way analogous 
to the way protamine prolongs the activity of insulin. However, the 
complexation of protamine with heparin has found other therapeutic uses 
since that time when Thompson initially speculated about the use of 
protamine with heparin. In 1938, Crafoord stated that it was not 
advisable to administer heparin earlier than 4 hours after finishing an 
operation because there may be difficulty in controlling hemorrhage in 
heparinized patients during the operation (Jorpes et al. 1939). When 
patients are treated with heparin it is sometimes desirable to neutra-
lize its activity in order to control any bleeding which may occur as a 
result of its administration. Chargraff and Olson, in 1937, demonstra-
ted that protamine may be used to neutralize the anticoagulant action 
of heparin and this use of protamine would allow the interruption of 
heparin activity at any time (Chargaff and Olson, 1937). 
B. Biosynthesis of Protamine 
Protamine is synthesized in the cytoplasm on ribosomes which are 
present in high concentration during the period of rapid protamine 
synthesis (Gatewood 1989). These ribosomes incorporate arginine very 
rapidly. Lysine incorporation on these ribosomes is very slow 
suggesting that these structures are principally engaged in protamine 
synthesis (Ling et al. 1969). Protamine appears in the nuclei at a 
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late stage of spermatogenesis and this newly synthesized protamine 
progressively replaces histones in combination with DNA. When prota-
mine synthesis begins, histone synthesis declines and eventually ceases 
(Ingles et al. 1966; Ling et al. 1969). Although his tones are 
structurally conserved, protamines differ considerably from one species 
to another (Gusse et al. 1983). The newly synthesized protamine is 
phosphorylated by adenosine triphosphate in the cytoplasm. This 
phosphorylation occurs at the hydroxyl groups of serine residues, 
considerably reduces the net charge of protamine and may alter its 
interaction with DNA (Marushige et al. 1969). 
C. Biological Function of Protamines 
Relative amounts of the protamine components (C1, C11, and C111) 
present in spermatid nuclei vary during the different stages of 
spermatogenesis. Relative amounts of C1 decrease, while C111 increase 
during testis maturation. This is probably as a result of differing 
rates of synthesis of each component. The independent synthesis of the 
individual protamine components suggests that, in spite of their 
similarities, individual protamines may have specific functions (Ling 
et al. 1971). 
There are two probable functions of protamine in the formation 
of sperm cells: (a) the clustering of DNA into the sperm head and (b) 
the total repression of gene expression in the totally differentiated 
sperm cell. It is possible that packing is the primary function of 
protamine and that repression of gene expression occurs only as a 
consequence of the packaging of DNA which makes the genome unavailable 
for transcription (Ling et al. 1971). Sequence-specific packaging 
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would suggest distinct structural and functional roles for the nucleoh-
istone and nucleoprotamine in late spermatogenesis or early development 
or both. Human sperm DNA is packaged into nucleohistone and nucleopro-
tamine in a sequence specific manner (Gatewood et al. 1988). 
In a pure system, using labelled thrombin and AT III, protamine 
inhibits the inactivation of thrombin (Cobel-Geard and Hassouna 1983). 
In clotting assays, protamine sulfate has an inhibitory effect on 
thrombin in the conversion of fibrinogen to fibrin. This inhibition is 
concentration dependent, partial anq reversible. It is postulated that 
the mode of neutralization of alpha thrombin by protamine is similar to 
the mechanism by which thrombin is inhibited by AT III with its natural 
substrate fibrinogen (Cobel-Geard and Hassouna 1983). 
D. Chemistry of Protamine 
Protamines are a mixture of simple basic proteins containing 
several components which are similar in structure and amino acid 
content. Protamines contain mostly arginine although alanine, serine, 
pro line, valine, glycine, isoleucine and threonine are present (Ando 
et al. 1973). Thes~amino acids have been isolated from the sperm of 
several mammals, including the boar, ram, rat, guinea pig, rabbit, 
mouse and human (Tobita et al. 1982). Protamines can also be prepared 
from various types of fish including herring, salmon and trout. 
The molecular weight of various protamines have been determined 
by a number of chemical methods and found to be between 4500 and 5000 
daltons (Ling et al. 1971). Therefore, protamines contain approximate-
ly 30 amino acid residues. Fractionation techniques such as counter-
current distribution and chromatography on paper, alumina or ion 
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exchange columns have revealed the presence of more than one component 
in each protamine examined (Ling et al. 1971). Heterogeneity is an 
inherent part of protamines. Differences in amino acid composition are 
often found among specimens of protamines supposed to have been 
prepared from the same species. The discrepancy most often occurs in 
the fractions of lower molecular weight. Deviations of this kind may 
be accounted for by differences in the maturity and freshness of the 
starting materials and method of isolation and purification (Ando et 
al. 1973). 
Commercially available protamine is currently prepared from 
salmon milt, consisting of secretion-laden male gonads. The ground and 
filtered milt is heated with alcohol (defatted), precipitated with 
alcohol and sodium chloride, then heated, filtered and depyrogenated. 
The dried powder, prepared by various manufacturers is packaged and 
marketed as either powder (Upjohn Company, Kalamoazoo, MI; Institut 
Choay, Paris, France) or solution (Eli Lilly and Company, Indianapolis, 
IN), (Horrow 1985). 
E. Toxicity of Protamine 
Toxicity associated with the administration of protamine sulfate 
includes: cellular derangements, complement activation, adverse 
hemodynamic reactions and anaphylaxis. High doses of protamine sulfate 
can cause mast cell and basophil degranulation with subsequent release 
of histamine (Frater et al. 1984). Protamine also can cause platelet 
agglutination and formation of platelet aggregates. Positively charged 
polymers such as polybrene and protamine could adhere to negatively 
charged platelet membrane and induce platelet aggregation by forming 
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bridges between adjacent platelets in a ca+2 independent interaction 
(Eika 1972). 
Protamine administration in experimental animals causes a mild, 
transient granulocytopenia and thrombocytopenia (Al-Mondhiry et al. 
1985;Eika et al. 1971). Protamine is toxic to rats, guinea pigs and 
mice with an intravenous LD50 of approximately 100 mg/kg. 
Injection of protamine into rabbits causes a rapid transient 
fall in platelet number with pulmonary symptoms such as transient 
coughing, increased respiration and cyanosis (Horrow 1985). Protamine 
also precipitates fibrinogen in rabbits (Eika and Godal 1971; Gans et 
al. 1966). Cardiovascular changes also occur including: hypotension, 
decrease in systemic vascular resistance, an increase in peripheral 
vascular resistance and increase in cardiac index occur after protamine 
sulfate administration (Jaques et al. 1949; Conzen et al. 1989). 
Recently it has been demonstrated that protamine inhibits 
carboxypeptidase N, the inactivator of anaphylatoxins and kinins. 
Heparin competes with carboxypeptidase N for protamine. At high 
concentrations of heparin (18 U/ml) it reverses the inhibition by 
protamine. Thus by blocking the inactivation of the mediators released 
in shock, protamine inhibition of carboxypeptidase N my be partially 
responsible for the catastrophic reaction which can occur in some 
patients (Tan et al. 1989). 
Low dose protamine pretreatment attenuates the adverse effects 
of intravenously administered protamine which is used to reverse 
heparin anticoagulation in clinical settings. Pretreatment with 
protamine compared with saline solution prevented the hypotension 
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(+6vs. -16 mmHg p.< 0.01) observed with protamine reversal of heparin. 
Protamine pretreatment lessened the thrombocytopenia found during 
reversal as compared with saline pretreatment (Wakefield et al. 1986). 
Although rare, major reactions to protamine which simulate 
anaphylaxis occur and have been associated with an allergic reaction to 
fish. Neutral protamine insulin contains protamine and it has been 
shown that the incidence of major protamine reaction was 27 % (4/15) in 
the NPH insulin dependant diabetics vs. 0.5% (3/636) in those with no 
history of NPH insulin use (Stewart et al. 1984). 
Although protamine has been shown to have in vitro anticoagulant 
effects, overdoses of protamine of as much as 800 mg/70 kg had minimal 
effects on the coagulation mechanisms of both patients and volunteers. 
These effects consisted of a slight increase in the Lee-White coagula-
tion time without a concomitant increase in the APTT (Ellison et al. 
1971). 
F. Other Agents Which Neutralize Heparin Effects 
In addition to protamine, several other agents interact with 
heparin to neutralize its activity, however, protamine is used most 
widely because it the least toxic of the other antagonists. Polybrene 
(hexadimethrine bromide) a synthetic heparin antagonist is used in 
clinical laboratories to neutralize the anticoagulant effects of 
heparin. In dogs, polybrene has been associated with reduced cardiac 
output and increased pulmonary vascular resistance. These changes are 
greater than those demonstrated with the use of protamine. Polybrene 
has been demonstrated to inhibit factor XII activation (Castenda et 
al, 1967). 
40 
Conley, in 1948, observed that patients with thrombocytopenia 
exhibited an increased sensitivity to heparin and suggested that 
platelets could antagonize the anticoagulant effect of heparin. Human 
platelets contain a heparin-neutralizing protein known as platelet 
factor 4 (PF4) which is located with other proteins in the alpha 
granules of platelets and released during platelet aggregation (Dawes 
et al. 1982). 
Protamine is superior to histones in neutralizing heparin. The 
antiheparin potency of different histone fractions shows differences 
between fractions (lysine rich histone > crude histone > arginine-rich 
histone). Poly-DL-lysine is shown to have a wider range of neutraliza-
tion than protamine (Fabian and Aronson 1980). 
Histidine rich glycoprotein also binds heparin and interferes 
with its interaction with AT III resulting in a neutralization of its 
anticoagulant activity. In purified systems, histidine rich glycopro-
tein and high affinity heparin react with apparent 1:1 stoichiometry to 
form a dissociation constant of 7 nM compared to a dissociation 
constant of 65 to 200 nM for AT III-heparin complexes (Lijnen et al. 
1983; Fabian and Aronson 1980). Another physiological heparin-neutral-
izing substance is S protein, a major inhibitor of the assembly of the 
membrane attack complex of complement. S protein, also known as 
vitronectin, effectively 
7,200. This is unlike 
neutralized oligosaccharides of Mr 2,400-
the two other physiological inhibitors of 
heparin, histidine rich glycoprotein and platelet factor 4. In 
addition, S protein/vitronectin neutralized the anti factor Xa activity 
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of a synthetic pentasaccharide comprising the antithrombin III binding 
sequence of heparin (Lane et al. 1987). 
III. fROTAMINE-HEPARIN-INTERACTIONS 
A, Molecular Aspects of Heparin-Protamine Interactions 
Many factors influence the interaction of heparin with protamine 
which include: charge type, charge density and individual molecular 
weight of a given heparin or protamine. In view of the opposite 
surface charge of protamine, the neutralization of heparin activity is 
assumed to result from intermolecular charge neutralization (Schiele 
and Heuck 1986). In general, heparin which has high anticoagulant 
activity also possesses high charge density. In addition stronger 
polycation binding is observed as the charge density of the heparin is 
increased. Degree of neutralization of heparin by protamine depends 
upon the source of heparin (Lowary et al. 1971) . Beef lung heparin 
requires more protamine sulfate than porcine mucosal heparin for 
neutralization to occur (Racanelli et al. 1989). Each mg of protamine 
sulfate neutralizes approximately 90 USP Units of heparin of beef lung 
origin or 115 USP Units of heparin derived from intestinal mucosa (The 
Upjohn Company, Kalamazoo Michigan, package insert). 
Poly-L-lysine has a greater positive charge than protamine and 
binds to heparin more strongly than does protamine. In addition poly-
1-lysine neutralizes heparin over a larger range of concentrations than 
protamine. The binding strengths of both complexes decrease as the 
degree of sulfation of the heparin participating in the complex is 
reduced. Partial N-desulfation of heparin decreases the proportion of 
binding sites with high affinity for AT III. A complex of partially N-
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d,esulfated heparin and protamine binds more weakly than corresponding 
heparin-antithrombin III complexes (Jones et al. 1986). 
Dawes and Pepper (1982) have shown that the degree of sulfation, 
position of sulfate residues and molecular weight are important 
determinants of heparin affinity for protamine. In addition, protamine 
-binds to chondroitin-4-sulfate with greater affinity than chondroitin-
6-sulfate. These two chondroitin sulfates differ only by the position 
of sulfate substitution. Higher molecular weight glycosaminoglycans 
bind with lower affinity to protamine than the lower molecular weight 
glycosaminoglycans (Dawes and Pepper 1982). 
'Whether protamine binds to heparin to form an equimolar complex 
or a ternary complex has not yet been determined. Using 1251 heparin 
and chromatographic techniques, Dawes and Pepper (1982) speculated that 
each molecule of protamine binds one molecule of glycosaminoglycan 
irrespective of molecular weight. A heparin poly-L-lysine complex is 
formed by the nonstoichiometric binding of poly-L-lysine around a rigid 
heparin molecule. Jones et al. (1986) using fluorescence techniques 
have determined that the heparin protamine complex is probably a large 
cross linked stoichiometric structure. In vitro 1 mg protamine totally 
bound 1 mg of heparins as determined by HPLC, after the heparin-
protamine complex was sedimented by centrifugation (Huang 1989). 
I. In Vitro Interactions of Protamine and Heparin 
Many in vitro experiments have been performed in order to 
elucidate the mechanism of the neutralization of heparin by protamine. 
Protamine sulfate binds to heparin and (1) either prevents the form-
etion of the heparin AT III complex or (2) disrupts the activated 
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heparin-AT III complex (Hubbard and Jennings 1985). Neutralization of 
heparin in plasma by protamine represents an equilibrium reaction in 
which an excess of protamine is necessary to maintain heparin protamine 
complexes. If this excess is lost, through metabolism by a naturally 
occurring protaminase the complexes dissociate so that immediate 
antithrombin activity is reestablished (Shanberge et al. 1987). 
Okajima et al. (1981) have demonstrated that protamine dissociates 
heparin-AT III complexes by means of binding to heparin. In vitro, 
when protamine sulfate is added to heparinized human plasma, the 
activated heparin-antithrombin Ill complex is broken. AT Ill is freed 
and able to reestablish its original slow antithrombin activity. In 
neutralized plasma, antithrombin Ill exists in its native state and can 
be reactivated by any free heparin to become a potent inhibitor of 
factor Xa and factor Ila (Kitani et al. 1980). 
Conventional heparin is neutralized more effectively in vitro by 
protamine than is low molecular weight heparin (Racanelli et al. 1985; 
Gram et al. 1988). Protamine chloride inhibited the clot based 
antifactor Xa activity 95% for conventional heparin and only 55% for 
low molecular weight heparin, while thrombin inhibition was completely 
neutralized. At equigravimetric concentrations of a low molecular 
weight heparin fragment and protamine, only 25% of the antifactor Xa 
activity was neutralizable by protamine sulfate. Protamine neutraliz-
ation is not related to the anticoagulant potency of heparins. At 
concentrations of unfractionated heparin (0 .17 µg), heparan sulfate 
(0.6 µg), or low molecular weight heparin (1.65 µg) which prolonged the 
APTT to a similar degree; low molecular weight heparin required more 
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protamine sulfate by weight than unfractionated heparin for complete 
neutralization of APTT activity. Neutralization of the anti Xa 
activity of unfractionated heparin required 4 µg of protamine sulfate 
to neutralize 1 µg of unfractionated heparin. 12 µg of protamine 
sulfate was required to completely neutralize the anti Xa activity of 1 
µg of low molecular weight heparin (Hubbard and Jennings 1985). 
Two hypotheses have been proposed to explain the different 
behavior of protamine with regard to heparin and low molecular weight 
heparin. This differential interaction may be could be related to the 
size of the anticoagulant molecule. Either protamine sulfate can bind 
to a long chain more easily or low molecular weight heparin induces the 
generation of protamine-resistant anti Xa activity in vivo (Thomas 
1984). 
Nonspecific interactions between protamine sulfate and plasma 
proteins such as PF4 and histidine rich glycoprotein inhibit the 
binding of protamine sulfate to heparins (Lane et al. 1987). There-
fore, more protamine sulfate is required to neutralize heparin activity 
in a plasma system as compared to a purified system. Unfractionated 
heparin, heparan sulfate and low molecular weight heparins were all 
neutralized completely by 4 µg protamine sulfate for every 1 µg 
glycosaminoglycan when the antifactor Xa clotting assay was carried out 
using purified AT III in the absence of plasma. 
Platelet factor 4, released from platelet granules, neutralizes 
the in vitro activity of heparin in a similar manner to protamine 
•ulfate. 0.8 U/ml of heparin was totally neutralized by 15 µg/ml of 
Platelet factor 4 and by 16 µg/ml of protamine sulfate in vitro. In 
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C)ther studies, 1. 0 U of heparin was neutralized by PF4 or protamine 
(lS-20 µg/ml). This represents a 2: 1 (protamine :heparin) ratio as 
aeasured by the kaolin cephalin clotting time, the thrombin clotting 
time, and modified Yin Wessler antifactor Xa clotting assays (Michalski 
et al. 1978). However, complexes formed between heparin and either 
platelet factor 4 or protamine are not equivalent. When heparinized 
plasma is treated with an excess of platelet factor 4, in contrast to 
protamine no large platelet factor 4-heparin-complexes form which are 
able to activate AT III (Shanberge et al. 1987). 
The action of protamine and platelet factor 4 is complimentary. 
Vben a neutralizing dose of protamine was added to plasma supplemented 
with platelet factor 4 and heparin, the protamine displaced the 
platelet factor 4 from its complexes with heparin (Shanberge et al. 
1987). This phenomenon has also been observed in rabbits by Cella et 
al. (1987) and may have clinical significance. Platelet factor 4 may 
stabilize heparin-protamine complexes even if excess of protamine no 
longer remains, since platelet factor 4 is not broken down in plasma as 
protamine is (Shanberge et al. 1987). The amount of protamine needed 
to neutralize heparin following extracorporeal bypass procedures may be 
less when large amounts of platelet factor 4 are released. 
In vitro heparinized plasmas are readily neutralizable by 
protamine and PF4 in all assay systems. However neutralization of~ 
~ heparinized plasmas are dependant upon the assay used to determine 
heparin activity. Ex vivo antifactor Xa activity differs from in vitro 
anti factor Xa activity. Only 1/2 of the antifactor Xa activity of 
injected heparin could be neutralized, even heparin (0. 68 U/ml is 
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approximately 4. 5 g/ml) obtained ~ vivo was not completely neutra-
lized by 320 µg/ml platelet factor 4. In addition only 50% of this 
heparin activity could be removed using a column of ECTEOIA-cellulose 
(Michalski et al. 1978). A possible explanation for the lack of 
neutralization of the anti Xa activity of injected heparin could be 
that heparin administered intravenously binds tightly to AT III while 
still retaining anti Xa activity or that intravenous injection of 
heparin releases cellular or intravascular components that interact 
with the anti Xa assay but not with other assays (Michalski et al. 
1978). Hubbard and Jennings have speculated that heparan sulfate may 
be released upon heparin administration and that these glycosaminogly-
cans may be less neutralizeable by protamine sulfate (Hubbard and 
Jennings 1985). 
C. In Vivo Interactions of Protamine and Heparin 
Many animal models have been used to study the bleeding, anti-
thrombotic effects and endogenous cellular interactions after neutrali-
zation of heparins by protamine. It has been demonstrated that 
protamine neutralizes the anti protease, anti thrombotic and antihemo-
static effects of heparin to different degrees (Diness and Ostergaard 
1986). In a rat tail bleeding model and vena caval ligation model, 
APTT and antifactor Xa, hemorrhagic and antithrombotic effects of 
heparin were completely neutralized at equigravimetric dosages of 
protamine sulfate (3 mg/kg i. v.). Equivalent doses with respect to 
antithrombotic potency of heparin and a low molecular weight heparin 
(LHN-1) was administered to rats. The hemorraghic effect of a large 
dose of LHN-1 in this experimental model was efficiently counteracted 
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by protamine sulfate, however higher doses of protamine sulfate were 
required to neutralize the anti thrombotic effects. The hemorrhagic 
effects were neutralized even though some~ vivo activities were still 
present (Diness and Ostergaard 1986). 
Similar results have been reported by Doutremepuich et al. 
(1985) and Racanelli et al. (1988) using low molecular weight heparin 
CY 216 in rabbits. Protamine did not neutralize all the biologic 
effects of CY 216, but completely neutralized the bleeding time when 
protamine was administered in the ratio of 1 antiheparin U to 2 IC anti 
Xa U of CY 216 (Doutremepuich et al. 1985). 
Dogs have also been used to study whether total reversal of 
heparin immediately after endarterectomy has an adverse effect on the 
thrombogenicity of the endarectomized vessel wall (Chandler et al. 
1982). Scanning electron microscopy revealed nearly total coverage of 
exposed collagen of the media with flattened platelets, scattered 
leukocytes, little fibrin and no thrombi. No differences were seen 
between those dogs which received protamine reversal and those which 
did not. Therefore total reversal of heparin does not increase the 
thrombogenicity of endartectomized vessels (Chandler et al. 1982). 
It has been demonstrated in dogs that protamine neutralization 
of low molecular weight heparin causes less thrombocytopenia as 
compared to protamine neutralized heparin although neutropenia occurred 
equally in both groups . No differences were seen in eicosanoid or 
complement factors after protamine reversal of unfractionated heparin 
as compared to low molecular weight heparin (Lindblad et al. 1987). 
Protamine did not reverse the elevated antifactor Xa levels in low 
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aolecular weight heparin anticoagulated dogs to the same degree as 
unfractionated heparin. 
D. Igxicity of Heparin-Protamine Complexes 
The cardiovascular changes which occur after protamine ad-
ministration are dependant upon the route of administration and whether 
tbe heparin-protamine complex is formed before the protamine reaches 
the lungs. Plasma histamine levels were significantly higher after 
right atrial injection. Histamine is released as protamine traverses 
the lungs following right atrial injection and produces peripheral 
vasodilation. Histamine has been shown to have an H2 receptor-mediated 
positive inotropic effect in man. It may be possible that protamine 
degranulates mast cells directly while protamine-heparin complexes do 
not. Heparin-protamine complexes may be involved in complement 
activation (Frater et al. 1982). 
The administration of heparin followed by protamine results in a 
more severe cytopenia than protamine administration alone which lasts 
30 to over 60 minutes. 1251- labelled protamine in the presence of 
heparin binds tightly to platelets and granulocytes. Sequestration of 
the coated cells in the lungs results in transient granulocytopenia and 
thrombocytopenia (Al-Mondirhy, 1985). 
A decrease in f ibrinogen concentration has also been observed 
during cardiopulmonary bypass. Although the initial decline occurs 
during the first five minutes of cardiac bypass, another drop in 
fibrinogen concentration is always observed immediately after heparin 
neutralization (Gans et al. 1966). Cardiopulmonary bypass procedures 
often result in significant thrombocytopenia. Further decrease of the 
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platelets due to protamine could pose a serious threat in the immediate 
postoperative period (Al-Mondirhy 1985). 
Dose dependant activation of the complement system by heparin-
protamine complexes has been shown in man. A significant increase in 
activated components of the complement system (C3d, C3a, C4a and C4d) 
were obtained in patients after the administration of protamine sulfate 
(Best et al. 1984; Kirklin et al. 1986). Peak levels of C3a and C4a 
were seen in samples taken 10 minutes after protamine administration. 
C4d peak levels were obtained at 5 hours. The level of C3a, 3 hours 
after cardiopulmonary bypass with protamine administration has been 
shown to be a risk factor for postoperative morbidity (Kirklin et al. 
1986). Protamine acts as a substrate for C reactive protein, a potent 
activator of the complement system at Cl (Frater et al. 1984). Also 
activation of the classic complement pathway occurs by protamine-
heparin polycation-polyanion. complexes. In vitro combination of 
protamine sulfate and heparin, but neither heparin nor protamine alone 
resulted in a increase in C3a and C4a levels (Kirklin et al. 1986). 
Activation of complement may cause an increase in vascular permeability 
and could contribute to the pathogenesis of noncardiogenic pulmonary 
edema (Best et al. 1984). 
Adverse reactions which occur after the administration of 
protamine include:hypotension, anaphylactoid responses and catastrophic 
pulmonary vasoconstriction. Rapid administration of protamine results 
in pulmonary vasoconstriction. Rapid administration of protamine 
results in systemic hypotension in most patients (Horrow 1985), however 
Coulon et al. (1982) speculate that even a small dose of protamine 
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sulfate will change systolic blood pressure. Anaphylactoid responses 
to protamine are characterized by edema of the skin, mucosa, viscera 
decreased systemic vascular resistance and bronchospasm (Horrow 1985). 
Antihistamines, aminophylline and steroids are employed in the treat-
ment of anaphylactic reactions after protamine administration (Stoelti-
ng 1983). Catastrophic pulmonary vasoconstriction (type III) is 
accompanied by right ventricular dilation, pulmonary arterial hyperten-
sion, decreased left ventricular filling pressure and systemic hyper-
tension, decreased left ventricular filling pressure and systemic 
hypotension. This syndrome has occurred after minimal doses of 
protamine (10 mg) and may resolve spontaneously (Horrow 1985). 
Treatment with isoproterenol or epinephrine has been successful in the 
reversal of these effects (Lowenstein et al. 1983). 
IV. CLINICAL IMPLICATIONS OF PROTAMINE NEUTRALIZATION OF HEPARINS 
A. Protamine Neutralization of Heparin in Patients 
Reversal of the anticoagulant activity of heparin has con-
tributed significantly to the field of cardiovascular surgery. 
Monitoring of a patient's state of anticoagulation during this proced-
ure is crucial (Bull et al. 1975) since the amount of heparin required 
to produce an arbitrary prolongation in clotting times has been shown 
to vary 3 fold from patient to patient and the rapidity with which the 
administered heparin dose disappears from the blood may vary fourfold. 
76% of patients receiving common doses of heparin during cardiopul-
monary bypass were found to have plasma heparin levels that were 
potentially too low (<1.7 U/ml; recommended level is 2 U/ml), (Umlas et 
al. 1983). 
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During cardiopulmonary bypass, high doses of heparin ( 3 mg/kg 
i. v.) are used to prevent thrombosis in patients amd to prevent clot 
formation within the heart lung machine (Shanberge et al. 1986). Since 
such high doses of heparin are used which result in hemorrhage, 
neutralization by protamine sulfate is necessary. 
Many different protocols have been used for the protamine 
neutralizaton of heparin activity by protamine after cardiopulmonary 
bypass. Some of these protocols are based on arbitrary amounts of 
protamine to neutralize a given amount of heparin while others are 
calculated from known heparin-protamine interactions. The inability to 
measure heparin levels accurately and rapidly has prevented the 
accurate prediction of the minimum dosages necessary to reverse heparin 
(Umlas et al. 1983). 
Reversal of heparin in patients has been shown to follow the 
same .in vitro pattern of dissociation of the neutralization of the anti 
Xa and anti Ila activities were observed in vitro (Racanelli et al. 
1985) Incomplete neutralization of the lipoprotein lipase, hepatic 
triglyceride lipase and factor Xa activities of a low molecular weight 
heparin by protamine chloride has been shown in patients (Harenberg et 
al. 1985). Similarly, after the administration of protamine chloride 
to patients who received either (7,500 or 18,750) anti Xa units of CY 
216, the inhibition of factor Xa was reduced to approximately 40 % 
inhibition. Similar results were obtained with a different low 
molecular weight heparin of similar molecular weight range. Therefore 
the molecular weight range of a low molecular weight heparin seems to 
be a more important determinant for protamine neutralization than the 
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J1ethod of preparation of the heparin (Harenberg et al. 1986). In 
n.tI-2• anti Xa and anti Ila activities and APTT activity of unfrac-
tionated heparin were neutralized with a gravimetric protamine:heparin 
ratio of 1.6 to 1, 1.3 to 1 and 2 to 1 respectively. Anti Ila and APTT 
activity induced by a low molecular weight heparin PK 10169 returned to 
baseline completely at a protamine: heparin ratio of 1 and 2 respec-
tively while anti Xa activity was not completely neutralized at a 
gravimetric protamine: heparin ratio of S to 1. 
Since the direct cause of blood loss is not always easy to 
determine, abnormal bleeding during or after cardiopulmonary bypass has 
been a serious problem. Residual heparin (due to an inadequate 
neutralizing dose of protamine), anticoagulation induced by excessive 
protamine, thrombocytopenia and a variety of other conditions such as 
disseminated intravascular coagulation, platelet dysfunction and 
fibrinolysis have all been postulated as causes for abnormal bleeding 
in patients undergoing cardiopulmonary bypass (Umlas et al. 1983). 
Bleeding times have been reported to be prolonged in patients 
after administration of unfractionated heparin and CY 216. Heparins 
may interact with platelets at the surface of the vessel wall by some 
unknown mechanism and thereby cause bleeding (Harenberg et al. 1986). A 
platelet effect is suspected to prolong the bleeding time since 
substances which influence platelet function prolong this test whereas 
Vitamin K antagonists such as coumadin have no effect of bleeding time 
(Harenberg et al. 1986). 
In a study by Massanet-Castel (1986) patients which were treated 
prophylactically with heparin, exhibited normal or only slightly 
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increased bleeding. In 3 patients given protamine because of hemor-
rhage, mean anti Xa and anti Ila levels were 2.3 an 0.54 U/ml respec-
tively before and 1.32-0.06 U/ml respectively after neutralization. A 
correlation between bleeding, anti Xa and anti Ila activities was not 
clearly evident. The dose of protamine which was used to neutralize 
low molecular weight heparin PK 10169 was 2 mg for every 1 mg of PK 
10169 as compared to 1. 3 mg of protamine for every 1 mg of unfrac-
donated heparin. 'Whether the difficulty in reversing the anti Xa 
activity constitutes a clinical drawback for the use of low molecular 
weight heparins remains to be seen (Massonet-Castel et al. 1986). 
B. Heparin Rebound 
In 1956, Kolff et al. first described heparin rebound as a 
"treacherous phenomenon in which heparin is neutralized by protamine 
sulfate and the clotting time becomes normal in a matter of minutes. 
However protamine seems to be eliminated from the blood before heparin 
is, thus leaving the heparin uncovered as demonstrated by protamine" 
(Ellison et al. 1974). Heparin rebound is defined as the reappearance 
of hypocoagulability after adequate neutralization (Pifarre et al. 
1981) which is restored to normal by further protamine administration 
(Gollub et al. 1967). Protamine neutralization of the heparin activa-
tion of antithrombin III in plasma, in vitro, represents an equilibrium 
reaction in which by mass action, heparin remains complexed only in the 
presence of an excess of protamine (Kitani et al. 1980). 
Many possible explanations have been suggested for the rebound 
of anticoagulant activity after protamine administration which include: 
heparin may be released by red blood cell breakdown, heparin may escape 
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from the circulation into the extravascular space and return via the 
lymphatics and thoracic duct to the circulation many hours after 
protamine has been administered and cleared. Heparin rebound may be 
more commonly observed with hypothermia, since hypothermia during 
cardiopulmonary procedures procedure produces a decrease in the 
elimination of heparin which may contribute to the phenomenon of 
heparin rebound (Cohen et al. 1977). 
The whole blood activated clotting time is widely used to 
monitor heparin anticoagulation during cardiopulmonary bypass and to 
predict the neutralizing dose of protamine sulfate (Piffare et al. 
1981). Recent reports suggest that this assay system may not give a 
true reflection of the plasma heparin levels and may give inaccurate 
predictions of the required protamine dose (Esposito et al. 1983). The 
accurate diagnosis of heparin induced bleeding is difficult to deter-
mine and it is not uncommon to empirically administer additional doses 
of protamine in the face of post bypass bleeding, especially if the 
APTT is prolonged (Ellison et al. 1974). 
Postoperative heparin rebound was investigated in 50 patients 
undergoing cardiopulmonary bypass who received 2 mg/kg of heparin 
preoperatively. The overall mean ratio of protamine to heparin 
administered was 1.25:1. One hour after heparin was completely 
neutralized, 26 patients (52%) had circulating heparin and required an 
additional dose of protamine averaging 70 mg (Piffarre et al. 1981). 
In another clinical situation, heparin rebound was observed in 29% of 
cases which correlated with circulating load (i.u. x 103) of heparin 
administered. The ratio of protamine sulfate to circulating load of 
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heparin was lower than 1.6 in all cases which exhibited rebound 
(Kesteven et al. 1986). In another study, 20 out of 40 patients 
exhibited heparin rebound (Gollub 1967). 
The occurrence of heparin rebound depends upon the ratio of 
protamine to heparin. Low incidence of heparin rebound was reported in 
- patients who received an excess of protamine after cardiopulmonary 
bypass as compared to those who received the minimum amount as deter-
mined by titration methods (Shanberge et al. 1986). In another study 
(Ellison et al. 1974), every patient who received the minimal dose of 
protamine exhibited, rebound phenomenon at some time between one and 
five hours after neutralization. In three cases rebound was associated 
with clinical bleeding which necessitated additional protamine. In 
contrast none of the patients who received a larger dose of protamine 
exhibited rebound (Gollub 1967). He suggested that patients be given 
the dose of protamine that is indicated by titration plus an additional 
10 mg of protamine per liter of blood volume (usually 50 mg of ad-
ditional protamine). Using this regimen, there was no danger of excess 
protamine administration and there was a noticeable decrease in the 
incidence and magnitude of heparin rebound in this study. 
Other factors which may cause heparin rebound include increased 
heparin binding to plasma proteins, the specific anion bound to 
protamine and the length of the bypass procedure. Heparin bound to 
other proteins such as alpha2 macroglobulin may be able to activate any 
fresh antithrombin III produced by the patient or administered through 
infusion of blood or plasma (Shanberge and Sridhar 1981). Protamine 
sulfate inactivates those heparin fractions that are bound to AT III 
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but not those bound to alpha2 macroglobulin. The stability of prota-
mine derivatives is not influenced by the specific anion which is 
bound to them. But rather, differences are acquired in the course of 
the manufacturing procedure involved in their preparation which 
influence the stability of the protamine preparation. Commercial 
protamine chloride is stable in the presence of plasma enzymes, whereas 
the sulfate is degraded (Benayahu and Aronson 1983). Heparin rebound 
could be reproduced with the sulfate but not with the chloride anion. 
The length of cardiopulmonary bypass influences the amount of protamine 
required postoperatively (Pifarre et al. 1981). 
In vitro heparin is neutralized at a gravimetric ratio of 1:1; 
therefore in vitro studies may seriously underestimate the required 
dose of protamine sulfate following surgery (Shanberge et al. 1986). 
In clinical situations 1.3 mg of protamine is used to neutralize 100 U 
of heparin (Massonnet-Castel et al. 1986). Other investigators have 
questioned the necessity of protamine reversal of heparin following 
bypass surgery, (Castenda et al. 1967). It may be advantageous to 
prolong the period of heparinization of the patient into the early 
postoperative period, if bleeding is not profuse. 
C. Clinical Trials With Low Molecular Weight Heparins 
Over the last decade, there has been a considerable amount of 
interest in the clinical use of low molecular weight heparin (Messmore 
et al. 1985). Low molecular weight heparins have been studied in 
randomized clinical trials to evaluate their effectiveness as well as 
the risk/benefit ratio of their routine use in postoperative prevention 
of deep venous thrombosis and pulmonary embolism (Samama et al. 1989). 
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several clinical studies have been conducted in which a low 
molecular weight heparin has been compared with standard unfractionated 
heparin following general and orthopedic surgery and in general 
medicine. Studies have also been performed in which low molecular 
weight heparins were compared to a placebo. A low molecular weight 
heparin, FragminR was studied in patients undergoing general surgery by 
Bergvist et al. (1986). Low rates of thrombosis were found in both 
treatment groups, 6% versus 4 % and no statistical significance between 
the drugs was observed. In a trial by Kakaar (1985), using the low 
molecular weight heparin, FraxiparineR, there was a statistically 
significant reduction in postoperative venous thrombosis in patients 
who received FraxiparineR. Similarly, in a study by Encke and Breddin 
(1988) where control groups received heparin 5000 U twice or three 
times daily, a significant difference was observed which supported the 
greater efficacy of FraxiparineR. In other studies by Koller et al. 
(1986) and Schmitz-Huebner et al. (1984) thrombosis rates were low in 
both groups however no statistical significance between groups was 
observed. 
Studies have shown that fixed-dose subcutaneous heparin ad-
ministration is partially effective in the prevention of deep vein 
thrombosis after total hip replacement surgery (Bergvist et al. 1980) 
and adjusted low-dose heparin administration leads to significant 
improvement (Leyvraz et al. 1983). It was the ref ore important to 
determine if low molecular weight heparins would be more useful during 
orthopedic surgery than heparin. In studies of patients undergoing hip 
surgery, the incidence of thrombosis was substantially reduced by low 
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aolecular weight heparin, EnoxaparinR, from 42 % to 12 % as compared to 
placebo (Turpie et al. 1986). These results may be compared with those 
obtained after a single injection of 40 mg of EnoxaparinR to patients 
undergoing hip surgery in a double blind study. The frequency of 
thrombosis as assessed by phlebography was significantly lower with low 
aolecular weight heparin than with three injections of 5000 IU of 
heparin (Planes et al. 1988). 
Prophylactic heparin is often used in hospitalized medical 
patients at high risk for thromboembolism. Two hundred seventy 
patients confined to bed rest and over 65 years of age were studied in 
a randomized double-blind trial (Dahan et al. 1986) comparing 60 mg of 
BnoxaparinR to a placebo over a 10-day period. EnoxaparinR produced a 
atatistically significant (p<. 05) reduction in isotopically detectable 
venous thrombosis (3% versus 9%). Twelve patients died during the 
trial (six in each group) and autopsy revealed three fatal recent 
pulmonary embolism in the placebo group and one in the treated group 
(Samama et al. 1989). 
The incidence of bleeding varied markedly in the clinical trials 
of low molecular weight heparins. This variation may be due to 
differences in the criteria used to define clinical important bleeding 
and also was dependant on the doses selected for the studies. In three 
out of five studies, the incidence of bleeding was significantly 
greater in the low molecular weight heparin group than in the unfrac-
tionated heparin group (Bergvist et al. 1986; Koller et al. 1986; 
Schmitz-Huebner et al. 1984). In the study reported by Koller, in 
1986, there was a 48 % rate of bleeding in 23 patients who received 
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FragminR compared to a 10 % rate in patients who received unfrac-
tionated heparin. This trial was terminated because of excess hemor-
rhage in the experimental group. The incidence of bleeding was low for 
clinical trial of 0RG 10172 heparinoid and for FraxiparineR. There was 
8 2 % rate of bleeding as compared to a 4 % rate for placebo. Kakaar 
(1985) reported a 5 % rate of bleeding in patients undergoing abdominal 
surgery who received FraxiparineR compared to a bleeding rate of 3.5 % 
in patients who received unfractionated heparin. A correlation (r-.54) 
between~ vivo anti Xa levels produced by low molecular weight heparin 
and clinically important bleeding was reported. 
Low molecular weight heparin EnoxaparinR has been studied in 15 
patients who underwent surgery with extracorporeal circulation which 
required reversal by protamine sulfate (Massonnet-Castel et al. 1986). 
ln vitro, anti Xa and anti Ila activities and APTT activities of 
heparin were neutralized by a protamine:heparin ratio of 1.6, 1.33 and 
2 respectively. Anti Ila activity and APTT induced by EnoxaparinR were 
completely neutralized a protamine to heparin ratio of 1 and 2 respec-
tively, while anti Xa activity was incompletely neutralized at a ratio 
of 5. In patients which did not receive protamine a good correlation 
was observed between doses of EnoxaparinR infused, anti Ila plasma 
levels and blood loss. In patients who received protamine because of 
hemorrhage, bleeding was stopped, however a poor correlation between 
bleeding, anti Xa or anti Ila activities was observed (Massonnet-Castel 
1986). 
CHAPTER II 
STATEMENT OF PURPOSE 
Protamine neutralization of the hemorrhagic effects of heparin has 
contributed to the widespread therapeutic acceptance of heparin. The 
routine use of heparin during surgical procedures such as cardiopulmonary 
bypass could not have been possible without the use of protamine as an 
antagonist. Although protamine has been used for decades to antagonize 
the bleeding effects of heparin, the biochemical and pharmacologic aspects 
of this interaction are still not completely understood. In addition, 
heparin protamine complexes are known to exert a variety of toxic effects 
which are not fully investigated at this time. Furthermore, with the 
development and increased clinical use of low molecular weight heparins, 
it is important to better characterize the interaction of protamine with 
heparins. 
Although protamine is administered primarily to neutralize the 
bleeding effects of heparin, this antagonist also influences several other 
activities of heparin. In addition, protamine has been shown to prolong 
clotting tests (Gans 1962), produce thrombocytopenia (Al-Mondhiry 1985), 
accelerate fibrin monomer polymerization and inhibit thrombin (Cobel-Geard 
1983). Since administration of protamine alone exerts effects on the 
hemostatic system, the study of the neutralization of heparin activity by 
protamine becomes complicated. It is the purpose of this dissertation to 
compare the protamine neutralization of heparin and a well characterized 
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low molecular weight heparin (CY 216), in terms of their anticoagulant, 
antiprotease, antithrombotic and pharmacodynamic actions. 
These studies provide integrated data on the differences between 
the neutralization profiles of heparin and a low molecular weight heparin 
(CY 216). Such information is needed to optimize the use of protamine 
especially for the neutralization of low molecular weight heparins. A 
better understanding of protamine-heparin interactions as investigated in 
this study may lead to safer use of these agents. 
A series of in vitro assays used to study the protamine 
neutralization of the heparins included global clotting assays and 
specific chromogenic substrate based assays. Use of these assays allowed 
for an integrated approach to profile the potency, sites of action and 
degree of neutralization of these heparins by protamine. 
Thrombosis involves a disruption of the delicate balance between 
blood vessels, platelets and coagulation factors. To address this area, 
two defined models of thrombosis, a modified version of the classical 
Wessler stasis thrombosis model (Wessler 1974) and a laser-induced model 
of thrombosis as developed by Breddin (1982) were used. Pharmacologically 
defined studies were carried out to approximate the current clinical use 
of heparins and focus on the antagonism of the antithrombotic effects of 
heparins by protamine. 
Since hemorrhage also is a multifactorial process involving many 
hemostatic components, two animal models of blood loss which have been 
Widely utilized in the study of heparins and other anticoagulant drugs, 
were used to study the antagonism of heparin and CY 216 by protamine. The 
relevance of ex vivo anticoagulant and antiprotease activities to the 
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observed blood loss and its antagonism was extensively addressed in this 
investigation. 
The pharmacodynamic time course parameters of both heparin and CY 
216 prior to and after the administration of protamine were determined 
utilizing an established pharmacokinetic model. A unique feature of this 
study is the use of a nonhuman primate (maccaca mulatta) model whose 
hemostatic profile has been found to approximate the human hemostatic 
system (King 1989). Intravenous and subcutaneous pharmacodynamic studies 
provided timely information on whether protamine alters the time course 
parameters of heparin or CY 216 and whether the observed protamine 
neutralization of heparin and CY 216 was assay dependent. This 
information is of crucial importance in the understanding of heparin 
rebound. This study also represents the first comprehensive approach to 
establish the differences in the in vitro protamine neutralization 
profiles and pharmacologic behavior of heparin and a low molecular weight 
heparin. 
The biochemical and pharmacologic experiments included in this 
investigation have been used as model systems to investigate the 
interactions of heparin with protamine. This dissertation thus emphasizes 
the need of an integrated approach to obtain crucial pharmacologic data 
on the interactions of polycomponent drugs. This may have a direct impact 
on the clinical management of patients administered heparin and protamine. 
CHAPTER III 
MATERIALS AND METHODS 
I. MATERIALS 
A. Antithrombotic Drugs 
1. Heparin 
Porcine mucosal heparin (lot H503) was obtained from Choay 
Institute (Paris, France). The mean molecular weight of heparin as 
determined by a computerized gel permeation chromatographic system was 
11,000 dal tons. The anticoagulant potency of this heparin is 165 
IU/mg. The analytical and molecular weight profiles of heparin (lot H 
503) are shown in Appendices II and III respectively. 
2. Low Molecular Weight Heparin 
CY 216 (lot P 533 XH), a low molecular weight heparin, produced 
from porcine mucosal heparin by nitrous acid depolymerization was 
obtained from Choay Institute (Paris, France). This low molecular 
weight heparin has a mean molecular weight of 5,000 daltons and is 
characterized by a narrower molecular weight distribution than heparin. 
Eighty per cent of the chains of CY 216 have a molecular weight within 
the range of 2,400-7,200 daltons which corresponds to 4 to 12 disac-
charide units. Dodeca-, tetradeca-,and hexadecasaccharidic chains 
account for 50% of the molecular species composing CY 216. In addition 
25% of the chains contain a specific pentasaccharide sequence that 
enables them to bind to AT III with high affinity (Lormeau 1989). The 
potency of CY 216 is 226 IC AXa U/mg and 58 USP U/mg. The analytical 
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and molelcular weight profiles of CY 216 (lot P 533 XH) are shown in 
Appendices IV and V respectively. 
B. frotamine Sulfate 
Protamine sulfate obtained from Choay Institute was produced from 
salmon sperm and contains 138 UAH/mg. The mean molecular weight of 
this protamine as determined by HPLC is 4,000 daltons. The analytical 
and molecular weight profiles of protamine sulfate are shown in 
Appendix VI and VII respectively. 
c. Spermidine 
Spermidine (N-(3-aminopropyl)-1,4-butanediamine) was purchased 
from Sigma Chemical Co. (St. Louis MO). 
D. Reagents 
All reagents obtained for use in the assays were of analytical 
grade. All drugs and reagents used in the studies were stored in 
desiccated storage containers at appropriate temperatures. 
1. Clotting Assays 
Automated APTT, a rabbit brain phospholipid reagent containing 
micronized silica as an activator, was obtained from General Diagnos-
tics (Morris Plains, NJ) in lyophilized form and reconstituted with 
distilled water according to manufacturer's instructions. 
FibrindexR human thrombin was purchased from Ortho Diagnostic 
Systems, Inc. (Raritan NJ) in lyophilized form and was reconstituted 
with saline to obtain a 5 NIH U/ml solution. The thrombin solutions 
were adjusted using normal human plasma to give a 20.0 ± 2.0 second 
clotting time using the thrombin time assay. Aliquots of thrombin were 
frozen at -70°c for periods of not more than 6 weeks. 
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HeptestR reagents were obtained from Haemachem (St. Louis, MO) 
and included bovine factor Xa and RecalmixR. This reagent contains 
optimal concentrations of calcium chloride and brain cephalin in a 
bovine plasma fraction. The reagents were obtained in lyophilized form 
and reconstituted according to manufacturer's instructions. 
2. Amidolytic Assays 
Reagents used for amidolytic anti Xa and amidolytic anti Ila 
assays include: 
Buffer consisting of O. 050 M Tris (hydroxymethyl aminomethane, 
TrizmaR HCL,;Sigma Chemical Co., St. Louis, MO) 0.175 M sodium chloride 
(Sigma Chemical Co.), and 0.0075 M EDTA (Sigma Chemical Co.) were 
prepared at pH 8.4 at room temperature. 
Bovine Factor Xs! was obtained from Enzyme Research Laboratories 
(South Bend, IN) in lyophilized form. This preparation was recon-
stituted in 1.0 ml Tris buffer, diluted 1:4 in saline and stored at-
700c for periods up to 6 weeks. Factor Xa was calibrated for the anti 
Xa amidolytic assay by adjusting the above solution to produce a change 
of 0.600 to 0.700 mau (maximal activity unit)/minute in the assay blank 
at 405 nm. 
Stock solutions (10 NIH U/ml) of FibrindexR human thrombin were 
reconstituted with saline and stored at -70°c. A working solution of 
thrombin was calibrated for the anti Ila amidolytic assay by adjusting 
a 10. 0 NIH U/ml solution to produce a change of O. 600 to O. 700 mau 
(maximal activity unit)/minute in the assay blank at 405 nm. 
Chromogenic substrates used in the amidolytic assays were 
purchased from American Diagnostica (Greenwich, CT). Spectrozyme xaR 
66 
cca3ocDHG-Gly-Arg-pNA) was reconstituted with distilled water to obtain 
a final concentration of 2.5 mM and was used in the amidolytic anti Xa 
assay. Spectrozyme THR (HDCT-Ala-Arg-pNA) was reconstituted with 
distilled water to obtain a final concentration of 1.0 mM and was used 
in the amidolytic anti Ila assay. 
3. Pooled Plasma Preparations 
For the in vitro studies, human plasma was obtained from the 
Loyola University Medical Center Blood Bank. All plasma preparations 
were screened for the presence of HIV (Abbott Laboratories, Chicago, 
IL) and hepatitis B virus (Abbott Laboratories, Chicago, IL) and found 
to be negative. The fresh frozen plasma packs obtained from 5 donors 
were thawed at 37° C, pooled (lot numbers for pool I: 1190423, 1190468, 
1190464, 1190322, 1190469, lot numbers for pool II: 1317061, 1192592, 
3142912, 1247780, 1196245) aliquoted in 10 ml volumes and frozen at-
700c for a period of not more than 2 months. Immediately before its 
use, pooled plasma was thawed at 37° C. 
a. Normal Monkey Plasma Preparation (NMP) 
Primates were anesthetized with ketamine HCL (10 mg/kg i.v.) and 
blood was drawn from the popliteal vein using a 21 gauge 3/4 inch 
butterfly needle and centrifuged at 4°c, 1200 x g for 20 minutes. 
Plasma from a minimum of 5 primates was pooled and aliquoted in 10 ml 
volumes. The pooled monkey plasma (NMP) was frozen in plastic tubes 
at -70°c for not more than 2 months. 
b. Normal Rabbit Plasma Preparation (NRP) 
'White New Zealand rabbits were anesthetized with intramuscular 
injections of xylazine (20 mg/kg) and ketamine (80 mg/kg). After 
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induction of anaesthesia, blood was drawn by cardiac puncture using a 
vacutainerR technique into tubes containing 3.8 % citrate (1:10). The 
blood was centrifuged at 4°C, 1200 x g for 20 minutes. Plasma from a 
minimum of 5 rabbits was pooled and aliquoted in 5 ml volumes. The 
pooled rabbit plasma (NRP) was frozen in plastic tubes at -70°C for not 
more than 2 months. 
c. Normal Rat Plasma Preparation (NratP) 
Rats were anesthetized with ketamine HCL (40 mg/kg i .m.) and 
Xylazine (20 mg/kg i.m.). Blood was drawn from the inferior vena cava 
using a 22 gauge needle and a syringe into tubes containg 3.8 % citrate 
(1:10). 5 ml of blood was drawn from each rat. The blood was centri-
fuged at 4° C, 1200 x g for 20 minutes. Plasma from a minimum of 5 
rats was pooled and aliquoted in 5 ml volumes. The pooled rat plasma 
(NratP) was frozen in plastic tubes at - 70°c for not more than 2 
months. 
4. Thrombogenic Agents 
Thrombogenic challenges used in the modified rabbit stasis 
thrombosis model included: prothrombin complex concentrate (PCC) and 
Russell's viper venom (RVV). KonyneR brand of human prothrombin 
complex concentrate containing factors II, VII, IX and X was obtained 
from Cutter Laboratories, Lot 3125-50-3. PCC was reconstituted with 
saline to 50.0 U/ml. Russell's viper venom (RVV), lot 027F9461 
obtained from Sigma Chemical Co. and was reconstituted to 0.1 U/ml with 
saline immediately before use. 
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5. Anaesthetics 
VetalarR (ketamine hydrochloride) anaesthetic was obtained from 
Parke-Davis, (Morris Plains, NJ) as a 100 mg/ml solution. After 
intramuscular injection, VetalarR produces rapid analgesia with mild 
.cardiac stimulation and respiratory depression. RompunR (xylazine) 
analgesic was obtained from Bayvet Division of Miles Laboratories, Inc. 
(Shawnee, KS) as a 100 mg/ml solution. Xylazine is a non-narcotic 
sedative, analgesic and muscle relaxant. 
Beuthanasia-pR euthanasia solution was obtained from Schering 
Corporation (Kenilworth, NJ). Each ml of beuthanasia contains 390 mg 
pentobarbital sodium and 50 mg phenytoin sodium in addition to inactive 
ingredients. 
E. Animals 
A colony of mature rhesus monkeys (macaca mulatta) consisting of 
2 males and 10 females, housed in the animal research facility of 
Loyola University Medical Center, were used for the pharmacodynamic 
time course studies. The animal research facility is accredited by the 
American Association for the Accreditation of Laboratory Animal Care 
and the health of the primates was monitored by a licensed doctor of 
veterinary medicine. All primates were maintained on a standard diet 
of Purina monkey chow, fruit, molasses sandwiches, had free access to 
water and were exposed to a regular 12 hour light/dark cycle. The 
primates weights ranged from 5.7 to 14.2 kg. The average weight of the 
primates was 8.6 ± 2.2 kg (mean± S.D.). No differences between the 
coagulation parameters of male and female primates are observed (Schalm 
1975) and females in menses were not included in the studies. 
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Male New Zealand rabbits (oryctolagus cuniculus) ranging in 
weight from 2.5 to 3.0 kg were obtained from Langshaw Farms (Augusta, 
MI). Rabbits were housed in the Loyola University Medical Center 
animal research facility. Environmental conditions included a 12 hour 
light/12 hour dark cycle. They were fed a standard diet of WayneR 
Rabbit Ration and water ad libitum. All animals were allowed to 
acclimate to the facilities for a minimum of 7 days post transport. 
Male Sprague Dawly rats (rattus norvegicus) ranging in weight 
from 240 to 260 g were obtained from Harlan (Indianapolis, IN). The 
rats were housed in the Loyola University Medical Center animal 
research facility. Environmental conditions included a 12 hour 
light/12 hour dark cycle. They were fed a standard diet of Wayne 
rodent lab blocks. All animals were allowed to acclimate to the 
facilities for a minimum of 7 days post transport. 
Male Wistar rats (rattus norvegicus) ranging in weight from 200 
to 250 g, used for the laser-induced thrombosis model, were housed in 
the accredited animal research facility of J.W. Goethe University, 
Frankfurt, West Germany. All animals were allowed to acclimate to the 
facilities for a minimum of 7 days post transport. 
F. Analytical Instrumentation 
Waters™ 840 Data and Chromatography Control Station manufactured 
by Millipore Corporation (Millford MA) was used to run high performance 
liquid chromatography (HPLC) analyses. This system uses Waters Expert 
TM chromatography software (Version 6. 2) and consisted of a Waters™ 
WISP, a Waters™ 510 HPLC pump, a Waters™ 410 Differential Refrac-
tometer and a Waters™ 490 Programmable Multiwavelength Detector. 
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TSK 2000 SW VIII column Beckman Instruments Inc. (Arlington 
Heights IL). 
FibrometerR, manufactured by Becton Dickinson and Co. (Ruther-
ford, NJ) is an electromechanical instrument used for clot detection at 
Spectrophotometer Model 35R and Model DU7R manufactured by 
Beckman Instruments, Inc. 
Hycel Cell Counter 300, (Houston TX) 
Argon Laser CR2R manufactured by Coherent (Palo Alto, CA). 
Microscope with interference contrast objectives and condensers 
and a 100 x water immersion objective was supplied by Leitz Wetzlar, 
Germany. 
Surgical instruments used include scalpels with No. 20 blades, 
Metzenbaum dissecting scissors, tissue forceps and haemostats. 
AccutempR Surgical Cautery manufactured by Concept, Inc. (Clear-
water, FL) was used to cut through tissue while producing a minimal 
amount of bleeding. 
An IBM PC-XT computer and a Blue Chip IBM compatible PC were used 
for word processing, graphics and statistics. The software used 
included: Word Perfect 4. 2R (Word Perfect Corporation, Orem, Utah), 
SigmaplotR (Jandel Scientific, Sausolito, CA), PCNONLINR (Statistical 
Consultants, Lexington, KY), and SystatR (Systat Inc., Evanston IL). 
II. METHODS 
A. Physiochemical Profiling of Heparin, CY 216 and Protamine 
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1. Molecular Weight Determination 
In order to determine the molecular weight profile of heparin, CY 
216 and protamine, gel permeation chromatography (Losito 1981) was 
performed on a Waters 840 Data and Chromatography and Control Station 
which utilized Waters Expert™ chromatography software. The system 
calculated not only mean molecular weight, but also values which 
indicate molecular weight distribution. These values were calculated 
from the chromatographic char,cteristics of standards with similar 
molecular composition on a TSK 2000 SW VIII column. Thus prior to use, 
the column was calibrated with anionic polymers consisting of sulfated 
glucuronic acid, uronic acid and glucosamine (Emanuele 1988). Values 
for retention time (RT) and polymer dispersity (D) were determined, and 
used along with molecular weights of the standards to calculate a 
calibration curve. This curve was calculated by third polynomial 
regression and yielded polynomial coefficients (D0 , D1, D2, D3) that 
characterized the average standard curve. The following equation was 
used: 
MW - D0 + D1 (RT)+ D2 (RT)2 + D3 (RT)3 
The molecular weight of the heparin and CY 216 were determined 
from their chromatographic characteristics under the following condi-
tions: 
Columns: TSK 2000 SW VIII (Beckman) 
Mobile Phase: Na2S04 0.5 M 
Detector: UV 205 run 
Flow Rate: 1 ml/min 
Sample: 20 µl of heparin or CY 216 (10 mg/ml) 
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The molecular weight of protamine was determined under the 
following conditions: 
columns: TSK 2000 (Beckman) 
Mobile Phase: Na2S04 0.5 M 
Detector: UV 205 nm 
Flow Rate: 1.0 ml/min 
Sample: 20 µl of protamine (10 mg/ml) 
2. NMR spectra 
The 1H NMR spectra of heparin, CY 216, protamine and a heparin-
protamine complex were obtained in collaboration with Professor Casu of 
Institute Ranzoni, Milan, Italy. A BrukerR AC 200 nuclear magnetic 
spectrometer was used to obtain the 1H spectra. Each agent was 
dissolved in deuterated water (D20) at 20% and a full span spectra was 
recorded according to a method described previously (Casu 1984). 
To prepare a complex between heparin and protamine sulfate, 20 mg 
of protamine was suspended in 0.5 ml of 0.1 N DCl, mixed well and 1 mg 
of heparin was added. This solution was incubated for 1 hour and a lH 
NMR spectrum of this mixture was obtained. A control spectrum of 
protamine was also determined using the same conditions. 
B. In Vitro Methods 
1. Clotting Assays 
The activated partial thromboplastin time (APTT), thrombin time 
and HeptestR are global clot based assays. These tests are sensitive 
to many factors which can influence the coagulation system by inhibit-
ing a variety of enzymatic processes. The end point of all clotting 
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tests is the formation of fibrin which is detected by a fibrometer, an 
instrument which mechanically detects clot formation. 
APTT is a test used to screen the intrinsic pathway of coagulation 
(factors XII, XI, IX, VIII, X, V, II, I) and for monitoring heparin 
therapy. It is based on the measurement of time to clot after citrated 
platelet poor plasma has been activated by a platelet substitute 
(phospholipid), silica activator and calcium chloride. The assay was 
performed by mixing 100 µl of citrated plasma with 100 µl of automated 
APTT reagentR and incubating for 5 minutes at 37°c. 100 µl of calcium 
chloride (0.025 M) prewarmed to 37°c was then added. The time to clot 
was determined immediately by a fibrometer. Any clotting time which 
was prolonged more than 150 seconds was reported as >150 seconds which 
is the upper limit of the linear range of this assay. 
Thrombin clotting time measures the conversion of fibrinogen to 
fibrin based on the time to clot after the addition of a known amount 
of thrombin to plasma. The assay was performed by incubating citrated 
plasma (200 µl) at 37°c for 3 minutes at which time 100 µl of 5 U/ml 
human thrombin was added. The time to clot was determined immediately 
by a fibrometer. Any clotting time which was prolonged more than 150 
seconds was reported as >150 seconds which is the upper limit of the 
linear range of this assay. 
HeptestR was performed according to manufacturer's instructions. 
The fundamental principle of the HeptestR heparin assay involves the 
ability of heparin or its derivatives to catalyze the inactivation of 
exogenous bovine activated factor X by antithrombin III in the presence 
of naturally occurring antagonists in the plasma sample. HeptestR 
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measures the anticoagulant property of heparin through the combined 
anti Xa/anti Ila actions of the drug. Citrated plasma (100 µl) was 
incubated with bovine factor Xa (100 µl) for exactly 120 seconds, at 
which time 100 µl of RecalmixR was added to the mixture and immediately 
the time to clot was determined by a fibrometer. Any clotting time 
which was prolonged more than 300 seconds was reported as >300 seconds 
which is the upper limit of the linear range of the HeptestR. 
2. Amidolytic Assays 
Amidolytic assays are characterized by an enzymatic reaction in 
which an oligopeptide synthetic 
cleaved by a given enzyme to 
substrate of semi-specific 1ructure is 
release an attached chromophore (para 
nitroaniline). Enzyme activity is determined by measuring the increase 
in absorbance of the free chromophore which is generated, in comparison 
to the original substrate, per minute at 405 nm (Fareed 1980, 1983; 
Hoppensteadt 1985) One advantage of amidolytic assays is the ability 
to directly quantitate specific enzymes rather than indirectly as in 
the case of the global assays. This technique, however, measures 
amidolytic activity on a semi-specific substrate which may not directly 
correspond to the specific function of the enzyme in coagulation 
processes. 
The amidolytic anti Xa assay provided a measure of absolute 
heparin concentration which is proportional to the inhibition of factor 
Xa by heparin. The assay was performed in the following manner: 375 µl 
of buffer (pH 8 .4) was equilibrated with 25 µl of plasma sample at 
37°c. 50 µl of 0.5 nkat/ml bovine factor Xa was added and allowed to 
react for exactly 2 minutes, at which time 50 µl of substrate (Spectro-
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zyme Xa 2.5 mM) was added. The change in absorbance was recorded at 
4os nm for one minute. 
lated as shown below. 
% Inhibition of factor Xa activity was calcu-
% Inhibition plasma sample delta A q05 nm/min - 1 x 100 
plasma blank delta A 405 nm/min 
The amidolytic anti Ila measures the inhibition of thrombin 
(factor Ila) which is proportional to the heparin concentration. The 
assay was performed in the following manner: 400 µl of buffer pH 8.4 
was equilibrated with 25 µl of plasma sample at 37°c. 25 µ1 of 10.0 
NIH U/ml human thrombin was added and incubated for exactly one minute 
at which time, 50 µl of spectrozyme TH 1 mM was added. The change in 
absorbance was recorded at 405 nm for one minute. % Inhibition of 
factor Ila activity was calculated as shown on the next page. 
% Inhibition plasma sample delta A q05 nm/min - 1 x 100 
plasma blank delta A 405 nm/min 
C. In Vitro Studies 
1. Baseline Values of NHP, NMP, NRP and NratP 
Human plasma obtained from Loyola University Blood Bank (NHP), 
and plasma obtained from primates (NMP), rabbits (NRP) and rats (NratP) 
was used to determine the clotting and amidolytic baseline values of 
these plasma preparations. 
triplicate on separate days. 
These experiments were performe~ in 
2. In Vitro Supplementation of Heparin or CY 216 to NHP, NMP, NRP and 
NratP 
Heparin or CY 216 was supplemented in a concentration range of 0 
to 10 µg/ml to NHP, NMP, NRP and NratP. APTT, HeptestR, amidolytic 
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anti Xa and amidolytic anti Ila assays were performed on these samples. 
3 . In Vitro Supplementation of Protamine to NHP, NMP, NRP and NratP 
Protamine sulfate (10 and 100 µg/ml) was supplemented to NHP, 
NMP, NRP and NratP. Additional protamine concentrations (1 mg/ml and 
10 mg/ml) were supplemented to NHP. APTT, HeptestR, amidolytic anti Xa 
and amidolytic anti Ila assays were performed on these samples. 
4. In Yit[Q Neutralization of Heparin and CY 216 by Protamine In 
Pooled Plasma Preparations 
Heparin or CY 216 was supplemented to NHP or NMP to obtain a 
final concentration of 5 µg/ml. Protamine sulfate was added to the 
heparin (5 µg/ml) and CY 216 (5 µg/ml) solutions to obtain final 
protamine concentrations of 2. 5, 5. 0 and 10. 0 µg/ml. Anticoagulant 
activity was determined by the APTT and thrombin time methods. 
Antiprotease activity was determined by the HeptestR, 
1 
amidolytic anti 
Xa and amidolytic anti Ila assays. The experiment was repeated five 
times on different days using the same pool. 
5. In Vitro Neutralization of Heparin and CY 216 by Spermidine In NHP 
Heparin or CY 216 was supplemented to NHP to obtain a final 
concentration of 5 µg/ml. Spermidine was added to the heparin (5 
µg/ml) and CY 216 (5 µg\ml) solutions to obtain final spermidine 
concentrations of 2.5, 5.0 and 10.0 µg/ml. Anticoagulant activity was 
determined by the APTT and thrombin time. Antiprotease activity was 
determined by the amidolytic anti Xa and amidolytic anti Ila methods. 
The experiment was repeated three times on different days using the 
same pool. 
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D. Rat Laser-Induced Thrombosis Studies 
The in vivo antagonism of heparin and CY 216 by pro~amine 
sulfate was studied in a rat model of laser-induced thrombosis. 
(Breddin et al. 1982; Weichert et al. 1983, 1984, 1986; Racanelli et 
al. 1989) This model provided a dynamic environment in which platelet 
activation and subsequent thrombus formation in rat mesenteric vessels 
can be visualized. 
Experiments were performed after anesthetizing the rats with 
Nembutal ( 60 mg/kg i. p. ) . The abdomen were shaved and a small ab-
dominal incision was made. Drugs were injected via the tail vein for 
intravenous administration and behind the neck for subcutaneous 
administration. A portion of the rat mesentery was exposed and 
positioned on an optical stage. In these studies the laser damage was 
produced by exposing terminal mesenteric venules of 25-30 um diameter 
to 0.05 Watts of laser energy for 1/30th of a second. Laser damage to 
the endothelium was visualized through the microscope and antithrom-
botic effect was calculated in terms of the number of laser injuries 
required to produce a defined thrombus. Laser injuries were produced 
in 3 distinct areas of the mesentery per rat. At the end of the 
experiment blood was drawn from the inferior vena cava and the rat was 
sacrificed by cardiac incision. 
follows: 
Intravenous Studies: 
0 5 
Inject Inject 
Heparin Protamine 
or CY 216 
The experimental schedule was as 
20 (minutes) 
Produce 
Laser 
Injury 
subcutaneous Studies: 
0 
Inject 
Heparin 
or CY 216 
E. Rat Tail Bleeding Studies 
120 140 (minutes) 
Inject Produce 
Protamine Laser 
Injury 
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A modified version of the rat tail bleeding time (Dejana 1982) 
was used to determine the hemorrhagic effect of heparin, CY 216 and 
protamine as well as bleeding time after antagonism of heparin and CY 
216 by protamine. The rats were anaesthetized with KetalarR (40 mg/kg 
i.m.) and the tail was cleansed with an alcohol swab. Two mm of the 
distal end of the tail was transected using a scalpel. Blood from the 
incision site was soaked with a piece of filter paper very carefully so 
as not to disrupt any hemostatic plug formation. Heparin (2 mg/kg i.v. 
and 2.5 mg/kg s.c.) and CY 216 (2 mg/kg i.v. and 2.5 mg/kg s.c.) and 
protamine (1, 2, and 2.5 mg/kg i.v.) were studied in this model. 
The experimental schedule was as follows: 
Intravenous Studies: 
0 
Inject 
Heparin 
or 
CY 216 
5 
Inject 
Protamine 
Subcutaneous Studies: 
0 
Inject 
Heparin or CY 216 
115 
Inject 
10 (minutes) 
Transect 
Tail 
120 (minutes) 
Transect 
Protamine Tail 
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F. Rabbit Stasis Thrombosis Studies 
The antithrombotic effects of heparin, CY 216 and protamine were 
studied in a modified stasis thrombosis model (Fareed et al. 1985). 
White New Zealand male rabbits were anaesthetized with Xylazine (20 
mg/kg i.m.) and KetalarR (80 mg/kg i.m.). If the rabbits showed signs 
of being too lightly anesthetized during the procedure, additional 
injections of KetalarR (25 mg/kg i .m.) were administered. After 
induction of anaesthesia, the rabbits were weighed, their neck area was 
shaved and positioned for surgery. Baseline blood samples were drawn 
by cardiac puncture using a VacutainerR. A vertical incision in the 
neck area was made using a scalpel. A blade, forceps and cautery were 
utilized to surgically isolate the jugular veins from the fascia. The 
dissection was done carefully so as not to damage or traumatize the 
vessels and collateral vessels were cauterized. A 2 to 3 cm segment of 
each jugular vein (including the bifurcation) was isolated and silk 
sutures were loosely tied around each branch of the jugular vein 
without interfering with blood circulation. The exposed neck area was 
kept moist with saline soaked gauze squares. 
An intravenous line was set up with a 23 gauge, 3/4 inch butter-
fly needle in the rabbit marginal ear vein. Heparin or CY 216 was 
injected and allowed to circulate for 5 minutes at which time, blood 
for tl vivo analysis was drawn by cardiac puncture. Immediately after 
the blood draw, PCC (25 U/kg) was administered through the marginal ear 
vein followed by RVV (0 .1 U/kg) which was allowed to circulate for 
exactly 20 seconds. At this time the isolated jugular vein segments 
were ligated and stasis produced. A schematic diagram of the isolated 
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jugular veins ar shown in Appendix VIII. Blood was drawn for ~ vivo 
analysis, five minutes post PCC/RVV injection. Exactly 10 minutes 
after stasis time, the isolated jugular segments were removed and 
placed in a petri dish with saline. The blood clots were visually 
examined and graded according to the following method. In this system 
+ o represented blood with no evidence of clotting,+ 1 represents some 
ainute clots however mostly blood, + 2 represents a large amount of 
small clots, +3 represents large clots with some free red blood cells, 
+ 4 represents a fully formed casted clot with no blood. A schematic 
diagram of the clot grading system which was used is shown in Appendix 
IX. Rabbits were euthanized with BeuthanasiaR (15 mg/kg i.v.). The 
experimental schedule was as 
rtravenous 
0 
Draw Blood 
Then 
Inject 
Heparin 
or 
CY 216 
Subcutaneous 
l 
0 
Draw Blood 
Then 
Inject 
Heparin 
or 
CY 216 
Studies: 
5 
Inject 
Protamine 
Studies: 
245 
Inject 
Protamine 
follows: 
• 
' - blood I 
10 
Draw Blood 
Inject 
PCC/RVV 
Then 
Ligate 
Vessel 
' 
l- blood 
255 
Draw Blood 
Inject 
PCC/RVV 
Then 
Ligate 
Vessel 
15 
Draw 
Blood 
draw 
l 
265 
Draw 
Blood 
20 (min) 
Remove 
Vessels 
and 
Evaluate 
Clots 
275 (min) 
Remove 
Vessels 
and 
Evaluate 
Clots 
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G. Rabbit Ear Blood Loss Studies 
A modified version of the rabbit ear blood loss model (Cade et. 
al. 1984), was used to compare the hemorrhagic potential of heparin, CY 
216, and protamine. The rabbits were anesthetized with Xylazine (10 
mg/kg i.m.) and KetalarR (40 mg/kg i.m.). After induction of anaes-
thesia, an intravenous line was set up with a 23 gauge, 3/4 inch 
butterfly needle inserted in the large marginal ear vein through which 
heparin, CY 216 and protamine were administered. The rabbit ear was 
immersed in a saline bath at 37°c and an area free of major blood 
vessels was selected. Using a scalpel, five uniform incisions of full 
thickness were made in the area which was free of major blood vessels 
as shown in the Appendix X. Immediately after the incisions were made, 
the rabbit ear was immersed in the saline bath and the red blood cells 
were collected for 10 minutes. The saline was collected and the red 
cells were counted using a HycelR cell counter. Heparin (2 mg/kg i.v.) 
and CY 216 (2 mg/kg i.v.) and protamine (1, 2 and 3 mg/kg i.v.) were 
studied. Heparin (1 mg/kg s.c.) and CY 216 (1 mg/kg s.c.) were also 
studied. The protocol used to study blood loss is in this model is 
shown below. After the experiment the rabbits were returned to their 
cages and used for the stasis thrombosis experiments, no less than one 
week later (Emanuele 1987; Boneu 1987). 
I Intravenous Studies: blood draw 
0 
Draw 
Blood 
Then 
Inject 
Heparin 
I 
5 10 
Inject Draw 
Protamine Blood 
Then Make 
Incisions 
or CY 216 and Collect RBCs 
20 (min) 
Count 
RBCs 
Subcutaneous Studies' 
~ 115 120 
Inject Draw 
Protamine Blood 
Then Make 
Incisions 
and 
J - blood draw 
130 (min) 
Count 
RBCs 
Draw 
Blood 
Then 
Inject 
Heparin 
or Collect RBCs 
CY 216 
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Protamine sulfate was administered at a dose of 2 .1 mg/kg i. v. 
and blood was drawn as shown below: l =blood draw 
0 1 2 3 (hours) 
The plasma samples were centrifuged and frozen at - 70° C. The 
pharmacodynamics of protamine were assayed indirectly by supplementing 
the plasma of the primates which received protamine (2 .1 mg/kg i. v.) 
with heparin in order to obtain a final heparin concentration of 2. 5 
µg/ml. APTT, thrombin time, HeptestR, amidolytic anti Xa and amido-
lytic anti Ila assays were performed. The ability of protamine in the 
plasma sample to neutralize the exogenously added heparin was indica-
tive of the protamine concentration in the plasma. Additional in vitro 
studies were carried out where APTT, thrombin time, HeptestR, amido-
lytic anti Xa and amidolytic anti Ila assays were performed on the ex 
vivo plasma samples after protamine administration. 
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}I. IJ.me Course of the Pharmacodynamic Effects of Heparin and CY 216 in 
_nimates 
The time course of pharmacodynamic activity of heparin, CY 216, 
and protamine sulfate was studied using a primate model (Fareed 1985). 
In addition, the time course of the neutralization of heparin and CY 
216 by protamine was studied. 
Baseline blood samples were drawn from all of the primates prior 
to beginning the study. Chemistry, coagulation and hematological 
profiles were determined by the Loyola University Medical Center 
department of clinical chemistry as shown in Appendix XI. Of the 12 
primates that were profiled, two were excluded from the study for 
health reasons. The remaining 10 primates were divided into 2 groups 
consisting of 5 primates each. These two groups were used alterna-
tively for the duration of the study. Each primate was only used once 
weekly which provided adequate time for drug clearance (Emanuele 1987). 
A one month rest period was given to the primates between the intra-
venous and subcutaneous time course studies. The primates were grouped 
in a random manner as shown below. -
Group I Group II 
M73 M70 
M74 M75 
M76 M2722 
M2730 M3630 
M3064 M4777 
All pharmacodynamic time course experiments began at the same 
time of the day (9:00 to 9:30 a.m.). Prior to blood sampling the 
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animals were anesthetized with KetalarR (10 mg/kg i.m.). Approximate-
ly 10 minutes after injection, the primates were removed from their 
cages and baseline blood samples were drawn from the popliteal vein. 
All drugs were injected through syringes incorporating sterile, pyrogen 
free 0.2 um Nalgene filters (Nalge Co. Rochester NY). Primates were 
returned to their cages and monitored as they recovered from their 
anesthetic. Studies have shown that repeated administration of 
KetalarR does not have an effect on the primate coagulation profile 
(Fareed et al. 1985). 
1. Heparin and CY 216 Pharmacodynamics 
a. Intravenous Studies 
After 0 hour blood samples were drawn from each primate, heparin 
or CY 216 were administered at doses of 0.35 mg/kg i.v. and 0.7 mg/kg 
i. v. Blood samples (2. 7 ml) were collected according to methods 
previously described in this section, into siliconized glass tubes 
containing 0. 3 ml of 3. 8 % sodium citrate and centrifuged to obtain 
plasma. The experimental schedule for the intravenous studies is shown 
below. The number in parentheses refers to primate group numbers. 
• l I i-blood draw 
0 5 30 minutes 
l l I 
1 2 3 4 5 6 hours 
1. Heparin 0.35 mg/kg i.v. (I) 
2. Heparin 0.70 mg/kg i.v. (II) 
3. CY 216 0.35 mg/kg i.v. (II) 
4. CY 216 0.70 mg/kg i.v. (I) 
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The clotting tests APTT, thrombin time and HeptestR were per-
formed on fresh samples and plasma was frozen for subsequent in vitro 
analysis. 
For the neutralization studies heparin (0.7 mg/kg i.v.) or CY 216 
(0. 7 mg/kg i. v.) was administered and protamine was given 5 minutes 
after heparin administration. Blood samples were drawn as shown below. 
Blood was drawn at time 0 
11 I I 
and then heparin or CY 216 was injected. 
,-blood draw 
O 5 15 30 minutes 
f I f 
1 2 3 4 5 6 hours 
The above schedule was used for the following studies. 
number in parentheses represents the primate group number. 
11 Heparin 0.7 mg/kg i.v. w/ Protamine Sulfate 0. 7 mg/kg i.v. (I) 
2. Heparin 0.7 mg/kg i.v. w/ Protamine Sulfate 1.4 mg/kg i.v.(II) 
3. Heparin 0.7 mg/kg i.v. w/ Protamine Sulfate 2.1 mg/kg i.v.(II) 
4. CY 216 0.7 mg/kg i.v. w/ Protamine Sulfate 0. 7 mg/kg i. v. (I) 
5. CY 216 0.7 mg/kg i.v. w/ Protamine Sulfate 1.4 mg/kg i.v.(II) 
6. CY 216 0.7 mg/kg i.v. w/ Protamine Sulfate 2 . 1 mg/kg i. V. (I) 
b. Subcutaneous Studies 
The 
Heparin and CY 216 were administered at O. 7 mg/kg s. c. by a 
single bolus injection to a site in the lower abdomen for all primates 
except M4777. This primate received a divided dose in order to keep 
the volume injected less than 1 ml. Blood samples were drawn as shown 
below. 
injected. 
Blood was drawn at time O and then heparin or CY 216 was 
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t =blood draw 
I l 
' ' 0 2 
4 6 9 12 (hours) 
The above schedule was used for the following studies. The 
number in parentheses represents the primate group number. 
1. Heparin 0.7 mg/kg s.c. (I) 
2. CY 216 0.7 mg/kg s.c. (II) 
Blood was drawn by the following schedule for primates which 
received protamine in addition to heparin (0. 7 mg/kg s. c.) or CY 216 
(0.7 mg/kg s.c.). Protamine was administered immediately after the 4 
hour blood draw . 
• 
I 
,-blood draw 
I 
0 2 4 6 9 12 (hours) 
1. Heparin 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (I) 
2. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (I) 
3. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (II) 
Studies on the neutralization of heparin (0.7 mg/kg s.c.) or CY 
216 (0. 7 mg/kg s. c.) by protamine were carried out at the following 
doses of protamine sulfate. 
primate group number. 
The number in parentheses refers to the 
1. Heparin 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v.(II) 
2. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (I) 
3. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 1.4 mg/kg i.v.(II) 
2. Calculation of Pharmacodyrtamic Time Course Parameters 
Pharmacodynamic time course parameters for the intravenous and 
subcutaneous studies were determined from concentrations (µg/ml) 
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obtained from calibration curves of heparin or CY 216 supplemented to 
NMl' as determined by the HeptestR and amidolytic anti Xa assays. These 
two assays were chosen to calculate the pharmacodynamic time course 
parameters since they primarily measure anti Xa activity. This 
activity is commonly used to monitor low molecular weight heparin 
therapy. In addition, these assays demonstrated the greatest linearity 
over the concentrations studied and only the linear portion of the 
calibration curves were used. If a primate sample was determined to be 
out of range of the curve, it was diluted 1:5 in normal monkey plasma, 
read off the curve and multiplied by the dilution factor (Sie et al. 
1989). The calibration curves of heparin and CY 216 supplemented in 
NMP are shown in the Appendix XII. 
Pharmacodynamic time course parameters were determined using 
noncompartmental methods as described by Gibaldi (1984). The pharm-
acodynamics of intravenously or subcutaneously administered heparin and 
CY 216 were characterized in terms of area under the concentration 
curve (AUC), area under the moment curve (AUMC), mean residence time 
(MRT), plasma clearance (Clp) and apparent volume of distribution 
(Vd). Area under the curve and AUMC were calculated using PCNONLIN 
software (Statistical Consultants, Lexington, KY). 
The mean residence time (MRT) is the time when 63. 2% of an 
intravenous dose has been eliminated. The concept is similar to the 
biologic half life when 50% of the dose has been eliminated. MRT is 
calculated by the ratio of the AUMC to AUC. 
MRT - 60(min) x AUMC 
AUC 
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plasma clearance was determined by the following formula: 
Clp - DOSE x _1 __ 
AUC 60(min) 
Apparent volume of distribution was determined by the following 
formula: 
Vd - dose x AUMC x 1 liter 
(AUC)(AUC) 1000 ml 
Bioavailability after subcutaneous administration was calculated 
by the following formula: 
Bioavailability mean AUC (s,c, dose) 
mean AUC (i.v. dose) 
Protamine Neutralization Index (PNI) (Bjornsson personal com-
munication) was calculated by the following formula: 
PNI - 1 - post protamine AUC 
(mean) pre protamine AUC 
In order to calculate PNI values for the primate studies, it was 
necessary to use the mean value for the protamine neutralization, since 
the experiments were performed using groups and not all of the primates 
were used for all of the studies. 
For the amidolytic assays, % neutralization was calculated by the 
following formula: 
% Neutralization - post protamine ug/ml - 1 
pre protamine µg/ml 
% N were calculated at 30 minutes for intravenous studies and at 
245 minutes for the subcutaneous studies for the primates. In the 
rabbit studies, % N was calculated after 10 minutes for the intravenous 
studies and after 120 minutes for the subcutaneous studies. % N was 
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not calculated for the APTT, thrombin time and HeptestR data since many 
values were outside of the linear range of the assay. 
I. Statistical Analysis 
l. Data Presentation 
The experimental data was compiled as mean± S.E. (standard error 
of the mean) . The sample mean was the average of the measurements 
within each experimental group. The standard error of the mean (S.E.) 
was reported along with the mean in order to provide an indication of 
the precision of estimation of the population mean. The S.E. was also 
used in order to facilitate comparison of the means of one group to 
another. The S.E. was calculated by dividing the standard deviation 
(S.D.) by the square root of the number in the experimental population. 
S.E. - S.D. 
nl/2 
The data in the figures was represented as mean ± S. E. Error 
bars were drawn using the SigmaplotR software and the error bars are 
not shown if they are not larger than the size of the symbol in the 
figure. 
2. Statistical Tests 
Statistical tests performed on the experimental data include: 
Students t-test (unpaired), one way ANOVA, two way ANOVA, Students-
Newman Keuls multiple comparison test, Kruskal Wallis nonparametric 
ANOVA, nonparametric multiple comparison test and linear regression. 
All tests with the exception of the Kruskall-Wallis nonparametric ANOVA 
and the linear regression tests were performed utilizing Systat. The 
linear regressions were performed utilizing Sigmaplot and the non-
parametric tests were calculated manually. All test statistics were 
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calculated at a significance level of .05. Critical values fort, F, 
H, and q distributions were obtained from Zar (1984). 
a. Student's t test 
The student's t test was used to compare the means from the 
heparin group to the means from the CY 216 group in the primate 
pharmacodynamic time course data. Two tailed t tests were used for all 
of the analyses which indicates the mean value obtained could be 
greater or less than the mean value from the other group. 
b. Analysis of Variance 
The one way AN0VA was used to compare the effect of a single 
factor on a single variable although different factor levels exist. 
The one way AN0VA was used to compare several group means after a 
treatment. The test for the equality of means is a one-sided variance-
ratio test as shown below: 
F - group mean square 
error mean square. 
The critical value for this test is F alpha (l),(k-l)(N-k) where 
N - total number of data points and k - number of groups. If the 
calculated F is at least as large as the critical value, then H0 is 
rejected. The AN0VA does not determine where the differences between 
means exist, if indeed this test concludes that a significant dif-
ference does exist between the means. If the AN0VA revealed a sig-
nificant difference, the Student-Newman-Keuls multiple comparison test 
was used to determine the location of the differences between the 
means. 
The two way AN0VA simultaneously analyzes the effect of more than 
one factor on a group mean. This test considers the effects of two 
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factors independently of each other. For a two way ANOVA, three F 
values are obtained. F values for Factor A, Factor Band the interac-
tion between Factors A and Bare obtained. An interaction between two 
factors indicates that the effect of one factor is not independent of 
-the presence of a particular level of the other factor. 
c. Student-Newman-Keuls Test 
The Student-Newman-Keuls test was applied in addition to the 
ANOVA to determine which means were statistically different from the 
other. This multiple comparison was selected since it is more powerful 
and widely accepted than the other multiple comparison tests (Zar 
1984). The test statistic q is calculated and the critical value is 
qa lpha, DF, p where p is the number of means in the range of means 
being tested. 
q - XP>--:.-.XA 
S.E. 
If the number of groups (k) were equal, the S.E. was calculated as 
S.E. - (s 2/n) 1/ 2 
where s 2 - error mean square. 
If the number within each group were not equal, the S.E. was calculated 
as 
For S.E. n- number of data points in each level, v- with in cells 
degrees of freedom. Newman-Keuls multiple comparison tests were 
performed following 2 way ANOVAs. The comparisons were made between 
the levels of a fixed effects factor having more than two levels. 
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d, Kruskall-Wallis Test 
The Kruskal Wallis nonparametric ANOVA was used to test for 
differences between the clot scores obtained in the stasis thrombosis 
11<>del. The Kruskal Wallis test statistic H was calculated as 
H - l.2...__Ri2 - 3(N + 1) 
N(N+l)ni 
where N - total number of observations in all groups, ni - number of 
observations in group I and Ri - sum of ranks of ni observations in a 
group. 
e. Nonparametric Multiple Comparison Test 
Nonparametric multiple comparison tests were used when the 
nonparametric Kruskal-Wallis test was applied and significant dif-
ference between means was obtained. Nonparametric comparisons are 
performed in a similar manner to the Tukey test, however the rank sums 
are used instead of means. The S.E. was calculated as 
S. E. {n{nk}(nk+l) 
12 
f. Simple Regression 
Simple regression analysis was performed to establish the 
relationship between ~ vivo activity and either blood loss or % 
inhibition of thrombosis. The coefficient of determination R2 was 
computed using SigmaplotR solftware and the r value was reported. The 
average number of data points used to calculate each r value was 10. 
Chapter IV 
RESULTS 
A. In Vitro Studies 
1. Molecular Weight Profiles of Heparin, CY 216 and Protamine 
The molecular weight profile for heparin as determined by a high 
pressure liquid chromatographic (HPLC) method as previously described 
by Losito (1981) is shown in Appendix III. Heparin exhibited a 
polydisperse molecular weight profile with a mean molecular weight of 
11,000 daltons. 
The molecular weight profile for CY 216 as determined by a high 
pressure liquid chromatographic (HPLC) method using a UV detector is 
shown in Appendix V. CY 216 exhibited a polydisperse molecular weight 
profile with a mean molecular weight of 5,200 daltons. 
The molecular weight profile for protamine as determined by a 
high pressure liquid chromatographic (HPLC) method using a UV detector 
is shown in Appendix VII. Protamine exhibited a polydisperse molecular 
weight profile with a mean molecular weight of 4,000 daltons. 
The molecular weight profiles for heparin and CY 216 were 
obtained in collaboration with Institut Choay. 
2. NMR Spectra of Heparin, CY 216 and Protamine 
Proton NMR spectra were also used to profile heparin, CY 216, and 
protamine. The 1H NMR spectras were obtained in collaboration of 
Professor Casu of Institute Ronzoni, Milan Italy. The spectra were 
measured with a Bruker HX-270 spectrometer operating at 300 MHz. 
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Chemical shifts were measured with reference to internal TSP. The lH 
NMR spectrum (300 MHz, D20) of heparin is shown in Appendix XIII. This 
spectrum shows the regular regions consisting of GlcNS03 and IdoA-2S 
residues of the regular sequences of heparin. This data is consistent 
with the proposed structure of heparin. Appendix XIV shows a com-
parable spectrum of CY 216 which was obtained under identical con-
ditions as the heparin spectrum. Differences between the spectral 
characteristics of heparin and CY 216 were observed in the region of 3-
4.5 ppm. Furthermore the spectra demonstrated the presence of anhydro-
aannose residues which are present at the terminal end groups of some 
low molecular weight heparins. Appendix XV shows the NMR spectrum of 
protamine and a complex formed between heparin and protamine. The 
spectrum obtained for protamine was markedly different than the spectra 
obtained for the heparins. Preliminary analysis of this heparin-
protamine complex data demonstrates a chemical shift in the 3.4-3.6 ppm 
region (see box) as shown in Appendix XV. 
3. Baseline Values of NHP, NMP, NRP and NratP in the Clotting and 
Amidolytic Assays. 
Human pooled plasma was obtained from Loyola University Blood 
Bank (NHP), and pooled plasma obtained from primates (NMP), rabbits 
(NRP) and rats (NratP) were used in this study. Baseline values of 
these plasma preparations were determined in the clotting and amido-
lytic assays and statistical analysis was performed by a one way ANOVA. 
The results are shown in Table 1. Variations in the baseline APTT 
values for NHP, NMP and NratP were observed. The baseline values for 
NRP and NratP were significantly different (p<.05) from NHP. The 
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baseline clotting values obtained for NHP and NMP were similar as 
determined by the thrombin time, however the baseline values for NRP 
and NratP were significantly longer (p<.05) as compared to NHP. The 
values were similar for NHP and NMP as determined by the HeptestR (15.5 
and 20.5 seconds) respectively, however, the NratP baseline value was 
significantly longer (p<.05) than NHP at 56.6 seconds. The baseline 
chromogenicity of NMP as determined by the amidolytic anti Xa and 
amidolytic anti Ila assays were slightly higher than for the other 
plasma samples studied. However, % inhibition of amidolytic factor Xa 
or amidolytic factor Ila activity was calculated as a ratio. Any 
variations between the absorbances of the plasma samples were minimized 
after the calculation of % inhibition was performed. Control values 
for the amidolytic assays were designated as 0% inhibition. 
4. In Vitro Supplementation of Protamine Sulfate to NHP, NMP, NRP and 
NratP 
The in vitro results of protamine sulfate supplementation to the 
various plasma preparations in a concentration range of O - 100 µg/ml 
are shown in Table 2. Additional concentrations of protamine (1 and 10 
mg/ml) were supplemented to NHP in order to demonstrate the effects of 
high concentrations of protamine on human plasma. These concentrations 
of protamine were larger than doses which would be administered to a 
patient after cardiopulmonary bypass. 
NRP was more sensitive to the effects of protamine in the in 
vitro assays than the other plasma preparations. NHP was not sig-
nificantly prolonged, (as determined by a one way ANOVA), by protamine 
sulfate until the protamine concentration reached 1 mg/ml. Protamine 
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(100 µg/ml) did not have any effect on the absorbance values as 
determined by the amidolytic anti Xa and amidolytic anti Ila methods in 
any of the plasma systems as shown in Table 2. 
5. l!! Vitro Supplementation of Heparin and CY 216 to NHP, NMP, NRP and 
NratP 
Heparin or CY 216 was supplemented to NHP, NMP, NRP and NratP in 
a concentration range of 0 to 10 µg/ml. Plasma preparations were 
obtained as previously described in methods. The experiment was 
performed on 3 separate days using aliquots of the same frozen pooled 
plasma preparations. APTT, HeptestR, amidolytic anti Xa and amidolytic 
anti Ila assays were performed on these samples. 
The anticoagulant effects of heparin supplemented to the various 
plasma systems as determined by the APTT are shown in Figure 1. In a 
concentration range of 0-10 µg/ml, heparin produced a similar dose 
dependant prolongation of NHP and NMP. In addition dose dependant 
increases in the APTT were observed for NRP and NratP. The responses 
in NRP were stronger than for NHP, whereas NratP exhibited weaker 
responses. 
The anticoagulant effects of CY 216 supplemented to the plasma 
systems as determined by the APTT are shown in Figure 2. NRP was also 
prolonged to the same degree although the curve was shifted along they 
axis due to variations in baseline values for NRP. NratP was less 
sensitive to the effects of CY 216 than the other plasma preparations 
as determined by the APTT. 
The antiprotease activity of heparin in various plasma systems as 
determined by the HeptestR is shown in Figure 3. At the lower con-
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centrations, heparin prolonged NHP, NMP and NratP to the same extent, 
however, a divergence in this activity was seen at concentrations> 5 
µg/ml. The HeptestR was very sensitive to the effects of heparin (5 
µg/ml) supplemented to NRP and a prolongation of > 300 seconds was 
observed. 
The antiprotease activity of CY 216 in the various plasma systems 
as determined by the HeptestR is shown in Figure 4. CY 216 prolonged 
NHP and NMP in a similar manner while CY 216 prolonged the HeptestR to 
a slightly lesser degree as compared to heparin. NRP and NratP were 
also prolonged to the same extent, although the NratP baseline was 
elevated as compared to the other plasmas. 
The amidolytic anti Xa activity of heparin supplemented to 
various plasma systems is shown in Figure 5. In a concentration range 
of 0-10 µg/ml, heparin produced a similar dose dependant increase in 
the inhibition of amidolytic anti Xa activity of NHP and NMP. NRP and 
NratP also produced a dose dependant inhibition, however it was 
somewhat weaker than the response of NHP. 
The amidolytic anti Xa activity of CY 216 supplemented to various 
plasma systems is shown in Figure 6. CY 216 in a concentration range of 
0-10 µg/ml, produced a similar dose dependant increase in the inhib-
ition of amidolytic anti Xa activity of NHP and NMP, however the assay 
exhibited the most sensitivity to the antiprotease effects of CY 216 
supplemented to NHP. NRP and NratP also produced dose dependant 
inhibition, however these responses were somewhat weaker than the 
response of NHP. NRP was less sensitive to the antiprotease effects of 
cY 216 than the other plasma preparations. 
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The amidolytic anti Ila activity of heparin supplemented to 
rious plasma systems is shown in Figure 7. In a concentration range va . 
of o-1.25 µg/ml, heparin produced a similar dose dependant increase in 
the inhibition of amidolytic anti Ila activity of NHP and NMP. However 
NMP reached the upper limit of the linear range of this amidolytic anti 
Ila assay at a lower concentration than did the NHP. 
also produced similar dose dependant inhibition, 
somewhat weaker than the response of NHP. 
NRP and NratP 
however it was 
The amidolytic anti Ila activity of CY 216 supplemented to 
various plasma systems is shown in Figure 8. In a concentration range 
of 0-10 µg/ml, CY 216 produced a similar dose dependant increase in the 
inhibition of amidolytic anti Ila activity of NHP, NRP and NratP, 
however, the assay exhibited the greatest sensitivity to the anti-
protease effects of CY 216 supplemented to NMP. 
The numerical values for the data plotted in Figures 1-8 are 
shown in Appendix XXIII. A comparison of the amidolytic anti Xa and 
anti Ila activities of heparin is shown in Appendix Xlle. A comparison 
of the amidolytic anti Xa and anti Ila activities of CY 216 is shown in 
Appendix Xllf. 
6. In Vitro Protamine Neutralization of Heparin and CY 216 in NHP 
The in vitro protamine neutralization of heparin and CY 216 
supplemented to NHP or NMP as determined by the APTT is shown in Figure 
9. At a concentration of 5 µg/ml, CY 216 only slightly prolonged the 
APTT, while heparin prolonged the APTT to> 150 seconds. A progressive 
degree of neutralization of heparin by protamine (0-10 µg/ml) was 
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noted. At equigravimetric concentrations of heparin and protamine (5 
µg/ml) a complete neutralization of APTT activity was seen. 
The in vitro protamine neutralization of heparin and CY 216 in 
NHP or NMP as determined by the thrombin time assay is shown in Figure 
10. Heparin (5 µg/ml) prolonged the thrombin time to a greater extent 
than CY 216 (5 µg/ml). Complete neutralization of the thrombin time 
activity of heparin was seen at a gravimetric protamine to heparin 
ratio of 1:1 while the thrombin time activity of CY 216 was completely 
neutralized at a gravimetric protamine to CY 216 ratio of 1:2. 
The in vitro protamine neutralization of heparin and CY 216 in 
NHP or NMP as determined by the HeptestR is shown in Figure 11. 
Heparin (5 µg/ml) prolonged the HeptestR to a greater extent than CY 
216 (5 µg/ml). Almost complete neutralization of the HeptestR activity 
was seen at a gravimetric protamine to heparin ratio of 2:1. Only a 
slight degree of neutralization of HeptestR activity was seen at a 
gravimetric protamine to CY 216 ratio of 2:1. 
The in vitro protamine neutralization of heparin and CY 216 in 
NHP or NMP as determined by the amidolytic anti Xa assay is shown in 
Figure 12. Heparin (5 µg/ml) inhibited the amidolytic activity of 
factor Xa to a greater extent than CY 216 (5 µg/ml). Almost complete 
neutralization of the amidolytic anti Xa activity of heparin was seen 
at a protamine to heparin ratio of 1: 1. Only a slight degree of 
neutralization of amidolytic anti Xa activity was seen at a gravimetric 
protamine to CY 216 ratio of 2:1. 
The in vitro protamine neutralization of heparin and CY 216 in 
NHP or NMP as determined by the anti Ila assay is shown in Figure 13. 
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Heparin (5 µg/ml) inhibited amidolytic factor Ila activity to a greater 
extent than CY 216 (5 µg/ml). Almost complete neutralization of the 
anti Ila activity of heparin and CY 216 was seen at a gravimetric 
protamine to heparin (or CY 216) ratio of 1:1. 
The numerical values for the data plotted in Figures 9-13 are 
shown in Appendices XXIIIi and XXIIIj. 
7 . .In Vitro Neutralization of Heparin and CY 216 By Spermidine In 
NHP 
The in vitro neutralization of heparin by spermidine in NHP is 
shown in Table 3. Supplementation of spermidine (10 µg/ml) had no 
effect on the clotting or amidolytic assays. Heparin (5 µg/ml) 
prolonged the APTT and thrombin time assays to> 150 while the HeptestR 
was prolonged to a lesser degree by heparin (5 µg/ml). Heparin (5 
µg/ml) exhibited substantial inhibition of the amidolytic anti Xa and 
amidolytic anti Ila activity. Spermidine was a less potent antagonist 
of the anticoagulant and antiprotease activities of heparin than 
protamine. The APTT and thrombin time activity of heparin (5.0 µg/ml) 
remained prolonged to> 150 seconds even after supplementation of a two 
fold gravimetric amount of spermidine. The anti Ila activity of 
heparin was neutralized to a greater degree than the other activities. 
In contrast, complete neutralization of the anticoagulant and anti-
protease activity of heparin was observed at two fold gravimetric 
concentrations of protamine or less. 
The in vitro neutralization of CY 216 by spermidine in NHP is 
shown in Table 4. CY 216 (5.0 µg/ml) prolonged the APTT to a lesser 
degree than heparin (5.0 µg/ml). No neutralization of the APTT or 
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. HeptestR activity was seen by spermidine (2.5, 5.0, or 10 µg/ml) while 
complete neutralization of the APTT activity was noted at a spei:midine 
concentration of 1 mg/ml. In contrast, HeptestR activity was only 
partially neutralized by spermidine (1 mg/ml). The amidolytic anti Xa 
activity of CY 216 was less neutralizeable than the amidolytic anti Ila 
activity of CY 216. It is interesting to note that the amidolytic 
activity was neutralized to a greater degree than the thrombin time 
clotting activity which suggests that there may be specific structural 
requirements for the neutralization of the different activities of 
heparin as determined by the laboratory assays. 
B. In Vivo Studies 
1. Rat Model of Laser-Induced Thrombosis 
a. Antithrombotic Effects of Protamine 
The effects of protamine sulfate on laser induced thrombosis in 
rats is shown in Figure 14. An increase in number of laser injuries 
required to produce a defined thrombus is related to the antithrombotic 
effect of the drug. Protamine (0.74 mg/kg i.v.) increased the number 
of laser injuries however this increase was not significant (p>.20) as 
determined by an unpaired student t test. 
b. Intravenous Studies 
Protamine antagonism of heparin ( 1 mg/kg i. v. ) in the laser 
induced model of thrombosis is shown in Figure 15. Heparin (1 mg/kg 
i.v.) significantly (p<.05), (as determined by a one way ANOVA) 
increased the number of laser injuries needed to produce a defined 
thrombus. This increase correlates to antithrombotic effect in this 
model. Protamine (0.32 mg/kg i.v.) did not reduce the number of laser 
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injuries needed to produce a defined thrombus and therefore did not 
antagonize the anti thrombotic activity of heparin (1 mg/kg i. v.). A 
protamine concentration of (0.64 mg/kg i.v.) was needed to sufficiently 
antagonize these antithrombotic effects. 
Protamine antagonism of CY 216 ( 1 mg/kg i. v. ) in the laser 
induced model of thrombosis is shown in Figure 16. CY 216 (1 mg/kg 
i.v.) significantly (p<.05), (as determined by a one way ANOVA) 
increased the number of laser injuries required to produce a defined 
thrombus in the laser model of thrombosis. A protamine concentration 
of (0.74 mg/kg i.v.) completely antagonized the antithrombotic effects 
of CY 216. 
c. Subcutaneous Studies 
The effect of subcutaneously administered heparin and CY 216 is 
•hown in Figure 17 . Both heparin and CY 216 at doses of (10 mg/kg 
• .c.) significantly (p <.05), (as determined by a one way ANOVA), 
increased the number of laser injuries required to produce a defined 
thrombus. 
The numerical values for the data plotted in Figures 14-17 are 
shown in Appendix XXIVa. 
2. Rabbit Stasis Thrombosis Model 
A rabbit stasis thrombosis model was used to evaluate the 
antithrombotic effects of heparin and CY 216 and the comparative 
~rotamine neutralization profiles of these drugs. Ex vivo blood 
Samples were analyzed to determine the ex vivo levels of the various 
activities at the time thrombosis was induced. Prothrombin complex 
concentrate and Russel's viper venom were administered to rabbits as a 
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thrombogenic challenge and clots were graded as described in the 
methods section. Antithrombotic effects were studied after intravenous 
and subcutaneous administration of heparin or CY 216 in addition to 
protamine sulfate. 
a. Protamine Sulfate 
The antithrombotic activity of protamine sulfate in a rabbit 
stasis thrombosis model is shown in Figure 18. Concentrations of up to 
500 µg/kg i.v. did not have any significant (p>.10), (as determined by 
a Kruskall Wallis test), inhibitory effect upon thrombus formation in 
this model. 
The APTT, thrombin time, HeptestR, amidolytic anti Xa and 
amidolytic anti Ila results of rabbits administered protamine sulfate 
(100 and 500 µg/kg i.v.) are shown in Table 5. Protamine sulfate did 
not exhibit any significant effects (p>. 20), (as determined by an 
unpaired t test), upon the clotting tests or amidolytic at the doses of 
protamine which were used during the stasis thrombosis experiments. 
b. Heparin 
The anti thrombotic activity of heparin (25, 50 and 100 µg/kg 
i.v.) is shown in Figure 19. Heparin produced significant (p<.05), (as 
determined by a Kruskall Wallis test), dose dependant inhibition of 
clot formation at the three doses studied. 
The APTT, thrombin time and HeptestR results of rabbits admin-
istered heparin (25, 50 and 100 µg/kg i. v.) as demonstrated by the 
APTT, thrombin time and HeptestR are shown in Table 6. Heparin (100 
µg/kg i.v.) produced a significant (p<.05), (as determined by a one way 
ANOVA) prolongation of the APTT and HeptestR. Thrombin time was more 
104 
sensitive to the effects of heparin than the other clotting tests. A 
significant elevation (p<.05) was observed for heparin (50 µg/kg ~.v.). 
Statistical analysis was not performed on the heparin (100 µg/kg i.v.) 
thrombin time data since an indefinite number (> 150 seconds) was 
obtained as a result. 
The ex vivo amidolytic anti Xa and amidolytic anti Ila activity 
of rabbits administered heparin (25, 50 and 100 µg/kg i.v.) is shown in 
Figure 20. Heparin produced an inhibition of the amidolytic action of 
factors Xa and Ila in a dose dependant manner. Significant (p<.05) 
anti Xa activity was seen for heparin (100 µg/kg i.v.) and significant 
anti Ila activity was seen for heparin (50 µg/kg i. v. and 100 µg/kg 
i.v.) as determined by a two way ANOVA. 
Correlation coefficients were calculated to determine the extent 
of the relationship between the circulating ex vivo pharmacodynamic 
activity of intravenously administered heparin and % inhibition of 
thrombosis in a stasis thrombosis model. Poor correlations were 
obtained for all of the tests. Anti Ila had the best correlation 
coefficient (r-.552). The other r values are as follows: APTT-.002, 
thrombin time -.352, HeptestR -.144, anti Ila -.515. 
c. CY 216 
The antithrombotic activity of CY 216 (25, 50 and 100 µg/kg i.v.) 
is shown in Figure 21. CY 216 produced a dose dependant inhibition of 
thrombosis while CY 216 (100 µg/kg i.v.) significantly (p<.05) in-
hibited clot formation as compared to the control group as determined 
by a Kruskall Wallis test. 
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The APTT, thrombin time and HeptestR results of rabbits admin-
istered CY 216 (25, 50 and 100 µg/kg i.v.) is shown in Table 7. CY 216 
(25 µg/kg i. v.) did not have a significant effect upon the clotting 
tests. CY 216 (50 µg/kg i.v.) significantly (p<.05) prolonged the 
thrombin time while CY 216 (100 µg/kg) significantly (p<.05) prolonged 
the thrombin time and HeptestR as determined by a one way ANOVA. 
The fili vivo anti Xa and anti Ila activity of rabbits administered 
CY 216 (25, 50 and 100 µg/kg i. v.) is shown in Figure 22. Minimal 
inhibition (<10%) of factor Xa and factor Ila was shown for CY 216. 
Correlation coefficients were calculated to determine the 
relationship between the circulating ex vivo pharmacodynamic activity 
of intravenously administered CY 216 and% inhibition of thrombosis in 
a stasis thrombosis model. Poor correlations were obtained for all of 
the tests. HeptestR had the best correlation coefficient (r-.806). 
The other r values are as follows: APTT-.152, thrombin time -.570, 
anti Xa -.306 and anti Ila -.311. 
d. Protamine Antagonism of the Effects of Heparin and CY 216 
1. Intravenous Studies 
The clot scores obtained after protamine neutralization of either 
heparin (100 µg/kg i.v.) or CY 216 (100 µg/kg i.v.) is shown in Figure 
23. Protamine completely antagonized the anti thrombotic activity of 
heparin (100 µg/kg i. v.) at equigravimetric amounts of protamine and 
heparin. The antithrombotic activity of CY 216 (100 µg/kg i.v.), 
however, was not completely antagonized even at a gravimetric ratio 
protamine to heparin ratio of 2:1. This residual antithrombotic 
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activity which remained after protamine was significant (p<. 05) as 
compared to the control group as determined by a two way ANOVA. 
The coagulation parameters of rabbits administered intravenous 
heparin or CY 216 and protamine as determined by the APTT, thrombin 
time and HeptestR are shown in Table 8. Protamine (200 µg/kg i. v.) 
completely neutralized the thrombin time and HeptestR activity of 
heparin (100 µg/kg i. v.) and CY 216 (100 µg/kg i. v.). The HeptestR 
activity of heparin was neutralized to a greater degree than the 
HeptestR activity of CY 216. 
The ~ vivo anti Xa activity after protamine neutralization of 
heparin or CY 216 in rabbits is shown in Figure 24. Heparin exhibited 
a significant (p<.05) degree of inhibition of amidolytic factor Xa 
activity which was completely neutralized by protamine. CY 216 
inhibited factor Xa by approximately 10 % while only a slight degree 
of neutralization of the anti Xa activity of CY 216 was seen. 
The~ vivo anti Ila activity after protamine neutralization of 
heparin or CY 216 in rabbits is shown in Figure 25. Heparin exhibited 
significant (p<.05), (as determined by a two way ANOVA), inhibition of 
amidolytic anti Ila activity which was completely neutralized by 
protamine sulfate. CY 216 administration did not have any effect on 
this activity. 
Poor correlation coefficients were obtained for residual activity 
after heparin neutralization and clot score (r-. 246 for APTT, r-. 685 
for thrombin time, r-.107 for HeptestR, r-.246 for anti Xa and r-.148 
for anti Ila). The correlation obtained for residual activity after CY 
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216 neutralization and clot score (r-.185 for APTT, r-.001 for thrombin 
time, r-.433 for HeptestR, r-.473 for anti Xa and r-.153 for anti Ila). 
2. Subcutaneous Studies 
Clot scores obtained in the rabbit stasis thrombosis after the 
administration of heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) and 
subsequent antagonism by protamine sulfate (1 mg/kg i.v.) are shown in 
Figure 26. Heparin (1 mg/kg s.c.) and CY 216 (1 mg/kg i.v.) exhibited 
significant (p<.05), (as determined by a two way ANOVA) inhibition of 
thrombus formation as compared to the control group. Protamine sulfate 
(1 mg/kg i. v.) completely antagonized the anti thrombotic effects of 
heparin (1 mg/kg s.c.). CY 216 exhibited a 30% inhibition of throm-
bosis as compared to control, however, this was not significant. 
Protamine sulfate did not antagonize the antithrombotic effects of CY 
216 (1 mg/kg s.c.). 
The coagulation parameters of rabbits administered subcutaneous 
heparin or CY 216 and protamine sulfate are shown in Table 9. Assay 
dependant differences in the neutralization of heparin and CY 216 were 
observed. The APTT was not significantly (p>.50), (as determined by a 
two way ANOVA) prolonged after heparin or CY 216 administration. The 
thrombin time for heparin (1 mg/kg s. c.) was prolonged to a greater 
extent than after the administration of CY 216. After equigravimetric 
protamine administration, the thrombin time activity of CY 216 was 
completely neutralized while this activity of heparin was substantially 
neutralized however not to baseline levels. The HeptestR was sig-
nificantly (p<.05) prolonged by heparin (1 mg/kg s.c.) and by CY 216 (1 
mg/kg s.c.). Protamine completely neutralized the HeptestR activity 
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of heparin, however not all of HeptestR activity of CY 216 was neutral-
ized. 
Heparin (1 mg/kg s.c.) and CY 216 (1 mg/kg s.c.) significantly 
(p<.05) inhibited amidolytic factor Xa activity as shown in Figure 27. 
This activity was not neutralized by protamine (1 mg/kg i. v.) to 
control levels. 
Heparin (1 mg/kg s. c). and CY 216 (1 mg/kg s. c.) exhibited a 
significant (p<.05), (as determined by a two way ANOVA), inhibition of 
the amidolytic activity of factor Ila as shown in Figure 28. Protamine 
neutralized this activity of heparin to a greater degree than CY 216. 
The numerical values for the data plotted in Figures 18-27 are 
shown in Appendix XXIVg - XXIVj. 
3. Rat Tail Bleeding Model 
a. Intravenous Studies 
The effects of saline, protamine (1 mg/kg i.v.), heparin (2 mg/kg 
i. v.) and CY 216 (2 mg/kg i. v.) are shown in Figure 29. Heparin (2 
mg/kg i.v.) significantly (p <.05), (as determined by a one way ANOVA), 
prolonged the bleeding time while CY 216 or protamine had lesser 
effects on the bleeding time. 
The antagonism of the bleeding effects of intravenously ad-
ministered heparin and CY 216 by equigravimetric doses of protamine are 
shown in Figure 30. Heparin (2 mg/kg i.v.) significantly (p<.05), (as 
determined by a one way ANOVA) prolonged the bleeding time in this 
model, however, the bleeding time returned to control values after the 
administration of protamine (2 mg/kg i. v.). CY 216 did not sig-
nificantly prolong the bleeding time in rats as compared to the control 
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group and subsequent protamine administration had no further effect on 
the bleeding time after subcutaneous administration of CY 216. 
b. Subcutaneous Studies 
The antagonism of subcutaneously administered heparin and CY 216 
in a rat tail bleeding model is shown in Figure 31. Heparin (2.5 mg/kg 
s.c.) or CY 216 at (2.5 mg/kg s.c.) did not significantly (p>.50), (as 
determined by a one way ANOVA) , prolong the bleeding time which was 
determined 2 hours after drug administration. 
protamine did not further affect the bleeding time. 
Administration of 
The numerical values for the data plotted in Figures 29-31 are 
shown in Appendix XXIVb. 
4. Rabbit Ear Blood Loss Model 
The antagonism of heparin or CY 216 induced blood loss was 
studied in a rabbit ear model. Heparin and CY 216 were administered by 
intravenous and subcutaneous routes of administration and blood samples 
were obtained by cardiac puncture. Plasma was analyzed using the APTT, 
thrombin time, HeptestR, amidolytic anti Xa and amidolytic anti Ila 
methods. 
a. Intravenous Studies 
1. Protamine Sulfate 
The effect of protamine sulfate in a rabbit ear model of blood 
loss is shown in Figure 32. As previously described in methods, the 
red blood cells resulting from 5 full thickness cuts in the medial 
portion of the rabbit ear were collected in 1 liter of saline for 10 
minutes at 37°c. The cells were counted using a HycelR cell counter and 
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blood loss was reported as RBCs x 109/liter. Protamine sulfate (2 and 
3 mg/kg i.v.) did not increase blood loss as compared to control. 
Figure 33. demonstrates the ex vivo anticoagulant effect of 
protamine sulfate (2 and 3 mg/kg i.v.) administered to rabbits as 
·determined by the APTT. Protamine prolonged the APTT in a dose related 
manner, however this increase in clotting time was not significant 
(p>.01) as determined by a one way ANOVA. 
The effects of protamine sulfate administration to rabbits as 
determined by the thrombin time, HeptestR, amidolytic anti Xa and 
amidolytic anti Ila methods are shown in Table 10. Protamine (2 and 3 
mg/kg i. v.) did not prolong th.e clotting times to any great extent or 
have any effect on the amidolytic anti Xa or amidolytic anti Ila 
assays. 
2. Heparin 
The effect of heparin (1 and 2 mg/kg i.v.) is shown in Figure 34. 
Heparin produced a dose related increase in blood loss which was 
significant (p <.05) as compared to control as determined by a one way 
ANOVA. 
The effects of heparin administration to rabbits as determined by 
the APTT, thrombin time and HeptestR are shown in Table 11. The high 
doses of heparin used in the rabbit ear blood loss studies significant-
ly prolonged the clotting times to > 150 seconds for the APTT and 
thrombin time and> 300 seconds for the HeptestR. 
The ex vixo amidolytic anti Xa activity after heparin administra-
tion to rabbits is shown in Figure 35. Heparin produced a dose related 
inhibition of the amidolytic action of factor Xa. Heparin (2 mg/kg 
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i.v.) caused a significant (p <.05) inhibition of factor Xa as compared 
to control as determined by a one way ANOVA. 
Similarly, heparin inhibited the amidolytic action of factor Ila 
in a dose related manner. Figure 36 shows the ~ vivo anti Ila 
activity of heparin after intravenous administration to rabbits. 
Heparin (1 and 2 mg/kg i.v.) significantly (p <.05) inhibited factor 
Ila as compared to control as determined by a one way ANOVA. 
Correlation coefficients were calculated to determine the 
relationship between circulating pharmacodynamic activity and heparin-
induced blood loss. Poor correlations (r-.690 for anti Xa and r-.564 
for anti Ila) were obtained for the laboratory tests. 
3. CY 216 
The effect of CY 216 (1, 2 and 3 mg/kg i. v.) in a rabbit ear 
model of blood loss is shown in Figure 37. CY 216 produced a dose 
related increase in blood loss. CY 216 (3 mg/kg i. v.) produced 
significant (p < 0.05) increase in blood loss as compared to control as 
determined by a one way ANOVA. 
The effects of CY 216 administered to rabbits as determined by 
the APTT, thrombin time and HeptestR are shown in Table 12. The high 
doses of heparin used in the rabbit ear blood loss studies significant-
ly prolonged the clotting times to > 150 seconds for the APTT and 
thrombin time and> 300 seconds for the HeptestR. 
The ~ vivo amidolytic anti Xa activity of CY 216 after ad-
ministration to rabbits is shown in Figure 38. CY 216 increased the 
inhibition of the amidolytic factor Xa activity in a dose related 
manner. Significant (p<.05) inhibition of amidolytic factor Xa 
112 
activity was seen at the three doses studied (1, 2 and 3 mg/kg i.v.) as 
compared to control as determined by a one way ANOVA. 
Similarly, CY 216 produced a dose dependant inhibition of the 
amidolytic action of factor Ila. Figure 39 shows the ex vivo amido-
lytic anti Ila activity of CY 216 after administration to rabbits. CY 
216 (1, 2 and 3 mg/kg i.v.) significantly (p <.05) inhibited factor Ila 
as compared to control as determined by a one way ANOVA. 
Correlation coefficients were calculated to determine the 
relationship between circulating ex vivo activity and the CY 216 
induced-blood loss. Poor correlations were obtained (r-.515 for 
HeptestR, r-.102 for anti Xa and r-.186 for anti Ila) for the various 
laboratory tests. 
4. Protamine Antagonism of the Effects of Heparin and CY 216 
a. Intravenous Studies 
The protamine antagonism of heparin (2 mg/kg i.v.) and CY 216 (2 
mg/kg i.v.) induced blood loss is shown in Figure 40. Heparin (2 mg/kg 
i.v.) produced a significant (p <.05), (as determined by a two way 
ANOVA), increase in blood loss as compared to control. The blood loss 
induced by CY 216 was completely antagonized by an equigravimetric 
amount of protamine, however a two fold gravimetric amount of protamine 
was needed to completely antagonize the blood loss induced by heparin. 
Ex vivo coagulation parameters as determined by the APTT, 
thrombin time and HeptestR obtained after heparin or CY 216 and 
protamine administration in rabbits are shown in Table 13. Although 
the clotting times were significantly prolonged by heparin (2 mg/kg 
i.v.) and CY 216 (2 mg/kg i.v.), protamine completely neutralized the 
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,APTT activity at equigravimetric amounts of protamine and heparin or CY 
16 The thrombin time activity was completely neutralized at a 2 . 
gravimetric heparin (or CY 216) to protamine ratio of 1: 2. Although 
protamine (3 mg/kg i.v.) significantly neutralized the HeptestR 
activity of heparin (2 mg/kg i. v.), CY 216 was not completely neutral-
ized at this dose. Significant (p<.05), (as determined by a two way 
ANOVA), activity remained after protamine (3 mg/kg i.v.) administration 
to rabbits which received CY 216 (2 or 3 mg/kg i.v.) as compared to 
the control group. 
The~ vivo amidolytic anti Xa activity after protamine neutral-
ization of heparin or CY 216 administered to rabbits is shown in Figure 
41. Both heparin and CY 216 significantly (p<.05) inhibited the 
amidolytic actions of factor Xa as determined by a two way ANOVA. 
Protamine (2 and 3 mg/kg i. v.) completely neutralized the anti Xa 
activity of heparin, however these doses of protamine did not complete-
ly neutralize the anti Xa activity of CY 216. Significant (p<.05) 
inhibition of factor Xa remained after protamine (2 and 3 mg/kg i.v.) 
administration. The ex vivo anti Ila activity after protamine neutral-
ization of heparin or CY 216 in rabbits is shown in Figure 42. Both 
heparin and CY 216 caused a significant increase in the inhibition of 
factor Ila. Protamine (2 and 3 mg/kg i.v.) completely neutralized this 
activity. 
The correlation coefficients obtained for residual activity after 
heparin neutralization and blood loss are as follows: r-.421 for APTT, 
r•.765 for thrombin time, r-.391 for HeptestR, r-0 for anti Xa and r-0 
for anti Ila. The correlation obtained for residual activity after CY 
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216 neutralization and blood loss are as follows: r-.576 for APTT, 
t-9.812 for thrombin time, r-.460 for anti Xa and r- 0 for anti Ila. 
b. Subcutaneous Studies 
Heparin and CY 216 (3 mg/kg s.c.) did not increase the blood loss 
which was determined 2 hours after the administration of these agents. 
,rotamine (3 mg/kg i.v.) administration to rabbits did not have any 
additional effects on blood loss as shown in Figure 43. 
The neutralization of heparin (3 mg/kg s.c.) and CY 216 (3 mg/kg 
1 .c.) by equigravimetric protamine as determined by APTT, thrombin time 
and HeptestR is shown in Table 14. Although the clotting times were 
elevated by heparin (3 mg/kg s. c.), protamine completely neutralized 
the APTT and thrombin time activity at a gravimetric protamine to 
heparin ratio of 1:1. After administration of heparin (3 mg/kg s.c.) 
the HeptestR clotting time was significantly prolonged (p<.05), (as 
determined by a two way ANOVA). Protamine (3 mg/kg i.v.) neutralized 
the HeptestR activity to almost control levels. CY 216 (3 mg/kg s.c.) 
did not prolong the APTT. The thrombin time activity of CY 216 (3 
• g/kg s. c.) was completely neutralized at equigravimetric protamine 
dose and CY 216 (3 mg/kg s.c.) significantly (p<.05) prolonged the 
HeptestR, however, this activity was not neutralized by protamine (3 
• g/kg i. V. ) • 
The~ vivo amidolytic anti Xa activity after protamine neutrali-
zation of heparin or CY 216 in rabbits is shown in Figure 44. Both 
heparin (3 mg/kg s.c.) and CY 216 (3 mg/kg s.c.) exhibited significant 
(P<.05) inhibition of amidolytic factor Xa activity as determined by a 
two way ANOVA. Heparin (3 mg/kg s.c.) produced an inhibition of the 
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amidolytic action of factor Xa which was completely neutralized by 
protamine (3 mg/kg i.v.) while, this activity of CY 216 (3 mg/kg s.c.) 
was not completely neutralized. 
The~ vivo amidolytic anti Ila activity after protamine neutral-
ization of heparin or CY 216 in rabbits is shown in Figure 45. Both 
heparin (3 mg/kg s.c.) and CY 216 (3 mg/kg s.c.) exhibited significant 
(p<.05) inhibition of amidolytic factor Ila activity as determined by a 
two way ANOVA. The amidolytic anti Ila activity of heparin (3 mg/kg 
s.c.) and CY 216 (3 mg/kg s.c.) was completely neutralized by protamine 
( 3 mg/kg i. v. ) . 
The numerical values for the data plotted in Figures 32-45 are 
shown in Appendix XXIV. 
5. Protamine Administration to Primates 
The time course of the anticoagulant effects of protamine (2 .1 
mg/kg i. v.) administration to primates is shown in Figure 46. This 
dose of protamine had minimal effects on clotting as determined by the 
APTT, thrombin time and HeptestR assays. A slight decrease in thrombin 
time activity was seen immediately after protamine administration, 
however this activity returned to control values by 30 minutes. 
The time course of the antiprotease effects protamine (2.1 mg/kg 
i. v.) in primates as determined by amidolytic anti Xa and anti Ila 
assays is shown in Figure 47. Protamine (2.1 mg/kg i.v.) had no effect 
on amidolytic anti Xa activity, however, it produced a significant 
increase (p<.05),(as determined by a two way ANOVA), in the inhibition 
of factor Ila as compared to control values. As shown earlier in 
Figures 46 and 4 7, the clotting and amidolytic methods were not very 
nsitive to the effects of protamine sulfate. se 
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In order to determine 
the time course of protamine sulfate activity in primates, ex vivo 
plasma samples obtained from the primates administered protamine (2.1 
mg/kg i.v.) were supplemented with heparin (25 µg/ml to obtain a final 
• heparin concentration of 2. 5 µg/ml. The degree of neutralization of 
the HeptestR activity for the heparin (2.5 µg/ml) by protamine in the 
exvivo plasma sample was an indirect measure of the circulating levels 
of protamine activity. The results from this study are shown in Figure 
48. At 5 minutes after supplementation a measurable amount decrease in 
heparin activity suggesting protamine activity. Statistical analysis 
by a two way ANOVA revealed no significant differences in HeptestR 
activity at the dosages studied, however this data suggests that the 
t1;2 of protamine is less than 30 minutes. 
6. Time Course of The Protamine Neutralization of Heparin and CY 
216 in Primates 
Protamine neutralization of the pharmacodynamic time course of 
intravenously and subcutaneously administered heparin and CY 216 was 
studied in the primate (Macaca mulatta) . Activity of heparin and CY 
216 was determined using APTT, thrombin time, HeptestR, amidolytic 
anti Xa and amidolytic anti Ila methods. Pharmacodynamic time course 
parameters were calculated from concentrations obtained from HeptestR 
and amidolytic anti Xa activity data which was extrapolated from 
calibration curves of heparin or CY 216 supplemented to NMP. 
a. Intravenous Administration 
The time course of APTT activity of heparin (0. 7 mg/kg i. v.) 
prior to and after neutralization by protamine sulfate ( 0. 7, 1. 4 and 
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2 .1 mg/kg i. v. ) is shown in Figure 49. After administration of 
heparin, the clotting time was > 150 seconds and remained elevated 
above baseline until 3 hours after injection. Complete neutralization 
of APTT activity was seen immediately after protamine sulfate (1.4 
mg/kg i. v. and 2 .1 mg/kg i. v.) administration. However, significant 
(p<.05) APTT activity remained 5 minutes after protamine (0. 7 mg/kg 
i.V.) administration as determined by a two way ANOVA. Partial 
neutralization of the APTT activity of heparin by protamine sulfate 
(0.7 mg/kg i.v.) was observed. 
The time course of thrombin time activity of heparin (0.7 mg/kg 
i.v.) prior to and after neutralization by protamine sulfate (0.7, 1.4 
and 2 .1 mg/kg i. v.) is shown in Figure 50. After administration of 
heparin, the clotting time was> 150 seconds and returned to baseline 
at 6 hours. Complete neutralization of thrombin time activity was 
seen for protamine (1. 4 and 2 .1 mg/kg i. v.) at 60 minutes. Wide 
variation in the neutralization by protamine (0.7 mg/kg i.v.) was seen 
during the first hour after protamine administration. 
The time course of HeptestR activity of heparin (0.7 mg/kg i.v.) 
prior to and after neutralization by protamine sulfate (0. 7, 1. 4 and 
2.1 mg/kg i.v.) is shown in Figure 51. After administration of heparin 
(0.7 mg/kg i.v.), the clotting time was> 300 seconds and returned to 
baseline values by 6 hours. Protamine sulfate substantially neutral-
ized the HeptestR activity of heparin (0.7 mg/kg i.v.). Complete 
neutralization of HeptestR activity by protamine (2 .1 mg/kg i. v.) was 
seen at 1 hour while complete neutralization of HeptestR activity by 
protamine (1.4 and 0.7 mg/kg i.v.) occurred by 3 hours. 
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The time course of the amidolytic anti Xa activity of heparin 
(0.7 mg/kg i.v.) prior to and after neutralization by protamine sulfate 
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 52. After administra-
tion of heparin (0.7 mg/kg i.v.), the% inhibition of amidolytic factor 
xa activity was 92% which returned to baseline activity by 6 hours. 
Dose dependant protamine neutralization of this anti Xa activity was 
seen. 
The time course of the amidolytic anti Ila activity of heparin 
(0.7 mg/kg i.v.) prior to and after neutralization by protamine sulfate 
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 53. After administra-
tion of heparin (0.7 mg/kg i.v.) the% inhibition of factor Ila was 91 
% which did not completely return to baseline until 6 hours. At the 3 
hour time period, complete neutralization of the amidolytic anti Ila 
activity of heparin was seen with all doses of protamine sulfate 
administered. The time course of APTT activity of CY 216 (0. 7 mg/kg 
i.v.) prior to and after neutralization by protamine sulfate (0.7, 1.4 
and 2.1 mg/kg i.v.) is shown in Figure 54. CY 216 (0.7 mg/kg i.v. and 
0. 35 mg/kg i. v.) prolonged the clotting time to a lesser degree than 
heparin at the same dose. Complete neutralization of the APTT activity 
of CY 216 was seen after the administration of protamine (0.7, 1.4 and 
2 . 1 mg/kg i. V. ) • 
The time course of thrombin time activity of CY 216 (0. 7 mg/kg 
i.v.) prior to and after neutralization by protamine sulfate (0.7, 1.4 
and 2 .1 mg/kg i. v.) as shown in Figure 55. CY 216 (0. 7 mg/kg i. v.) 
prolonged the clotting time to a lesser degree than heparin at the same 
dose. While neutralization of the thrombin time activity of CY 216 was 
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seen after the administration of protamine (1.4 mg/kg i.v.). Complete 
neutralization of thrombin time activity by protamine (0.7 mg/kg i.v.) 
was seen at 1 hour. 
The time course of HeptestR activity of CY 216 (0.7 mg/kg i.v.) 
prior to and after neutralization by protamine sulfate (0. 7, 1. 4 and 
2 .1 mg/kg i. v. ) is shown in Figure 56. CY 216 (0. 7 mg/kg i. v.) 
prolonged the HeptestR to> 300 seconds. CY 216 (0.7 mg/kg i.v.) did 
not prolong the HeptestR to the same extent as did the same concentra-
tions of heparin. Protamine sulfate (0.7, 1.4 and 2.1 mg/kg i.v.) did 
not neutralize the HeptestR activity of CY 216 to any significant 
extent. 
The time course of the amidolytic anti Xa activity of CY 216 (0.7 
mg/kg i. v. ) prior to and after neutralization by protamine sulfate 
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 57. Inhibition of the 
amidolytic actions of factor Xa by CY 216 (0.7 mg/kg i.v.) was seen for 
over 6 hours. Dose dependant neutralization of this activity of CY 216 
was seen by protamine ( 0. 7 mg/kg i. v. ) . Statistically significant 
(p<. 05) differences in neutralization were seen after protamine (0. 7 
mg/kg i.v.) and protamine (2.1 mg/kg i.v.) as determined by a two way 
ANOVA. Complete neutralization of the factor Xa inhibition was not 
seen at these doses of protamine studied. 
The time course of amidolytic anti Ila activity of CY 216 (0. 7 
mg/kg i. v. ) prior to and after neutralization by protamine sulfate 
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 58. Inhibition of the 
amidolytic action of factor Ila by CY 216 (0.7 mg/kg i.v.) was seen at 
3 hours. Dose dependant neutralization of the anti II activity of CY 
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216 (0.7 mg/kg i.v) was seen, with complete neutralization of anti Ila 
activity at 3 hours. With protamine (0.7 mg/kg i.v.), a slight rebound 
of anti Ila activity which returned to baseline after 3 hours. 
b. Subcutaneous Studies 
The time course of HeptestR activity after administration of 
heparin (0.7 mg/kg s.c.) prior to and after neutralization by protamine 
sulfate (0. 7 mg/kg i. v.) as shown in Figure 59. Protamine was ad-
ministered at 4 hours, at a time when the heparin activity was strong. 
complete neutralization of the HeptestR activity of heparin was seen at 
this time. 
As shown in Figure 60, CY 216 was not readily neutralized by 
protamine sulfate in the HeptestR assay. Even two fold gravimetric 
amount of protamine sulfate did not neutralize this activity of 
subcutaneously administered CY 216. At 9 hours, after the administra-
tion of protamine the HeptestR clotting time was prolonged to almost 
two times the baseline levels. 
The time course of the neutralization of heparin (0.7 mg/kg s.c.) 
as shown in Figure 61. Low levels of amidolytic anti Xa inhibition 
were noted after the administration of heparin (0.7 mg/kg s.c.) and no 
changes in the amidolytic anti Xa activity after protamine administra-
tion of this activity was seen. Heparin contains less low molecular 
weight components than CY 216 and therefore exhibits less anti Xa 
activity after subcutaneous administration. 
The time course of the neutralization of amidolytic anti Xa 
activity of CY 216 (0.7 mg/kg s.c.) is shown in Figure 62. After 
protamine administration, at 4 hours, CY 216 inhibited the amidolytic 
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anti Xa activity approximately 50 %. As time continued, this activity 
of the group of primates which received protamine closely followed the 
time course of the group which received CY 216 (0.7 mg/kg s.c.). This 
data suggests that protamine initially neutralized the anti Xa activity 
of CY 216 but failed to neutralize the activity of CY 216 which was 
absorbed at a later time period. 
c. Pharmacodynamic Time Course Parameters 
Pharmacodynamic time course parameters were calculated using a 
noncompartmental model as previously described in methods. Concentra-
tions (µg/ml) were obtained after extrapolation from calibration curves 
of anti Xa or HeptestR activity of heparin and CY 216 after supplemen-
tation to NMP. 
The numerical values for the data plotted in Figures 49-62 are 
shown in Appendix XXV. 
1. Anti Xa 
a. Intravenous Studies 
The pharmacodynamic time course parameters for heparin (0. 35 
mg/kg i.v). and CY 216 (0.35 mg/kg i.v). as calculated from amidolytic 
anti Xa activity data are shown in Table 15. A comparison of these 
parameters reveal that the AUC: CY 216 > heparin , MRT: CY 216 > 
heparin, Clp: heparin> CY 216 and Vd: heparin> CY 216. The AUC, MRT 
and Clp of CY 216 were significantly (p<.05) than the similar paramet-
ers for heparin as determined by an unpaired student's t test. 
Table 16 shows the pharmacodynamic time course parameters for 
heparin (0.7 mg/kg i.v). and CY 216 (0.7 mg/kg i.v.) as calculated from 
amidolytic anti Xa activity data. A comparison of these parameters 
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reveal that the AUC: heparin> CY 216, MRT: CY 216 > heparin, Clp: CY 
216 > heparin, Vd: CY 216 > heparin. However there was no significant 
(p>.10) difference between the AUC, MRT, Clp and Vd values of heparin 
(0. 7 mg/kg i. v). and CY 216 (0. 7 mg/kg i. v.) as determined by an 
unpaired student's t test. 
When protamine sulfate was administered in equigravimetric doses 
to heparin (0. 7 mg/kg i. v.) or CY 216 (0. 7 mg/kg i. v.), the pharm-
acodynamic time course parameters obtained are shown in Table 17. A 
comparison of these parameters revealed that the AUC: CY 216 > heparin, 
MRT: CY 216 > heparin, PNI: heparin> CY 216. However, AUC and PNI 
values after equigravimetric neutralization of heparin or CY 216 by 
protamine (0.7 mg/kg i.v.) were significantly different as determined 
by an unpaired student's t test. 
When protamine sulfate (1.4 mg/kg i.v.) was administered in a two 
fold gravimetric dose to heparin (0.7 mg/kg i.v.) or CY 216 (0.7 mg/kg 
i.v.), the pharmacodynamic time course parameters obtained are shown in 
Table 18. A comparison of these parameters revealed that following: 
AUC: CY 216 > heparin, MRT: CY 216 > heparin and PNI: heparin> CY 216. 
The AUC of CY 216 (0.7 mg/kg i.v.) and protamine (1.4 mg/kg i.v.) was 
significantly greater (p <.05) than the AUC of heparin (0.7 mg/kg i.v.) 
and protamine (1.4 mg/kg i.v.) as determined by an unpaired student's t 
test. The PNI was also significantly (p<.05) greater for heparin (0.7 
mg/kg i.v) and protamine (1.4 mg/kg i.v.) than CY 216 (0.7 mg/kg i.v.) 
and protamine (1.4 mg/kg i.v.). 
When protamine sulfate (2 .1 mg/kg i. v) was administered in a 
three fold gravimetric dose of heparin (0.7 mg/kg i.v.) and CY 216 (0.7 
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mg/kg i.v.), the primate pharmacodynamic time course parameters 
obtained are shown in Table 19. A comparison of these parameters 
revealed that following: AUC: CY 216 > heparin, MRT: heparin> CY 216, 
and PNI: heparin > CY 216. The AUC of CY 216 (0. 7 mg/kg i. v.) and 
protamine (2 .1 mg/kg i. v.) was significantly greater (p<. 05) than the 
AUC of heparin (0. 7 mg/kg i. v.) and protamine (2 .1 mg/kg i. v.) as 
determined by an unpaired student's t test. The PNI was significantly 
greater (p<.05) for heparin (0.7 mg/kg i.v.) and protamine (2.1 mg/kg 
i.v.) than for CY 216 (0.7 mg/kg i.v) and protamine (2.1 mg/kg i.v.). 
In summary, while studying the neutralization intravenously 
administered heparin and CY 216, the AUC of CY 216 was generally 
greater than the AUC of heparin after neutralization by protamine 
sulfate. In most cases the MRT of CY 216 was longer than that of 
heparin, in most cases. After protamine administration, the PNI of 
heparin was greater than the PNI of CY 216 which indicated that heparin 
was more neutralizable than CY 216 as determined by the anti Xa method. 
b. Subcutaneous Studies 
The pharmacodynamic time course parameters for heparin (0.7 mg/kg 
s.c.) and CY 216 (0.7 mg/kg s.c.) as calculated from amidolytic anti Xa 
activity data are shown in Table 20. A comparison of these parameters 
revealed that the AUC: CY 216 > heparin, MRT: CY 216 > heparin, Clp: 
heparin> CY 216, and Vd: heparin> CY 216. The AUC, MRT, Clp, Vd of 
CY 216 (0.7 mg/kg s.c.) were significantly different (p<.05) than 
similar parameters of heparin (0. 7 mg/kg s. c.) as determined by an 
unpaired student's t test. 
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When protamine was administered in equigravimetric doses to 
primates which received heparin (0.7 mg/kg s.c.) or CY 216 (0.7 mg/kg 
s.c.), the following pharmacodynamic time course parameters which were 
obtained are shown in Table 21. A comparison of these parameters reveal 
that the AUC: CY 216 > heparin, MRT: heparin> CY 216, PNI: heparin> 
CY 216. The AUC of CY 216 was significantly (p<.05) greater than the 
AUC of heparin as determined by an unpaired student's t test. No 
significant differences were seen between the other pharmacodynamic 
time course parameters. 
When protamine was administered in two fold gravimetric doses to 
primates given CY 216, the pharmacodynamic time course parameters which 
were obtained are shown in Table 22. There was no difference in the 
time course parameters of CY 216 (0.7 mg/kg s.c.) and protamine (0.7 or 
1. 4 mg/kg i. v. ) . 
2. HeptestR 
a. Intravenous Studies 
The pharmacodynamic time course parameters for heparin (0. 35 
mg/kg i. v.) and CY 216 (0. 35 mg/kg i. v.) as calculated from HeptestR 
activity data are shown in Table 23. A comparison of these parameters 
reveal that the AUC: CY 216 > heparin, MRT: CY 216 > heparin, Clp: 
heparin> CY 216, Vd: heparin> CY 216. Significant differences were 
seen for AUC, MRT (p<.05) and Clp (p<.05) of heparin and CY 216 as 
determined by an unpaired student's t test. 
The pharmacodynamic time course parameters for heparin (0.7 mg/kg 
1. v.) and CY 216 (0. 7 mg/kg i. v.) as calculated by the HeptestR are 
shown in Table 24. A comparison of these parameters reveal that the 
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AUC: CY 216 > heparin, MRT: heparin> CY 216, Clp: heparin> CY 216, 
Vd: heparin > CY 216. Significant (p<.05) differences were seen 
between the AUC and MRT values of heparin (0.7 mg/kg i.v.) and CY 216 
(0.7 mg/kg i.v.) as determined by an unpaired student's t test. 
'When protamine sulfate was administered in equigravimetric doses 
to heparin (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg i.v.), the pharmaco-
dynamic time course parameters which were obtained are shown in Table 
25. A comparison of these parameters reveal that the AUC: CY 216 
>heparin, MRT: CY 216 > heparin, PNI: heparin - CY 216. However, the 
AUC was the only parameter of CY 216 which was significantly (p<.05) 
different from heparin as determined by an unpaired student's t test. 
'When protamine sulfate was administered in twice gravimetric 
dosages to heparin (0. 7 mg/kg i. v.) and CY 216 (0. 7 mg/kg i. v.) the 
following primate pharmacodynamic time course parameters were obtained 
as shown in Table 26. A comparison of these parameters reveal that the 
AUC: CY 216 >heparin, MRT: heparin> CY 216, PNI: heparin> CY 216. 
the AUC, MRT and PNI values of CY 216 (0.7 mg/kg i.v.) after the 
administration of two fold gravimetric amounts of protamine were 
significantly (p<.05) different as determined by an unpaired student's 
t test. 
When protamine sulfate was administered in three times gravi-
metric dosages to heparin (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg i.v.) 
the following primate pharmacodynamic time course parameters were 
obtained as shown in Table 27. A comparison of these parameters reveal 
that the results are AUC: CY 216 >heparin, MRT: CY 216 > heparin, PNI: 
heparin> CY 216. After protamine (2.1 mg/kg i.v.) neutralization of 
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heparin (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg i.v.) the AUC and PNI of 
CY 216 was significantly (p<.05) different than for heparin. 
b. Subcutaneous Studies 
The pharmacodynamic time course parameters for heparin (0.7 mg/kg 
s.c.) and CY 216 (0.7 mg/kg s.c.) as calculated from HeptestR activity 
data are shown in Table 28. A comparison of these parameters reveal 
that the AUC: CY 216 > heparin, MRT:heparin > CY 216, Clp: heparin> CY 
216, Vd: heparin - CY 216. The AUC was the only parameter which was 
significantly (p<.05) different between the heparin and CY 216 groups. 
Bioavailability after subcutaneous administration of heparin and CY 216 
as determined by the amidolytic anti Xa assay was calculated. CY 216 
(0.7 mg/kg s.c.) exhibited 80% greater bioavailability than heparin 
(0.7 mg/kg s.c.) 
The pharmacodynamic time course parameters for heparin (0.7 mg/kg 
s.c.) with protamine (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg s.c.) with 
protamine (0.7 mg/kg i.v.) as calculated from the HeptestR method are 
shown in Table 29. A comparison of these parameters reveal that the 
results are AUC: CY 216 > heparin, MRT: CY 216 > heparin and PNI: 
heparin> CY 216. Significant (p<.05) differences between the AUC, MRT 
and PNI of heparin and CY 216 were observed as determined by an 
unpaired student t test. 
The primate pharmacodynamic time course parameters obtained when 
protamine (1.4 mg/kg i. v.) was administered to primates given CY 216 
(0. 7 mg/kg s. c.) are shown in Table 30. A comparison of these para-
meters reveal that the AUC < for CY 216 (0.7 mg/kg s.c.) and protamine 
(0.7 mg/kg i.v.) than for CY 216 (0.7 mg/kg s.c.) and protamine (1.4 
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mg/kg i.v.) than when equigravimetric protamine was given to neutralize 
CY 216 (0.7 mg/kg s.c.). The MRT and PNI were slightly increased as 
compared to CY 216 (0.7 mg/kg s.c.) and protamine (0.7 mg/kg i.v.). 
7. Comparative% Neutralization of Heparin and CY 216 in the 
Animal Models 
Per cent neutralization values of the ex vivo activities obtained 
in the animal models were calculated as previously described in 
methods. These calculations provided a means of comparison of the 
degree of neutralization observed in the animal models at the various 
doses studied. Per cent neutralization values which were calculated at 
gravimetric protamine to heparin ratio of 1:1, 2:1 and 3:1 were 
compared for the intravenous studies are shown in Table 31 (anti Xa) 
and Table 32 (anti Ila). Per cent neutralization values for the 
subcutaneous studies are shown in Table 33 (anti Xa) and Table 34 (anti 
Ila). 
Lower % neutralization values were observed for CY 216 as 
compared to heparin as determined by the amidolytic anti Xa and anti 
Ila assays. In rabbits, the amidolytic anti Ila activity was complete-
ly neutralized at a gravimetric protamine to heparin ratio of 2: 1, 
while the amidolytic anti Xa activity was not completely neutralized. 
After subcutaneous administration of heparin a decreased amount of 
neutralization was observed for most cases as compared to intravenous 
administration. 
CHAPTER V 
DISCUSSION 
Heparin has been used effectively as an antithrombotic drug for 
over 50 years, however its multicomponent structure makes the complete 
elucidation of its mechanism of action difficult. Commercial heparin 
is heterogenous with respect to internal structure (Casu 1984), 
molecular size (Andersson 1979), degree of sulfation (Hurst et al. 
1979) and anticoagulant activity (Hurst et al. 1981). The molecular 
heterogeneity within heparin preparations contributes to the complexity 
of the interaction of this drug with components of the hemostatic 
system. Heparin interacts with platelets (Salzman 1980), plasma 
proteins (Rosenberg et al. 1985) and the endothelium (Barzu 1985) and 
depending upon the dose and route of administration produces anti-
coagulant, antithrombotic or antihemostatic effects. 
The anticoagulant effects of heparin are the result of heparin 
forming a complex with AT III and inhibiting activated coagulation 
factors via this plasma cofactor. This activity of heparin has been 
used for many years to monitor heparin therapy through the use of 
global tests such as the APTT and thrombin time. This effect of 
heparin is differentially related to molecular weight. Anticoagulant 
activity decreases with decreasing molecular weight while both low and 
high molecular weight heparins can exert antithrombotic activity. 
The antithrombotic effects of heparin are related to the ability 
of heparin to inhibit thrombus formation in vivo. Components of 
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heparin with high affinity to antithrombin III can exert antithrombotic 
effects and low affinity heparin can potentiate these effects_ (Bar-
rowcliffe 1984). 
Antihemostatic effects of heparin occurring after high dose 
administration may result from the inhibition of coagulation enzymes 
and platelets and cause bleeding. The antihemostatic effects of heparin 
are influenced by a number of variables including dose and patient 
characteristics. 
Fractionation and depolymerization of heparin by a variety of 
techniques (Casu 1985) results in the production of heparin derivatives 
with a decreased molecular weight, an increased ability to inhibit 
factor Xa and a decreased ability to inhibit thrombin. These compounds 
were developed in order that the heparin derivatives would retain 
antithrombotic activity and exhibit reduced hemorrhagic potential. 
Low molecular weight heparins are currently being developed clinically 
for the prophylaxis and therapy of thrombosis (Samama 1989) and these 
therapeutic agents exhibit certain advantages as compared to heparin. 
At equivalent doses, they cause a decreased amount of blood loss as 
compared to standard heparin in man (Kakaar et al. 1985; Schmitz-
Huebner et al. 1984;Turpie et al. 1986) and they only require once 
daily subcutaneous injections for the prophylaxis of thrombosis as 
compared to 2-3 times daily for heparin. 
Low molecular weight heparins exhibit decreased anticoagulant 
activity per mg as determined by clotting tests such as the APTT and 
thrombin time. These agents contain a decreased proportion of molec-
ules with a molecular weight > 5600 daltons which is the minimum 
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molecular weight required to inhibit thrombin. The degree of prolong-
ation of the APTT by heparins is related to the% of compounds of low 
molecular weight heparin with a molecular weight less than 5600 
daltons. 
A large proportion of the molecules contained within low molecular 
weight heparins inhibit factor Xa. This factor occupies a central 
position in the coagulation cascade where the extrinsic and intrinsic 
pathways meet to form the common pathway of coagulation. Factors Xa, 
v, phospholipid and ca+2 form the prothrombinase complex which is 
involved in the formation of thrombin. Low molecular weight heparins 
exhibit antithrombotic actions through the inhibition of thrombin 
generation, while unfractionated heparins, inhibit thrombin generation 
in addition to thrombin activity. 
Low molecular weight heparin produce less antihemostatic effects 
than equivalent dosages of heparin (Kakaar et al. 1986). This decrease 
in blood loss may be related to a decreased proportion of components 
with high molecular weight and high charge density contained within the 
low molecular weight heparin. These components are reported to inhibit 
thrombin and collagen-induced platelet aggregation (Cade 1984). 
Although the use of low molecular weight heparin is associated 
with less bleeding than heparin, under certain circumstances it may be 
necessary to neutralize the blood loss induced by low molecular weight 
heparin. These instances include: overdose or reversal of anticoag-
ulation following procedures involving extracorporeal circulation such 
as cardiopulmonary bypass and hemodialysis for renal failure. Although 
protamine is administered specifically to neutralize the bleeding 
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induced by heparin, protamine also influences the anticoagulant, 
antiprotease and antithrombotic activities of the heparins. 
Protamine has been used for many years to neutralize the bleeding 
induced by heparins, and protamine antagonism of heparin has been 
associated with a variety of adverse effects. In addition, assays with 
increased sensitivity toward low molecular weight heparins have been 
developed which can detect activities of heparins which are not 
completely neutralizable by protamine. Protamine has been shown to 
exhibit a differential degree of neutralization in these assays 
(Racanelli et al. 1985) . Although in vitro assays are useful to 
predict the hemorrhagic potential of heparins, the relevance of ex vivo 
laboratory parameters of experimental animals and patients receiving 
heparin and protamine requires further investigation. 
Preliminary in vitro studies (Racanelli et al. 1985) have 
demonstrated that low molecular weight heparins exhibit characteristic 
protamine neutralization profiles which differ significantly from the 
neutralization profiles of heparin. In addition, the protamine 
neutralization profile of heparin and low molecular weight heparins are 
assay dependant. After supplementation of heparin and CY 216 in vitro 
to NHP, the clotting and anti Ila activities of the heparins are more 
readily neutralized by protamine than the anti Xa activities of the 
heparins. 
A variety of approaches utilizing in vitro assays and in vivo 
models of thrombosis and bleeding were used to study the antagonism of 
heparin and CY 216 by protamine. The in vitro assays were targeted to 
different sites in the coagulation cascade in order to provide a 
132 
sensitive means of determining the activity of the heparins. Animal 
models of thrombosis with differing activation mechanisms, and animal 
aodels of bleeding were utilized to address the in vivo antagonism of 
heparins. This integrative approach was used to determine whether the 
'in vivo neutralization profiles of heparin and CY 216 were similar and 
whether partial neutralization of low molecular weight heparins which 
was observed in vitro contributes to hemorrhagic or antithrombotic 
effects. The current study also determined whether protamine ad-
ministration altered the pharmacodynamic time course parameters of 
heparin and CY 216. An integrated approach to the study of the 
neutralization of heparin and CY 216 has provided information on the 
endogenous behavior of the heparins after antagonism by protamine which 
aay influence the management of patients undergoing antithrombotic 
therapy. 
A. The Assessment of the Potency of Heparins 
When heparin was first introduced into therapeutic use, its in 
yitro anticoagulant action was equated with its in vivo antithrombotic 
effects. However, the mechanism of action of heparin is complex and an 
ideal assay for heparin has not yet been developed. "Laboratory 
evaluation of the efficacy of heparin therapy is an inherently complex 
problem, as it entails the assessment of the effects of a variable and 
heterogenous mixture of substances on a complex biological system whose 
actions and interactions are incompletely understood" (Gawoski 1987). 
The assays in routine use for determining heparin potency are 
either based upon the overall anticoagulant activity of heparin or on 
specific properties of heparin such as the inactivation of thrombin or 
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factor Xa (Dawes et al. 1986.) . The APTT remains the most commonly 
used assay for monitoring heparin effects, however it is less sensitive 
to the effects of low molecular weight heparin since it measures 
thrombin inhibition rather than the inhibition of the other activated 
coagulation factors such as factor Xa. An amplification mechanism 
within the coagulation cascade exists such that a ten fold fold molar 
increase occurs at each step in the cascade and only a low level of 
thrombin is required to generate clot formation (McFarlane 1964). 
Nearly a complete inhibition of factor Xa which is generated during 
clotting is required to inhibit thrombin generation, therefore the APTT 
may be more sensitive to components of heparin which inhibit thrombin 
rather than factor Xa (Ofosu et al. 1985). Plasma based global assays 
such as APTT which use physiologic concentrations of activators and 
inhibitors may be more sensitive to agents which inhibit thrombin as 
opposed to the other coagulation factors. 
Recently, more specific tests have been developed where activated 
enzymes are supplemented to heparinized plasma in order to identify the 
various sites of heparin action. The HeptestR which was developed by 
Yin (1983), represents a modified version of the APTT which is more 
sensitive to low molecular weight heparins since exogenous factor Xa is 
used. This clot based anti Xa/Ila method, may have an advantage over 
amidolytic assays in that it utilizes undiluted plasma and a clotting 
endpoint. Arnidolytic assays have been useful in the study the neutral-
ization of heparins and have added a degree of specificity in the 
determination of coagulation enzyme inhibition. Isolated enzyme assay 
systems, however, may not reflect the physiologic or true function of 
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the coagulation enzymes and inhibitors because they use diluted plasma 
and synthetic substances. 
It was necessary, therefore in these studies to determine heparin 
concentration indirectly by using assays which measure heparin activ-
·ity. The in vitro clotting assays were used in these studies to 
determine the collective action of the heparins on the coagulation 
system. Although these assays are similar in their method of end point 
detection (clot formation), they differ in the sensitivity to the 
various sites within the coagulation cascade to which the heparins are 
targeted. The APTT measures the intrinsic system, the thrombin time 
assay measures the conversion of fibrinogen to fibrin and the HeptestR 
measures the collective inhibitory effects at the level of factor Xa 
and factor Ila. The amidolytic anti Xa and amidolytic anti Ila assays, 
on the other hand, measure the specific ability of the heparins to 
inhibit the amidolytic activity of factor Xa or factor Ila. 
B. Selection of Doses Used in the Studies 
Gravimetric amounts of heparin, CY 216 and protamine were 
compared in the in vitro assays and in the animal models. Adminis-
tration of the drugs was carried out in gravimetric amounts for several 
reasons. First, administration of polycomponent drugs on a unitage 
basis introduces a bias toward the specific activity on which the unit 
is based. Studies by Fareed et al. (1988) have shown that potency 
adjustment of low molecular weight heparins based upon amidolytic anti 
Xa activity does not minimize the variations of the heparins observed 
in other in vitro assays or in animal models of thrombosis and bleed-
ing. Second, it is not appropriate to administer molar amounts of the 
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heparins. Using the mean molecular weight to calculate approximate 
molar amounts of an equigravimetric amount of CY 216 and heparin, it 
was found that CY 216 contains approximately twice the number of 
molecules as heparin. However, since heparin and CY 216 are dis-
tributed over a fairly wide molecular weight range, this calculation 
was not very accurate. Furthermore, in addition to containing a 
heterogenous mixture of components with varying chain lengths, heparins 
also exhibit internal structural microheterogenity since all heparin 
components do not contain the identical chemical sequences (Casu 1985). 
Differences are noted in the degree of sulfation (Hurst 1979) and 
affinity toward AT III (Casu 1985) of the individual heparin molecules. 
A series of experiments were performed in order to investigate 
the feasibility of using molar amounts in the study of the antagonism 
of heparin and CY 216. A laser-induced thrombosis model was used for 
these studies. One mg amounts of heparin and CY 216 were converted to 
apparent molar amounts, as shown in Appendix XVI, and this molar 
quantity of protamine was administered to rats. No additional inform-
ation about the comparative protamine neutralization of heparin and CY 
216 was obtained when the drugs were administered in approximate 
equimolar amounts. In fact, comparisons of heparins based on apparent 
molar amounts led to completely opposite conclusions regarding the 
degree of protamine neutralization of heparin and CY 216 as when 
gravimetric doses of these drugs are administered. When apparent 
equivalent molar amounts were used the antithrombotic activity of 
heparin appeared to be less neutralizeable than the anti thrombotic 
activity of CY 216. As our studies have demonstrated using the rabbit 
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stasis thrombosis model and as others have reported (Dinness 1986), the 
antithrombotic effects of heparin were neutralized to a greater degree 
than the antithrombotic effects of low molecular weight heparins by 
protamine. In addition, the therapeutic use of heparin involves 
administration of U/mg amounts of heparin to gravimetric amounts of 
protamine. 
The doses which were used in the animal experiments were selected 
in order that the plasma concentrations were in the approximate range 
of clinically used heparin and protamine. Appendix XVII shows the 
doses used in the animal models and the doses of heparin and protamine 
used for cardiopulmonary bypass at Foster G. McGaw Hospital. Higher 
doses (1-3 mg/kg) of heparin and CY 216 were required to induce blood 
loss in the animal models than were required to inhibit thrombosis (25-
100 µg/kg). The doses used in the rat tail bleeding model and rabbit 
ear blood loss model were in the approximate range of doses which are 
used during cardiopulmonary bypass procedures. The gravimetric ratio 
of protamine:heparin of 1.4:1 which was used in the primate studies was 
similar to the ratio of protamine to heparin which is used clinically 
(1.3 mg of protamine to 1 mg of heparin). 
C. Molecular Weight Determination 
Gel permeation chromatography was used to determine the molecular 
weight profiles of heparin, CY 216 and protamine. This technique has 
been previously utilized to determine the molecular weight of glycosam-
inoglycans (Losito et al. 1981) and was useful to determine the 
molecular weight of polycomponent compounds since this procedures 
relies almost exclusively on size for separation. Although the elution 
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profiles of both heparin and CY 216 were bell-shaped, the molecular 
weight distribution of CY 216 was narrower than that of heparin. 
The frequency and molecular weight distribution averages of heparin and 
CY 216 were also determined. Although the molecular weight distri-
bution profile of protamine was narrower than the heparins, the 
elution profile of protamine was characteristic of a compound contain-
ing more than one chemical species. Of the three compounds, CY 216 
exhibited the lowest mean molecular weight (5400 daltons), followed by 
protamine (4,000 daltons) then heparin (11,000 daltons). Determination 
of the molecular weight of these agents was important in the under-
standing of their interactions. 
D. NMR Spectra of Heparin, CY 216 and Protamine 
Until recently, the complete analysis of the 1H NMR spectrum of 
heparin has not been feasible since several signals overlap heavily 
even at resolutions at 270 MHz instruments. Another problem has been 
signal broadening due to the effect of the viscosity of the con-
centrated solutions used for the NMR analysis (Gatti et al. 1979). 
Casu and coworkers have used a resolution enhancement method which was 
originally utilized for the study of proteins, to assign all of the 
proton signals. This approach has now provided us with a complete 
elucidation of the structure of heparin. 
In collaboration with Casu and coworkers, we have compared the 1H 
NMR. spectra of heparin and CY 216. While the NMR spectra of heparin 
was consistent with the known structure of heparin, CY 216 exhibited 
signals which differed from heparin signals. These signals of CY 216 
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were characteristic of the presence of anhdromannose residues and 
partial desulfation. 
Utilizing this technique, it was demonstrated that heparin 
induces a spectral shift in the 3.3-3.6 ppm region after complexation 
with protamine. This finding has not been previously reported and 
requires further validation. The nature of this shift with low 
molecular weight heparins may provide some useful information on the 
interaction and binding region of heparins with protamine. 
E. In Vitro Studies on Heparin and CY 216 and Their Interaction with 
Protamine 
1. Comparison of Pooled Animal Plasma Preparations 
The focus of this dissertation was to use established animal 
models of bleeding and thrombosis and extrapolate the results to the 
human plasma response. Since the animal models used in the studies 
incorporated three different animal species (rats, rabbits and pri-
mates) it was necessary to compare the in vitro baseline responses of 
the plasma preparations in the clotting and amidolytic assays to a 
standard normal human plasma preparation. A study of in vitro baseline 
responses of the plasma preparations facilitated the evaluation of the 
~ vivo results. 
The APTT, thrombin time and HeptestR activity of NratP differed 
significantly (p<.05) from NHP as determined by a one way ANOVA. The 
thrombin time and HeptestR baseline values were elevated while the APTT 
baseline values were decreased as compared to NHP. The baseline 
clotting values for NRP were elevated as compared to NHP and the degree 
of this elevation was dependant on the individual clotting tests. 
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These differences may be related to compositional variations between 
the plasma preparations. The composition of NRP differs greatlr from 
that of NHP. All coagulation factors of NRP except factor X and 
fibrinogen are elevated 2 to 18 fold as compared to NHP (Walenga 
1987). Nonhuman primates demonstrate marked similarities to humans in 
almost all aspects of their anatomy, endocrinology and physiology and 
these similarities underlie the value of these animals for appropriate 
studies in neurobiology, immunology, pathology, cardiology and psych-
ology (King et al. 1989). Evaluation of baseline clotting values 
confirmed reports that the clotting activity of NHP and NMP was very 
similar. 
2. The In Vitro Effects of Protamine on Plasma 
In vivo administration of protamine has been reported to in-
fluence the hemostatic system in a variety of ways. Protamine has been 
reported to decrease fibrinogen levels (Gans 1962; Godal 1960), 
aggregate platelets by direct effects (Eika et al. 1972) and produce 
thrombocytopenia and leukopenia (Al-Mondhiry 1985, Eika et al. 1971). 
However, Ellison et al. (1971) have shown that overdoses of protamine 
(800 mg/70 kg) had minimal effects on the coagulation mechanisms of 
both patients and volunteers. Therefore studies were carried out in 
order to determine whether protamine had any effect on the in vitro 
clotting tests and amidolytic assays used in these studies. This 
information was needed in order to evaluate the~ vivo data. After 
administration of 2 drugs such as heparin and protamine, it was 
necessary to determine the individual contribution of each drug to the 
prolongation of clotting time and amidolytic activity. The APTT was 
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significantly (p<.05) prolonged, (as determined by a one way ANOVA) 
after the in vitro supplementation of protamine (100 µg/kg i. v.) to 
NHP, NMP, NRP and NratP. The extent of the prolongation of the 
clotting times of the plasma preparations was similar. 
In order to test the effect of high concentrations of protamine 
on the laboratory assays, protamine (1 mg/ml and 10 mg/ml) was supple-
mented to NHP. Protamine sulfate (1 mg/ml) prolonged the APTT to> 150 
seconds, however, had no effect on the other tests. This concentration 
of protamine is much greater than is routinely achieved clinically. 
Protamine (10 mg/ml) significantly prolonged all of the clotting tests 
and exhibited inhibition of amidolytic anti Xa activity, however, 
protamine at this concentration also caused the plasma to become 
turbid. The effects of protamine may be nonspecific and it is unlikely 
that these effects of protamine occur under physiological conditions. 
The APTT was most sensitive to the anticoagulant effects of 
protamine and was the only test which exhibited significant anticoag-
ulant and antiprotease effects in all of the plasma preparations. The 
other assays were relatively insensitive to protamine. 
3. In Vitro Supplementation of Heparin and CY 216 to Various Plasma 
Preparations 
Although the constituents of primate plasma are similar to human 
plasma, differences between rat, rabbit and human plasma have been 
reported (Schalm 1975). Before beginning the animal experimentation, 
it was necessary to compare the in vitro heparinizability of the 
various animal plasma preparations in order to determine the extent the 
plasma differences might have on heparin and CY 216 anticoagulant and 
141 
antiprotease activities. Varying levels of endogenous neutralizing 
agents like PF4 can modify the activity of heparin and CY ~16 to 
varying degrees and may influence their in vitro activity profiles in 
the plasma preparations. 
After supplementation of heparin and CY 216 to the plasma 
preparations, the APTT was equally sensitive to the heparins when 
supplemented to NHP and NMP. The baseline APTT value for NRP was 
elevated as compared to the other plasma preparations therefore at CY 
216 (2. 5 µg/ml) the APTT was prolonged to > 150 seconds. The APTT, 
however, exhibited less sensitivity to heparin supplemented to NratP. 
In addition, since heparin must bind to AT III in order to exert 
anticoagulant effects, differing levels of AT III in the plasma 
preparations could result in variations in heparin and CY 216 activity. 
Even though the APTT is less sensitive to the effects of low 
molecular weight heparin than to heparin, a similar pattern of clotting 
time elevation was seen for CY 216 and heparin after supplementation to 
the various plasmas. Since the APTT was relatively insensitive to the 
anticoagulant effects of CY 216 and it was important to determine the 
global clotting activity of CY 216 the HeptestR was used to determine 
CY 216 activity in the plasma preparations. This assay which has 
recently developed is sensitive to the collective effects of heparins 
and other substances which inhibit factor Xa and factor Ila. The 
HeptestR exhibited increased sensitivity to the effects of heparin and 
to CY 216 supplemented to NRP than to the other plasma preparations. 
The clotting assays (APTT and HeptestR) were more sensitive to NRP 
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which may be related to increased clotting factor levels in NRP as 
compared to the other plasma preparation. 
The% inhibition of factor Xa and factor Ila by heparin and CY 
216, in general, followed a similar pattern in the various plasma 
preparations, however once again the response of NHP to heparin and CY 
216 was most similar to the NMP response. Equigravimetric amounts of 
heparin exhibited greater clotting and amidolytic activity than CY 216 
when supplemented in vitro to NHP, NMP, NRP and NratP. 
4 . .In Vitro Neutralization of Heparin and CY 216 by Protamine 
Although many different animal plasmas were studied in vitro, the 
primary objective of these studies was to relate the data obtained from 
the animal models to what occurs in human plasma. Therefore the in 
vitro neutralization of heparin and CY 216 was studied only in NHP. 
Although heparin and CY 216 exhibited assay dependant protamine 
neutralization in vitro, significant differences between the neutraliz-
ation profiles of heparin and CY 216 were noted. In order to compare 
these differences the ratios of protamine to heparin required to 
completely neutralize the activity of the heparins in the individual 
assays were determined. 
Differential neutralization of the activities of heparin and CY 
216 was noted. All of the in vitro activities of heparin except 
amidolytic factor Xa activity were completely neutralized at a prota-
mine to heparin ratio of 2: 1. However the activities of CY 216 were 
neutralized to varying degrees depending upon the test. In general, 
the activity of CY 216 and heparin in the assays which primarily 
measure the inhibition of thrombin (thrombin time and amidolytic anti 
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Jla assays) were neutralized more readily than the assays which measure 
anti Xa activity (amidolytic anti Xa method and HeptestR). The 
activity of CY 216 in the thrombin time assay was completely neutra-
lized at a protamine to CY 216 ratio of 1:1, while the amidolytic anti 
Xa activity of CY 216 was neutralized by a protamine to CY 216 ratio of 
2:1. The HeptestR was only slightly neutralized at a protamine to CY 
216 ratio of 2:1. A comparison of the protamine to heparin (or CY 216) 
ratios at which complete neutralization occurred for the in vitro and 
in vivo studies in shown in the Appendix XVIII and XIX respectively. 
All of the anticoagulant and antiprotease activities of heparin and all 
activities except for the anti Xa activity of CY 216 in the primates 
was neutralized at a gravimetric 1:1 ratio. The anti Xa activity of CY 
216 after administration to the primates was completely neutralized by 
a 2: 1 protamine to CY 216 ratio. In general both in vitro and in 
rabbits, the activity of heparin was more readily neutralizeable than 
CY 216. 
5. In Vitro Neutralization of a Chemically Synthesized Pentasaccharide 
by Protamine 
The in vitro neutralization of a chemically synthesized penta-
saccharide by protamine has been studied by Walenga (1987). Although 
pentasaccharide itself is not present in CY 216, the neutralization of 
pentasaccharide can be considered as a good model for some ultra low 
moleclular weight oligosaccharides which are present in CY 216. The 
pentasaccharide posseses the minimum binding region of heparin which is 
able to induce a conformational change in AT III thus increasing the 
inhibitory activity of this protein towards factor Xa. However, this 
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. activity was not neutralizeable by a 30 fold gravimetric excess of 
protamine. In addition, the heptestR activity of pentasacchari~e was 
neutralized approximately 60% and the anti Xa activity of penta-
saccharide was neutralized approximately 90 % by polybrene. It is not 
. 1cnown whether the lack of neutralization of the pentasaccharide by 
protamine is due to a lack of binding of protamine to the penta-
saccharide due to molecular size or charge characteristics or whether 
the lack of neutralization of pentasaccharide is due to the inability 
of protamine to disrupt a formed pentasaccharide-AT III complex. Since 
polybrene was able to neutralize the anti Xa and heptestR activity of 
the pentasaccharide more readilly than protamine, the charge density of 
the neutralizing agent may be important. Other structural character-
istics may be required for the neutralization of the antiprotease 
activities of oligosaccharides. Vitronectin has been shown to ef-
ficiently neutralize oligosaccharides of Mr 2,400 - 7,200 daltons (Lane 
1987). 
6. In Vitro Neutralization of Heparin and CY 216 by Spermidine 
Protamine has been used clinically to antagonize the hemorrhagic 
effects of heparin for many years and much information is known about 
this interaction of heparin with protamine. However, less is known 
about the interaction of protamine with low molecular weight heparins. 
The primary intent of this dissertation was to obtain practical 
clinically relevant information of the interaction of heparin with 
polybasic agents. Therefore, protamine was selected to antagonize the 
effects of the heparins. However it was also of interest to study the 
interaction of the heparins with chemically defined polybasic sub-
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stances such as spermidine since this agent has a defined structure. 
Studies were performed on the interaction of heparin and CY 216 with 
spermidine to compare the in vitro protamine neutralization of the 
heparins to the spermidine neutralization profiles in order to in-
vestigate whether assay dependant neutralization of heparin and CY 216 
exists when a pure substance was used as the neutralizing agent. 
Spermidine was less potent as an antagonist to the anticoagulant 
and antiprotease effects of heparin and CY 216 than protamine. In 
addition, spermidine exhibited a characteristic assay dependant 
neutralization profile. These preliminary studies indicated that the 
differential neutralization of heparins after protamine and spermidine 
antagonism may be related to differences in their chemical structure, 
charge distribution or molecular weight. A comparison of the structure 
of spermidine and protamine is shown in Appendix XX. Protamine 
contains proteins of differing amino acid length which contain mostly 
arginine. Spermidine, on the other hand is a positively charged linear 
polyamine. Systematic structure activity studies are needed to further 
characterize the differential neutralization of the in vitro anti-
coagulant and antiprotease activities of heparin and CY 216. 
F. In Vivo Studies 
1. In Vivo Studies on the Effects of Protamine 
Protamine sulfate ( 200 µg/kg i. v. ; 2 and 3 mg/kg i. v. ) was 
administered to rabbits in the doses which were used to antagonize 
heparin and CY 216 in the stasis thrombosis and the rabbit ear blood 
loss experiments. No significant effect of protamine on ex vivo 
clotting and antiprotease activity was seen at these doses. Similarly, 
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administration of protamine (2.1 mg/kg i.v.) to primates had no effect 
upon clotting or amidolytic anti Xa activities. Protamine exerted a 
significant (p<.05) effect on the amidolytic anti Ila assay. This may 
be related to a report that protamine act as a competitive inhibitor of 
. thrombin- fibrinogens interaction and can also act as a substrate for 
thrombin (Cobel-Geard 1983). The observed amidolytic anti Ila 
activity may result from protamine acting as a secondary substrate for 
thrombin. Therefore less synthetic substrate is cleaved by thrombin and 
it appear that thrombin is inhibited after protamine administration in 
this assay. 
It was not possible to administer increased amounts of protamine 
to the primates to determine whether higher doses of protamine would 
exert increased ex vivo anticoagulant effects since some primates did 
not tolerate protamine administration very well. Although protamine 
was administered very slowly as a bolus injection, certain primates 
vomited after administration of this drug. Similar reactions have been 
observed when other protein drugs have been administered to the 
primates. 
2. Animal Models Used To Study The Antithrombotic Effects of Heparin 
and CY 216 and Protamine 
Animal models of thrombosis have contributed to the current 
knowledge of thrombosis and have been useful in the study and develop-
ment of newer therapeutic agents. In the present studies, two es-
tablished animal models of thrombosis were utilized. A modified 
version of the classic Wessler model (Wessler 1974) of venous throm-
bosis and a laser-induced model of thrombosis (Weichert 1984) were used 
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to study the differential protamine neutralization of heparin and CY 
216. Since many factors can trigger thrombosis, it was necessa~y to 
use models with different activation mechanisms in order to investigate 
the neutralization of the anti thrombotic activity of heparins. This 
has provided an opportunity to determine whether similar potency and 
neutralization profiles are obtained when thrombosis is induced by 
differing mechanisms. These two thrombosis models differ in the animal 
species used, type of vessel under investigation, degree of blood flow, 
thrombogenic stimuli and method of end point detection. 
Factors which promote thrombosis include: vascular damage, 
stimulation of platelet aggregation and intravascular activation of 
blood coagulation (Hirsh et al. 1983). A central hypothesis describing 
the initiation of thrombosis focuses on endothelial cell injury and 
resultant thrombus formation. Endothelial damage exposes the underly-
ing subendothelium to platelets which adhere, release their cytoplasmic 
constituents and aggregate at the surface. 
Although endothelial injury may result in thrombosis, it is not a 
prerequisite in all cases. As first described by Hewson as early as 
1771, stasis alone, after a period of a several hours can induce 
thrombosis. However, usually a thrombogenic stimulus or challenge must 
be present for thrombosis to occur. Although patients are often 
described as being in a hypercoagulable state, the triggering mechanism 
for thrombosis is rarely evident. In animals and presumably in humans 
as well, a thrombus can be induced in an area of stasis within minutes 
when such agents as serum, serum factors, endotoxin and ellagic acid 
are present (Colman et al. 1987). 
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Blood flow is also an important factor in the progression of 
thrombogenesis. Thrombi usually do not form in normal vessels from 
which the endothelium has been removed if flow is laminar, however, if 
blood flow is disturbed materials released by adherent platelets and 
thrombin can accumulate in the vortices and thrombi may form. 
For many years the Wessler thrombosis model has been the accepted 
model used in the evaluation of antithrombotic drugs. It is based on a 
fundamental concept of Virchow (1856) in which thrombosis is described 
as resulting from a hypercoagulable state, localized diminished flow 
(or stasis) and cellular interactions. The hypercoagulable state in 
the present studies was produced after the injection of PCC and RVV. 
PCC contains a complex of human factors II, VII, IX and X, RVV (Rus-
sell's viper venom) activates factor X to Xa. When used in combina-
tion, these agents produce high levels of factor Xa, which is thought 
to be the primary target of low molecular weight heparin and causes an 
activation of coagulation and subsequent clot formation. PCC is 
standardized in terms of vitamin K dependant factors, therefore the use 
of batches of the agents can result in reproducible results. 
Localized diminished flow, the second component in Virchow' s 
triad is achieved in the stasis thrombosis model through the use of 
ligatures. Following infusion, the surgically isolated jugular veins 
were ligated and localized stasis in addition to hypercoagulable blood, 
produced clot formation within the jugular veins. 
Although the Wessler model is still widely used, experimental 
data and clinical observation has shown that endothelial damage alone 
is sufficient to produce thrombosis and that complete stasis is rarely 
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found during the progression of thrombosis in man. Therefore this 
model possesses certain limitations (the use complete stasis and the 
lack of any endothelial injury) and may not be as physiologically 
relevant as other models. The thrombotic stimulus in the laser-induced 
thrombosis model, namely, endothelial damage is thought to be a more 
physiologically relevant stimulus for thrombosis. 
While stasis is an important parameter in the 'Wessler model, 
blood flow is an integral parameter of the laser-induced model. 
complete blood flow is maintained in the vessels under investigation 
throughout the entire experiment and any blockage to flow which occurs 
is a direct result of thrombus formation. In the laser model, after 
the laser injury is produced any blood elements which become coagulated 
as a result of the laser injury are swept away by the blood flow and 
the several seconds elapse before the first platelets stick to the 
damaged vessel wall area. Therefore, it is unlikely that thrombus 
formation results form coagulable protein but rather forms as a result 
of platelets becoming activated after interaction with the subendo-
thelium ('Weichert 1983; 1984; 1986). As the experiment is carried 
out, blood flow carries away any platelet aggregates which initially 
form and break apart from the growing thrombus. 
a. Antithrombotic Effects of Protamine 
Protamine is administered clinically to antagonize the hemor-
rhagic effects which sometimes occur during antithrombotic therapy with 
heparins. Administration of protamine has been shown to influence 
coagulation proteins (Gans 1962; Godal 1960) and platelets (Eika 1972: 
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Al-Mondhiry 1985). It was interesting to note that protamine ad-
ministration to rabbits and rats exhibited antithrombotic effects. 
Protamine (100 and 740 µg/kg i. v.) produced a slight nonsign-
ificant degree of inhibition of thrombosis in the rabbit stasis 
thrombosis model and the laser-induced thrombosis model respectively. 
Protamine was much less potent as an antithrombotic agent than the 
heparins in the stasis thrombosis model, however protamine was nearly 
as potent as heparin and CY 216 in the laser-induced thrombosis model 
which is very sensitive to platelet-vessel wall interactions. The 
antithrombotic activity of protamine in the laser model may be related 
to protamine effects on platelets (Al-Mondhiry 1985; Eika 1971) and 
inhibition of platelet-vessel wall interactions. 
b. Intravenous and Subcutaneous Antithrombotic Actions of Heparin and 
CY 216 
Equigravimetric amounts of heparin were more potent than CY 216 
in both the stasis thrombosis and the laser-induced thrombosis models. 
However, in the stasis thrombosis model, complete neutralization of the 
antithrombotic effects of heparin were observed at equigravimetric 
amounts of protamine, while significant (p<.05),(as determined by a two 
way ANOVA) antithrombotic activity of CY 216 were observed after 
equigravimetric protamine. In the laser-induced thrombosis model, 
heparin and CY 216 were completely neutralized by protamine. The 
differing results between models may be related to the activation 
mechanisms used to induce thrombosis in the models. In the stasis 
model, the primary activator is targeted toward the coagulation system 
While, in the laser-induced thrombosis model, damaged endothelium is 
the primary activator for thrombosis to occur. 
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While in the laser 
aodel, although damaged endothelium activates platelets, fibrin helps 
to stabilize the platelet aggregates which form. The differential 
degree of neutralization of CY 216 observed in the stasis thrombosis 
·aodel may be related to components within CY 216 which can still 
inhibit the coagulation system after protamine administration. These 
effects may be related to amidolytic anti Xa inhibition, however this 
is unlikely since the levels of amidolytic anti Xa activity were very 
low after the administration of CY 216 (100 µg/kg i. v.) used in the 
stasis thrombosis experiments. In addition, correlations between 
antiprotease activity and% inhibition of thrombosis were poor ranging 
from ( . 002 - . 806) depending upon the as say used. Bianchini et al. 
(1985) found a similar lack of correlation between in vitro activity 
and antithrombotic effects of heparins. Perhaps some mechanism exists 
which is responsible for this antithrombotic activity after protamine 
antagonism of CY 216 which is not measurable at this time. 
Significant antithrombotic activity was observed after ad-
ministration of heparin (1 mg/kg s. c.) and CY 216 (1 mg/kg s. c.) to 
rabbits. Similarly, significant ex vivo activity was observed. The 
anti Ila activity of heparin and CY 216 was completely neutralized, 
while the anti Xa activity after subcutaneous administration of heparin 
and CY 216 was not neutralized. Once again there was a poor relation-
ship between mt vivo activity and protamine neutralization of the 
antithrombotic activity. In the intravenous studies, CY 216 exhibited 
significant antithrombotic activity with slight mt vivo antiprotease 
activity after subcutaneous administration of CY 216. Therefore mt vivo 
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antiprotease activity is not the only determinant of antithrombotic 
activity. 
3. Hemorrhagic Effects of Heparins 
Many animal models have been used to determine the hemorrhagic 
potential of drugs. Two models used in this study, the rabbit ear 
blood loss model and the rat tail bleeding model, exhibit differential 
sensitivity to hemostatic and physiologic components including: 
platelets, coagulation factors, blood pressure, and smooth muscle. The 
differential sensitivity of the models may be related to the type of 
vessels which were transected during the experiments to induce blood 
loss. 
In 1934, when heparin was being developed for clinical use, it 
was thought that surgical patients who would receive heparin might 
bleed to death. However, the administration of heparin to patients 
since that time without the occurrence of spontaneous hemorrhage, even 
during major operations has disputed this concern (Jaques 1973). For 
hemorrhage to occur after the administration of heparin means that 
several factors of hemostasis may be deranged simultaneously (Jaques 
1949). Abnormalities in the normal hemostatic mechanism which can lead 
to bleeding include: defects in blood vessels, a deficiency in the 
number of circulating platelets, abnormal platelet function, defects in 
blood coagulation and excess fibrinolytic activity (Hirsh 1983). The 
hemorrhagic risk of heparin could be theoretically influenced by a 
number of variables including (1) the dose of heparin (2) the anti-
coagulant effect of heparin as measured by a laboratory test (3) the 
route of heparin administration and (4) patient characteristics such as 
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concurrent administration of antiplatelet drugs. A commonly held 
clinical view is that the risk of bleeding increases with either 
increasing doses of heparin or with the heparin response as reflected 
by .in vitro coagulation tests. Bleeding is more likely to occur when 
'an .in vitro test of coagulation is excessively prolonged. 
In the rabbit ear model of blood loss, as developed by Cade et 
al. (1984), 5 uniform incisions were made in the lower portion of the 
rabbit ear and the incisions were standardized in such a manner that 
the microcapillary section of the rabbit ear was transected as shown in 
Appendix X. In the rat tail transection model a 2 mm section of the 
distal end of the tail vein was transected. These differences in 
methodology may lead to differing sensitivities of the models to agents 
which induce blood loss. The rat tail transection bleeding model is 
sensitive to the effect of platelets as well as coagulation factors 
(Dejana 1982), whereas the rabbit ear bleeding model is more sensitive 
to primary hemostasis (Cade et al. 1984) which involves the adherence 
of platelets to damaged endothelium after an injury. Heparin and low 
molecular weight heparin have been reported to decrease platelet 
adhesiveness in vivo which may cause a prolongation in the rat tail 
transection bleeding model (Harenberg 1985;Weichert and Breddin 1986). 
Differences in methodology between the rat tail bleeding time and 
the rabbit ear blood loss model include: animal species, temperature, 
method of end point detection and number of determinations which can be 
performed per animal. Dejana et al. (1982) have demonstrated that 
temperature has an effect on bleeding times. Tail transection 
bleeding times in the rat were shown to be significantly shorter at 
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370c than at 23°c. This result is in agreement with the fact that 
bleeding times measured in human fingers are prolonged at tempe~atures 
below 37°c (Copley 1974). One advantage of the rabbit ear blood loss 
model as compared to the rat tail bleeding model is that in the rabbit 
. model temperature is more tightly controlled. In this model, the red 
cells are collected in a saline bath at 37° C. Also this method of end 
point detection is more precise than the measurement of bleeding time 
in the rat tail bleeding model where bleeding time was visually 
determined as the time when bleeding stopped. A practical advantage of 
the rabbit ear blood loss model is that 2 blood loss determinations can 
be made per rabbit (one determination on each ear) whereas only one 
determination can be performed on each rat. 
a. Effect of Protamine in the Blood Loss Models 
Protamine administration had a differential effect in the two 
blood loss models. The rabbit ear model of blood loss was not effected 
by protamine (1 and 2 mg/kg i.v.) while the rat tail bleeding model was 
prolonged by protamine (1 mg/kg i. v.). The prolongation in the rat 
tail model may be due to inhibition of primary hemostasis. Protamine 
has been shown to exhibit antithrombotic effects in the rat laser model 
of thrombosis. These antithrombotic effects of protamine may be 
related to inhibition of platelet adhesion and this mechanism may cause 
an increase in bleeding time in the rat model. 
b. Intravenous and Subcutaneous Studies On the Hemorrhagic Effects of 
Heparin and CY 216 
Good agreement between the results of blood loss induced by 
heparin and CY 216 was observed in the two bleeding models. Heparin (2 
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mg/kg i.v.) produced a significant (p<.05),(as determined by a one way 
ANOVA), amount of blood loss as compared to the control groups in both 
models. CY 216 produced less blood loss than heparin at equigravi-
metric concentrations as determined by both models. CY 216 (2 mg/kg 
i.v.) did not produce a significant increase in blood loss, however, 
the blood loss induced by CY 216 (3 mg/kg i.v.) was significant (p<.05) 
as compared to the control group, as determined by a one way ANOVA. CY 
216 produced approximately 67 % of the blood loss induced by equi-
gravimetric amounts of heparin as determined by the rabbit ear blood 
loss model. Low molecular weight heparins are not endowed with any 
special properties which would allow the clinician to ignore the 
dangers of hemorrhagic side effects (Thomas 1986). Since the hemor-
rhagic effects of heparins are dose dependant, the true efficacy of 
these new antithrombotic agents may not be completely realized if 
improper doses are administered. 
Even though heparin (2 mg/kg i.v.) exhibited a greater amount of 
amidolytic anti Xa activity than CY 216 (2 mg/kg i.v.), the activity of 
heparin was more readily neutralized than the corresponding activity of 
CY 216. Anti Xa potency of heparins may not be directly correlated to 
the extent of neutralization. Differential interactions of heparin and 
low molecular weight heparin with protamine may be related to the size 
of the anticoagulant molecule. Either protamine sulfate binds to long 
chains more easily than to a shorter chains (Thomas 1984) or protamine 
may have to bind with a certain affinity to the components of heparin 
which inhibit factor Xa for neutralization to occur (Massonet-Castel 
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1986). A schematic representation of the binding of heparin to 
protamine is shown in the Appendix XX.II. 
Blood samples drawn 10 minutes after the administration of 
heparin or CY 216, allowed for the ex vivo analysis of blood levels of 
. amidolytic anti Xa and amidolytic anti Ila activity at the time when 
the blood loss determinations were initiated. Correlations between 
antiprotease activity and blood loss after the administration of 
heparin or CY 216 were calculated. Poor correlations between~ vivo 
activity and blood loss were obtained for CY 216 (r-.102 for anti Xa, 
r-.186 for anti Ila). The correlation for HeptestR and CY 216-induced 
blood loss was better (r-.515). It seems therefore that the hemor-
rhagic side effects of CY 216 are somewhat dissociated from their 
antiprotease activity. Similar correlations between the amidolytic 
anti Xa and amidolytic anti Ila activities and heparin-induced blood 
loss (r-.690 for anti Xa) and (r-.564 for anti Ila) were obtained. 
A poor correlation between blood loss and~ vivo activity after 
protamine neutralization of heparin and CY 216 was seen. Heparin 
produced a greater amount of blood loss than CY 216 at equigravimetric 
doses and also exhibited greater amidolytic anti Xa and amidolytic anti 
Ila activity than CY 216 at equivalent doses. However, it was interest-
ing to note that although the blood loss induced by CY 216 was com-
pletely neutralized by protamine while the amidolytic anti Xa activity 
of CY 216 was not. Significant amounts of amidolytic anti Xa activity 
of CY 216 remained after two fold gravimetric amounts of protamine was 
administered to rabbits. 
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No significant increase in blood loss was seen after subcutaneous 
administration of heparin (3 mg/kg s.c.) or CY 216 (3 mg/kg s.c.) to 
rabbits, even though significant ex vivo activity was observed in 
several assays. Similarly, there was no increase in blood loss after 
subcutaneous administration of heparin (2. 5 mg/kg s. c.) or CY 216 (2. 5 
mg/kg s . c . ) to rats . Reports have shown that bleeding occcurs more 
frequently when heparin is given therapeutically in large doses than 
when it is administered prophylactically in small doses (Colman 1987). 
The amidolytic anti Ila activity of subcutaneously administered heparin 
and CY 216 and the amidolytic anti Xa activity of heparin was complete-
ly neutralized by protamine. However, the anti Xa activity of sub-
cutaneously administered CY 216 was not neutralized. The results 
correspond with the in vitro and other in vivo protamine neutralization 
profiles of these heparins. 
4. Pharmacodynamic Effects of Heparin and CY 216 and their Modulation 
By Protamine 
Pharmacokinetics by the strict sense of the word refers to the 
processes by which a drug enters and is moved around within the body 
(thus reaching its site of action) and is eliminated. Thus the term 
pharmacokinetics embraces the (1) absorption, (2) distribution and (3) 
elimination of drugs but not their action. Pharmacodynamics, on the 
other hand refers specifically to the activity of drugs (Bourne et al. 
1986). Since heparin is a polycompnent drug which exerts its effects 
at various sites of action, it was not possible to directly measure the 
concentration of the active components of heparin. Therefore it was 
necessary to determine pharmacodynamic activities of heparin and 
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correlate activity data to concentration through the use of calibration 
curves. The pharmacokinetics of heparin are more properly termed time 
course of pharmacodynamic effects. 
In order to directly compare the activity of heparin and CY 216 
.in vivo, a noncompartmental model was used to calculate pharmacodynamic 
time course parameters in primates. Noncompartmental methods for 
calculating pharmacodynamic time course values are based on statistical 
moment theory and utilize calculations of area under the concentration 
curve which is a simple expression of drug disposition (Gibaldi et al. 
1982). To date, statistical moments have been applied to pharmaco-
kinetic and biopharmaceutic processes dealing primarily with drug 
absorption and distribution. These concepts were initially used in the 
biomedical literature by Perl and Samuel (1969) to analyze cholesterol 
input and output in man and by Oppenheimer et al. (1975) in describing 
the disposition of iodothyronine. 
Noncompartmental analysis is not "model independent" but rather 
is based on a model with a far more restricted structure and realm of 
applicability than multicompartmental models. A major conceptual 
advantage of a noncompartmental model is that any number of recircula-
tions or exchanges can occur with any number of noncentral pools, none 
of which has to be identified with any physiological structures (Di 
Stefano 1984). A diagrammatic representaion of a noncompartmental model 
is shown in Appendix XX.I. 
Study of the time course of the neutralization of the heparins 
presented some interesting problems. It was not possible to calculate 
all of the pharmacodynamic time course parameters after neutralization 
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of the heparins by protamine since the initial heparin-protamine 
activity level (concentration) at time 0 must be known in order to 
calculate Clp and Vd. This value could not be obtained from the data 
since heparin was administered 5 minutes prior to protamine. The study 
was designed in this way in order to simulate the protamine neutral-
ization of heparin in patients. In order to calculate Vd and Clp of 
heparin and protamine an in vitro heparin-protamine complex would have 
to be administered to the primates and the calculations determined. 
a. Differential Neutralization of Heparin and CY 216 By Protamine 
Assay dependant protamine neutralization after administration of 
heparin (0. 7 mg/kg i. v.) and CY 216 (0. 7 mg/kg i. v.) was observed in 
the primates. Both heparin and CY 216 exhibited strong anticoagulant 
and antiprotease effects. After the administration of protamine, the 
degree of neutralization of these effects varied with the laboratory 
assays and heparin and CY 216 exhibited characteristic neutralization 
profiles in the primates. 
The HeptestR activity of heparin was the only activity which was 
completely neutralized by equigravimetric protamine, while the APTT and 
thrombin time activities of heparin were completely neutralized at a 
two fold gravimetric amount of protamine. The neutralization patterns 
of amidolytic anti Xa and amidolytic anti Ila activity of heparin were 
very similar. Varying degrees of neutralization of the activities were 
seen up to 3 hours. The APTT, thrombin time, and anti Ila activities 
of CY 216 were completely neutralized by equigravimetric protamine. A 
dose dependant neutralization of the amidolytic anti Xa of CY 216 was 
seen. Complete neutralization of the amidolytic anti Xa activity of CY 
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216 was not observed at three fold gravimetric concentrations of 
protamine. Virtually no neutralization of the HeptestR activity of CY 
216 was seen after administration of three fold gravimetric amounts of 
protamine. 
b. Intravenous Studies 
Protamine neutralization of the pharmacodynamic time course of 
intravenously administered heparin and CY 216 was studied in the 
primate (macaca mulatta). Activity of heparin and CY 216 was deter-
mined using APTT, thrombin time, HeptestR, amidolytic anti Xa and 
amidolytic anti Ila methods. Pharmacodynamic time course parameters 
were calculated from concentrations obtained from HeptestR and amido-
lytic anti Xa activity data which was extrapolated from calibration 
curves of heparin or CY 216 supplemented to NMP. It was not possible 
to calculate pharmacodynamic time course parametres for the anti Ila 
data since a large proportion of the data points were out side of the 
linear range. Also after protamine administration, the anti Ila 
activity of the heparins was completely neutralized therefore it was 
not possible to calculate area under the curve with only a few data 
points. To determine the anti Ila time course parameters, it would be 
necessary to use lower doses of the heparins and draw blood more 
frequently. 
1. Area Under the Concentration Curve (AUC) 
Increasing the doses of heparin and CY 216 administered to the 
primate groups from O. 35 mg/kg i. v. to O. 7 mg/kg i. v. resulted in a 
dose dependant increase in AUC values . In most cases as the doses 
doubled the AUC values increased more than two fold. This is related 
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to decreases in the plasma clearance which were observed as the dose of 
heparin was increased as determined by the amidolytic anti Xa and 
HeptestR methods. Similar findings have been reported by Worth and 
Estes (1969) and Bjornsson et al. (1981). 
In general, the differences between the time course parameters of 
heparin and CY 216 lessened as the dose was increased to 0. 70 mg/kg 
i.v. At lower doses, differences between drugs may be more pronounced 
since drug elimination mechanisms do not become saturated and dose-
dependant pharmacodynamics are not apparent at lower doses. The AUC 
for CY 216 as determined by the amidolytic anti Xa method did not 
increase proportionately with the increase in dose. This may be 
related to the plasma clearance of CY 216. The Clp for CY 216 as 
measured by the amidolytic anti Xa method was not dose related, while 
the Clp decreased with increasing dose as determined by the HeptestR. 
From the AUC values of heparin and CY 216 after protamine 
administration it was apparent that both heparin and CY 216 demonstr-
ated characteristic protamine neutralization profiles as determined by 
the amidolytic anti Xa assay and HeptestR. Comparison of AUC values 
provided a means of quantitating the activity and degree of neutraliza-
tion of the heparins over an extended period of time rather than at one 
certain time period. Both assays demonstrated that the~ vivo activity 
of CY 216 was less neutralizable by protamine than the~ vivo activity 
of heparin. 
2. Mean Residence Time (MRT) 
Increasing the doses of heparin administered to the primates from 
0. 35 mg/kg i. v. to 0. 7 mg/kg i. v. resulted in a significant (p<. 05) 
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dose dependant increase in the MRT as determined by the HeptestR but 
not the amidolytic anti Xa method. Once again differences in sen-
sitivity of the assays may lead to different pharmacodynamic time 
course parameters. Differences in MRT values could also be related to 
intergroup differences within the primate groups. Increasing the dose 
of CY 216 from 0.35 mg/kg i.v. to 0.7 mg/kg i.v., however, resulted in 
a significant (p<. 05) decrease in MRT values as determined by both 
methods. Protamine (0.7, 1.4 or 2.1 mg/kg i.v.) administration did not 
have any significant effect on the MRT valued of heparin or CY 216 
determined by both methods. 
3. Plasma Clearance (Clp) 
Increasing the dose given to the primates from 0.35 to 0.70 mg/kg 
i.v. significantly (p<.05) decreased the clearance of heparin as 
determined by both methods. 
Clp of CY 216 was noted. 
In contrast, no significant change in the 
This may be related to the differing route 
and kinetics involved in their elimination of heparin and CY 216. 
Heparin is primarily cleared by the liver and kidneys (Palm and Mattson 
1987) from a combination of saturable and nonsaturable mechanisms. 
(DeSwart 1982) The saturable mechanism of heparin clearance involves 
binding to the endothelium (Dawes and Pepper 1979) while the non-
saturable mechanisms may involve renal elimination (Piper 1947). Low 
molecular weight heparins, on the other hand, are cleared primarily via 
the kidneys through renal filtration (Goudable et al. 1986). Certain 
routes of elimination such as endothelial cell binding may become 
saturated for heparin and renal and hepatic elimination may predominate 
and as a result, clearance may increase with increasing dose. 
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4 . Apparent Volume of Distribution (Vd) 
A significant (p<.05) dose dependant decrease in the Vd of 
heparin was observed as the dose of heparin was doubled as determined 
by the amidolytic anti Xa method but not as determined by the HeptestR. 
Intuitively one would not expect the Vd to decrease as the dose 
increased. This anomalous result was not found with the HeptestR, 
which suggest that an assay which measures the collective activities of 
heparin may be a more reliable method for determining heparin pharmaco-
dynamic time course parameters than a specific assay. Although both Vd 
values for heparin and CY 216 < 0. 05 1/kg which indicated that the 
drugs remained within the plasma compartment. The Vd of heparin was 
generally greater than for CY 216 which may be related to the increas-
ing endothelial affinity of heparin with increasing molecular weight. 
No significant dose related change in the Vd of CY 216 was noted by 
either method. 
5. Protamine Neutralization Index (PNI) 
PNI values were calculated for intravenously administered heparin 
and CY 216 after neutralization by protamine. These values provided a 
means of quantitating the degree of neutralization of the drugs over an 
extended time period. PNI values were generally greater for heparin 
than for CY 216 as determined by both methods, however no difference 
was found between the PNI values of heparin and CY 216 at a gravimetric 
protamine to heparin (or CY 216) ratio of 1. A greater PNI value was 
observed at a gravimetric protamine to heparin ratio of 3:1 as deter-
mined by the amidolytic anti Xa method. 
c. Subcutaneous Administration 
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Protamine neutralization of the pharmacodynamic time course of 
subcutaneously administered heparin and CY 216 was studied in the 
primate (macaca mulatta). Pharmacodynamic time course parameters were 
calculated from concentrations obtained from HeptestR and amidolytic 
anti Xa activity data which was extrapolated from calibration curves of 
heparin or CY 216 supplemented to NMP. 
1. Area Under the Concentration Curve (AUC) 
The AUC values for CY 216 (0. 7 mg/kg s. c.) were increased as 
compared to heparin (0.7 mg/kg s.c.). Since the degree of absorption 
after subcutaneous administration of a drug depends upon molecular 
weight, greater antiprotease activity was observed after subcutaneous 
administration of CY 216. Heparin exhibits an increased mean molecular 
weight as compared to CY 216 and was not substantially absorbed after 
subcutaneous administration. After protamine administration to heparin 
(0.7 mg/kg s.c.) or CY 216 (0.7 mg/kg s.c.) a decrease in the AUC 
values were observed as determined by the amidolytic anti Xa method but 
not the HeptestR. 
2. Mean Residence Time (MRT) 
The MRT of CY 216 (0. 7 mg/kg s. c.) was longer than the MRT of 
heparin (0. 7 mg/kg s. c.) as determined by the amidolytic anti Xa 
method. This is consistent with literature reports (Palm and Mattson 
1987; Lockner et al. 1986). It was interesting to note that the MRT 
values for CY 216 (0. 7 mg/kg s. c.) were not greater than the MRT for 
heparin (0.7 mg/kg s.c.) as determined by the HeptestR. However this 
result may be related to the large standard errors which were obtained 
for the MRT values after subcutaneous administration of heparin and CY 
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216. There was no significant effect of protamine on the MRT values of 
CY 216 (0.7 mg/kg s.c.) as determined by both methods, or for h~parin 
(0. 7 mg/kg s. c. ) as determined by the amidolytic anti Xa method. 
However the MRT for heparin (0.7 mg/kg s.c.) was significantly (p<.05) 
less after the administration of protamine as determined by the 
HeptestR. 
3. Plasma Clearance (Clp) 
The plasma clearance values obtained after subcutaneous ad-
ministration of heparin (0. 7 mg/kg) were increase as compared to 
heparin (0. 7 mg/kg i. v.). The Clp of CY 216 (0. 7 mg/kg s. c.) was 
increased as compared to CY 216 (0.7 mg/kg i.v.) as determined by the 
HeptestR and amidolytic anti Xa methods. The clearance values were 
dependant upon the method of calculation used in the noncompartmental 
model. Clearance was calculated as Clp - (dose)/(AUC), however the 
absorption of heparin was very poor. Therefore the clearance values 
calculated by this method reflect the poor absorptive characteristics 
of heparin after subcutaneous administration rather than the actual 
clearance. The plasma clearance for CY 216 as determined by the 
HeptestR was greater than as determined by the amidolytic anti Xa 
method. Once again this result may be related to the absorptive 
characteristics of CY 216 and the sensitivity of the assay. HeptestR 
measures both low molecular weight components which inhibit factor Xa 
and high molecular weight components which may inhibit factors Xa and 
Ila. Since high molecular weight components are not absorbed as well 
as low molecular weight components, it may appear that more heparin 
molecules are cleared while actually they may not have been absorbed. 
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4 . Apparent Volume of Distribution (Vd) 
The Vd values for heparin (0.7 mg/kg s.c.) and CY 216 (0.7_ mg/kg 
) were low (<0.05 1/kg) which indicates after absorption, the drugs s.c. 
remain in the plasma compartment. The Vd for CY 216 (0.7 mg/kg s.c.) 
was 10 fold lower than the Vd for heparin as determined by both methods 
and the Vd for CY 216 (0.7 mg/kg s.c.) as determined by the HeptestR 
The Vd approximates the apparent volume into which a drug distributes 
and is not a real volume. Low values for Vd may have been obtained 
since the equation used to calculate Vd: 
Vd - dose x AUC x 1 liter 
(AUMC)(AUMC} 1000 ml 
is inversely related to the AUMC. This value which is related to the 
AUC was elevated 3 fold as compared to the AUMC for CY 216 (0.7 mg/kg 
s.c.) as determined by the HeptestR. Once again differing sensitiv-
ities of the assays contributed to variations in the calculated 
parameters. 
5. Protamine Neutralization Index (PNI) 
PNI values were calculated for subcutaneously administered 
heparin and CY 216 after neutralization by protamine. The activities 
of CY 216 were less neutralizeable than heparin as determined by the 
amidolytic anti Xa method as compared to the HeptestR. It is interest-
ing to note that a lesser degree of neutralization after subcutaneous 
administration of both drugs occurred as compared to intravenous 
administration. The activity of the drugs was neutralized approximate-
ly SO% less after subcutaneous administration. 
d. Practical Implications of Protamine Interactions with Heparin and 
cY 216 
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1. The Relevance of Laboratory Tests in the Assessment of Heparin 
and CY 216 After Neutralization By Protamine 
Very limited comparative information on the interaction of 
protamine with heparin and low molecular weight heparins is available. 
The information which is available is limited in that it does not 
address the practical considerations of the interaction of protamine 
with low molecular weight heparin such as the relevance of ~ vivo 
activity of low molecular weight heparins to thrombosis or bleeding 
after neutralization by protamine or low molecular weight heparin 
rebound. 
The current studies have addressed the relevance of ~ vivo 
activity as determined by anticoagulant and antiprotease assays to 
bleeding and antithrombotic effects. These tests may have some limited 
value in the prediction of which patients will exhibit blood loss after 
the administration of heparin or low molecular weight heparin. After 
heparin administration to rabbits in the blood loss studies, the anti 
Xa (r-.690) and anti Ila (r-.564) correlation coefficients were similar 
as well as the correlation coefficient obtained after administration of 
CY 216 to rabbits as determined by the HeptestR (r-.515). However the 
correlation coefficient for CY 216 as determined by the amidolytic anti 
Xa (r-.102) and anti Ila (r-.186) methods were poor. 
After protamine neutralization, the thrombin time exhibited the 
best correlation coefficients (r-. 765 for heparin), (r- . 812 for CY 
216) for blood loss and activity . The use of particular laboratory 
tests to measure heparin and low molecular weight heparin activity may 
not necessarily be sensitive to the effects of the heparins after 
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protamine neutralization. Although the studies were limited, the data 
suggests that of the tests used, either amidolytic anti Xa or amidoly-
tic anti Ila assay would be useful to predict the hemorrhagic effects 
of heparin however these tests do not predict the hemorrhagic potential 
of CY 216 as well as the HeptestR. After protamine neutralization of 
heparin and CY 216, the thrombin time assay best correlated with 
increased blood loss. These results demonstrate an important con-
sideration in the clinical monitoring of patients who receive heparins. 
a. Heparin Rebound 
Many factors may contribute to the phenomenon of heparin rebound 
which include: the recirculation of heparin (Gollub 1967), hypothermia 
(Gollub 1967) and the protamine to heparin ratio administered (Kesteven 
et al. 1986). Although the whole blood activated clotting time is 
widely used to predict the neutralizing dose of protamine sulfate 
(Piffare et al. 1981), this assay may not always give a true reflection 
of the dose of protamine required to neutralize heparin (Esposito et 
al. 1983). One objective of this dissertation was to investigate 
whether the individual activities of heparin and CY 216 exhibited any 
characteristic rebound patterns in the primate pharmacodynamic model. 
At these doses studied, no significant degree of heparin rebound was 
observed although a slight decrease in thrombin time was observed after 
the administration of protamine. The neutralization of this activity 
may appear as a slight degree of rebound, however protamine is known to 
have fibrinoplastic effects (Hougie 1958) which may be related to the 
shortening of the thrombin time and this apparent rebound of thrombin 
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time activity No physical signs of heparin rebound such as increased 
blood loss were observed in the primates. 
b. Clinical Indications for Low Molecular Weight Heparins 
In certain clinical conditions, such as atherosclerosis and 
diabetes (0 Brien 1984) and during procedures such as cardiopulmonary 
bypass and renal dialysis, platelets become activated and release PF4. 
Since platelet factor 4 is known to neutralize the effects of heparins 
in a similar manner to protamine, (Racanelli 1987), it may be ad-
vantageous for low molecular weight heparin to retain antithrombotic 
activity 
polybasic 
and amidolytic anti Xa activity 
proteins. This dissociation of 
after complexation with 
the antithrombotic and 
hemorrhagic activity of low molecular weight heparins after protamine 
reversal is a unique property not found in heparin. 
c. Future Studies 
The current studies have addressed such practical issues as the 
relevance of anticoagulant and antiprotease activity of heparins after 
neutralization by protamine, however many areas concerning the interac-
tion of heparins have not been addressed. Further studies are required 
to better understand the interaction of these drugs. Systematic 
structure activity studies are needed to characterize the interaction 
of heparins and protamine on the molecular level. The role of 
protamine neutralization of low molecular weight heparins as determined 
by newly developed assays which measure thrombin antithrombin complex 
formation or thrombin generation may provide additional insight into 
the exact mechanism of protamine antagonism of heparins. More exten-
sive studies on the rebound of low molecular weight heparins after 
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protamine administration should be carried out to see if these agents 
Also the exhibit rebound phenomenon in a way analogous to heparin. 
bemodynamic effects of the protamine reversal of low molecular weight 
heparin therapy should be addressed. Protamine antagonism of low 
molecular weight may provide therapeutic benefits as compared to the 
protamine antagonism of heparin. 
CHAPTER VI 
SUMMARY AND CONCLUSIONS 
Significant differences between the protamine neutralization of 
heparin and CY 216 have been observed both in vitro and in animal models 
of hemorrhage and thrombosis. 
1. The APTT was more sensitive to in vitro supplementation of 
protamine than the thrombin time, HeptestR, amidolytic anti Xa or 
amidolytic anti Ila assays. 
2. NHP and NMP exhibited similar activity in the clotting tests, 
amidolytic anti Xa and amidolytic anti Ila assays after supplementation 
of heparin or CY 216 as compared to NRP and NratP. 
3. The in vitro neutralization profiles of heparin and CY 216 by 
protamine differed significantly and demonstrated assay dependant 
characteristics. Most activities of heparin were completely neutralized 
at an equigravimetric protamine concentration, while the amidolytic anti 
Ila and thrombin time activities of CY 216 were neutralized to a greater 
extent than the amidolytic anti Xa and HeptestR activities. 
4. Administration of protamine sulfate (0.74 mg/kg i.v.) resulted 
in antithrombotic activity in the laser-induced thrombosis model and 
rabbit stasis thrombosis model. 
5. Both heparin and CY 216 exhibited significant inhibition of 
thrombosis in the laser-induced thrombosis model and the rabbit stasis 
thrombosis model. At concentrations of 25 µg/ml and 50 µg/ml, heparin was 
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aore potent as an antithrombotic agent than equivalent gravimetric amounts 
of CY 216. 
6. Protamine neutralized the antithrombotic activity of 
intravenously administered heparin and CY 216 in the laser-induced 
thrombosis model to a similar extent, however, the heparins exhibited 
differential neutralization in the rabbit stasis thrombosis model. The 
antithrombotic activity of heparin was completely neutralized at a 
gravimetric protamine to heparin ratio of 1:1, while CY 216 (100 µg/kg 
1.v.) exhibited significant (p<.05) antithrombotic activity even after the 
administration of equigravimetric protamine. 
7. Poor correlations coefficients were obtained between 
intravenously administered heparin and% of thrombosis in a rabbit stasis 
thrombosis model. The correlation coefficients ranged from .002 for the 
APTT to .515 for the amidolytic anti Xa assay. Similarly, correlation 
coefficients were obtained for CY 216 and % inhibition of thrombosis 
which ranged from .152 for the APTT to .806 for the HeptestR. 
8. Heparin and CY 216 (1 mg/kg s.c.) exhibited significant 
antithrombotic activity in the rabbit stasis thrombosis model. This 
activity of heparin was completely neutralized by protamine (1 mg/kg i.v.) 
while the antithrombotic activity of CY 216 was not completely neutralized 
by equigravimetric protamine. 
9. Protamine sulfate (2 and 3 mg/kg i.v.) had no effect on blood 
loss in the rabbit ear model while an equivalent amount of protamine 
produced an in increase in bleeding time in the rat tail transection 
bleeding model. The rat tail transection data was associated with large 
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standard deviations. In addition, protamine administration alone caused 
a prolongation of bleeding time which makes the interpretation of these 
experiments difficult. 
10. CY 216 produced approximately 60% less blood loss as 
equigravimetric amounts of heparin as determined by a rabbit ear blood 
loss model. The blood loss induced by CY 216 exhibited a poor correlation 
to amidolytic anti Xa (r-.102) and arnidolytic anti Ila (r-.186) activity. 
CY 216 induced blood loss demonstrated a better correlation to the HeptestR 
(r-.515). Heparin-induced blood loss exhibited poor correlations to 
amidolytic anti Xa (r-.690) and amidolytic anti II (r-.564) activity. 
11. Subcutaneous administration of heparin or CY 216 (3 mg/kg s.c.) 
did not produce an increase in blood loss in the rabbit ear model. A 
similar result was obtained in the rat tail transection model where 
heparin or CY 216 (2. 5 mg/kg s. c.) did not increase the bleeding time 
after tail transection. 
12. The differential neutralization observed for heparin and CY 216 
in vitro was observed in vivo as well. The anticoagulant and antiprotease 
activities of heparin were neutralized to a greater degree than the 
similar activities of CY 216. In general, assays which measure the anti 
Xa activity of CY 216 were less neutralizeable than assays which measure 
thrombin inhibition. 
13. After intravenous and subcutaneous administration of 
equigravimetric doses of heparin and CY 216 to primates, the AUC of CY 216 
was greater than for heparin as determined by the amidolytic anti Xa assay 
and HeptestR. 
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14. In the intravenous studies the anticoagulant and antiprotease 
activities of heparin were more readily neutralized by protamine than the 
activities of CY 216. 
15. Neutralization after subcutaneous administration of heparin and 
CY 216 was dependant upon the bioavailability and time course of the 
drugs. In general, heparin was neutralized more readily than CY 216. 
16. A greater dose dependant decrease in the AUC of heparin was 
seen after increasing doses of protamine were administered. Above a 
protamine to heparin (or CY 216) ratio of 2:1, the PNI of heparin was 
significantly greater than the PNI value for CY 216. 
CHAPTER VII 
TABLE 1 
BASELINE VALUES OF NHP, NMP, NRP AND NratP 
Test NHP NMP NRP NratP 
APTT (seconds) 30.5 ± 2.2 24.4 ± 0.7 56.6 ± 0.8 * 16.1 ± 0.9 * 
Thrombin Time 21.1 ± 0.9 31.3 ± 3.6 42.3 ± 2.9 * >150 
(5 U/ml) 
(seconds) 
HeptestR 15.5 ± 1.2 20.5 ± 1. 7 25.3 ± 0.6 56.6 ± 0.8 * 
(seconds) 
Anti Xa 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
(% Inhibition) 
Anti Ila 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
(% Inhibition) 
Data represents a mean± S.E. N=3. Statistical Analysis was performed 
for each laboratory test by a one-way ANOVA, followed by a Newman-Keuls 
multiple comparison test. * represents a significant (p <.05) 
difference from NHP. 
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Table 2·. Da,ta rep.:esents a mean ± S. E. , N=3. 
Statistical anaiysis was performed for each laboratory test by a one way 
ANOVA, follow~d by a Newrnan-Keuls multiple comparison test. 
* represents a significant difference (p <.05) from NHP. 
** Pr_otamine caused turbidity in the solution which may be related to 
the experimental result. 
N.D. - not.determined. 
TABLE 2 
r--- IN VITRO SUPPLEMENTATION OF PROTAMINE TO r---
..-I NHP, NMP, NRP AND NratP 
Protamine 
Test Concentration NHP NMP NRP NratP 
APTT (seconds) 0 µg/ml 30.5 ± 2.2 24.4 ± 0.7 56.6 ± 0.8* 16.1 ± 0.9 
10 µg/ml 38.9 ± 1.2 26.5 ± 0.7 96.5 ± 8.3* 15.6 ± 1.1 
100 µg/ml 50.2 ± 0.6 51.1 ± 3.7 154.0 ± 15.3* 29.5 ± 5.2 
1 mg/ml >150 N.D. N.D. N.D. 
10 mg/ml >150 N.D. N.D. N.D. 
Thrombin Time (5 ULml} 0 µg/ml 21.1 ± 0.9 31. 3 ± 3.6 42.3 ± 2.9* >150 
(seconds) 10 µg/ml 24.7 ± 0.7 34.6 ± 4.3 30.7 ± 3.6 >150 
100 µg/ml 23.8 ± 1.9 33.8 ± 1.9 32.3 ± 3.7 >150 
1 mg/ml 19.7 ± 0.8 N.D. N.D. N.D. 
10 mg/ml >150 N.D. N.D. N.D. 
HeI!testR (seconds) 0 µg/ml 15. 5 ± 1. 2 20.5 ± 1. 7 25.3 ± 0.6 56.6 ± 0.8* 
10 µg/ml 18.0 ± 0.2 23.1 ± 1.2 28.9 ± 1.2 63.3 ± 0.8* 
100 µg/ml 23.0 ± 0.5 25.7 ± 4.0 28.3 ± 2.5 56.2 ± 3.1* 
1 mg/ml 27.3 ± 2.8 N.D. N.D. N.D. 
10 mg/ml >300 N.D. N.D. N.D. 
Anti Xa (% Inhibition} 0 µg/ml 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
10 µg/ml 4.6 ± 3.3 0 ± 0 0 ± 0 0 ± 0 
100 µg/ml 0 ± 0 2.0 ± 2.0 2.5 ± 1.5 0 ± 0 
1 mg/ml 1 ± 1** N.D. N.D. N.D. 
10 mg/ml 53.3 ± 3.0 N.D. N.D. N.D. 
Anti Ila (% Inhibition} 0 µg/ml 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
10 µg/ml 0 ± 0 1. 2 ± 0 0 ± 0 2.6 ± 1.5 
100 µg/ml 6.4 ± 3.8 0 ± 0 0.3 ± 0.3 5.0 ± 1.8 
1 mg/ml 0 ± 0 N.D. N.D. N.D. 
10 mg/ml 0 ± 0 N.D. N.D. N.D. 
APTT 
(seconds) 
NHP 30.1 ± 0.3 
NHP + 36.2 ± 0.3 
Spermidine 
(10 Mg/ml) 
Heparin >150 
(5.0 Mg/ml) 
Heparin >150 
(5.0 Mg/ml 
and 
Spermidine 
(2.5 Mg/ml) 
Heparin >150 
(5.0 Mg/ml) 
and 
Spermidine 
(S.0 Mg/ml) 
Heparin >150 
(S.0 Mg/ml 
and 
Spermidine 
(10.0 Mg/ml) 
Heparin 109.3 
(5.0 Mg/ml) 
and 
Spermidine 
(1.0 mg/ml) 
TABLE 3 
IN VITRO NEUTRALIZATION OF 
HEPARIN BY SPERMIDINE 
Thrombin 
Time Heptest 
(seconds) (seconds) 
22.3 ± 4.8 15.4 ± 0.1 
20.6 ± 0.3 16.7 ± 0.4 
>150 115.2 ± 5.8 
>150 108.9 ± 2.2 
>150 111.3 ± 3.9 
>150 106.2 ± 5.3 
>150 95.7 
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Anti Xa Anti Ila 
% I % I 
0 ± 0 0 ± 0 
0 ± 0 0 ± 0 
44.0 ± 1.5 81.0 ± 1.1 
52.7 ± 0.6 85.0 ± 1.0 
49.5 ± 1.6 81.0 ± 3.3 
49.0 ± 4.4 67.3 ± 3.2 
66 54 
Data represents a mean± S.E., N=3, (except for heparin and spermidine 
1.0 mg/ml) where data has an N=l. 
APTT 
(seconds) 
TABLE 4 
IN VITRO NEUTRALIZATION OF 
CY 216 BY SPERMIDINE 
Thrombin 
Time 
(seconds) 
Heptest 
(seconds) 
Anti Xa 
% I 
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Anti Ila 
% I 
NHP 
NHP + 
Spermidine 
30 .1 ± 0. 3 22. 3 ± 0 .1 15. 4 ± 0 .1 
36. 2 ± 0. 3 20. 6 ± 0. 2 16. 7 ± 0. 4 
0 ± 0 
0 ± 0 
0 ± 0 
0 ± 0 
CY 216 48.0 ± 2.4 
(5.0 Mg/ml) 
CY 216 47.2 ± 2.4 
(5.0 Mg/ml) 
and 
Spermidine 
(2.5 Mg/ml) 
CY 216 46.4 ± 2.3 
(5.0 Mg/ml) 
and 
Spermidine 
(5.0 Mg/ml) 
CY 216 44.7 ± 0.7 
(5.0 Mg/ml) 
and 
Spermidine 
(10 Mg/ml) 
CY 216 
(5.0 Mg/ml) 
and 
Spermidine 
(1 mg/ml) 
36.8 
>150 68.9 ± 5.7 38.5 ± 2.6 30.8 ± 3.2 
>150 46 . 2 ± 4. 1 14. 0 ± 1. 8 2 . 7 ± 0. 4 
>150 72 . 4 ± 1. 7 15 . 7 ± 1. 2 8 . 0 ± 0. 1 
>150 64. 1 ± 4. 6 17 . 3 ± 2 . 9 0 . 3 ± 0. 0 
148 43.8 45 0 
Data represents a mean± S.E., N = 3, (except for CY 216 and spermidine 
1.0 mg/ml) where data has an N - 1. 
TABLE 5 
COAGULATION PARAMETERS OF RABBITS ADMINISTERED 
INTRAVENOUS PROTAMINE SULFATE 
Thrombin Time 
APTT (5 U/ml) HeptestR Anti Xa Anti 
Treatment (seconds} (seconds} (seconds} (% I} (% 
Saline Control 83.9 ± 1.0 32.0 ± 4.1 30.8 ± 3.8 0 ± 0 0 
Protamine 102.3 ± 9.0 35.3 ± 3.3 28.7 ± 4.2 0 ± 0 0 
100 Mg/kg i.v. 
Protamine 97.6 45.6 41.3 0 
500 Mg/kg i.v. 
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Ila 
I} 
± 0 
± 0 
0 
Saline or protamine was administered to groups of rabbits (N-5) and 
allowed to circulate for 10 minutes. Protamine (500 ug/kg i.v.) group 
contained 2 rabbits. Blood was drawn by cardiac puncture just prior to 
thrombogenic challenge. APTT, thrombin time, HeptestR, amidolytic anti 
Xa and amidolytic anti Ila assays were performed. The results represent 
a mean± S.E. Statistical analysis was performed for the APTT results 
by an unpaired t-test (two tailed), t=l.649, df-6, p >.20, N.S. 
Treatment 
TABLE 6 
COAGULATION PARAMETERS OF RABBITS 
ADMINISTERED INTRAVENOUS HEPARIN 
Thrombin Time 
APTT (5 U/ml) 
(seconds) (seconds) 
181 
HeptestR 
(seconds) 
Saline Control 83.9 ± 1.0 32.0 ± 4.1 30.8 ± 3.8 
Heparin 124.7 ± 13.2 46.7 ± 4.4 44.9 ± 9.7 
25 Mg/kg i.v. 
Heparin 111.2 ± 17.2 132.3 ± 57.1* 76.8 ± 10.6 
50 Mg/kg i.v. 
Heparin 146.8 ± 29.7* >150 128.9 ± 27.7* 
100 Mg/kg i.v. 
Saline or protamine was administered to groups of rabbits (N-5) and 
allowed to circulate for 10 minutes. Blood was drawn by cardiac 
puncture just prior thrombogenic challenge. APTT, thrombin time, and 
HeptestR were performed. The results represent the mean± S.E. 
Statistical analysis was performed by a one-way ANOVA. 
for APTT, F(3,16)=5.847 p <.05 
for thrombin time, F(3,16)-7.028 p <.05 
for HeptestR, F(3,16)=5.352 p <.05 
Newman-Keuls multiple comparison tests were also performed. 
* represents a significant difference from the control group 
Treatment 
Saline Control 
CY 216 
25 Mg/kg i.v. 
CY 216 
50 Mg/kg i.v. 
CY 216 
100 Mg/kg i.v. 
TABLE 7 
COAGULATION PARAMETERS OF RABBITS 
ADMINISTERED INTRAVENOUS CY 216 
Thrombin Time 
APTT (5 U/ml) 
(seconds) (seconds) 
83.9 ± 1.0 32.0 ± 4.1 
58.0 ± 6.4 37.0 ± 1.6 
49.1 ± 14.4 50.7 ± 9.3* 
67.7 ± 12.9 49.1 ± 10.1* 
182 
HeptestR 
(seconds) 
30.8 ± 3.8 
42.4 ± 4.1 
42.1 ± 2.1 
63.6 ± 11.8* 
Saline or protamine was administered to groups of rabbits (n=S) and 
allowed to circulate for 10 minutes. Blood was drawn by cardiac 
puncture just prior to thrombogenic challenge. APTT, Thrombin time, and 
HeptestR were performed. The results represent the mean± S.E. 
Statistical analysis was performed by a one way ANOVA for each 
individual assay followed by a Newman-Keuls multiple comparison test. 
for APTT;F(3,12)=.468 p >50, N.S. 
for thrombin time:F(3,12)=19.860, p <.05 
for HeptestR:F(3,12)=5.488, p <.05 
* represents a significant difference from the control group. 
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Table 8 .· .-. S~line ,. heparin or CY 216 was administered to groups of 
.. , 
rabbits (N-5) and allowed to circulate for 5 minutes at which time 
protamine was administered to groups which received heparin or CY 216. 
Blood was drawn 5 minutes after protamine administration or 10 minutes 
after saline administration for the control group. A thrombogenic 
challenge was· administered immediately after blood draw. APTT, thrombin 
time, and·HeptestR were performed. The results represent the mean± 
S.E. Statistical analysis was performed by a two-way ANOVA. 
for APTT 
Factor A (drug treatment):F(2,36)-2.655 p >.10 N.S. 
Factor B (protamine concentration):F(2,36)-4.365 p <.05 
Factor Ax B:F(4,36)-3.288 p >.10 N.S. 
for thrombin time 
Factor A (drug treatment):F(2,36)-55.707 p <.05 
Factor B (protamine concentration):F(2,36)-65.638 p <.05 
Factor Ax B:F(4,36)-56.264 p <.001 
for HeptestR 
Factor A (drug treatment):F(2,36)-7.142 p <.05 
Factor B (protamine concentration):F(2,36)-7.443 p<.05 
Factor Ax B:(4,36)-4.198 p>.05 N.S. 
Newman-Keuls multiple comparison tests were also performed. 
* represents a significant difference from the control group. 
** represents a significant difference from the heparin (100 
*** 
µg/kg i.v.) and protamine (100 µg/kg i.v.) group. 
represents a significant difference from the CY 216 (100 µg/kg 
i.v.) and protamine (100 µg/kg i.v.) group. 
Treatment 
TABLE 8 
COAGULATION PARAMETERS OF RABBITS ADMINISTERED 
INTRAVENOUS HEPARIN OR CY 216 AND PROTAMINE 
Thrombin Time 
APTT (5 U/ml) 
(seconds) (seconds) 
Saline Control 83.9 ± 1.0 32.0 ± 4.1 
184 
HeptestR 
(seconds) 
30.8 ± 3.8 
Heparin 146.8 ± 29.7 >150 128.9 ± 27.7* 
100 Mg/kg i.v. 
Heparin 57.6 ± 10.2 40.3 ± 5.2 37.2 ± 6.8 
100 Mg/kg i.v. 
and Protamine 
100 Mg/kg i.v. 
Heflarin 122.9 ± 12.3** 37.5 ± 1. 9 47.0 ± 2.0 10 Mg/kg i.v. 
and Protamine 
200 Mg/kg i.v. 
CY 216 67.7 ± 12.9 49.1 ± 10.7* 63.6 ± 11.8* 
100 Mg/kg i.v. 
CY 216 58.0 ± 13.6 34.1 ± 3.4 46.2 ± 4.1 
100 Mg/kg i.v. 
and Protamine 
100 Mg/kg i.v. 
CY 216 113.0 ± 6.6*** 38.4 ± 3.1 43.4 ± 1. 3 
100 Mg/kg i. v. 
and Protamine 
200 Mg/kg i.v. 
185 
. 
. •. 
Table 9; :::Salin~, . heparin or CY 216 was administered to groups of 
rabbits' (N-5'-) a~d allowed to circulate for 5 minutes at which time 
protamine.wai'administered to groups which received heparin or CY 216. 
Blood was drawn 5 minutes after protamine administration or 10 minutes 
after saline administration for the control group. Thrombogenic 
challenge was ~dministered immediately after blood draw. APTT, thrombin 
time, and HeptestR were performed. The results represent the mean± 
S.E. Statistical analysis was performed by a two-way ANOVA. 
for APTT 
Factor A (drug treatment):F(2,24)-1.032 p >.SO N.S. 
Factor B (protamine concentration):F(l,24)-.33 p >.50 N.S. 
Factor Ax B:F(2,24)-2.793 p >.10 N.S. 
for thrombin time 
Factor A (drug treatment):F(2,24)-12.245 p <.05 
Factor B (protamine concentration):F(l,24)-2.401 p <.05 
Factor Ax B:F(2,24)-1.061 p >.50 N.S. 
for HeptestR 
Factor A:F(2,24)-2.999 p >.10 N.S. 
Factor B:F(l,24)-.184 p >.SO N.S. 
Factor Ax B:F(2,24)-1.982 p >.20 N.S. 
Newman-Keuls multiple comparison tests were also performed. 
* Represents a significant difference from the control group. 
Treatment 
TABLE 9 
COAGUI.ATION PARAMETERS OF RABBITS ADMINISTERED 
SUBCUTANEOUS HEPARIN OR CY 216 AND PROTAMINE 
Thrombin Time 
APTT (5 U/ml) 
(seconds) (seconds) 
Saline Control 83.9 ± 1.0 32.0 ± 4.1 
Heparin 61. 0 ± 10. 5 128.8 ± 13.4* 
1 mg/kg s.c. 
Heparin 78.8 ± 18.7 85.9 ± 25.1* 
1 mg/kg s.c. 
and Protamine 
1 mg/kg i.v. 
CY 216 95.4 ± 4.4 54.8 ± 8.9 
1 mg/kg s.c. 
CY 216 73.7 ± 12.0 37.8 ± 5.2 
1 mg/kg s.c. 
and Protamine 
1 mg/kg i.v. 
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HeptestR 
(seconds) 
30.8 ± 3.8 
62.4 ± 12.4* 
39.5 ± 5.7* 
42.7 ± 12.2* 
58.4 ± 10.2* 
Treatment (N) 
TABLE 10 
COAGUIATION PARAMETERS AFTER INTRAVENOUS 
PROTAMINE ADMINISTRATION IN RABBITS 
Thrombin Time 
(5 U/ml) HeptestR Anti Xa 
(seconds) (seconds) (% I) 
Saline Control (5) 30.1 ± 3.3 24.8 ± 3.0 0 ± 0 
Protamine 37.0 ± 1.5 26.4 ± 3.7 2.0 ± 1. 7 
2 mg/kg i.v. (4) 
Protamine 33.2 ± 7.3 22.4 ± 0.7 0 ± 0 
3 mg/kg i.v. (3) 
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Anti Ila 
(% I) 
0 ± 0 
0 ± 0 
0 ± 0 
Saline or protamine was administered to rabbits and allowed to circulate 
for 10 minutes. Blood was drawn by cardiac puncture just prior to blood 
loss determination. Thrombin time, HeptestR, amidolytic anti Xa and 
amidolytic anti Ila assays were performed. The results represent a mean 
± S.E. 
TABLE 11 
COAGULATION PARAMETERS AFTER INTRAVENOUS 
HEPARIN ADMINISTRATION IN RABBITS 
Thrombin Time 
APTT (5 U/ml) 
Treatment (N) (seconds) (seconds) 
Saline Control (5) 83.2 ± 11.5 30.l ± 3.3 
Heparin >150 >300 
1 mg/kg i.v. (6) 
Heparin >150 >300 
2 mg/kg i.v. (14) 
188 
HeptestR 
(seconds) 
24.8 ± 3.0 
>271. 5 
>300 
Saline or heparin was administered to rabbits and allowed to circulate 
for 10 minutes. Blood was drawn by cardiac puncture just prior to blood 
loss determination. Thrombin time, HeptestR, amidolytic anti Xa and 
amidolytic anti Ila assays were performed. The results represent a mean 
± S.E. 
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TABLE 12 
COAGULATION PARAMETERS AFTER INTRAVENOUS 
CY 216 ADMINISTRATION IN RABBITS 
Thrombin Time 
APTT (5 U/ml) 
Treatment (N) (seconds) (seconds) 
Saline Control (5) 83.2 ± 11.5 30.1 ± 3.3 
CY 216 >150 >150 
1 mg/kg i.v. (5) 
CY 216 >150 >150 
2 mg/kg i.v. (13) 
CY 216 >150 >150 
HeptestR 
(seconds) 
24.8 ± 3.0 
138.1 ± * 7.0 
>296.1 ± 3.9 
>300 
Saline or CY 216 was administered to rabbits and allowed to circulate 
for 10 minutes. Blood was drawn by cardiac puncture Just prior to blood 
loss determination. APTT, Thrombin time, and Heptest were performed. 
The results represent a mean± S.E. Statistical analysis for the 
heptestR data was performed by an unpaired t test (two tailed). 
t=6.332, df=8, p <.05. * represents a significant difference from the 
control group. 
190 
' 
... 
Table 13. S�line,, heparin, or CY 216 was administered to rabbits and 
allowed to circulate for 5 minutes at which time protamine was 
administered _to groups which received heparin or CY 216. Blood was 
drawn 5 minutes after protamine administration or 10 minutes after 
saline administration for the control group. Blood loss was determined 
immediately after the blood draw. APTT, thrombin time, and HeptestR 
were performed. The results represent the mean± S.E. Statistical 
analysis was performed by a two way ANOVA. 
for thrombin time 
Factor A (drug treatment):F(2,36)=34.960 p <.05 
Factor B (protamine concentration):(2,36)=37.654 p <.05 
Factor Ax B:F(4,36)=12.382 p <.05 
for HeptestR 
Factor A (drug treatment):F(2,36)=22.275 p <.05 
Factor B (protamine concentration):F(2,36)=19.477 p <.OS 
Factor Ax B:F(4,36)=5.684 p <.05 
Newman-Keuls multiple comparison tests were also performed. 
* represents significant difference from control group.
** represents a significant difference from CY 216 (2 mg/kg i.v.)
and protamine (3 mg/kg i.v.) group.
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TABLE 13 
COAGUIATION PARAMETERS OF RABBITS ADMINISTERED INTRAVENOUS 
HEPARIN OR CY 216 AND PROTAMINE 
Thrombin Time 
APTT (5 U/ml) HeptestR 
Treatment (N) (seconds) (seconds) (seconds) 
Saline Control (5) 83.2 ± 11.5 32.0 ± 3.1 24.8 ± 3.0 
Heparin >150 >150 >300 
2 mg/kg i.v. (14) 
Heparin 82.7 ± 11.5 >150 166.o ± 55_5* 
2 mg/kg i.v. (6) 
and Protamine 
2 mg/kg i.v. 
Heparin 87.6 ± 7.5 33.4 ± 2.4 58.4 ± 3.7 
2mg/kg i.v. (5) 
and Protamine 
3 mg/kg i.v. 
CY 216 >150 >150 >296.1 ± 3.9 
2 mg/kg i.v. (13) 
CY 216 111.3 ± 24.5 73.3 ± 18.8** 138.1 ± 45.5* 
2 mg/kg i.v. (6) 
and Protamine 
2 mg/kg i.v. 
CY 216 108.1 ± 14.5 47.1 ± 10.5 153 ± 47.l* 
2 mg/kg i.v. (5) 
and Protamine 
3 mg/kg i.v. 
TABLE 14 
COAGULATION PARAMETERS OF RABBITS ADMINISTERED SUBCUTANEOUS 
HEPARIN OR CY 216 AND PROTAMINE 
Thrombin Time 
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APTT (5 U/ml) HeptestR 
Treatment (N) (seconds) (seconds) (seconds) 
Saline Control (5) 
Heparin 
3 mg/kg s . c . ( 5) 
Heparin 
3 mg/kg s.c. (5) 
and Protamine 
3 mg/kg i.v. 
83.2 ± 11.5 
>130.8 ± 11. 7 
80.1 ± 9.0 
32.0 ± 3.1 24.8 ± 3.0 
>150 >216.9 ± 49.4 
27.5 ± 2.0 42.3 ± 7.3 
CY 216 89.2 ± 18.4 >150 67.7 ± 18.5* 
3 mg/kg s . c . ( 5) 
CY 216 
3 mg/kg s.c. (5) 
and Protamine 
3 mg/kg i.v. 
71.7 ± 16.7 31.0 ± 3.1 62.9 ± 12.5* 
Saline, heparin or CY 216 was administered subcutaneously to rabbits and 
allowed to circulate for 125 minutes at which time protamine was 
administered to groups which received heparin or CY 216. Blood was 
drawn 5 minutes after protamine administration or 130 minutes after 
saline administration for the control group. Blood loss was determined 
immediately after blood draw. APTT, thrombin time, and HeptestR were 
performed. The results represent the mean± S.E. Statistical analysis 
was performed bl a two way ANOVA. 
for Heptest 
Factor A (drug treatment):F(2,17)-10.131 p <.05 
Factor B (protamine concentration):F(l,17)-8.902 p <.05 
Factor Ax B:F(2,17)-10.365 p <.05 
¼ Newman-Keuls multiple comparison test was also performed. 
represents a significant difference from the control group. 
TABLE 15 
COMPARATIVE PHARMACODYNAMIC TIME COURSE 
PARAMETERS OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti Xa 
Heparin CY 216 
(0,35 mgLkg i.v, l (0,35 mgLkg 
AUC (µg-hr-m- 1 ) 5.97 ± 0.70 14.91 ± 
AUMC (µg-hr 2 -ml-1 ) 7.83 ± 1.60 33.08 ± 
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i,v, l 
2.46* 
7.93 
MRT (min) 77.4 ± 8.68 127.80 ± 12.05* 
Clp (ml-min-1 - kg-1 ) 1.00 ± 0.20 0.43 ± o.05* 
Vd (l-kg-1 ) 0.08 ± 0.01 0.05 ± 0.01 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-4 for heparin (0.35 mg/kg i.v.) group. 
N-5 for CY 216 (0.35 mg/kg i.v.) group. Statistical analysis was 
performed by an unpaired student's t-test: 
for AUC:t-3.340, df-8, p <.05 
for MRT:t-3.244, df-8, p <.05 
for Clp:t-2.555, df-8, p <.05 
for Vd:t-1.716, df-8, p >.10 N.S. 
* represents a significant difference from the heparin (0.35 mg/kg i.v.) 
group. 
TABLE 16 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti Xa 
AUC (µg-hr-ml- 1 ) 
AUMC (µg-hr 2 -ml-1 ) 
MRT (min) 
Clp (ml-min-1 -kg-1 ) 
Vd (l-kg-1 ) 
Heparin 
(0.7 mg/kg i.v.) 
22.41 ± 3.06 
21.50 ± 4.25 
55.80 ± 5.74 
0.55 ± 0.07 
0.03 ± 0.01 
CY 216 
( 0 • 7 mg/kg i. v. ) 
19.32 ± 2.37 
24.02 ± 4.78 
71.40 ± 8.04 
0.65 ± 0.09 
0.05 ± 0.00 
Primate pharmacodynarnic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg i.v.) group. 
N-5 for CY 216 (0.7 mg/kg i.v.) group. Statistical analysis was 
performed by an unpaired student's t-test: 
for AUC:t-0.853, df=9, p >.20 N.S. 
for MRT:5-1.549, df-9, p >.10 N.S. 
for Clp:t-0.832, df-9, p >.20 N.S. 
for Vd:t-1.332, df-9, p >.20 N.S. 
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TABLE 17 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti Xa 
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Heparin (0.7 mg/kg i.v.) 
with 
CY 216 (0.7 mg/kg i.v.) 
with 
AUG 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
Protamine (0,7 mg/kg i.v,) 
3.73 ± 0.60 
6 .09 ± 1. 35 
93.00 ± 13.90 
0.83 ± 0.01 
Protamine (0,7 mg/kg i,v,) 
8. 26 ± 1. 35* 
15.52 ± 3.63 
112.70 ± 15.30 
0.57 ± 0.04* 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-4 for heparin (0.7 mg/kg i.v.) and 
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg i.v.) and 
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by 
an unpaired student's t-test: 
for AUC:t-3.084, df-7, p <.05 
for MRT:t-0.862, df-7, p >.20 N.S. 
for PNI:t-3.109, df-7, p <.05 
* represents a significant difference from the heparin (0.7 mg/kg i.v.) 
with protamine (0.7 mg/kg i.v.) group. 
TABLE 18 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti Xa 
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Heparin (0.7 mg/kg i.v.) 
with 
CY 216 (0.7 mg/kg i.v.) 
with 
AUC 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
Protamine (1.4 mg/kg i.v.) 
3.60 ± 0.74 
6.88 ± 2.37 
102.60 ± 17.14 
0.84 ± 0.02 
Protamine (1.4 mg/kg i.v.) 
9.50 ± 0.98* 
19.19 ± 2.89 
124.80 ± 20.80 
0.51 ± 0.06* 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 
protamine (1.4 mg/kg i.v.) group. 
protamine (1.4 mg/kg i.v.) group. 
an unpaired student's t-test: 
for heparin (0.7 mg/kg i.v.) and 
for AUC:t-4.614, df-8, p <.05 
N-4 for CY 216 (0.7 mg/kg i.v.) and 
Statistical analysis was performed by 
for MRT:t-0.800, df-8, p >.20 N.S. 
for PNI:t-5.281, df-8, p <.05 
* represents a significant difference from heparin (0.7 mg/kg i.v.) and 
protamine (1.4 mg/kg i.v.) group. 
TABLE 19 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti Xa 
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Heparin (0.7 mg/kg i.v.) 
with 
CY 216 (0.7 mg/kg i.v.) 
with 
AUC 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
Protamine (2.1 mg/kg i.v.) 
2.35 ± 0.21 
8.43 ± 3.81 
67.80 ± 48.00 
0.90 ± 0.01 
Protamine (2.1 mg/kg i.v.) 
5.14 ± 0.64* 
5.27 ± 1.34 
58.20 ± 7.50 
0.73 ± .02* 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-4 
protamine (2.1 mg/kg i.v.) group. 
protamine (2.1 mg/kg i.v.) group. 
an unpaired student's t-test: 
for heparin (0.7 mg/kg i.v.) and 
for AUC:t-3.788, df-6, p <.05 
N-3 for CY 216 (0.7 mg/kg i.v.) and 
Statistical analysis was performed by 
* 
for MRT:t-1.334, df-6, p >.20 N.S. 
for PNI:t-4.362, df-6, p <.05 
represents a significant difference from heparin (0.7 mg/kg i.v.) and 
protamine (2.1 mg/kg i.v.) group. 
TABLE 20 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti Xa 
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Heparin (0.7 mg/kg s.c.) 
4. 33 ± .1. 33 
CY 216 (0.7 mg/kg s.c.) 
31.61 ± 4.32* 
AUMC 
(µg-hr 2 -ml-1) 
MR.T (min) 
Clp 
(ml-min-1 -kg-1 ) 
20.23 ± 6.64 
276.00 ± 6.46 
3.70 ± 0.44 
0.01 ± 0.00 
178.24 ± 29.89 
335.10 ± 11.87* 
o.39 ± o.05* 
0.001 ± o.oo* 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by 
an unpaired student's t-test: 
* 
for AUC:t-6.683, df-8, p <.05 
for MRT:t-3.006, df-8, P <.05 
for Clp:t-2.988, df-8, p <.05 
for Vd:t-2.813, df-8, p <.05 
represents a significant difference from heparin (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. 
TABLE 21 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti Xa 
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Heparin (0.7 mg/kg s.c.) 
with 
CY 216 (0.7 mg/kg s.c.) 
with 
Protamine (0.7 mg/kg i.v.) Protamine (0.7 mg/kg i.v.) 
AUC 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
2.58 ± 0.41 
13.56 ± 2.00 
330.60 ± 37.00 
0.40 ± 0.09 
22. 70 ± 1.40* 
107.58 ± 8.05 
286.10 ± 3.59 
0.20 ± 0.06 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 
protamine (0.7 mg/kg i.v.) group. 
protamine (0.7 mg/kg i.v.) group. 
an unpaired student's t-test: 
for heparin (0.7 mg/kg s.c.) and 
N-4 for CY 216 (0.7 mg/kg s.c.) and 
Statistical analysis was performed by 
for AUC:t-13.843, df-8, p <.05 
for MRT:t-1.058, df-8, p >.20 N.S. 
for PNI:t-1.655, df-8, p >.10 N.S. 
* represents a significant difference from heparin 
protamine (0.7 mg/kg i.v.) group. 
(0.7 mg/kg s.c.) with 
TABLE 22 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Anti-Xa 
AUC (µg-ml -l) 
AUMC (µg-hr 2 -ml-1) 
MRT (min) 
PNI 
CY 216 (0.7 mg/kg s.c.) with 
Protamine (1,4 mg/kg i.v.) 
22.30 ± 1.30 
89.34 ± 17.77 
237.00 ± 35.1 
0.21 ± 0.05 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 for CY 216 (0.7 mg/kg s.c.) and 
protamine (1.4 mg/kg i.v.) group. 
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TABLE 23 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: HeptestR 
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AUC 
(µg-hr-ml- 1 ) 
Heparin (0.35 mg/kg i.v.) 
3.73 ± 0.56 
CY 216 (0.35 mg/kg) i.v.) 
6. 54 ± 1. 67* 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
Clp 
(ml-min-1 -kg-1 ) 
1.55 ± 1.00 
24.00 ± 12.00 
1.59 ± 0.23 
0.04 ± 0.02 
11.20 ± 0.45 
114. 72 ± 13.68* 
1.07 ± 0.18* 
0.02 ± 0.01 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-3 for heparin (0.35 mg/kg i.v.) group. 
N-4 for CY 216 (0.35 mg/kg i.v.) group. Statistical analysis was 
performed by an unpaired student's t-test: 
for AUC:t-3.476, df-6, p <.05 
for MRT:t-4.128, df-6, p <.05 
for Clp:t-6.666, df-6, p <.05 
for Vd:t=0.398, df-6, p >.70 N.S. 
* represents a significant difference from heparin (0.35 mg/kg i.v.) 
group. 
TABLE 24 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: HeptestR 
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He~arin (0.7 mgLkg i,v, l CY 216 (0, 7 mgLkg) i.v. l 
AUC 18.36 ± 1.28 27.15 ± 3.45* 
(µg-hr-ml- 1 ) 
AUMC 18.37 ± 2.94 24.84 ± 5.56 
(µg-hr 2 -ml-1 ) 
MRT (min) 58.80 ± 6.79 53.28 ± 7.27 
Clp 
(ml-min-1 -kg-1 ) 
0.65 ± 0.05 0.56 ± 0.14* 
Vd 0.04 ± 0.01 0.02 ± 0.00 
(l-kg-1) 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 for both groups. Statistical 
analysis was performedby an unpaired student's t-test: 
for AUC:t-2.540, df-9, p <.05 
for MRT:t-0.128, df-9, p >.50 N.S. 
for Clp:t-2.488, df-9, p <.05 
for Vd:t-0.416, df-9, p >.50 N.S. 
* represents a significant difference from the heparin (0.7 mg/kg i.v.) 
group. 
TABLE 25 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: HeptestR 
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Heparin (0.7 mg/kg i.v.) 
with 
CY 216 (0.7 mg/kg i.v.) 
with 
AUC 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
Protamine (0.7 mg/kg i.v.) 
12.41 ± 2.14 
12.63 ± 2.99 
59.40 ± 7.50 
0.30 ± 0.06 
Protamine (0,7 mg/kg i,v,) 
18.96 ± 0.64* 
23.90 ± 3.31 
75.20 ± 9.01 
0.30 ± 0.01 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-4 for both groups. Statistical analysis 
was performed by an unpaired student's t-test: 
for AUC:t-2.601, df-7, p >.05 
for MRT:t-1.187, df-7, p >.20 N.S. 
for PNI:t-0.186, df-7, p >.50 N.S. 
* represents a significant difference from the heparin (0.7 mg/kg i.v.) 
with protamine (0.7 mg/kg i.v.) group. 
TABLE 26 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: HeptestR 
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Heparin (0.7 mg/kg i.v.) 
with 
CY 216 (0.7 mg/kg i.v.) 
with 
Protamine (1.4 mg/kg i.v.) Protamine (1.4 mg/kg i.v.) 
AUC 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
3.72 ± 0.52 
5 .42 ± 1.48 
81. 60 ± 10. 98 
0.80 ± 0.01 
12.01 ± 1.09* 
9 .13 ± 1. 70 
46.20 ± 4.20* 
0.56 ± 0.04* 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 
protamine (1.4 mg/kg i.v.) group. 
protamine (1.4 mg/kg i.v.) group. 
an unpaired student's t-test: 
for heparin (0.7 mg/kg i.v.) and 
for AUC:t-3.878, df-8, p <.05 
for MRT:t-9.043, df-8, p <.05 
for PNI:t-4.247, df-8, p >.05 
N-4 for CY 216 (0.7 mg/kg i.v.) and 
Statistical analysis was performed by 
* represents a significant difference from heparin (0.7 mg/kg iv.) and 
protamine (1.4 mg/kg i.v.) group. 
TABLE 27 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: HeptestR 
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Heparin (0.7 mg/kg i.v.) 
with 
CY 216 (0.7 mg/kg i.v.) 
with 
AUC 
(µg-hr-ml -l) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
Protarnine (2.1 mg/kg i.v.) 
2.17 ± 0.27 
2.73± 1.13 
75.20 ± 28.40 
0.88 ± 0.01 
Protamine (2.1 mg/kg i.v.) 
11.210 ± 0.64* 
19.250 ± 4.94 
100. 200 ± 21. 70* 
0.59 ± 0.01 
Primate pharmacodynamic time course parameters were determined by a 
noncompartrnental model. 
Data represents a mean± S.E. N-4 for heparin (0.7 mg/kg i.v.) and 
protarnine (2.1 mg/kg i.v.) group. N-3 for CY 216 (0.7 mg/kg i.v.) and 
protarnine (2.1 mg/kg i.v.) group. Statistical anqalysis was performed 
by an unpaired student's t-test: 
for AUC:t-12.862, df-6, p <.05 
for MRT:t-1.755, df-6, p <.10 N.S. 
for PNI:t-11.218, df-6, p <.05 
* represents a significant difference from heparin (0.7 mg/kg i.v.) and 
protarnine (2.1 mg/kg i.v.) group. 
TABLE 28 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: Heptest 
206 
Heparin (0.7 mg/kg s.c.) 
4.33 ± 1.33 
CY 216 (0.7 mg/kg) s.c.) 
AUC 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
Clp 
(ml-min-1 -kg-1 ) 
20.23 ± 6.64 
276.00 ± 6.46 
3.70 ± 0.44 
0.01 ± 0.00 
* 31. 61 ± 4. 32 
178.24 ± 29.89 
335 .10 ± 11. 87* 
0.39 ± o.os* 
0.001 ± o.oo* 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by 
an unpaired student's t-test: 
for AUC:t-6.683, df-8, p <.05 
for MRT:t-3.006, df-8, p <.05 
for Clp:t-2.988, df=8, p <.05 
for Vd:t-2.813, df-8, p <.OS 
* represents a significant difference from the heparin (0.7 mg/kg s.c.) 
group. 
TABLE 29 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: HeptestR 
207 
Heparin (0.7 mg/kg s.c.) 
with 
CY 216 (0.7 mg/kg s.c.) 
with 
AUC 
(µg-hr-ml- 1 ) 
AUMC 
(µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
Protamine (0.7 mg/kg i.v.) 
2.77 ± 0.29 
8.93 ± 1.08 
192.60 ± 10.45 
0.51 ± 0.05 
Protamine (0.7 mg/kg i.v.) 
20.62 ± 3.86* 
77.86 ± 16.28 
225.00 ± 7.17* 
0 ± 0.19* 
Primate pharmacodynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by 
an unpaired student's t-test: 
for AUC:t-5.110, df-8, p <.05 
for MRT: t-2.401, df-8, P <.05 
for PNI: t-8.746, df-8, p >.05 
* represents a significant difference from heparin (0.7 mg/kg s.c.) and 
protamine (0.7 mg/kg i.v.) group. 
TABLE 30 
COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS 
OF PRIMATES ADMINISTERED HEPARIN OR CY 216 
Test: HeptestR 
AUC (µg-ml- 1 ) 
AUMC (µg-hr 2 -ml-1 ) 
MRT (min) 
PNI 
CY 216 (0.7 mg/kg s.c.) with 
Protamine (1.4 mg/kg i.v.) 
10.08 ± 1.47 
42.36 ± 4.44 
257.40 ± 11.70 
0.03 ± 0.14 
Primate pharmacdynamic time course parameters were determined by a 
noncompartmental model. 
Data represents a mean± S.E. N-5 for CY 216 (0.7 mg/kg s.c.) and 
protamine (1.4 mg/kg i.v.) group. 
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TABLE 31 
% NEUTRALIZATION OF INTRAVENOUSLY ADMINISTERED 
HEPARIN OR CY 216 
Test: Anti-Xa 
Protamine:Heparin (mg/kg) 
or 
frotamine:CY 216 (mgLkg} 1:1 2;1 
%N (% I.)* %N (% I.)* 
Heparin (100 µg/kg i.v.) 90 (25.0) 90 (25.0) 
in rabbits 
Heparin (2 mg/kg i.v.) 96 (70. 2) 100 (70. 2) 
in rabbits 
%N 
Heparin (0.7 mg/kg i.v.) 88 (92) 89.6 (92.0) 100 
in primates 
CY 216 (100 µg/kg i.v.) 0 (1.8) 0 (1.8) 
in rabbits 
CY 216 (2 mg/kg i.v.) so (50.9) 75 (50.9) 
in rabbits 
CY 216 (0.7 mg/kg i.v.) 89.3 (91) 79.8 (91) 92.7 
in primates 
* - heparin or CY 216 activity (pre protamine). 
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3;1 
(% I.)* 
(92) 
(91) 
Percent neutralization for the amidolytic anti Xa data obtained from the 
rabbit stasis thrombosis experiments (100 µg/kg i.v.), the rabbit blood 
loss experiments (2 mg/kg i.v.) and the primate pharmacodynamic 
experiments were calculated as described in methods. Percent N was 
calculated at the 30 minute time period for the primates and the 10 
minute time period for the rabbits. 
TABLE 32 
% NEUTRALIZATION OF INTRAVENOUSLY ADMINISTERED 
HEPARIN OR CY 216 
Test: Anti-Ila 
Protamine:Heparin (mg/kg) 
or 
Protamine:CY 216 (mgLkg) 1;1 2:1 
210 
3:1 
%N (% I.)* %N (% I.)* %N (% I.)* 
Heparin (100 µg/kg i.v.) 96 (32.4) 92 (32.4) 
in rabbits 
Heparin (2 mg/kg i.v.) 94 (92.4) 99 (92.4) 
in rabbits 
Heparin (0.7 mg/kg i.v.) 91 (90.6) 89.6 (90.6) 100 (90.6) 
in primates 
CY 216 (100 µg/kg i.v.) 0 (5.8) 0 (5.8) 
in rabbits 
CY 216 (2 mg/kg i.v.) 64 (72.1) 100 (72.1) 
in rabbits 
CY 216 (0.7 mg/kg i.v.) 89 (68.2) 80 (68.2) 83 (68.2) 
in primates 
* - heparin or CY 216 activity (pre protamine). 
Percent neutralization for the amidolytic anti Ila data obtained from 
the rabbit stasis thrombosis experiments (100 µg/kg i.v.), the rabbit 
blood loss experiments (2 mg/kg i.v.) and the primate pharrnacodynamic 
experiments were calculated as described in methods. Percent N was 
calculated at the 30 minute time period for the primates and the 10 
minute time period for the rabbits. 
TABLE 33 
% NEUTRALIZATION OF SUBCUTANEOUSLY ADMINISTERED 
HEPARIN OR CY 216 
Test: Anti-Xa 
Protamine:Heparin (mg/kg) 
or 
lrotamine:CY 216 (mg/kg) 
Heparin (1 mg/kg s.c.) in rabbits 
Heparin (2.5 mg/kg S. C.) in rabbits 
Heparin (0.7 mg/kg s .c.) in primates 
CY 216 (1 mg/kg s.c.) in rabbits 
CY 216 (2.5 mg/kg s .c.) in rabbits 
CY 216 (0.7 mg/kg s .c.) in primates 
% N 
19 
94 
18 
33 
31 
41 
* - heparin or CY 216 activity (pre protarnine). 
1:1 
(% I.)* 
(15.8) 
(30.0) 
(7. 3) 
(22.5) 
(40.3) 
(53.0) 
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Percent neutralization for the amidolytic anti Xa data obtained from the 
rabbit stasis thrombosis experiments (1 mg/kg s.c.), the rabbit ear 
blood loss experiments (2.5 mg/kg s.c.) and the primate pharmacodynarnic 
experiments was calculated as described in methods. Percent N was 
calculated at the 245 minute time period for the primates and the 120 
time period for the rabbits. 
TABLE 34 
% NEUTRALIZATION OF SUBCUTANEOUSLY ADMINISTERED 
HEPARIN OR CY 216 
Test: Anti-Ila 
Protamine:Heparin (mg/kg) 
or 
Protamine:CY 216 (mg/kg) 
Heparin (1 mg/kg s.c.) in rabbits 
Heparin (2.5 mg/kg s .c.) in rabbits 
Heparin (0. 7 mg/kg s .c.) in primates 
CY 216 (1 mg/kg s.c.) in rabbits 
CY 216 (2.5 mg/kg s .c.) in rabbits 
CY 216 (0.7 mg/kg S. C.) in primates 
% N 
14 
95 
28.6 
0 
91 
71 
* - heparin or CY 216 activity (pre protamine). 
1:1 
(% I.)* 
(16.2) 
(73.0) 
(7.0) 
(7 .0) 
(51.3) 
(13.0) 
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Percent neutralization for the amidolytic anti Ila data obtained from 
the rabbit stasis thrombosis experiments (1 mg/kg s.c.), the rabbit ear 
blood loss experiments (2.5 mg/kg s.c.) and the primate pharmacodynamic 
experiments was calculated as described in methods. Percent N was 
calculated at the 245 minute time period for the primates and the 120 
time period for the rabbits. 
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FIGURES 
IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA 
TEST:APTT 
)150.0~ 
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7.5 10.0 
Figure 1. Heparin was supplemented to NHP, NMP, NRP and NratP in a 
concentration range of 0-10 µg/ml. Anticoagulant activity was 
determined by the APTT. Data represents a mean± S.E. The experiment 
was performed in triplicate on seperate days. 
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA 
TEST:APTT 
150.0 
125.0 
100.0 
75.0 
50.0 
25.0 
0.0 
0.0 2.5 5.0 
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•-• Normal Rabbit Plasma 
•-• Normal Rat Plasma 
7.5 10.0 
J.19/ml CY 216 
Figure 2. CY 216 was supplemented to NHP, NMP, NRP and NratP in a 
concentration·· range of 0-10 µ.g/ml. Anticoagulant activity was 
determined by the APTT. Data represents a mean± S.E. The experiment 
was performed in triplicate on separate days. 
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IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA 
TEST:HEPTEST 
).300.0~ 
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• -• Normal Rot Plasma 
7.5 10.0 
_µg/ml HEPARIN 
Figure 3. Heparin was supplemented to NHP, NMP, NRP and NratP in a 
concentration range of 0-10 µg/ml. Antiprotease activity was determined 
by the Heptes tR. Data represents a mean ± S. E. The experiment was 
performed in triplicate on separate days. 
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA 
TEST:HEPTEST 
300.0 
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•-• Normal Rot Plasma 
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µg/ml CY 216 
Figure 4. CY 216 was supplemented to NHP, NMP, NRP and NratP in a 
concentration range of 0-10 µg/ml. Antiprotease activity was determined 
by the HeptestR. Data represents a mean± S.E. The experiment was 
performed in triplicate on separate days. 
217 
IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA 
TEST:ANTI XA 
100.0 
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Figure 5. Heparin was supplemented to NHP, NMP, NRP and NratP in a 
concentration range of 0-10 µg/ml. Antiprotease activity was determined 
by an amidolytic anti Xa assay. Data represents a mean± S.E. The 
experiment was performed in triplicate on separate days. 
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA 
z 
0 
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TEST:ANTI XA 
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Figure 6. CY 216 was supplemented to NHP, NMP, NRP and NratP in a 
concentration range of 0-10 µg/ml. Antiprotease activity was determined 
by an amidolytic anti Xa assay. Data represents a mean± S.E. The 
experiment was performed in triplicate on separate days. 
219 
IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA 
TEST :ANTI IIA 
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Figure 7. Heparin was supplemented to NHP, 1'.'M.P, NRP and NratP in a 
concentration range of 0-10 µg/ml. Antiprotease activity was determined 
by an amidolytic anti Ila assay. Data represents a mean± S.E. The 
experiment was performed in triplicate on separate days. 
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA 
TEST:ANTI IIA 
100.0 
z 75.0 
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Figure 8. CY 216 was supplemented to NHP, NMP, NRP and NratP in a 
concentration range of 0-10 µg/ml. Antiprotease activity was determined 
by an amidolytic anti Ila assay. Data represents a mean± S.E. The 
experiment was performed in triplicate on separate days. 
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Fig'll'.te 9. Heparin or CY 216 was supplemented to NHP (upper panel) 
or ... t:o::NMP (lower panel) to obtain a final concentration of 5 
µg/rnL 'Pr.otamine sulfate was added to the heparin and CY 216 
solut\qns to obtain final protamine concentrations of 2.5 µg/ml, 
5.0 µg/ml and 10 µg/ml. Anticoagulant activity was determined 
µsing the APTT. The control value for NHP was 33.2 ± 0.4 seconds 
and the control value for NMP was 22. 3 ± 0. 3 seconds. Data 
represents a mean± S.E. The experiments were performed five 
times on separate days. 
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IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN AND CY 216 
AFTER PROTAMINE ADMINISTRATION 
TEST:APTT 
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Figur� �1'0., Heparin or 
to NMP,·: (l;o·wer panel) 
Protami�e suifate was .. . 
CY 216 was supplemented to NHP (upper panel) or 
to obtain a final concentration of 5 µg/ml. 
added to the heparin and CY 216 solutions to 
obtain finsl•protamine concentrations of 2.5 µg/ml, 5.0 µg/ml and 10 
µg/ml. · Anficoagulant activity was determined using the thrombin time. 
The control value for NHP was 27.2 ± 0.7 seconds and the control value 
for NMP was 33.5 ± 0.3 seconds. Data represents a mean ± S.E. The 
experiments were performed five times on separate days. 
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IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN AND CY 216 
AFTER PROTAMINE ADMINISTRATION 
TEST:THROMBIN TIME (5 U/ml) 
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,. . 
Figur.e ll~: Heparin or CY 216 was supplemented to NHP (upper panel) or 
to NM.P.' · (.i'ower panel) to obtain a final concentration of 5 µg/ml. 
Probamiti~ s~lf9 te was added to the heparin and CY 216 solutions to 
obtain fi.naJ: protamine concentrations of 2. 5 µg/ml, 5. 0 µg/ml and 10 
µg/ml.· A~ticoagulant activity was determined using the HeptestR. The 
control value for NHP was 17.6 ± 1.6 seconds and the control value for 
NMP was 21. 5 ± 0 .1 seconds. Data represents a mean ± S. E. The 
experim_ents were performed five times on separate days. 
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IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN AND CY 216 
AFTER PROTAMINE ADMINISTRATION 
TEST:HEPTEST 
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Fig_wre:12. Heparin or CY 216 was supplemented to NHP (upper panel) or 
to NM?, (iow~r panel) to obtain a final concentration of 5 µg/ml. 
Protami,ne • sulfate was added to the heparin and CY 216 solutions to 
obtain. final protamine concentrations of 2.5 µg/ml, 5.0 µg/ml and 10 
µg/ml. Antiprotease activity was determined using an amidolytic anti 
Xa assay. The control values for NHP and NMP were 0 % inhibition. Data 
represents a mean± S.E. The experiments were performed five times on 
separate days. 
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IN VITRO ANTIPROTEASE ACTIVITY OF HEPARIN AND CY 216 
AFTER PROTAMINE ADMINISTRATION 
TEST:ANTI XA 
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F:i:'gu_re 13. Heparin or CY 216 was supplemented to NHP (upper 
panel,) or to NMP to obtain a final concentration of 5 µg/ml. 
Protamin~ sulfate was added to the heparin and CY 216 solutions 
to.obt,ain final protamine concentrations of 2.5 µg/ml, 5.0 µg/ml 
and 10 µg/ml. Antiprotease activity was determined using an 
amidoly_tic anti Ila assay. The control values for NHP and NMP were 
0 %,inhibition. Data represents a mean± S.E. The experiments 
were performed five times on separate days. 
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IN VITRO ANTIPROTEASE ACTIVITY OF HEPARIN AND CY 216 
AFTER PROTAMINE ADMINISTRATION 
TEST:ANTI IIA 
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EFFECT OF PROTAMINE SULFATE 
IN A LASER-INDUCED THROMBOSIS MODEL 
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Figure 14. Two groups of rats were used in this study. Group I 
received a laser injury consisting of 0.18 \ifatts for 1/30 second. 
Protamine sulfate (0. 74 mg/kg i. v.) was administered to the second 
group of rats via the tail vein, 15 minutes prior to laser injury. The 
number of laser injuries needed to produce a thrombus at least as long 
and as broad of the diameter of the vessel was recorded. Data 
represents a mean ± S. E. N - 11 for the contro 1 group. N - 3 for 
protamine (0.74 mg/kg i.v.) group. Statistical analysis was performed 
by an unpaired student's t test: 
t- 1.110, df-13, p>.20, N.S. 
PROTAMINE NEUTRALIZATION OF HEPARIN 
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Figure 15. Heparin (1 mg/kg i.v.) was administered to 3 groups of rats 
via the tail vein 15 minutes prior to laser injury. Two groups of rats 
received either protamine (0.32 or 0.64 mg/kg i.v.), 5 minutes after 
heparin and was allowed to circulate for 10 minutes. Immediately after, 
a laser injury was inflicted at the mesenteric vessel wall. The number 
of laser injuries needed to produce the standard thrombus was recorded. 
Data represents a mean± S.E. N - 11 for control group. N - 4 for 
heparin (1 mg/kg i.v.) group. N - 6 for heparin (1 mg/kg i.v.) and 
protamine (0.32 mg/kg i.v.) group. N - 5 for heparin (1 mg/kg i.v). and 
protamine (0.64 mg/kg i.v.) group. Statistical analysis was performed 
by a one way ANOVA: F(3,22) - 26.7555, p <.05 and followed by a Newman-
Keuls multiple comparison test. * represents a significant difference 
from control the group. 
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PROTAMINE NEUTRALIZATION OF HEPARIN 
IN A LASER-INDUCED THROMBOSIS MODEL 
* 
Figure 16. CY 216 (1 mg/kg i.v.) was administered to rats via the tail 
vein 15 minutes prior to laser injury. One group of rats received 
protamine (0.74 mg/kg i.v.) 5 minutes after CY 216 and was allowed to 
circulate for 10 minutes. Immediately after a laser injury was 
inflicted at the mesenteric vessel wall. The number of laser injuries 
needed to produce the standard thrombus was recorded. Data represents 
a mean± S.E. N - 11 for control group. N - 5 for CY 216 (1 mg/kg 
i.v.) group. N - 7 for CY 216 (1 mg/kg i.v.) and protamine (0.74 mg/kg 
i.v.) group. Statistical analysis was performed by a one way ANOVA: 
F(2, 20) - 6. 608, p <. 05 and followed by a Newman-Keuls multiple 
comparison test.* represents a significant difference from the control 
group. 
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EFFECT OF HEPARIN AND CY 216 
IN A LASER-INDUCED THROMBOSIS MODEL 
* 
CONTROL HEPARIN CY216 
10 mg/kg s.c. 10 mg/kg a.c. 
Figure 17. Heparin (10 mg/kg s. c.) or CY 216 (10 mg/kg s .c.) was 
administered to rats 2 hours prior to laser injury. The number of laser 
injuries needed to produce the standard thrombus was recorded. Data 
represents a mean± S.E. N - 11 for control group. N - 5 for heparin 
(10 mg/kg s.c.) group and N - 5 for CY 216 (10 mg/kg s.c.) group. 
Statistical analysis was performed by a one way ANOVA: F(2,18) -47.681, 
p <.05 and followed by a Newman-Keuls multiple comparison test. 
* represents significant difference from control group. 
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS M_ODEL 
AFTER PROTAMINE ADMINISTRATION 
CLOT SCORE 
·4 .. 
3 .. 
2 .. 
1 .. 
0 
CONTROL PROTAMINE 
100 pg/kg i.v. 
PROTAMINE 
500 µg/kg i.v. 
Figure 18. Rabbits were anaesthetized and segments of the rabbit 
jugular veins were surgically exposed. Protamine (100 or 500 µg/kg 
i.v.) or an equivalent volume of saline was administered via the rabbit 
ear vein and allowed to circulate for 10 minutes at which time, blood 
was drawn by cardiac puncture and a thrombogenic challenge comprised of 
PCC/RVV was given. After exactly 20 seconds, both jugular veins were 
ligated for 10 minutes, excised and evaluated for degree of clot 
formation as described in the methods section. Data represents a mean 
± S.E. N - 5 for control group. N - 3 for protamine (100 µg/kg i.v.) 
group. N - 3 for protamine (500 µgjkg i. v.) group. Statistical 
analysis was performed by a Kruskal-~allis test: H - 2.610, p >.10, 
N.S. 
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL 
AFTER HEPARIN ADMINISTRATION 
CLOT SCORE 
4 ... 
2 ... 
* 
1.· 
·* * 
CONTROL HEPARIN HEPARIN HEPARIN 
25 ,ug/kg i.v. 50 IJ9/kg l.v. 100 µg/kg J.v; 
Figure 19. Four groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
Heparin (25 µgjkg i.v.), heparin (50 µg/kg i.v.) or heparin (100 µgjkg 
i.v.) or an equivalent volume of saline was administered via the ear 
vein and allowed to circulate for 10 minutes at which time a 
thrombogenic challenge comprised of PCC/RVV was given. After exactly 
20 seconds both jugular veins were ligated for 10 minutes, excised and 
evaluated for degree of clot formation. Data represents a mean± S.E. 
Statistical analysis was performed by a Kruskal-'\.iallis test: H -14.308, 
P <.05 and followed by a nonparametric Tukey multiple comparison test. 
* represents a significant difference from control group. 
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EX VIVO ANTI XA AND ANTI IIA ACTIVITY AFTER HEPARIN 
ADMINISTRATION TO RABBITS 
~ INHIBITION 
100 
75 
50 
25 
* 
TIME:PRECHALLENGE 
• ANTI XA 
~ANTI IIA 
* 
o------_.____.__,x.;~--_.__---'-..IIQiC~--'--_.__.........,..__ __ ___, 
HEPARIN 
25 }J9/kg i.v. 
HEPARIN 
50 }Jg/kg i.v. 
HEPARIN 
100 pg/kg i.v. 
Figure 20. Three groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
Heparin (25 µgjkg i.v.), heparin (50 µgjkg i.v.) or heparin (100 µg/kg 
i.v.) or an equivalent volume of saline was administered via the ear 
vein and allowed to circulate for 10 minutes at which time blood was 
dra-.."Il by cardiac puncture. Antiprotease activities were determined 
using amidolytic anti Xa and amidolytic anti Ila assays. Control values 
for normal rabbit plasma were 0 % inhibition. Data represents a mean 
± S.E. Statistical analysis was performed by a two way ANOVA: 
Factor A (heparin dose): F(2,24) - 10.059 p <.05 
Factor B (test): F(l,24) - 0.672 p >.50 N.S. 
Factor Ax B: F(2,24) - 0.444 p >.50 N.S. 
followed by Newman-Keuls multiple comparison tests. * represents a 
significant difference from the control group. 
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL 
AFTER CY 216 ADMINISTRATION 
CLOT SCORE 
4 .. 
3--
2- .. 
1 -
* 
I-..IwI• 0 -'----J.6.i:I.O,,.j~~-....cia::::icx:.::ioc:::ia__JOoooo~iL...-JC.~,.xT-xT-xxixT"xT"L-~--.J 
CONTROL CY 216 CY 216 CY 216 
25 }Jg/kg 1.v. 50 }Jg/kg i.v. 100 µg/kg l.v. 
Figure 21. Four groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
CY 216 (25 µgjkg i.v.), CY 216 (50 µgjkg i.v.) or CY 216 (100 µg/kg 
i.v.) or an equivalent volume of saline was administered via the ear 
vein and allowed to circulate for 10 minutes at which time a 
thrombogenic challenge comprised of PCC/RVV was given. After exactly 
20 seconds both jugular veins were ligated for 10 minutes, excised and 
evaluated for degree of clot formation. Data represents a mean± S.E. 
Statistical analysis was performed by a Kruskal-iJallis test: H -
26.988, p <.05 and followed by a nonparametric Tukey multiple comparison 
test. * represents a significant difference from control group. 
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EX VIVO ANTI XA AND ANTI IIA ACTIVITY AFTER CY 216 ·. 
% INHIBITION 
100 
75 
50 
25 
ADMINISTRATION TO RABBITS 
TIME:PRECHALLENGE 
• ANTI XA 
~ANTI IIA 
0 -'-------r.......,;;;i_..,a _____ ...._.__.__ ___ ..___._.......,""""'-----
CY 216 
25 µg/kg i.v. · 
CY 216 
50 pg/kg i.v. 
CY 216 
100 .,ug/kg i.v. 
Figure 22. Three groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
CY 216 (25 µg/kg i.v.), CY 216 (50 µg/kg i.v.) or CY 216 (100 µg/kg i.v.) 
or an equivalent volume of saline was administered via the ear vein and 
allowed to circulate for 10 minutes at which time blood was drawn by 
cardiac puncture. Anti protease activities were determined using the 
amidolytic anti Xa and amidolytic anti IIa assays. Control values for 
normal rabbit plasma was 0% inhibition. Data represents a mean± S.E. 
Statistical analysis were performed by a two way ANOVA: 
Factor A (CY 216 dose): F(2,24) - 1.070 p >.50 N.S. 
Factor B (test): F(l,24) - 0.843 p >.50 N.S. 
Factor Ax B: F(2,24) - 1.408 p >.50 N.S. 
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL 
CLOT SCORE 
5.0 
4.0 
3.0 
2.0 
1.0 
1. HEPARIN 100 µg/kg t.v. 
2. ~ra~NkO? lfa9t;,~;tt. 
3. HEPARIN 100 µg/kg 1.v. + 
.PROTAMINE 200 }J97kg t.v. 
1. 2. 3. 4. 
4. c:Y 216 100 µg/kg t.v. 
5. c:r 216 100 pa/kg t.v.+ 
PROTAMINE 1® ug/kg l.v. 
6. c:r 216 1001.J_g/kg l.v. + 
PROTAMINE 20~ µg/kg l.v. 
7.CONTROL 
5. 6. 7. 
Figure 23. Seven groups consisting of five rabbits each were anaes-
thetized and segments of the jugular veins were surgically exposed. 
Heparin (100 µg/kg i. v.) or CY 216 (100 µg/kg i. v.) was administered via 
the ear vein and allowed to circulate for 10 minutes and blood was drawn 
by cardiac puncture. To groups of rabbits which received protamine (100 
µgjkg i. v. or 200 µg/kg i. v.) , this drug was administered 5 minutes 
after heparin (100 µg/kg i.v.) or CY 216 (100 µgjkg i.v.) and allowed 
to circulate for 5 minutes at which time blood was drawn. Immediately 
after blood draw, a thrombogenic challenge comprised of PCC/RVV was 
given. After exactly 20 seconds both jugular veins were ligated for 10 
minutes, excised and evaluated for degree of clot formation. Data 
represents a mean± S.E. Statistical analysis was performed by a two 
,,:ay ANOVA: 
Factor A (drug treatment): F(2,36) - 18.049 p < .05 
Factor B (protamine dose): F(2,36) - 16.810 p > .20 N.S. 
Factor Ax B: F(4,36) - 5.453 p <.05 
followed by a Newman-Keuls multiple comparison test. * represents a 
signifiacant difference from the control group. 
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EX \/NO ANTI XA ACTIVITY AFTER PROTAMINE NEUlRALIZAllON 
OF HEPARIN OR CY 216 IN RABBITS 
~ INHIBmON 
1 OO.O 1. HEPARIN 100 ,ug/kg l.v. 
2
• ~rom~N1°~ tcPt~JJ;tt. 
3. HEPARIN 100 µg/kg t.v. + 
75.0 PROTAMINE 200 1J97kg t.v. 
50.0 
* 
25.0 
1. 2. 3. 4. 
TIME: PRECHALLENGE 
4. r:f 216 100 µg/kg I.v. 
5. r:f 216 100 ).l_g/kg t.v.+ 
PROTAMINE 10ll pg/kg t.v. 
6. r:f 216 100 J,Jg/kg t.v. + 
PROTAMINE 206 µg/kg 1.v. 
7.CONTROL 
0% 
5. 6. 7. 
Figure 24. Seven groups consisting of five rabbits each were anaes-
thetized and segments of the jugular veins were surgically exposed. 
Heparin (100 µg/kg i. v.) or CY 216 (100 µg/kg i. v.) was administered via 
the ear vein and allowed to circulate for 10 minutes and blood was draw'"Il 
by cardiac puncture. To groups of rabbits which received protamine (100 
µg/kg i. v. or 200 µg/kg i. v. ) , this drug was ad.ministered 5 minutes 
after heparin (100 µg/kg i.v.) or CY 216 (100 µg/kg i.v.) and allowed 
to circulate for 5 minutes at which time blood was dra~'"Il. Antiprotease 
activity was determined using an amidolytic anti Xa assay. Data 
represents a mean± S.E. Statistical analysis was performed by a two 
way /illOVA: 
Factor A (drug treatment): F(2,36) - 5.167 p < .OS 
Factor B (protamine dose): F(2,36) - 1.635 p > .20 N.S. 
Factor Ax B: F(4,36) - 5.104 p <.05 
followed by a Ne~'Illan-Keuls multiple comparison test. * represents a 
signifiacant difference from the control group. 
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EX VNO ANTI IIA ACTMlY AFTER PROTAMINE NEUTRALIZATION 
OF HEPARIN OR CN 216 IN RABBITS -
% INHIBmON 
1 OO.O 1. HEPARIN 100 pg/kg t.v. 
2. ~ra~N\:O~~d1t~,J;ti 
3. HEPARIN 100 µg/kg t.v. + 
75.0 PROTAMINE 200 JJ97kg t.v. 
50.0 
* 
25.0 
. 1. 2 . 3. 
TIME:PRECHALLENGE 
4. r:f 216 100 µg/kg t.v. 
s. r:f 216 100 µa/kg t.v.+ 
PROTAMINE 1 cf6 pg/kg t.v. 
6. r:f 216 100 }Jg/kg t.v. + 
PROTAMINE 200 pg/kg t.v. 
7.CON'TROL 
5. 6. 7. 
Figure 25. Seven groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
Heparin (100 J.Lg/kg i. v.) or CY 216 (100 J,Lg/kg i. v.) was administered via 
the ear vein and allowed to circulate for 10 minutes and blood was drawn 
by cardiac puncture. To groups of rabbits which received protamine (100 
µg/kg i. v. or 200 J,Lg/kg i. v.), this drug was administered 5 minutes 
after heparin (100 J,Lg/kg i.v.) or CY 216 (100 µg/kg i.v.) and allowed 
to circulate for 5 minutes at which time blood was drawn. Antiprotease 
activity was determined using an amidolytic anti Ila assay. Data 
represents a mean± S.E. Statistical analysis was performed by a two 
way ANOVA: 
Factor A (drug treatment): F(2,36) - 25.553 p <.05 
Factor B (protamine dose): F(2,36) - 16.684 p <.05 
Factor Ax B: F(4,36) - 4.850 p <.05 
followed by a Newman-Keuls multiple comparison test. * represents a 
significant difference from control group. 
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL 
CLOT SCORE 
5.0 
4.0 
3.0 
2.0 
. 1 .0 
1. HEPARIN 1 mg/kg s.c. 
2. HEPARIN 1 mg/k~_ s.c. + 
PROTAMINE 1 mg/kg t.v. 
* * 
3. C'f 216 1 mg/kg s.c. 
4. C'f 21 6 1 mg/kg s.c. + 
PROTAMINE 1 mg/kg 1.v. 
5.CONlROL 
0. 0 ........ --"'--,,l.~_:;:w~~L...-..J..L.-C..."""'-L____,l,,,il,,,,,ll,,11.A.A,,W---"-...,c_~L.--...J 
1. 2. 3. 4. 5. 
Figure 2~. Five groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
Heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) was administered and 
allowed to circulate for 2 hours. Blood was drawn by cardiac puncture. 
To groups of rabbits which received protamine (1 mg/kg i.v.), this drug 
was administered 2 hours after heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg 
s.c.) and allowed to circulate for 5 minutes at which time blood was 
drawn. Immediately after blood draw, a thrombogenic challenge comprised 
of PCC/RVV was given. After exactly 20 seconds both jugular veins were 
ligated for 10 minutes, excised and the jugular vein segments were 
evaluated for degree of clot formation. Data represents a mean± S.E. 
Statistical analysis was performed by a two way ANOVA: 
Factor A (drug treatment): F(2,24) - 5.298 p <.05 
Factor B (protamine dose): F(2,24) - 1.739 p >.20 N.S. 
Factor Ax B: F(4,24) - 5.428 p <.05 
followed by a Ne .. "lllan Keuls multiple comparison test. * represents a 
significant difference from the control group. 
% INHIBITION 
100 
75 . 
50 -
25 ... 
0 
244 
EX VIVO ANTI XA ACTIVllY OF RABBITS 
AFTER DRUG ADMINISTRATION 
TIME: PRECHALLENGE 
1. HEPARIN 1 mg/kg s.c. 4. CY 216 1 mf/kg s.c. + 
2. ~~b~IN kmuk, s.c;.+ PROTAMINE mg/kg i.v. AMIN 1 g kg 1.v. 5. CONTROL 3. CY 21 6 1 mf /kg s.c. 
PROTAMINE mg/kg i.v. 
* 
* 
I 
T * ~ * ~ XX lO ½-'~ a• I -- ... AIIX- 0% .•.x_ 
1. 2. 3. 4. 5. 
Figure 27. Five groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
Heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) was administered and 
allowed to circulate for 2 hours at which time blood was drawn by 
cardiac puncture. To groups of rabbits which received protamine (1 
mg/kg i.v.), this drug was administered 2 hours after heparin (1 mg/kg 
s.c.) or CY 216 (1 mg/kg s.c.) and allowed to circulate for 5 minutes 
at which time blood was drawn. Antiprotease activity was determined 
using an amidolytic anti Xa assay. Statistical analysis was performed 
by a two way ANOVA: 
Factor A (drug treatment): F(2,24) - 13.401 p <.05 
Factor B (protamine dose): F(l,24) - 6.079 p <.05 
Factor Ax B: F(2,24) - 6.557 p <.05 
followed by a Ne,nnan-Keuls multiple comparison test. * represents a 
significant difference from the control group. 
% INHIBITION 
EX VIVO ANTI IIA ACTIVl1Y OF RABBITS 
AFrER DRUG ADMINISTRATION 
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100 1 __________ T_IM_E_:_P_R......:E_:_C.:..:.HA:...::L=LE=-:.N=GE:__ 
75 
50 
25 
1. HEPARIN 1 mg/kg s.c. 
2" ~~bm~Nt q'g/kgks.c;.+ ltlg/ g I.V. 
3. CY 216 1 mg/kg s.c. 
PROTAMINE 1 mg/kg i.v. 
* 
4. CY 216 1 mg/kg s.c. + 
PROTAMINE 1 mg/kg i.v. 
5. CONTROL 
Figure 28. Five groups consisting of five rabbits each were 
anaesthetized and segments of the jugular veins were surgically exposed. 
Heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) was administered and 
allowed to circulate for 2 hours at which time blood was drawn by 
cardiac puncture. To groups of rabbits which received protamine (1 
mg/kg i.v.), this drug was administered 2 hours after heparin (1 mg/kg 
s.c.) or CY 216 (1 mg/kg s.c.) and allowed to circulate for 5 minutes 
at which time blood was drawn. Antiprotease activity was determined 
using an amidolytic anti Ila assay. Statistical analysis was performed 
by a two way ANOVA: 
Factor A (drug treatment): F(2,24) - 8.446 p <.05 
Factor B (protamine dose): F(l,24) - .620 p >.50 N.S. 
Factor Ax B: F(2,24) - .246 p >.50 N.S. 
followed by a Newman-Keuls multiple comparison test. * represents a 
significant difference from the control group. 
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EFFECT OF VARIOUS DRUGS IN A RAT TAIL BLEEDING MOOEL 
SECONDS 
800 
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SALINE 
* 
PROTAMINE HEPARIN CY 216 
1 mg/kg i.v. 2 mg/kg i.v. 2 mg/kg i.v. 
Figure 29. Groups of rats received either protamine (1 mg/kg i.v.), 
heparin (2 mg/kg i.v.), CY 216 (2 mg/kg i.v.) or an equivalent volume 
of saline via the tail vein. After 10 minutes bleeding time 
determinations were performed as described in the methods section. Data 
represents a mean± S.E.M. N - 9 for saline group. N - 7 for protamine 
(1 mg/kg i.v.) group. N - 7 for heparin (2 mg/kg i.v.) group. N - 7 
for CY 216 (2 mg/kg i.v.) group. Statistical analysis was performed by 
a one way ANOVA: F(3,26) - 12.482 p <.05 followed by a Newman-Keuls 
multiple comparison test:* represents a significant difference from CY 
216 (2 mg/kg i.v.) group. 
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NEUTRALIZATION OF HEPARIN AND CY 216 IN A 
RAT TAIL BLEEDING MODEL 
* 
SALINE HEPARIN HEPARIN CY 216 CY 216 
2 mg/kg i.v. 2 mg/kg J.v. 2 mg/kg i.v. 2 mg/kg lv. 
ANO PROTAMINE ANO PROTAMINE 
2 mg/kg i.v. 2 mg/kg Lv. 
Figure 30. Groups of rats received either heparin (2 mg/kg i.v.), CT 
216 (2 mg/kg i.v.) or an equivalent volume of saline via the tail vein. 
To rats which recieved protamine, this drug was administered 5 minutes 
after heparin or CT 216. After 10 minutes post heparin (or CT 216), 
bleeding time determinations were performed as described in the methods 
section. Data represents a mean± S.E.M. N - 9 for saline group. N 
- 7 for heparin (2 mg/kg i.v.) group. N - 7 for CT 216 (2 mg/kg i.v.) 
group. N - 7 for heparin (2 mg/kg i.v.) and protamine (2 mg/kg i.v.) 
group. N - 7 for CT 216 (2 mg/kg i. v.) and protamine (2 mg/kg i. v.) 
group. Statistical analysis was performed by a one way ANOVA: F(4,32) 
- 9.458 p <.05 followed by a Newman-Keuls multiple comparison test: * 
represents a significant difference from CT 216 (2 mg/kg i.v.) group. 
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NEUTRALIZATION OF HEPARIN AND CY 216 IN A 
RAT TAIL BLEEDING MODEL 
SALINE HEPARIN HEPARIN CY 21 6 CY 216 
2.5 m9/kg a.c. 2.5 mg/kg a.c. • 2.5 mg/kg a.c. 2.5 ~ ..._ 
ANO PROTAMINE AND PROTAMINE 
2.5 mg/kg LY. 2.5 ~ LY. 
Figure 31. Groups of rats received heparin (2.5 mg/kg s.c.), CT 216 
(2.5 mg/kg s.c.) or an equivalent volume of saline. Two groups of rats 
received protamine (2.5 mg/kg i.v.) in addition to heparin (2.5 mg/kg 
s. c.) or CT (2. 5 mg/kg s. c.) After 120 minutes, bleeding time 
determinations were performed as described in the methods section. Data 
represents a mean± S.E. N - 9 for saline group. N - 7 for all other 
groups. Statistical analysis was performed by a one way AN0VA: F(4,32) 
- 1.294 p >.50 N.S. 
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EFFECT OF PROTAMINE IN A RABBIT EAR MODEL OF BLOOD LOSS 
RBC'S x 1 o9 /liter 
1.000 
0.800 
0.600 
0.400 
0.200 
CONTROL PROTAMINE 
2 mg/kg i.v. 
PROTAMINE 
3 mg/kg i.v. 
Figure 32. Individual groups of rabbi ts were administered either 
protamine (2 or 3 mg/kg i. v.) or an equivalent volume of saline which 
was allowed to circulate for 10 minutes. At this time, blood was drawn 
by cardiac puncture and 5 uniform incisions were made in the rabbit ear. 
Blood loss was determined by immersing the ear in a saline bath (1 
liter) at 37°C for 10 minutes. Red cell count in the bath solution was 
determined using a Hycel cell counter. The results are expressed as 
RBCs x 105 /liter. Data represents a mean ± S. E. N - 5 for saline group. 
N - 4 for protamine (3 mg/kg i.v.) group. N - 3 for protamine (2 mg/kg 
i. v. ) group . 
tn 
0 
z 
0 
u 
w 
tn 
250 
EX VIVO ANTICOAGULANT ACTMTY AFTER PROTAMINE 
ADMINISTRATION TO RABBITS 
TEST:APTT 
150 
125 
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25 
0 
CONTROL PROTAMINE 
2 mg/kg i.v. 
PROTAMINE 
3 mg/kg i.v. 
Figure 33. Individual groups of rabbits were administered protamine (2 
or 3 mg/kg i. v.) or. an equivalent volume of saline. Each drug was 
allowed to circulate for 10 minutes at which time blood was drawn by 
cardiac puncture. Anticoagulant activity was determined by the APTT. 
Data represents a mean ± S. E. N - 5 for control group. N - 4 for 
pro ta.mine (3 mg/kg i. v.) group. N - 3 for pro ta.mine (2 mg/kg i. v.) 
group. Statistical analysis was performed by a one way ANOVA: 
F(2,9) - 4.628, p >.05, N.S. 
251 
EFFECT OF HEPARIN IN A RABBIT EAR MODEL OF BLOOD LOSS 
RBC'S x 1 o9 /LITER 
1.000 
* 
0.750 
0.500 
0.250 
CONTROL HEPARIN HEPARIN 
1 mg/kg i.v. 2 mg/kg i.v. 
Figure 34. Individual groups of rabbits were administered heparin (1 
or 2 mg/kg i.v.) or an equivalent volume of saline which was allowed to 
circulate for 10 minutes. At this time, blood ,;.as drawn by cardiac 
puncture and 5 uniform incisions were made in the rabbit ear. Blood 
loss ,;.as determined by immersing the ear in a saline bath (1 liter) at 
37°C for 10 minutes. Red cell count in the bath solution ,;.as determined 
using a Hycel cell counter. The results were expressed as RBCs x 
105/liter. Data represents a mean± S.E. N - 5 for saline group. N - 6 
for heparin (1 mg/kg i.v.) group. N - 14 for heparin (2 mg/kg i.v.) 
group. Statistical analysis ,;.as performed by a one way ANOVA: F(2,22) 
- 8.473, p <.05 followed by a Newman-Keuls multiple comparison test.* 
represents a significant difference from the control group. 
EX vrvo ANTI XA ACTIVITY AFTER HEPARIN 
ADMINISTRATION TO RABBITS 
% INHIBmON 
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0% 0------------.L..c....C...,:~.J._-~~~£.l..----' 
CONTROL HEPARIN 
1 mg/kg i.v. 
HEPARIN 
2 mg/kg l.v. 
Figure 35. Individual groups of rabbits were administered heparin (1 
mg/kg i. v.) or heparin (2 mg/kg i. v.) or an equivalent volume of saline. 
The drugs were allowed to circulate for 10 minutes at which time blood 
was drawn by cardiac puncture. Antiprotease activity was determined by 
an amidolytic anti Xa assay. Data represents a mean± S.E. N - 5 for 
saline group. N - 6 for heparin (1 mg/kg i. v.) group. N - 14 for 
heparin (2 mg/kg i.v.) group. Statistical analysis was performed by a 
one way ANOVA: F(2,22) - 32.433, p <.05 followed by a Newman-Keuls 
multiple comparison test. * represents a significant difference from 
the control group. 
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Figure 36. Individual groups of rabbits were administered either heparin 
(1 or 2 mg/kg i.v.) or an equivalent volume of saline. The drugs were 
allowed to circulate for 10 minutes at which time blood was drawn by 
cardiac puncture. Antiprotease activity was determined by an amidolytic 
anti Ila assay. Data represents a mean± S.E. N - 5 for saline group. 
N - 6 for heparin (1 mg/kg i.v.) group. N - 14 for heparin (2 mg/kg 
i.v.) group. Statistical analysis was performed by a one way ANOVA: 
F(2,22) - 34.378, p <.OS followed by a Newman-Keuls multiple comparison 
test.* represents a significant difference from control group. 
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Figure 37. Individual groups of rabbits were administered, CY 216 (1, 
2 or 3 mg/kg i.v.) or an equivalent volume of saline which was allowed 
to circulate for 10 minutes. At this time, blood was drawn by cardiac 
puncture and 5 uniform incisions were made in the ear. Blood loss was 
determined by immersing the ear in a saline bath (1 liter) at 37°C for 
10 minutes. Red cell count in the bath solution was determined using 
a Hycel cell counter. The results were expressed as RBCs x 109/liter. 
Data represents a mean± S.E. N - 14 for CY 216 (2 mg/kg i.v.) group. 
N - 5 for all other groups. Statistical analysis was performed by a one 
way AN0VA: F(3,25) - 8.505, p <.05 and followed by a Newman-Keuls 
multiple comparison test. * represents significant difference from 
control group. 
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Figure 38. Individual groups of rabbits were administered CY 216 
(1 mg/kg i.v.), CY 216 (2 mg/kg i.v.) or CY 216 (3 mg/kg i.v.) or an· 
equivalent volume of saline. The drugs were allowed to circulate for 
10 minutes at which time blood was drawn by cardiac puncture. An-
tiprotease activity was determined by an amidolytic anti Xa assay. Data 
represents a mean± S.E. N - 14 for CY 216 (2 mg/kg i.v.) group. N - 5 
for all other groups. Statistical analysis was performed by a one way 
AN0VA: F(3,25) - 16.450, p <.05 and followed by a Newman-Keuls multiple 
comparison test. * represents a significant difference from the control 
group. 
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Figure 39. Individual groups of rabbits were administered CY 216 (l, 2 
or 3 mg/kg i.v.) or an equivalent volume of saline. The drugs were 
allowed to circulate for 10 minutes at which time blood was drawn by 
cardiac puncture. Antiprotease activity ·.:as determined by an amidolytic 
anti Ila assay. Data represents a mean± S.E. N - 14 for CY 216 (2 
mg/kg i.v.) group. N - 5 for all other groups. Statistical analysis 
was performed by a one way AN0VA: F(3,25) - 78.307, p <.05 and followed 
by a Newman-Keuls multiple comparison test.* represents a significant 
difference from the control group. 
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Figure 40. Seven groups of rabbits were administered heparin (2 mg/kg 
i.v.) or CY 216 (2 mg/kg i.v.) or an equivalent volume of saline via the 
right ear vein. Each drug was allowed to circulate for 10 minutes at 
which time blood .:as drawn by cardiac puncture and blood loss was 
determined. Four groups received protamine (2 or 3 mg/kg i.v.) via the 
left ear vein, 5 minutes after the administration of heparin (2 mg/kg 
i.v.) or CY 216 (2 mg/kg i.v.) and blood was drawn by cardiac puncture. 
Five uniform incisions were made in the ear. Blood loss was determined 
by immersing the ear in a saline bath (1 liter) at 37°C for 10 minutes. 
Red cell count in the bath solution was determined using a Hycel sell 
counter. The results were expressed as RBCs x 108/liter. Data 
represents a mean± S.E. N - 6 for heparin (2 mg/kg i.v.) or CY 216 (2 
mg/kg i.v.) and protamine (2 mg/kg i.v.). N - 5 for all other groups. 
Statistical analysis was performed by a two way ANOVA: 
Factor A (drug treatment): F(2,36) - 17.494 p <.05 
Factor B (protamine dose): F(2,36) - 12.806 p <.05 
Factor Ax B: F(4,36) - 6.318 p <.05 
followed by a Newman-Keuls multiple comparison test. * represents a 
significant difference from the control group. 
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Figure 41. Individual groups of rabbits were administered heparin (2 
mg/kg i.v.) or CY 216 (2 mg/kg i.v.) or an equivalent volume of saline 
via the right ear vein. Each drug was allowed to circulate for 10 
minutes at which time blood was drawn by cardiac puncture and blood loss 
~as determined. Four groups received protamine (2 or 3 mg/kg i.v.) via 
the left ear vein, 5 minutes after the administration of heparin (2 
mg/kg i.v.) or CY 216 (2 mg/kg i.v.) and blood was drawn by cardiac 
puncture. Antiprotease activity was determined by an amidolytic anti 
Xa assay. Data represents a mean± S.E. N - 6 for heparin or CY 216 
(2 mg/kg i.v.) and protamine (2 mg/kg i.v.) group. N - 5 for all other 
groups. Statistical analysis was performed by a two way ANOVA: 
Factor A (drug treatment): F(2,36) - 29.090 p <.05 
Factor B (protamine dose): F(2,36) - 62.246 p <.05 
Factor Ax B: F(4,36) - 18.790 p <.05 
followed by a New-man-Keuls multiple comparison test. 
* represents a significant difference from control group. 
** represents a significant difference from heparin (2 mg/kg i.v.) and 
Protamine (2 mg/kg i.v.) group. 
*** represents a significant difference from heparin (2 mg/kg i.v.) and 
protamine (3 mg/kg i.v.) group. 
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Figure 42. Individual groups of rabbits were administered an equivalent 
amount of saline, heparin (2 mg/kg i.v.) or CY 216 (2 mg/kg i.v.) via 
the right ear vein. Each drug was allowed to circulate for 10 minutes 
at which time blood was dra~-n by cardiac puncture and blood loss was 
determined. Four groups received protamine (2 or 3 mg/kg i.v.) via the 
left ear vein, 5 minutes after the administration of heparin (2 mg/kg 
i.v.) or CY 216 (2 mg/kg i.v.) and blood was drawn by cardiac puncture. 
Antiprotease activity was determined by a amidolytic anti Ila assay. 
Data represents a mean± S.E. N - 6 for heparin or CY 216 (2 mg/kg 
i.v.) and protamine (1 mg/kg i.v.) group. N - 5 for all other groups. 
Statistical analysis was performed by a two way ANOVA: 
Factor A (drug treatment): F(2,36) - 71.372 p <.OS 
Factor B (protamine dose): F(2,36) - 213.532 p <.OS 
Factor Ax B: F(4,36) - 55.335 p <.05 
followed by a Newman-Keuls multiple comparison test. 
* represents significant difference from the control group. 
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Figure_ 43. Individual groups consisting of five rabbits each were 
administered heparin or CY 216 (3 mg/kg s.c.) or an equivalent volume 
of saline via the right ear vein. The drugs were allowed to circulate 
for 120 minutes at which time blood was drawn by cardiac puncture. Blood 
loss was determined by immersing the ear in a saline bath (1 liter) at 
37°C for 10 minutes. Red cell count in the bath solution was determined 
using a Hycel cell counter. The results were expressed as RBCs x 
10;/liter. Data represents a mean ± S.E. Statistical analysis was 
performed by a two way ANOVA: 
Factor A (drug treatment): F(2,24) - .601 p >.50 N.S. 
Factor B (protamine dose): F(l,24) - 18.175 p <.05 
Factor Ax B: F(2,24) - 4.239 p >.05 N.S. 
followed by a Ne~"lllan Keuls multiple comparison test. * represents a 
significant difference from the CY 216 (3 mg/kg s.c.) and protamine (3 
mg/kg i.v.) group. 
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Figure 44. Individual groups consisting of five rabbits each were 
administered heparin (3 mg/kg s.c.) or CY 216 (3 mg/kg s.c.) Each agent 
was allowed to circulate for 120 minutes at which time blood was drawn 
by cardiac puncture. Two groups received protamine sulfate (3 mg/kg 
i.v.) 120 minutes after the administration of heparin (3 mg/kg s.c.) or 
CY 216 (3 mg/kg s.c.). Protamine was allowed to circulate for 5 minutes 
at which time blood was drawn by cardiac puncture. Antiprotease 
activity was determined by an amidolytic anti Xa assay. Data represents 
a mean± S.E. Statistical analysis was performed by a two way ANOVA: 
Factor A (drug treatment): F(2,24) - 26.802 p <.05 
Factor B (protamine dose): F(l,24) - 17.158 p <.05 
Factor Ax B: F(2,24) - 8.056 p <.05 
followed by a Newman-Keuls multiple comparison test. 
* represents a significant difference from the control group. 
** represents a significant difference from the heparin (3 mg/kg s.c.) 
and protamine (3 mg/kg i.v.) group. 
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Figure 45. Individual groups consisting of five rabbits each were 
administered heparin (3 mg/kg s.c.) or CY 216 (3 mg/kg s.c.). The drugs 
were allowed to circulate for 120 minutes at which time blood was dra~"Il 
by cardiac puncture. Two groups received protamine sulfate (3 mg/kg 
i.v.) 120 minutes after the administration of heparin (3 mg/kg s.c.) or 
CY 216 (3 mg/kg s.c.). Protamine was allowed to circulate for 5 minutes 
at which time blood was dra~"Il by cardiac puncture. Antiprotease 
activity was determined by an amidolytic anti Ila assay. Data 
represents a mean± S.E. Statistical analysis was performed by a two 
• .-ay ANOVA: 
Factor A (drug treatment): F(2,24) - 198.315 p <.05 
Factor B (protamine dose): F(l,24) - 488.486 p <.05 
Factor Ax B: F(2,24) - 162.957 p <.05 
follo.;ed by a Ne~-man-Keuls multiple comparison test. * represents a 
significant difference from the control group. 
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Figure 46. A group of five primates was administered protamine (2.1 
mg/kg i.v.). Blood samples were drawn at 0, 5, 30, 60 and 120 minutes. 
Anticoagulant and antiprotease activity was determined using the APTT, 
thrombin time and HeptestR. Each data point represents a mean± S.E. 
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Figure 47. A group of 5 primates was administered protamine (2.1 mg/kg 
i. v.). Blood samples were drawn at O, 5, 30, 60 and 120 minutes. 
Antiprotease activities were determined using amidolytic anti Xa and 
amidolytic anti Ila assays. Each data point represents a mean± S.E. 
Statistical anlysis was performed by a two way ANOVA: 
Factor A (time): F(4,40) - 3.160 p>.05 N.S. 
Factor B (test): F(l,40) - 26.873 p<.05 
Factor Ax B: F(4,40) - 3.160 p>.05 N.S. 
followed by a Newman-Keuls multiple comparison test. * represents a 
significant difference from the control group. 
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Figure 48. A group of four primates was administered protamine 
(2.1 mg/kg i.v.). Blood samples were drawn at 0, 5, 30, 60 and 
180 minutes. The plasma samples were centrifuged and frozen at -
70°C. The pharmacodyna.mics of protamine were assayed indirectly 
by supplementing 0. 63 ml of plasma obtained after prot:amine 
administration to the primates with 70 µl of heparin 25 µg/ml. 
T'ne final concentration of heparin in the plasma sample was 2.5 
µg/ml. HeptestR was performed. Data represents a mean± S.E. 
Statistical analysis was performed by a two way ANOVA: 
Factor A (time): F(4,40) - 1.728 p>.50 N.S. 
Factor B (protamine dose): F(l,40) - .167 p>.50 N.S. 
Factor (Ax B): F(4,40) - 1.728 p>.50 N.S. 
266. 
Fi,gu're,.49. Four groups of primates were included in this study. The 
fi:r:~t ~group (N - 4) was administered heparin (0. 7 mg/kg i. v.) (upper 
pa~el:). · Th~ other three groups (N - 5) received heparin (0. 7 mg/kg 
i.v.)''fpl;J..owed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
minutes after heparin administration (lower panel). Blood samples from 
~ach of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes. 
An additional blood sample was obtained at 15 minutes from primates 
which w~re treated with protamine at the 5 minute time period. 
Anticoagulant activity was determined using the APTT. Each data point 
represents a mean± S.E. Statistical analysis was performed by a two 
way ANOVA: 
Factor A (time): F(3,40) - 3.398 p>.05 N.S. 
Factor B (protamine dose): F(2,40) - 25.634 p<.05 
Factor Ax B: F(6,40) - 1.300 p>.20 N.S. 
followed by a Newman-Keuls multiple comparison test. * represents a 
significant difference from heparin (0.7 mg/kg i.v.) and protamine (1.4 
mg/kg i.v.) group and heparin (0.7 mg/kg i.v.) and protamine (2.1 mg/kg 
i. v. ) group . 
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Figur-ii: 5C( . Four groups of primates were included in this study. 
The· firs.t group (N - 4) was administered heparin (0.7 mg/kg i.v.), 
(upper patlei). The other three groups (N - 5) received heparin (0.7 
mg/kg"i.v..) followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg 
i. v·.), five minutes after heparin administration (lower panel). 
B.lood samples from each of these 4 groups were drawn at 0, 5, 30, 
60, 180 an·d 360 minutes. An additional blood sample was obtained 
at 15 minutes from primates which were treated with protamine at the 
5 minute time period. Anticoagulant activity was determined using 
the thrombin time. Each data point represents a mean ± S. E. 
Statistical analysis was performed by a two way AN0VA: 
Factor A (protamine dose): F(2,29) - 1.863 p>.50 N.S. 
Factor A (time): F(2,29) - 6.648 p<.01 
Factor Ax B: F(4,29) - 3.121 p>.05 N.S. 
followed by a Newman-Keuls Multiple comparison test. * represents 
a significant difference from heparin (0.7 mg/kg i.v.) and protamine 
( 1 . 4 mg/kg i. v. ) group and the heparin ( 0. 7 mg/kg i . v. ) and 
protamine (2.1 mg/kg i.v.) group. 
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Figur:·~. 51· .• · Four groups of primates were included in this study. The 
fir-st g:t;oup (N - 4) was administered heparin (0. 7 mg/kg i. v.) (upper 
panel) .. '•Tl\e other three groups (N - 5) received heparin (0. 7 mg/kg 
i.v.)·fo~lowed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
minutes after heparin administration (lower panel). Blood samples from 
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes. 
An additional blood sample was obtained at 15 minutes from primates 
which 'were treated with protamine at the 5 minute time period. 
Antiprotease activity was determined by the HeptestR. Each data point 
represents a mean± S.E. 
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Figure ~;'i:, · F~ur • groups of primates were included in this study. The 
first group,.(N - 4) was administered heparin (0.7 mg/kg i.v.), (upper 
panel). · The other three groups (N - 5) received heparin (0. 7 mg/kg 
i.v.) .followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
minutes after heparin administration (lower panel). Blood samples from 
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes. 
An additional blood sample was obtained at 15 minutes from primates 
which were treated with protamine at the 5 minutes time period. 
Antiprotease activity was determined using an amidolytic anti Xa assay. 
Each data point represents a mean± S.E. 
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Figur~~si. °Foyr groups of primates were included in this study. The 
first gr~up •(N - 4) was administered heparin (0.7 mg/kg i.v.), (upper 
panel)•, · The other three groups (N - 5) received heparin (0. 7 mg/kg 
i.v,) foliowed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
minutes after heparin administration (lower panel). Blood samples from 
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes. 
An additional blood sample was obtained at 15 minutes from primates 
which received protamine at the 5 minute time period. Antiprotease 
activity was determined using an amidolytic anti Ila assay. Each data 
point represents a mean± S.E. 
275 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY 
OF HEPARIN IN PRIMATES 
TEST:ANTI IIA 
100--------------------
z 
0 
I-
CD 
75 
:r: 50 
z 
~ 
25 
HEPARIN(0.7 mg/kg i.v.) 
o-----+---+----+-------1-----....-----+---+-----f 
0 50 1 00 1 50 200 250 300 350 400 
TEST :ANTI IIA 
100 
z 80 
0 
I-
co 60 
-
-
z 40 
~ 
20 
MINUTES 
WITH PROTAMINE SULFATE 
o-CWITH PROTAMINE[0.7 mg/kg J.v.j 
•-•WITH PROTAMINE 1.4 mg/kg !.v. 
b.- 11. WITH PROTAMINE 2.1 mg/kg 1.v. 
-------I 
o L--4---4--~~===+==~.====p1~ 
0 50 1 00 1 50 200 250 300 350 400 
MINUTES 
27 6 : 
,. ; 
. '· 
Figu:i:f 54. Four groups of primates were included in this study. The 
firs·t' ·&rou'p (.N - 4) was administered CY 216 (0. 7 mg/kg i. v.) (upper 
panel).',Xhe other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.) 
followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
minutes after heparin administration (lower panel). Blood samples from 
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes. 
An additional blood sample was obtained at 15 minutes from primates 
which· were treated with protarnine at the 5 minute time period. 
Anticoagulant activity activity was determined using the APTT. Each 
data point represents a mean± S.E. 
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protamine at the 5 minute time period. Anticoagulant activity was 
determined using the thrombin time. Each data point represents 
a mean± S.E. 
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F�sur�·· 5,6. Four groups of primates were included in this study. The
fir'st group, (N - 4) was administered CY 216 (0. 7 mg/kg i. v.), (upper
panef}. •The other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.) 
followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
JI1inute
0
s after heparin administration (lower panel). Blood samples from 
each of these 4 groups were drawn at 0, 5, 30, 60, 180, and 360 minutes. 
An additional blood sample was obtained from primates which were treated 
with protamine at the 5 minute time period. Antiprotease activity was 
determined by the HeptestR. Each data point represents a mean± S.E. 
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Figu·r.~ :5?,, ·. Four groups of primates were included in this study. The 
fir~t'. '·group (N - 4) was administered CY 216 (0. 7 mg/kg i. v.), (upper 
panel). ~~h~ other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.) 
follo'::led· by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
minutes a-fter heparin administration (lower panel). Blood samples from 
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes. 
An additi~nal blood sample was obtained at 15 minutes from primates 
which .were treated with protamine at the 5 minute time period. 
Antiprotease activity was determined using an amidolytic anti Xa assay. 
Each data point represents a mean ± S. E. Statistical anlaysis was 
performed by a two way AN.OVA: 
Factor A (time): F(4,60) - 48.857 p <.001 
Factor B (protamine dose): F(4,60) - 32.178 p <.001 
Factor Ax B: F(8,60) - .737 p >.50 N.S. 
followed by a Newman-Keuls multiple comparison test. * represents a 
significant difference from the CY 216 (0.7 mg/kg i.v.) and protamine 
(2.1 mg/kg i.v.) group. 
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Figure:5~_. Four groups of primates were included in this study. The 
first~group (N - 4) was administered CY 216 (0.7 mg/kg i.v.), (upper 
panel).·, The other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.) 
followed'•by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five 
minutes after heparin administration (lower panel). Blood samples from 
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes. 
An additional blood sample was obtained at 15 minutes from primates 
which were treated with protamine at the 5 minute time period. 
Antiprotease activity activity was determined using an amidolytic anti 
Ila assay. Each data point represents a mean ± S. E. Statistical 
analysis was performed by a two way ANOVA: 
Factor A (time): F:(3,48) - 1056.337 p<.001 
Factor B (protamine dose): F(2,48) - .033 p>.50 N.S. 
Factor Ax B: F(6,48) - .267 p>.50 N.S. 
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TEST: HEPTEST 
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Figure 59. T..o groups of primates were included in this study. The 
first group (N - 5), (open circles) was administered heparin (0.7 mg/kg 
s.c.). The second group (N - 4), (closed circles) received heparin (0.7 
mg/kg s.c.) followed by protamine sulfate (0.7 mg/kg i.v.) 240 minutes 
after heparin administration. Blood samples were dra~--n at 0, 120, 240, 
360 and 540 minutes. An additional blood sample was obtained at 245 
minutes from primates which were treated with protamine. A final blood 
sample was dra~--n at 720 minutes from the heparin group. Antiprotease 
activity was determined using the HeptestR. Each data point represents 
a mean± S.E. 
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Figure 60. Two groups of primates were included in this study. The 
first group (N - 5), (open circles) was ad.ministered CY 216 (0.7 mg/kg 
s.c.). The second group (N - 4), (closed circles) received CY 216 (0.7 
mg,lkg s.c.) followed by protamine sulfate (1.4 mg/kg i.v.) 240 minutes 
after heparin ad.ministration. Blood samples were drawn at 0, 120, 240, 
360 & SL.O minutes. An additional blood sample .,as obtained at 245 
~inutes from primates which were treated with protamine. A final blood 
sample was dra~-n at 720 minutes from the heparin group. Antiprotease 
activity was dete=mined using a clot based assay (HeptestR). Each data 
point represents a mean± S.E. 
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Figure 61. Two groups of primates were included in this study. The 
first group (N - 5), (open circles) was administered heparin (0.7 mg/kg 
s.c.). The second group (N - 4), (closed circles) received heparin (0.7 
mg/kg s.c.) followed by prota.mine sulfate (0.7 mg/kg i.v.) 245 minutes 
after heparin administration. Blood samples were dra~"n at 0, 120, 240, 
360 and 540 minutes. An additional blood sample was obtained at 245 
minutes from primates which received protamine. A final blood sample 
~as dra~-n at 720 minutes from the heparin group. Antiprotease activity 
~as. determined using an a.midolytic anti Xa assay. Each data point 
represents a mean± S.E. 
z 
0 
t--
CD 
:r: 
z 
289 
TIME COURSE OF THE PHARMACODYNAMIC ACT1Vl1Y OF 
CY 216 IN PRIMATES 
TEST:ANTI XA 
100-----------------------, 
75 
50 
o-o CY 216 0.7 mg/kg s.c. 
•-•WITI-i PROTAMINE 0.7 mg/kg i.v. 
~ 25 
04i---"l----+----+---+----i---t----t-----1 
0 100 200 300 400 500 
MINUTES 
600 700 800 
Figure 62. Two groups of primates were included in this study. Yne 
first group (N - 5), (open circles) was administered CY 216 (0.7 mg/kg 
s.c.). Yne second group (N - 4), (closed circles) received CY 216 (0.7 
mg/kg s.c.) followed by protamine sulfate (0.7 mg/kg i.v.) 240 minutes 
after heparin administration. Blood samples were dra~'Tl at 0, 120, 240, 
360 and 540 minutes. An additional blood sample was obtained at 240 
minutes for primates which received protamine. A final blood sample was 
dra~"!l at 720 minutes from the heparin group. Antiprotease activity was 
determined using an amidolytic anti Xa assay. Each data point 
represents a mean± S.E. 
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Analytical Profile of Cy 216 
46, Avenue Theophile Gautier 75782 Paris - Cedex 16 
Tel. 524.46.77 
INSTITUT CHOAY 
PRODUCT CY 216 (D) 
REFERENCE Batch P 533 XH 
CHARACTERS 
IDENTIFICATION 
A. Coloured reaction 
a. Specific optical rotation 
C. Calcium reactions 
•. Antithrombin activity 
TESTS 
Clarity of the solution S 
Colour of the solution S 
pH of the solution S 
Heavy meta ls 
Loss on drying 
Sulphated ash 
Nitrogen 
Proteins 
UV extinction 
Calcium 
Fractionation conformity 
Nitrites 
Boron 
Pyrogens 
ASSAY 
Potency anti-factor Xa 
November, 6 1986 
CONTROL SHEET 
N° 131813 
Limits 
White powder, 
soluble in water 
Positive 
Not less than +35• 
Positive 
Passes 
Clear or slightly 
opalescent 
Not more than JS 
5.0 to 7 .5 
Not more than 40 ppm 
Not more than 8 p.100 
Not more than 35 p.100 
Not more than 2.5 p.100 
Passes 
Passes .. 
Not les~ than 7 p.100 
Conform to the. .standard 
Not more than 1 ppm 
Not more than 20 ppm 
2,000 uAXa IC/kg rabbit 
Not less than 180uAXa IC 
per mg calculated with 
reference to the dried 
Control 
Passes 
Passes 
+49° 8 
Positive 
Passes 
Passes 
Passes 
6.54 
Less than 40 ppm 
2.7 p. lD0 
32.5 p. 100 
1.87 p. 100 
Passes · 
Passes .. 
9.43 p.100 
Passes 
Less than 1 ppm 
Less than 20 ppm 
Passes 
substance 226 uAXa IC/mg 
C. CUR.L7 ~ 
Phar~ 
V 
rcchcrchc ct 
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Molecular Weight Profile of CY 216 
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Analytical Profile of Protamine Sulfate 
,- ·--·•· - ·- ·----·-··· --·---------·- ·-----····- ----- ··-··--·--·- ---
BULLETIN DE CONTROLE 
Produil . 
SlJLFATl( DE PROT/\HINt 
suivant projet PE 
C:ir:ici-crcs 
Identification : 
A 
B 
C 
D 
E 
. f.r.s:i ir- : 
solution S 
Ab::orh:ince 
Azotc 
Fer 
Mcrcnrc 
~:i:r:iur. lourds 
Sulf:itc-s 
Pcrte ft la dessication 
~ss:ii des pyro~!nes 
Tm:i.citc :mor:::ale 
Do!-nhC: 
du p~o<luit tel qucl 
du procluit anhydrc 
Ccnrlrcs sulfuriQues 
Ari:enic. 
Conclusion : Conforme 
29 Janvier 1985 
Lot : 2-85 
An.il)•sc : P. ?8,078 
Code : ?.198 
: conforne:: 
: co::formc 
: conforme 
: -e1•,3 
: conforr.in 
: conf oi:1~c 
: limpi<lc,incolorc 
: co:iforrnc 
: 24,ih 
: conformc 
: conforrnc 
: confo::mes 
: 20,357. 
: ~,:!i. 
! ap:,•ror,i;ne (0°, Q7) 
: coriro!"me 
: 138 UAH/m3 
: 144 U/111/mr, 
: 0,2~ 
: conforma 
! ~ L .. ~~boraloi~o CHOAY, 1, Ruo ~o l'ktt~y:~ :~~~~~-~~:•.~-~~;:!: _-,~1~0_;;;~:10 
... ---.-.. 
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Molecular Weight Profile of Protamine 
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kesults and Conditions of GPC analvsis 
Reoort Method: third Analvsis Method: 
Calibration Method: third Norm~l1zat1on: 
Baseline: Start 5.00 min End 
Number of Data Points in Baseline Region 
Processina: Start 5.00 min End 
Number of-Slices 100 Area Rejection 
Negative Slices Disabled 
r 
20 
l 
f 
I 
t 
1·0 
third 
Nor,e 
18.00 min 
50 
15.00 min 
(l 
Molecular Weicht calculation bv Narrow Standard Calibration Curve. 
Mark-~ouwink ~quation: Not Used. 
Number Averaae 
Weight Aver ... ~e 
Z Averaoe -
V iscositv Averaoe 
z .., l Aver ... ae -
1216 
3036 
3612 
3036 
3855 
Intrinsic Viscosity 
Peak Molecular Weight 
Dispersitv 
Z avg / W .:1vg 
Z+l avg/ W avg 
0.0000 
3953 
2. 49644:, 
1.189657 
1.269650 
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APPENDIX VIII 
Rabbit Stasis Thrombosis Model Showing 
Ligatures on Isolated Jugular Veins 
(Walenga, J.M., 1987.) 
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APPENDIX IX 
Diagram of the Clot Grading System Used in the 
Rabbit Stasis Thrombosis Model 
no clot 
0 = a II free erythrocytes 
+ 
- ./--
= 
- -
-----
-.,,-=-
I + = ~-'=---i -2+ = -'!)-;~ 
-- • --==-
--
-~· d 
3+ -~~ = -·-  p 
4+ = ii 
(Walenga, J.M., 1987.) 
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APPENDIX X 
Rabbit Ear Bleeding Model 
Diagram Showing the Location of Incisions Made in the Rabbit Ear Blood 
Loss Model. 
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CUMULATIVE RESULTS OF PRIMATE BLOOD CHEMISTRY PROFILES 
Date of Blood Draw 6-7-88 11-7-88 Normal Range* 
---
CL (meq/1) 116. 0± 10.4 110. 7± 2. 5 84.0 - 126.0 
I<"' (meq/1) 4,1± 0.7 8. 2±13. 6 2.3 - 6.7 
Na+ (meq/1) 149.8± 12.8 151.4± 3.2 102.0 - 166.0 
Total bilirubin 
(mg/dl) 0,1± 0.3 0.3± 0.3 0.1 - 2.0 
GOT (IU/1) 60.9± 53.3 N/A 16.0 - 97.0 
GPT (IU/1) 114.4±236.3 N/A 0.0 - 68.0 
creatinine (mg%) 1.0± 0.7 0,8± 0.3 0.1 - 2.8 
Uric acid (mg%) 0.9± 1. 7 1.4± 1. 3 0.1 - 1.4 
ca2+ (mg%) 9.6± 1.4 10.0± 0.6 6.9 - 13.0 
Alkaline 
phosphatase (U) 147.4±267.8 147.9±84.7 9.7 - 89.0 
GT (IU/1) 72.9±143.2 78.2±43.0 N/A 
Total protein (g/dl) 6.8± 1.0 7.2± 0.3 4.9 - 9.3 
Triglyceride (mg/dl) 160.8±394.1 215.5±170.6 N/A 
Carbohydrate (mm/1) 22.4± 8.7 N/A N/A 
Albumin (g/dl) 4.5± 1.4 4.6± 0.3 2.8 - 5.2 
BUN (mg%) 16.8± 10.4 17.1± 4.1 8.0 - 40.0 
Glucose (mg%) 72.5±159.2 87.7±73.0 46.0 - 178.0 
Cholesterol (mg%) 173.8±115.6 178.0±28.8 108.0 - 263.0 
LDH (IU/1) 583.3±549.4 819.1±187.4 N/A 
Phosphorous (mg%) 3.3±3.1 3. 2±1. 3 3.1 - 7.1 
Primate blood chemistry profiles were performed before beginning the 
pharrnacodynamic studies and at their completion by the Loyola University 
Clinical Chemistry Department. Values represent x ± S.D. N=l2 for 6-7-
88, N=lO for 11-7-88. 
*Normal ranges for rhesus monkeys were obtained from McClure (1975) 
N/A - not available. 
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CUMULATIVE RESULTS OF PRIMATE HEMATOLOGIC PROFILES 
6-7-88 11-7-88 Normal Range* 
WBC (xl03) 5. 8±1. 4 6.1±1.3 2.5 - 26.7 
RBC (xl06) 5.6±0.7 5.4±0.7 3.6 - 7.0 
HGB (g/dl) 13. 5±1.4 12.4±1.9 8.8 - 16.5 
HGT (%) 40.4±3.5 37.8±4.8 26.0 - 48.0 
MCV (µm3) 72 .0±4. 2 70.0±6.7 58.1 - 116. 9 
MCH (µµg) 24. 0±1.4 22.9±2.6 18.5 - 36.6 
MCHC (g/dl) 33.4±2.8 32.6±1.3 25.6 - 40.2 
ROW 13. 8±1.4 14.1±2.6 N/A 
PLT (xl03) 357.7±84.4 173.3±168.9 109.0 - 597.0 
MPV (µm3) 9.3±2.7 10.0± 1.0 N/A 
Lymphocyte (%) 20.5±106.2 14.1± 9.0 8.0 - 92.0 
Lymphocyte (x103) 1. 2±6. 6 2.8± 1.0 0.69 - 14.5 
TPA (ng/ml) N/A 1. 5±0. 6 N/A 
Primate blood hematologic profiles were performed before beginning the 
pharmacodynamic studies and at their completion by the Loyola University 
Clinical Chemistry Department. Values represent x ± S.D. N-12 for 
6-7-88, N=lO for 11-7-88. 
*Normal ranges for rhesus monkeys were obtained from McClure (1975). 
N/A - not available 
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CUMULATIVE RESULTS OF PRIMATE COAGULATION PROFILES 
6-7-88 11-7-88 
APTT (seconds) 27.4±4.2 29.6±2.6 
TT (SU/ml) (seconds) 30.9±5.2 24.8±4,8 
Heptest (seconds) 21.5±3.1 22. 5±1. 3 
primate coagulation profiles were performed before beginning the 
pharmacodynamic studies and at their completion. Values represent x ± 
s.D. N-12 for 6-7-88, N=lO for 11-7-88. 
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CALIBRATION CURVE OF HEPARIN SUPPLEMENTED TO NMP 
USED TO CALCULATE PHARMACODYNAMIC TIME COURSE PARAMETERS 
100 
TEST:ANTI XA 
80 
z 
0 
1- 60 
Ol 
::r: 40 
z 
~ 
20 
o..----+----+----+----+-----4---' 
0.0 1.0 2.0 3.0 4.0 5.0 
pg/ml 
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CALIBRATION CURVE OF HEPARIN SUPPLEMENTED TO NMP 
5£D TO CALCULATE PHARMACODYNAMIC TIME COURSE PARAMETERS 
250 
(/) 200 
Cl 
z 
o 150 
(.) 
w 
(/) 100 
50 
0 -r---+----,t----t---1-----+----+---+---1---.J----I~ 
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 
JJ9/ml 
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CALIBRATION CURVE OF CY 216 SUPPLEMENTED TO NMP 
USED TO CALCULATE PHARMACODYNAMIC TIME COURSE PARAMETERS 
100--------------------, 
z 80 
0 
f-
- 60 (D 
:c 
z 40 
~ 
20 
TEST:ANTI XA 
0 
oJ..:::::::=----t----1------+--~~----+-:-__. 
0.0 1.0 2.0 3.0 4.0 5.0 
pg/ml 
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CALIBRATION CURVE OF CY 216 SUPPLEMENTED TO NMP 
USED TO CALCULATE PHARMACODYNAMIC PARAMETERS 
SECONDS 
120-r------------------------, 
100 
80 
60 
40 
20 
0--1-------~-----------..,__. 
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 
pg/ml 
100.0 
z 75.0 
0 
I-
m 50.0 
I 
z 
APPENDIX Xlle 342 
IN VITRO SUPPLEMENTATION OF HEPARIN TO NRP 
2.5 5.0 7.5 10.0 
µg/ml HEPARIN 
Heparin was supplemented to NRP in a concentration range of 0-10 µg/ml. 
Antiprotease activity was determined by the amidolytic anti Xa and anti 
. Ila methods. Data represents a mean ± S. E. The experiment was 
performed in triplicate on separate days. 
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IN VITRO SUPPLEMENTATION OF CY 216 TO NRP 
100.0 
z 75.0 
o-oANTI IIA 
•-•ANTI XA 
0 
._.. 
(D 50.0 
:c 
z 
~ 25.0 
0.0e..::;;.a_ ___________________ _ 
0.0 2.5 5.0 7.5 10.0 
JJ9/ml CY 216 
CY 216 was supplemented to NRP in a concentration range of 0-10 µg/ml. 
Antiprotease activity was determined by the amidolytic anti Xa and anti 
Ila methods. Data represents a mean ± S. E. The experiment was 
performed in triplicate on separate days. 
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Heparin H 503 
Proton NMR (300 MHz) in D2Q 
S.50 S.00 ,.so 4.00 S.50 3.00 2.50 2.00 1.50 
PPH 
1H NMR Spectrum (300 MHz) in n2o 
345 
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CY 211 PII BATCH PS33 XH,IH 0 
s.ao a.oo ,.so ,.oo 3.ao 3,oo 2.so 2.00 1.ao 
PPM 
1H NMR Spectrum (300 MHz) in DzO 
APPENDIX XV 
ffilli I ,](I __ 
5.00 
1H h1MR Spectra 
APPENDIX XV 349 
lH NMR SPECTRA (300 MHz) in DCl 
~II 
.I .. 
4.00 
(300 MHz) in 
Protamine 20 mg/0.5 ml DClN 0.lN 
Pratamine 20 mg and 1 mg Heparin 
0.5 ml DClN0.lN 
I 
PPH 
2.00 1.00 
DCL The upper spectrum is protarnine. 
The lower spectra is heparin and protamine. The box is an enlarge-
ment of the lower spectrum in the range of 3-5 ppm. The arrow 
represents an area of change in the chemical shift as compared to 
the upper spectrum. 
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CONVERSION OF GRAVIMETRIC AMOUNTS OF HEPARIN, CY 216 AND 
PROTAMINE TO APPROXIMATE MOLAR RANGES 
Cone. (µgml) 
S12ecies Dose (mgL'.kg2 He12arin CY 216 Protamine 
(µg/moles) (µg/moles) (µg/moles) 
In Vitro 0.6 .01-0.32 .04-0.86 .09-0.40 
1. 25 .02-0.66 .07-1.80 .18-0.83 
2.50 .04-1.31 .15-3.60 .36-1.67 
5.0 .09-2.63 .30-7.20 .72-3.33 
10.0 .18-5.26 .59-14.3 1.4-6.66 
Primate 0.7 .01-.37 . 04-1. 00 .10-.47 
1.4 .20-.93 
2.1 . 30-1. 40 
Rabbit 0.1 .002-.05 . 006- .14 .01-.07 
0.2 . 004- .11 .01-.29 .03-.13 
1.0 .02-.53 .06-1.4 .14-.67 
2.0 .04-1.05 .12-2.9 .29-1.33 
2.5 .04-1.32 .15-3.6 .36-1.7 
Rat .32 .010-.168 .02-.46 .05-.21 
.64 .012-.337 . 04-. 91 .09-.43 
. 72 .013-.379 .042-1.03 .10-.48 
1.0 .018-.526 .06-1.43 .14-.67 
2.0 .036-1.052 .12-2.86 .29-1.3 
The following molecular weight ranges were used for the ocnversion from 
gravimeter to molar amounts. Heparin (57,000 - 1,900) daltons; CY 216 
(17,000 - 700) daltons; Protamine (7,000 - 1,500) daltons. 
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Species 
Primate 
Rabbit 
Rat 
Man 
heparins 
heparins 
heparins 
Heparin 
Protamine 
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DOSAGES OF HEPARIN, CY 216 AND PROTAMINE WHICH WERE ADMINISTERED 
DURING THE ANIMAL EXPERIMENTS AS COMPARED TO DOSAGES 
Weight(kg) 
8.0 
2.5 
0.25 
70 
USED DURING CARDIOPULMONARY BYPASS 
Dose (mg/kg) Total mg 
0.70 5.6 
0.10 0.25 
2.0 5.0 
1.0 0.25 
2.5 0.63 
2.0a_3_ob 140.0 
2.5a 175.0 
Blood 
Volume 
(mg/kg b. w. ) 
75c 
53c 
65c 
78.6d 
Drug 
Concentration 
(µg/ml) 
9 
2 
38 
15 
39 
25-38 
32 
Concentrations were calculated for dosages of heparin, CY 216 and protamine which were used during the 
experiments and which are used for man during cardiopulmonary bypass procedures. 
a. Dosages·used at Foster McGaw Hospital. 
b. Physician's Desk Reference 1989. 
c. Davis P. Personal Communication 
d. Goodman and Gilman's The Pharmacological Basis of Therapeutics. MacMillan Publishing Company, 1985. w 
\Jl 
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Tost In 
APTT 
Thrombin Time 
HeptestR 
Anti-Xa 
Anti-Ila 
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RATIO OF PROTAMINE TO HEPARIN AT W'HICH 
COMPLETE NEUTRALIZATION OCCURRED 
Vitro (NHP) In Rabbits In 
1:1 1:1 
1:1 3:2 
2:1 3:2 
2:1 1:1 
2:1 1:1 
355 
Primates 
1:1 
1:1 
1:1 
1:1 
1:1 
Ratios were calculated from data obtained from the rabbit ear blood loss 
experiments and the primate pharmacodynamic time course experiments. 
Blood was drawn 5 minutes after the administration of protamine in the 
rabbit experiment and 15 minutes after the administration of protamine 
in the primate experiments. 
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Test 
-=---
APTT 
Thrombin Time 
HeptestR 
Anti-Xa 
Anti-Ila 
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RATIO OF PROTAMINE TO CY 216 AT WHICH 
COMPLETE NEUTRALIZATION OCCURRED 
In Vitro NHP In Rabbits In 
2:1 1:1 
1:2 3:2 
>2:1 >3:2 
>2:1 >2:1 
2:1 1:1 
357 
Primates 
1:1 
1:1 
1:1 
2:1 
1:1 
Ratios were calculated from data obtained from the rabbit ear blood loss 
experiments and the primate pharmacodynamic time course experiments. 
Blood was drawn 5 minutes after the administration of protamine in the 
rabbit experiment and 15 minutes after the administration of protamine 
in the primate experiments. 
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TLc :\m11w-Aci<l Sequence, of Component, of Sain:i'1l 
Table \'lll-6. Pcpridc, obtained by :\cutra] Prntca,c d,.:c-tic,n 
Salmine Al 
Structure 
Pro· Arg · Arg · Arg · Arg I 
Pro·Arg·Arg·Arg·Arg·Scr I 
Arg·Ser 
Pro· Arg · Arg · Arg 
(Ser)· Ser· Ser· Arg · Pro 
\"al· Arg·Arg ·Arg ·Arg· Arg· Pro• Arg 
Arg · Arg ·Pro· Arg 
Val· Arg · Arg · Arg 
\:al· Ser·Arg·Arg· Arg·Arg· Arg·Arg 
\·al · Ser·Arg· Arg · Arg·Arg•Arg·Arg·Gly 
Val· Ser·Arg· Arg · Arg 
Gly·Gly·Arg·Arg·Arg·Arg 
Gly · Arg · Arg · Arg· Arg 
Recc>\Try 
(mole/mole) 
0.37 
0.42 
0.44 
0.96 
0.80 
0.12 
0.07 
0.83 
0.10 
0.48 
0.50 
(Adapted from Ando T. et. al. Protamine - LSolation. 
Characterization, Structure and Function, Springer, Berlin 
Heidelberg, New York, 1973). 
H2 
<±>H3 N CH2 C H2 C H2 C H2 NCH 2 CH 2C H 2 N Hp (±) 
SPERMIDINE 
(Dentsman S.C. et. al. Biochemical and Biophysical Research 
Communication 149:(1) 194-201, 1987). 
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Noncompartmental Model Diagram 
TEST-INPUT 
I 
I 
a1 = MASS1 
v 1 = VOLUME 1 
~01 
1' 
MEASUREMENTS 
? 
kz1 
$INKS 
Oz= MASSz 
Vz = VOLUMEz 
/ 
FIG. 2. Mon general 2-compartrnent (2-pooH model. with lnput and 
output in the.same pool. 
(Bourne D.W.A. et.al. Pharmacokinetics for the non-mathematical, 
MTP Press Limited, Lancaster, Australia, 1988). 
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(al 
APPENDIX XXII 
Interactions of an Oligosaccharide 
Factor Xa, Thrombin, AT III and Protamine 
lbl 
lc1_8_Fxa-•-~--•• MNhoPQ __ 
BQ_ Mechanismll 0 ~, 
~,---
~ssible interactions of an oligosaccharide, the approximate size of the 
antithrombin binding region, and of a full-sized heparin chain, with anti-
thrombin (AT), factor Xa (Xa), thrombin (Ila) and protamine (prot.). a) 
an oligosaccharide containing only the antithrombin binding sequence binds 
to AT and accelerates the inhibition of Xa but not Ila (b). It cannot bind 
to protamine and its anti-factor Xa activity is therefore resistant to 
neutralization. (c). Protamine can bind to a full-sized heparin and 
neutralize its anti-factor Xa and antithrombin activities. 
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Two mechanisms (d) can be proposed to explain this neutralizing action. In 
mechanism I the neutralizing protein binds to a site adjacent to the anti-
thrombin binding site and sterically hinders formation of the antithrombin-
P:oteinase complex. Alternatively, in mechanism II the neutralizing protein 
b~nd~ immediately adjacent to (and perhaps overlapping with) the antithrombin 
binding site and displaces the inhibitor from the polysaccharide chain. 
(Adapted from Lane D.A., Heparin Neutralizing Proteins in Blood. Structure 
~Activities of Heparin and Related Mucopolysaccharides. Annals of the 
ew York Academy of Sciences 566: 473-475, 1989.) 
The differential neutralization of FraxiparineRobser.ved in the Xa (Heptest 
and amidolytic Xa) assays may be due to the fact that oligosa:cha~ides 
lmw <5,OOO) comprise almost 80% of this agent. Thus, protam~ne 1s un~b~e 
~o completely neutralize these activities effectively and residual act1v1ty 
15 Observed. On the other hand, the anti-Iia activities as measured by 
thrombin time and Alla are effectively neutralized by pro~amine. 
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APPENDIX XXIIIa 
IN VITRO SUPPLEMENTATION OF HEPARIN TO NHP 
concentration APTT Heptest Anti-Xa Anti- Ila 
_ (µ~/ml) (seconds) (seconds) (% inhibition) (% inhibition) 
10.0 >150 228.5 ± 14.6 90.8 ± 0.6 91.0 ± 1.0 
5.0 >150 116.0 ± 2.2 72.0 ± 3.0 84.2 ± 2.4 
2.5 80.4 ± 4.4 78.3 ± 1.2 49.8 ± 4.7 58.8 ± 2.9 
1. 25 50.9 ± 4.1 56.3 ± 1. 7 38.8 ± 5.7 44.8 ± 7.5 
0.6 37.5 ± 1. 3 32.7 ± 2.7 16.7 ± 4.4 15.8 ± 3.7 
0.0 30.5 ± 2.2 15.5 ± 1. 2 0 ± 0 0 ± 0 
Data represents a mean± S.E., N=5. 
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APPENDIX XXIIIb 
IN VITRO SUPPLEMENTATION OF HEPARIN TO NMP 
Concentration APTT Heptest Anti-Xa Anti-Ila 
(µg/ml) (seconds) (seconds) (% inhibition) (% inhibition) 
10.0 >150 287.9 ± 7.6 94.3 ± 4.0 92.7 ± 1.6 
5.0 >150 145.3 ± 1.6 80.3 ± 3.2 88.0 ± 1. 7 
2.5 78.5 ± 1. 3 78.9 ± 1. 3 50.3 ± 1.2 83.3 ± 3.5 
1. 25 42.6 ± 1. 2 54.0 ± 1.5 26.0 ± 2.6 50.3 ± 2.5 
0.6 32.7 ± 1.2 35.5 ± 0.5 11. 7 ± 0.6 35.7 ± 2.5 
0.0 24.5 ± 1. 6 18.0 ± 0.3 0 ± 0 0 ± 0 
Data represents a mean± S.E., N=3. 
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APPENDIX XXIIIc 
IN VITRO SUPPLEMENTATION OF HEPARIN TO NRP 
Concentration APTT Heptest Anti-Xa Anti-IIa 
(µg/ml) (seconds) (seconds) (% inhibition) (%inhibition) 
10.0 >300 >300 93.3 ± 3.0 83.0 ± 5.0 
5.0 >279.3 ± 21.1 >300 57.3 ± 5.1 72.0 ± 9.0 
2.5 157.7 ± 16.4 188.9 ± 8.3 43.7 ± 8.8 49.7 ± 8.6 
1. 25 100.4 ± 17.2 60.9 ± 0.6 22.0 ± 9.2 27.7 ± 6.6 
0.6 77. 7 ± 1.4 40.0 ± 3.3 3.5 ± 0.4 10.0 ± 1.5 
0.0 56.6 ± 0.8 20.5 ± 1. 7 0 ± 0 0 ± 0 
Data represents a mean± S.E., N-3. 
368 
APPENDIX XXIlld 
IN VITRO SUPPLEMENTATION OF HEPARIN TO NRatP 
Concentration APTT Heptest Anti-Xa Anti-Ila 
(µ~/ml) (seconds) (seconds) (% inhibition) (% inhibition) 
10.0 >150 >300 85.0 ± 0.6 86.3 ± 2.4 
5.0 78.l ± 5.3 163.8 ± 30.9 60.0 ± 3.6 59.3 ± 0.6 
2.5 36.4 ± 1.8 100.2 ± 12.5 32.7 ± 3.5 46.0 ± 6.6 
1. 25 26.l ± 0.8 76.1 ± 3.3 19.3 ± 4.3 17.7 ± 14.9 
0.6 22.6 ± 0.7 69.6 ± 1.5 3.0 ± 7.3 9.3 ± 9.5 
0.0 16.1 ± 0.9 56.6 ± 0.8 0 ± 0 0 ± 0 
Data represents a mean± S.E., N-3. 
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APPENDIX XXIIIe 
IN VITRO SUPPLEMENTATION OF CY 216 TO NHP 
Concentration APTT Heptest Anti-Xa Anti-Ila 
{µg/ml) {seconds) {seconds) (% inhibition) (% inhibition) 
10.0 67.2 ± 0.8 112.7 ± 3.2 65.2 ± 3.8 56.2 ± 7.9 
5.0 51. 2 ± 1. 9 81. 5 ± 5.5 45.4 ± 4.8 37.0 ± 2.2 
2.5 40.8 ± 0.6 66.4 ± 1.2 37.3 ± 2.2 13.6 ± 3.0 
1. 25 36.7 ± 0.3 54.7 ± 1. 6 27.0 ± 3.8 8.4 ± 2.2 
0.6 34.8 ± 0.6 38.2 ± 1. 6 14.2 ± 6.6 3.4 ± 1.8 
0.0 30.5 ± 2.2 15.5 ± 1.2 0 ± 0 0 ± 0 
Data represents a mean± S.E., N~5. 
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APPENDIX XXIIIf 
IN VITRO SUPPLEMENTATION OF CY 216 TO NMP 
Concentration APTT Hep test Anti- Xa Anti- Ila 
(µg/ml) (seconds) (seconds) (% inhibition) (%inhibition) 
10.0 72. 7 ± 4.3 >150 71. 3 ± 3.1 70.0 ± 6.2 
5.0 46.9 ± 0.6 41.0 ± 0 51.0 ± 2.6 53.3 ± 3.2 
2.5 35.4 ± 0.8 21.3±0.7 25.6 ± 1.2 34.3 ± 5.1 
1. 25 32.5 ± 3.3 17.3 ± 0.1 12.3 ± 0.6 22.3 ± 4.6 
0.6 27.2 ± 1. 2 15.0 ± 0.0 6.0 ± 1.0 16.0 ± 2.6 
0.0 24.5 ± 1. 6 18.0 ± 0.3 0 ± 0 0 ± 0 
Data represents a mean± S.E., N=3. 
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APPENDIX XXIIIg 
IN VITRO SUPPLEMENTATION OF CY 216 TO NRP 
Concentration APTT Heptest Anti-Xa Anti-Ila 
(µg/ml) (seconds) (seconds) (% inhibition) (% inhibition) 
10.0 99.9 ± 0 147.5 ± 17.6 31.0 ± 7.1 45.0 ± 2.8 
5.0 83.9 ± 5.4 64.5 ± 2.0 26.0 ± 2.0 31. 0 ± 5.0 
2.5 64.0 ± 1. 7 46.5 ± 1.8 13.3 ± 5.7 17.7 ± 4.8 
1. 25 67.1 ± 3.1 39.1 ± 1. 9 9.7 ± 5.3 9.3 ± 0.7 
0.6 62.5 ± 3.7 34.6 ± 2.6 5.3 + 2.8 2 ± 1. 6 
0.0 56.6 ± 0.8 20.5 ± 1. 7 0 ± 0 0 + 0 
Data represents a mean± S.E., N=3. 
372 
APPENDIX XXIIIh 
IN VITRO SUPPLEMENTATION OF CY 216 TO NRatP 
Concentration APTT Heptest Anti-Xa Anti-Ila 
(µg/ml) (seconds) (seconds) (% inhibition) (% inhibition) 
10.0 43.6 ± 1. 9 195.1 ± 2.2 62.7 ± 2.2 60.7 ± 2.8 
5.0 31. 3 ± 0.9 107.8 ± 3.2 38.0 ± 1.6 38.0 ± 3.6 
2.5 25.1 ± 0.1 82.8 ± 2.2 20.3 ± 2.1 25.7 ± 3.0 
1. 25 22.8 ± 0.3 75.3 ± 1.1 8.7 ± 4.6 17.7 ± 12.4 
0.6 21.7±0.1 72. 9 ± 1. 2 6.3 ± 1.5 5.3 ± 5.4 
0.0 16.1 ± 0.9 56.6 ± 0.8 0 ± 0 0 ± 0 
Data represents a mean± S.E., N-3. 
Plasma system: NHP 
Heparin Concentration: 
APPENDIX XXIIIi 
IN VITRO ANTICOAGULANT AND ANTIPROTEASE ACTIVITY OF 
HEPARIN AFTER PROTAMINE ADMINISTRATION 
5 µg/ml 
Protamine Concentration APTT Thrombin Time (SU/ml) Heptest Anti-Xa 
(µg/ml) (seconds) (seconds) (seconds) % Inhibition 
10.0 40.6 + 1.1 27.8 ± 3.2 30.7 ± 3.5 1. 2 ± 1.1 
5.0 43.6 ± 1. 7 37.8 ± 5.4 45.7 ± 7.8 7.8 ± 2.7 
2.5 94.9 ± 7.3 >150 86.7 ± 3.6 40.6 ± 5.1 
0 >150 >150 119.0 ± 9.6 67.2 ± 1. 6 
Saline control 33.2 ± 0.4 27.2 ± 0.7 17.6 ± 1. 6 0 ± 0 
Data represents a mean± S.E., N=S. 
Anti-Ila 
% Inhibition 
2.5 + 1.5 
12.8 ± 4. 5 
42.6 ± 7.3 
79.0 ± 0.0 
0 ± 0 
Protamine 
Plasma system: 
APPENDIX XXIIIj 
IN VITRO ANTICOAGUIANT AND ANTIPROTEASE ACTIVITY OF 
CY 216 AFTER PROTAMINE ADMINISTRATION 
NHP 
CY 216 Concentration: 5 µg/ml 
Concentration APTT Thrombin Time (SU/ml) Heptest Anti-Xa 
(µg/ml) (seconds) (seconds) (seconds) % Inhibition 
10.0 46.6 ± 1.4 33.3 ± 2.6 69.0 ± 1. 5 25.2 ± 4.9 
5.0 49.2 ± 1.5 37.8 ± 4.0 77 .0 ± 3.7 28.3 ± 1.0 
2.5 49.8 ± 1. 3 47.0 ± 3.3 76.4 ± 4.6 30.2 ± 1.8 
0 55.5 ± 1.4 >150 87.5 ± 2.5 38.5 ± 2.6 
Saline control 33.2 ± 0.4 27.2 ± 0.7 17.6 ± 1. 6 0 ± 0 
Data represents a mean± S.E., N=5. 
Anti-Ila 
% Inhibition 
4.8 ± 3.6 
5.8 ± 2.5 
17.0 ± 3.6 
30.8 ± 3.2 
0 + 0 
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CUMUIATIVE RESULTS OBTAINED IN A LASER-INDUCED THROMBOSIS MODEL 
Treatment N x + S.E .. 
Control (power - 1.8, objective - 1/30) 11 2.3 ± 0.04 
Control (power - 1.2, objective - 1/15) 5 3.1 ± 0.2 
Heparin 1 mg/kg i.v. 4 5.1 ± 0.23 
Heparin 1 mg/kg i.v. and Protamine 
0.32 mg/kg i.v. 6 5.7 ± 0.22 
Heparin 1 mg/kg i.v. and Protamine 
0. 64 mg/kg i. V. 5 3.2 ± 0.16 
CY 216 1 mg/kg i.v. 5 3.9 + 0.08 
CY 216 1 mg/kg i.v. and Protamine 
0. 7 4 mgjkg i. V. 7 2.5 ± 0.20 
Protamine 0.74 mg/kg i.v. 3 4.8 ± 0.45 
Heparin 10 mg/kg i.v. 3 from 5 to >15 
Heparin 10 mg/kg s.c. 5 5.8 ± 0.12 
CY 216 10 mg/kg s.c. 5 5.2 ± 0.26 
APPENDIX XXIVb 
CUMUI.ATIVE BLEEDING TIMES OBTAINED IN A 
RAT TAIL BLEEDING MODEL 
Treatment 
Saline 
Protamine 
1 mg/kg i.v. 
Heparin 
2 mg/kg i.v. 
CY 216 
2 mg/kg i.v. 
Heparin 2 mg/kg i.v. 
and protamine 
2 mg/kg i.v. 
CY 216 2 mg/kg i.v. 
and protamine 
2 mg/kg i.v. 
Heparin 
2.5 mg/kg s.c. 
CY 216 
2.5 mg/kg s.c. 
Heparin 
2.5 mg/kg s.c. and 
protamine 
2. 5 mg.kg i.v. 
CY 216 
2.5 mg/kg s.c. and 
protamine 
2.5 mg/kg i.v. 
N 
9 
7 
7 
7 
7 
7 
7 
7 
7 
7 
Data represents a mean± S.E. 
Tail Transection Time (seconds) 
355.0 ± 27.7 
531.4 ± 48.3 
,. 6 77 . 1 ± 8 7 . 1 
272.1 ± 28.2 
406.4 ± 46.2 
340.7 ± 50.7 
324.3 ± 51.7 
255.0 ± 40.2 
405.0 ± 54.2 
356.4 ± 64.3 
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APPENDIX XXIVc 
EX VIVO ACTIVITY AND BLOOD LOSS VALUES AFTER PROTAMINE ADMINISTRATION TO RABBITS 
Time: Pre-challenge 
Treatment N APTT TT SU Heptest Anti-Xa Anti-Ila 
(seconds) (seconds) (seconds) (% Inhibition) % Inhibition 
Control 5 83. 2±11. 5 30.1±3.3 24.8±3.0 0 0 
Protamine 4 133. 9± 5.4 37. 0±1. 5 26.4±3.7 2. 0±1. 7 0 
3 mg/kg i.v. 
Protamine 3 115.4±12.9 33.2±7.3 22.4±0.7 0 0 
2 mg/kg i.v. 
Data represents a mean± S.E. 
Blood Loss 
(RBCs x 109/ 
liter) 
0.10±0.01 
0.2±0.1 
0.04±0.01 
APPENDIX XXIVd 
EX VIVO ACTIVITY AND BLOOD LOSS VALUES AFTER HEPARIN AND PROTAMINE ADMINISTRATION TO RABBITS 
Blood Loss 
Treatment N APTT TT SU Heptest Anti-Xa Anti-Ila (RBCs x 109/ 
(seconds) (seconds) (seconds) (% Inhibition) (% Inhibition) liter) 
Heparin 6 >297.9±2,0 >300 >271. 5±5. 0 23.8±10.4 64.8±15.3 0.48±0,15 
1 mg/kg i.v. 
Heparin 14 >300 >300 >300 70.2± 4.9 92,4± 0.8 0.80±0,11 
2 mg/kg i.v. 
Heparin 6 82.7±11,5 160.5±38.9 166.0±55.5 3,0±3,0 5,8± 3.9 0.36±0,11 
2 mg/kg i. v. 
with Protamine 
2 mg/kg i. v. 
Heparin 5 87.6±7,5 33.4±2,4 58.4± 3.7 0.0±0,0 0,8±0,8 0.09±0,02 
2 mg/kg i. v. 
with Protamine 
3 mg/kg i.v. 
Data represents a mean± S.E. 
APPENDIX XXIVe 
EX VIVO ACTIVITY AND BLOOD LOSS VALUE AFTER CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS 
Blood Loss 
Treatment N APTT TT SU Heptest Anti-Xa Anti- Ila (RBCs x 109 
(seconds) (seconds) (seconds) (% Inhibition) (% Inhibition) liter) 
CY 216 5 >150 >150 138.1±7,0 42.3±2,0 49.5±1.8 0.42±0.10 
1 mg/kg i.v. 
CY 216 14 >150 >150 >296.1±3,9 50.9±6,9 72, 1±3. 0 0.30±0,08 
2 mg/kg i.v. 
CY 216 5 >150 >150 >150 65.0±6.9 82.8±5,8 0.84±0,22 
3 mg/kg i.v. 
CY 216 5 111. 3±24. 5 118.6±47.5 138.1±45.5 26.0±14.0 25.8±7.8 0.06±0.02 
2 mg/kg i.v. 
with Protamine 
2 mg/kg i.v. 
CY 216 5 108.1±14.5 47.1±10.5 153.0±47.1 12.6±4.8 0.14±0.17 0.06±0.02 
2 mg/kg i. v. 
with Protamine 
3 mg/kg i.v. 
Data represents a mean± S.E. 
l.,.) 
00 
0 
APPENDIX XXIVf 
EX VIVO ACTIVITY AND BLOOD LOSS VALUES AFTER HEPARIN OR CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS 
Blood Loss 
Treatment N APTT TT SU Heptest Anti-Xa Anti-Ila (RBCs x 109 
(seconds) (seconds) (seconds) (% Inhibition) (% Inhibition) liter) 
Heparin 5 >130.8±11. 7 >150 >216.9±49.4 37.0±8.0 81.0±7 .0 0.16±0.02 
3 mg/kg s.c. 
Heparin 5 80.1±9.0 27.5±2.0 42.3±7.3 1. 8±1. 7 3.6±2.0 0.08±0.07 
3 mg/kg s.c. 
with Protamine 
3 mg/kg i.v. 
CY 216 5 89.2±18.4 >150 67.7±18.2 40.3±8.9 51. 3±4. 5 0.18±0.04 
3 mg/kg s.c. 
CY 216 5 71. 7±16. 7 31.0±3.1 62.9±12.5 28.0±9.6 4. 5±2. 6 0.09±0.03 
3 mg/kg s.c. 
with Protamine 
3 mg/kg i.v. 
Data represents a mean± S.E. 
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APPENDIX XXVa 
EX VIVO ACTIVITY AND CLOT SCORES AFTER PROTAMINE ADMINISTRATION TO RABBITS 
Time: Pre-challenge 
Treatment N APTT TT SU Heptest Anti-Xa Anti-Ila 
(seconds) (seconds) (seconds) (% Inhibition) % Inhibition 
Control s 83. 9±1.0 32.0±4.1 30.8±3.8 0 0 
Protamine s 102.3±9.0 35.3±3.3 28.7±4.2 0 0 
100 µg/kg i.v. 
Protamine s 83.7 72.6 37.7 7.5 10 
500 µg/kg i.v. 
Data represents a mean± S.E. 
Clot Score 
3.1±0.3 
2.8±0.3 
2.3±0.2 
l,.) 
00 
l,.) 
APPENDIX XXVb 
EX VIVO ACTIVITY AND CLOT SCORES AFTER HEPARIN AND PROTAMINE ADMINISTRATION TO RABBITS 
Time: Pre-challenge 
Treatment 
Heparin 
25 µg/kg i. v. 
Heparin 
50 µg/kg i. v. 
Heparin 
100 µg/kg i.v. 
Heparin 
100 µg/kg i. v. 
with Protamine 
100 µg/kg i.v. 
Heparin 
100 µg/kg i.v. 
with Protamine 
200 µg/kg i.v. 
N 
5 
5 
5 
5 
5 
APTT 
(seconds) 
124.7±13.2 
111. 2±17. 2 
146.8±29.7 
57.6±10.2 
122.9±12.3 
Data represents a mean± S.E. 
TT SU 
(seconds) 
46. 7±4.4 
132.3±57.1 
>150±0 
40.3±5.2 
37. 5±1. 9 
Heptest Anti-Xa Anti-Ila 
(seconds) (% Inhibition) % Inhibition Clot Score 
44.9±9.7 4.8±2.9 2.0±0.9 1.4±0. 2 
76.8±10.6 5.0± 2.1 14.3±8.0 0.5±0.2 
128.9±27.7 25.0±10.4 32.4±9.0 0.6±0.3 
37.2±6.8 2.6±1.0 1. 25±2. 5 2.7±0.3 
47.0±2.0 2.4±2.4 12.4±3.9 2.9±0.3 
APPENDIX XXVc 
EX VIVO ACTIVITY AND CLOT SCORES AFTER CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS 
Time: Pre-challenge 
Treatment 
CY 216 
25 µg/kg i.v. 
CY 216 
50 µg/kg i.v. 
CY 216 
100 µg/kg i.v. 
CY 216 
100 µg/kg i. v. 
with Protamine 
100 µg/kg i.v. 
CY 216 
100 µg/kg i.v. 
with Protamine 
200 µg/kg i.v. 
N APTT 
(seconds) 
5 58.0±6.4 
5 49.1±14.4 
5 67.7±12.9 
5 58.0±13.6 
5 113±6.6 
Data represents a mean± S.E. 
TT SU 
(seconds) 
37. 0±1. 6 
50.7±9.3 
49.1±10.7 
34.1±3.4 
38.4±3.1 
Heptest Anti-Xa Anti- Ila 
(seconds) (% Inhibition) % Inhibition Clot Score 
42.4±4.1 1. 8±1. 2 1. 2±1. 2 2.2±0.5 
42.1±2.1 5.0±4.6 1. 3±1.4 1. 5±0. 2 
63. 6±11. 8 12.8±8.7 5.8±4.5 0.4±0.2 
46.2±4.1 8.8±2.8 7 .4±1. 9 1. 7±0.4 
43 .4±1. 3 9.2±2.4 6.4±2.8 2,2±0.2 
w 
00 
V, 
APPENDIX XXVd 
EX VIVO ACTIVITY AND CLOT SCORES AFTER HEPARIN AND CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS 
Time: Pre-challenge 
Treatment 
Heparin 
1 mg/kg s.c. 
Heparin 
1 mg/kg s.c. 
with protamine 
1 mg/kg i.v. 
CY 216 
1 mg/kg s.c. 
CY 216 
1 mg/kg s.c. 
with Protamine 
1 mg/kg i.v. 
N 
5 
5 
5 
5 
APTT 
(seconds) 
61.0±10.5 
78.8±18.7 
95.4±4,4 
73. 7±12.0 
Data represents a mean± S.E. 
TT SU 
(seconds) 
128.8±13,4 
85.9±25.1 
54.8±8,9 
37.8±5,2 
Heptest Anti-Xa Anti-Ila 
(seconds) (% Inhibition) % Inhibition Clot Score 
62.4±12.9 15.8±4,5 16.2±3,9 1. 5±0 .4 
39.5±5,7 12.8±3,9 18.5±9,4 2.8±0,4 
42.7±12.6 22.5±6,4 7. 0±1. 9 1. 9±0 .4 
58.4±10.9 15.0±2,9 9,8±2,5 2.0±0.4 
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APPENDIX XXVIa 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES 
Dose: 0.7 mg/kg i.v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% 
0 24.4 ± 1.3 28.l ± 0 25.4 ± 2.3 0 ± 0 
5 >150 ± 0 >150 ± 0 >300 ± 0 92.0 ± 2.2 
30 >150 ± 0 >150 ± 0 269.4 ± 30.5 83.4 ± 8.1 
60 129.4 ± 10.4 >150 ± 23.4 178.7 ± 24.3 77 .0 ± 4.8 
180 33.5 ± 6.1 80.2 ± 6.0 55.3 ± 6.0 17,0±6.1 
360 25.9 ± 1.6 25.9 ± 1. 2 23.0 ± 1. 2 4.2 ± 2.4 
Data represents a mean± S.E., N-4. 
Anti- Ila 
inhibition) 
0 ± 0 
90.6 ± 2.9 
87.8 ± 2.0 
85.0 ± 2.5 
28.4 ± 7.4 
9.2 ± 4.1 
l.,.) 
00 
00 
APPENDIX XXVIb 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN 
AND PROTAMINE SULFATE IN PRIMATES 
Heparin dose: 0 . 7 mg/kg i. v. 
Protamine dose: 0 . 7 mg/kg i. v . 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa 
(minutes) (seconds) (seconds) (seconds) (% inhibition) 
0 36.7 ± 5.3 19.8 ± 3.1 20.2 + 1.4 0 + 0 
5 >150 ± 0 >150 ± 0 >300 ± 0 97.3 ± 1.8 
15 86.8 ± 18.0 89.2 ± 11.2 79.9 ± 2.9 114.0 ± 6.7 
30 56.1 ± 7.5 73.9 ± 7.5 67.6 ± 3.0 45.8 ± 12.8 
60 55.1 + 10.7 25.5 ± 3.8 63.7 ± 2.0 26.8 ± 4.6 
180 46.8 ± 7.7 16.3 ± 2.0 24.8 ± 0.7 6.0 ± 3.3 
360 23.6 + 1. 3 17.0 + 1.5 26.1 ± 0.3 4.8 ± 2.0 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 5 minute blood draw. 
Anti-Ila 
(% inhibition) 
0 ± 0 
94.3 ± 0.5 
49.8 + 8.5 
35.0 ± 3.0 
31. 6 + 4.3 
5.1 ± 2.3 
0.8 + 0.8 
w 
00 
\0 
APPENDIX XXVIc 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES 
Heparin dose: 0 . 7 mg/kg i . v . 
Protamine dose: 1. 4 mg/kg i. v . 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% 
0 25.l ± 2.5 17.2 ± 0.8 26.5 ± 2.0 0 + 0 
5 >150 >150 + 0 >300 + 0 79.6 ± 4. 7 
15 34.1 ± 3.6 68.6 ± 40.8 60.4 + 5.5 58.6 ± 6.1 
30 28.6 ± 1. 9 26.7 + 1.5 60.3 ± 1. 6 49.3 ± 7.9 
60 28.0 + 2.9 22.5 ± 0.4 49.0 ± 2.2 50.3 ± 12.1 
180 24.7 ± 1. 6 21.4 ± 0.8 29.0 + 0.8 21. 3 ± 1. 2 
360 25.0 ± 2.1 18.8 ± 0.8 20.5 ± 0.8 4.8 ± 2.4 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 5 minute blood draw. 
Anti- Ila 
inhibition) 
0 ± 0 
94.4 ± 1. 3 
26.4 ± 7.7 
40.6 ± 6.6 
28.0 ± 2.1 
5.6 + 3.6 
2.4 + 2.4 
w 
\() 
0 
APPENDIX XXVId 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES 
Heparin dose: 0 . 7 mg/kg i. v . 
Protamine dose: 2 . 1 mg/kg i. v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti-Ila 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 25.2 + 1.0 25.0 ± 1.4 18.4 ± 1.5 0 ± 0 0 ± 0 
5 >150 + 0 >150 ± 0 234.1 ± 46.5 90.5 ± 2.6 90.3 ± 4.3 
15 28.2 + 1.0 50.6 ± 10.4 37.0 ± 1.4 52.8 ± 12.4 16.8 ± 2.8 
30 30.0 ± 0 94.0 ± 12.2 28.5 ± 0.5 15.0 ± 0.9 18.0 ± 0.8 
60 25.8 ± 1.0 63.5 ± 7.5 29.7 ± 5.2 24.3 ± 11.5 4.3 + 3.4 
180 23.6 ± 1.4 37.0 ± 3.6 25.6 ± 1. 7 14.2 ± 8.0 7.6 ± 2.6 
360 15.4 ± 2.0 23.3 + 2.5 21. 9 ± 1.1 7.3 ± 5.9 6.7 + 5.3 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 5 minutes blood draw. 
APPENDIX XXVIe 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 IN PRIMATES 
Dose: 0.7 mg/kg i. v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti- Ila 
(minutes) _lc:econds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 24.6 + 2.3 28.4 ± 3.9 31. 3 ± 1. 7 0 ± 0 0 
5 129.4 ± 20.7 >150 ± 0 >300 ± 0 91.0 ± 2.4 68.2 ± 7.9 
30 39.4 ± 3.9 121. 8 ± 16.5 120.4 ± 20.4 57.3 ± 9.4 39.0 ± 10.0 
60 33.9 ± 2.3 110.7 ± 24.0 92.1 ± 8.9 49.2 ± 5.0 27.8 ± 8.8 
180 26.1 ± 1.4 31. 7 ± 3.8 55.4 ± 3.2 19.2 ± 5.4 8.4 ± 3 .4 
360 23.8 ± 1.4 30.2 ± 6.0 38.7 ± 3.8 3 .4 ± 1. 6 4.0 + 0.0 
Data represents a mean± S.E., N=4. 
APPENDIX XXVIf 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 AND 
PROTAMINE SULFATE IN PRIMATES 
CY 216 dose: 0.7 mg/kg i.v. 
Protamine dose: 0.7 mg/kg i, V. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti- Ila 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 25.0 ± 2.6 21.4 + 2.5 21.4 ± 1.2 0 ± 0 0 ± 0 
5 98.6 ± 29.9 >150 + 0 >300 ± 0 93.6 ± 3.0 81. 6 ± 3.8 
15 37.4 ± 4.1 31. 8 ± 4.8 126.1 ± 14.1 68.4 ± 7.8 21. 8 ± 9.0 
30 34.5 ± 3.3 29.7 ± 2.4 132 .4 ± 19.0 77 .8 ± 5.2 41. 8 ± 7.1 
60 34.2 + 2.1 35.5 ± 4.2 92. 9 ± 2.4 67.3 ± 7.8 41. 3 ± 6.0 
180 28.0 ± 1. 2 18.9 ± 2.3 60.2 ± 3.1 42.6 ± 8.1 6.5 + 2.0 
360 24.6 ± 3.4 20.4 ± 1. 3 39.5 ± 0.9 22.8 ± 4.8 8.0 + 6.2 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 5 minute blood draw. 
APPENDIX XXVIg 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 AND 
PROTAMINE SULFATE IN PRIMATES 
CY 216 dose: 0. 7 mg/kg i. V, 
Protamine dose: 1.4 mg/kg i.v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti-Ila 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 30.5 ± 3.5 19.0 ± 0.90 21.0 + 0 0 + 0 0 ± 0 
5 >150 135. 9 ± 6.3 >300 ± 0 71. 3 ± 3.1 76.6 ± 6.1 
15 43.4 ± 8.1 65.1 ± 13. 9 109.0 ± 7.8 44.5 ± 6.2 33.3 ± 3.6 
30 50.4 ± 10.0 72.6 ± 13.5 95.5 ± 5.2 37.5 ± 3.9 20.0 + 11.5 
60 39.6 + 6.2 27.9 ± 3.3 83.9 ± 7.8 26.0 ± 10.0 21. 7 ± 11.0 
180 35.2 ± 6.1 15.0 + 0.1 55.1 ± 8.1 11. 3 ± 2.1 5.3 ± 3.0 
360 45.8 ± 2.0 15.2 ± 0.3 39.8 ± 4.8 5.0 + 5.0 2.5 ± 1.4 
Data represents a mean± S.E., N=S. 
Protamine was administered immediately after the 5 minute blood draw. 
APPENDIX XXVIh 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF 
CY 216 AND PROTAMINE SULFATE IN PRIMATES 
CY 216 dose: 0 . 7 mg/kg i . v . 
Protamine dose: 2.1 mg/kg i.v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti- Ila 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 25.5 ± 0.8 24.8 ± 2.8 20.6 ± 1.1 0 ± 0 0 ± 0 
5 63.6 + 13.0 >150 + 0 288.0 ± 11. 3 98.8 + 0.2 70.7 + 4.6 
15 34.7 + 1. 3 67.3 ± 15.0 95.5 ± 7.3 35.8 ± 7.3 33.3 + 12.7 
30 37.2 ± 3 .4 20.8 ± 0 117 .8 ± 6.0 25.6 ± 5.2 27.8 ± 11. 7 
60 35.l ± 3.9 24.1 + 1. 2 83.2 ± 1. 2 18.6 ± 2.2 10.5 ± 4.1 
180 27.5 + 1. 2 17.7 ± 0.5 61.0 ± 2.9 12.4 ± 4.2 10.3 ± 10.5 
360 24.6 ± 1. 6 21. 6 ± 0.3 49.9 + 1.4 5.8 ± 2.7 7.7 + 3.3 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 5 minute blood draw. 
APPENDIX XXVIi 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES 
Dose: 0.7 mg/kg s.c. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti-Ila 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 31.8 ± 3.2 25.4 ± 2.7 21. 6 ± 0. 7 0 ± 0 0 ± 0 
120 34.7 ± 2.5 37.8 ± 8.0 49.8 ± 3.0 8.2 ± 2.6 5.8 ± 3.7 
240 35.5 ± 2.9 29.7 ± 4.6 44.6 ± 4.1 7.3 ± 2.7 7.0 ± 3.3 
360 30.6 ± 3.3 27.5 ± 3.4 31.0 ± 2.2 3.8 ± 1.2 4.4 ± 2.3 
540 29.0 ± 3.1 25.6 ± 2.6 22.4 ± 1.2 4.4 ± 2.4 1.4 ± 1.4 
720 29. 7 ± 3.1 24.9 ± 2.2 24.1 ± 1.4 3.6 ± 0.7 0 ± 0 
Data represents a mean± S.E., N-5. 
APPENDIX XXVIj 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN WITH 
PROTAMINE SULFATE IN PRIMATES 
Heparin dose: 0.7 mg/kg s.c. 
Protamine dose: 0.7 mg/kg i.v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti-Ila 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 25.1 ± 1.0 26.4 ± 0.5 26.0 + 1. 2 0 ± 0 0 ± 0 
120 30.2 ± 2.8 30.8 ± 2.4 38.3 ± 5.7 7.8 ± 3.2 7.4 + 3.5 
240 26.5 ± 2.2 31. 7 ± 1. 6 40.2 ± 5.8 8.4 ± 2.1 8.4 ± 2.7 
245 26.4 ± 2.4 37.3 ± 10.9 26.9 ± 1.8 7.6 + 3.1 4.6 ± 2.7 
540 25.1 + 1. 9 26.1 ± 0.9 24.5 ± 1.4 4.4 ± 1.6 3.8 ± 3.8 
720 22.3 ± 1. 3 28.4 ± 1. 3 21. 2 + 1.1 7.4 ± 3.3 2.4 + 1. 6 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 240 minute blood draw. 
APPENDIX XXVIk 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 IN PRIMATES 
Dose: 0.7 mg/kg s.c. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% 
0 25.54 ± 0.8 27.8 ± 1.1 20.7 ± 0.9 0 ± 0 
120 29.7 ± 1. 2 34.8 ± 1. 9 62.2 ± 3.1 32.2 ± 4.9 
240 30.0 ± 1.2 38.8 ± 1. 7 60.2 ± 2.0 53.0 ± 5.2 
360 28.8 ± 1.2 19.9 ± 0.6 46.3 ± 2.6 27.8 ± 6.0 
540 27.4 ± 1.0 21. 6 ± 2.1 37.3 ± 2.1 18.8 ± 3.5 
720 28.6 ± 1.5 24.3 ± 0.9 36.0 ± 2.8 14.8 ± 5.3 
Data represents a mean± S.E., N-5. 
Anti-Ila 
inhibition) 
0 ± 0 
9.2 ± 3.2 
13.3 ± 5.2 
6.6 ± 2.7 
12.3 ± 2.7 
4.8 ± 2.0 
w 
\0 
00 
APPENDIX xxvn 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 WITH 
PROTAMINE SULFATE IN PRIMATES 
CY 216 Dose: 0.7 mg/kg s.c. 
Protamine Dose: 0.7 mg/kg i.v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa Anti-Ila 
(minutes) (seconds) (seconds) (seconds) (% inhibition) (% inhibition) 
0 26.5 ± 1.5 26.7 ± 1. 6 23.8 ± 1.4 0 ± 0 0 ± 0 
120 29.9 ± 2.4 32.8 ± 2.2 70.9 ± 1. 9 31. 5 ± 2.8 7.6 ± 3.2 
240 29.5 ± 1. 3 29.9 ± 1.0 66.0 ± 6.2 31. 2 ± 5.0 5.4 ± 2.4 
245 33.9 ± 3.3 30.6 ± 3.4 65.8 ± 5.0 26.8 ± 2.2 0 ± 0 
540 29.8 ± 1. 3 28.1 ± 1.5 58.8 ± 4.4 29.0 ± 2.5 5.4 ± 1.5 
720 29.9 ± 2.0 22.9 ± 3.6 36.4 ± 3.8 19.4 ± 2.1 3.6 ± 1.0 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 240 minute blood draw. 
APPENDIX XXVIm 
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 WITH 
PROTAMINE SULFATE IN PRIMATES 
CY 216 Dose: 0. 7 mg/kg s.c. 
Protamine Dose: 1.4 mg/kg i.v. 
Time APTT Thrombin Time (5 U/ml) HeptestR Anti-Xa 
(minutes) (seconds) (seconds) (seconds) (% inhibition) 
0 24.7 ± 0.9 22.5 ± 0.8 20.0 ± 1.1 0 ± 0 
120 27.8 ± 1. 3 23.9 ± 2.4 58.9 + 2.7 40.3 ± 4.5 
240 27.4 ± 1. 6 29.l ± 2.6 60.9 ± 3.0 42.5 ± 4.3 
245 30.0 ± 3.0 37.0 ± 9.2 47.6 ± 9.0 35.8 ± 1. 3 
540 25.6 ± 1.5 29.7 ± 2.6 52.7 ± 1.2 27.5 ± 5.8 
360 27.6 ± 1.5 28.5 ± 1. 6 41. 9 ± 3.2 9.0 ± 3.7 
Data represents a mean± S.E., N=5. 
Protamine was administered immediately after the 240 minutes blood draw. 
Anti-Ila 
(% inhibition) 
0 ± 0 
12.5 + 0.9 
11.0 + 1. 5 
2.8 ± 1. 7 
2.0 ± 2.0 
0 ± 0 
-"' 
0 
0 
APPENDIX XXVII 
APPENDIX XXVIl 
COMPARISON OF HEPARIN AND CY 216 SUPPLEMENTED 
TO VARIOUS PLASMA PREPARATIONS 
Plasma Preparation Heparin (µg/ml) CY 216 (µg/ml) 
Test: APTT 
NHP 1. 3 >10 
NMP 1.4 >10 
NRP 1. 9 >10 
NratP 3.8 >10 
Test: Heptest 
NHP .82 1. 3 
NMP .82 1. 3 
NRP 6.2 1. 3 
NratP 2.05 7.5 
Test: Anti-Xa 
NHP 2.5 6.0 
NMP 2.5 5.0 
NRP 3.8 9.0 
NratP 4.0 7.2 
Test: Anti- Ila 
NHP 1.5 8.2 
NMP 1. 3 4.6 
MRP 3.3 10.0 
NratP 2.5 7.4 
402 
Heparin or CY 216 was supplemented to NHP, NMP, NRP and NratP in a 
concentration range of 0-10 µg/ml. For the clotting tests the 
concentration of heparin or CY 216 at which the baseline was doubled is 
reported. For the amidolytic assays, the concentration which produced 
50% inhibition was reported. 
APPENDIX XXVIII 
APPEKDIX XX\'111 
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Very slight changes in retention time can cause large charqes in the mea.'1 
m:>lecular weight o! polymers. For this reason it is ir.portant to i.'1~'"Pret 
molecular weight data dete.rnu.ned by HPLC relative to various pa.ramete.'"S, 
Peak Molecular Weight: In:ilcates the 110lecular weight o! the greatest p:,rtion 
O! the eluti.rq materia1, 
Mz, M,., ard Mz+l: 'Ihese values are a!!ected by variations in the high ::olec..:.lar 
',,18ight region o! the eluti.n; material. 'lllus they cl-.aracterize t.".e high 
IICllecular weight o::irponent.s. 
Mn: 0--.ara~....e.rizes the low rolecular weight p:,rtion o! t."\e elution curve. '!his 
value is sensitive to a lorq tail o! low IICllecular weight c:arp:nents. 
Dispersity: \.'hen the polymer is c::at;,ose:i o! a \o/ide ran:;e o! IICllecular \o/eig.';t 
c:orrponents this value \o/ill be high. It irdicates t."le r-an;e of oolecular 
weights in the materia1. 
* Taken from technical manual Waters 410 Chromatography 
system 
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